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ABSTRACT 
Bladder dysfunctions associated with overactive bladder are highly prevalent in the aging 
population and impose a huge financial cost, however the underlying mechanisms are poorly 
understood. The newly recognised sensory role of the urothelium provides a new direction of 
research into the pathogenesis of overactive bladder. As the activity of this sensory structure 
is highly important for correct bladder function, it is imperative to identify new regulators of 
this tissue.  A role for transient receptor potential vallinoid 4 (TRPV4) channels in bladder 
function has been recently evidenced. This work aimed to explore the role of TRPV4 in 
urothelial ATP release, the key step in urothelial sensory transduction, elucidate the 
underlying mechanisms and assess changes to TRPV4 expression and function in aging 
and overactive bladders.  
Immunohistochemistry and western blotting assessed the expression and localization of 
TRPV4 throughout the bladder. Bladder strips from animals and humans were challenged 
with the selective TRPV4 agonist GSK1016790A and ATP release and tissue contractility 
measured. Various antagonists were employed to uncover the mechanisms. The role of Ca2+ 
in TRPV4-mediated responses was explored using live-cell Ca2+ imaging. The effect of 
TRPV4 activation on reactive oxygen species production was also measured. The 
interaction between TRPV4 and the principal urothelial receptor P2Y was assessed, 
supplemented with P2Y2 knockout mice. The responses between young and aging guinea 
pigs and normal and overactive human bladders were compared.  
This is the first study to establish a role for TRPV4 in mucosal ATP release and the 
underlying mechanisms. This study demonstrates increased TRPV4 expression with age 
and a functional link between TRPV4 and P2Y receptors as a result of aging. This work also 
provides preliminary evidence for an increased TRPV4-mediated ATP release in overactive 
human bladders. These novel findings identify a fundamental role for TRPV4 in bladder 
physiology and pathophysiology and present experimental evidence that pharmacological 
manipulation of this receptor may provide a novel method for treatment of overactive 
bladder.     
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1.1 THE URINARY BLADDER 
The urinary bladder is a hollow, smooth muscle organ that functions to periodically store and 
expel urine. Control of the bladder requires complex coordinated signalling between the 
neurones and various components of the bladder wall to achieve the necessary relaxed phase 
for storage and contractile phase for voiding. Importantly therefore, the bladder must be 
capable of recognising the volume of urine present and sensing a threshold volume, upon 
which a contraction is elicited.  
Disruptions in the control mechanisms for urine storage may often lead to lower urinary tract 
symptoms (LUTS), including urge incontinence, urgency and frequency, all of which comprise 
the overactive bladder syndrome (OAB) (Abrams P et al. 2002).  This is a very common 
chronic disorder in both sexes that increases in prevalence with age, posing a major problem to 
our aging society (Stewart et al., 2003). Currently, a poor understanding of the causative 
mechanisms of OAB means specific treatments are lacking, thus presenting the immediate 
need for further research. Accordingly, recent advances in our understanding of bladder 
physiology have revealed the importance of the urothelium in mediating bladder sensation 
(Birder et al., 2001). Therefore, progressing our knowledge of the mechanisms underlying the 
sensory functions of the urothelium may provide novel drug targets for control of micturition, 
and indeed treatment of OAB.  
 
1.1.1 ANATOMY OF THE LOWER URINARY TRACT 
The lower urinary tract (LUT) consists of the urethra (outflow region) and the urinary bladder, 
the latter of which can be divided into two further components: the main bladder body and the 
base. The bladder base refers to the urethrovesical junction, the trigone and anterior bladder 
wall. The bladder body, or dome, is composed of several muscular layers forming the detrusor 
smooth muscle (DSM), and is internally lined by a thin mucosal layer consisting of the 
urothelium, basement membrane and lamina propria (LP), or suburothelium. The urothelial 
layer directly separates the urine from the underlying tissues and the LP lies between the 
basement membrane and the DSM. Schematics demonstrating the structure of the bladder are 
shown in figure 1–1. 
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Figure 1 – 2. Organisation of the bladder wall. The urinary bladder wall consists of three highly 
organised cell layers; the urothelium, the lamina propria and the detrusor smooth muscle, which 
work together as a functional syncytium to achieve correct bladder function.  The urothelium 
prevents urine leakage into underlying tissues and plays an important role in bladder sensory 
pathways, the lamina propria provides nutritional and communicative support to the adjacent 
tissues and the detrusor smooth muscle generates force for successful voiding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 1 – 1. The lower urinary tract. A: Schematic diagram depicting the structure of the LUT, 
including the bladder body and outflow region. B: H&E stain of a transverse section of human bladder 
wall, highlighting in detail the detrusor muscle, urothelial and suburothelial layers (adapted from[Chan, 
2005]). 
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1.1.2 BLADDER WALL MORPHOLOGY 
1.1.2.1 DETRUSOR SMOOTH MUSCLE (DSM) 
The DSM is formed of many cell bundles arranged into three distinct layers, where the cells of 
the outer and inner layers are orientated longitudinally, compared to the circularly orientated 
middle layer (Andersson and Arner, 2004)(figure 1-2). The specific orientation of the bladder 
smooth muscle cells and their interactions between one another are important, as these factors 
will determine what effect activity in these cells has on bladder shape, intraluminal pressure 
and ultimately how the bladder wall will behave. Bladder smooth muscle cells exhibit the typical 
smooth muscle cellular morphology – long, spindle shaped cells containing a central nucleus 
and a cytoplasm packed with normal myofilaments and scattered dense bodies. When fully 
relaxed, these cells may reach lengths of up to several hundred microns. In human detrusor, 
the smooth muscle cells are arranged into large bundles, commonly a few mm in diameter, 
surrounded by collagen-rich connective tissue. These bundles, formed from smaller sub-
bundles, have no clear arrangement and run in all directions throughout the detrusor. The 
smooth muscle cells found within these bundles commonly exist in groups of small functional 
units, termed fascicles or functional modules (DeLancey et al., 2002). These modules are 
defined by their discrete supplies of individual intramural bladder ganglia and contraction of 
these modules is synchronised via various neural and hormonal control systems for correct and 
full bladder voiding (Drake et al., 2001). 
1.1.2.2 BASEMENT MEMBRANE AND LAMINA PROPRIA 
The basement membrane (BM) separates the urothelium from the lamina propria and has a 
composition typical of all basement membranes (including collagen IV, fibronectin, laminin), 
which function to maintain the spatial relationships between epithelia and the adjacent 
interstitial connective  tissues (Deen and Ball, 1994). The lamina propria (LP) is situated 
between the BM and detrusor muscle and is composed of an extracellular matrix (ECM) with a 
rich vascular supply, lymphatic channels, elastic fibers and smooth muscle fascicles (Wein et 
al., 2014). The cells found directly in the LP include interstitial cells (ICs), fibroblasts, 
adipocytes and sensory nerve endings. The ECM functions to provide support for the 
surrounding cells and mediates transduction of signals between the tissue layers, importantly 
those from nerve endings. It is mainly composed of collagen I and III, which orientate from a 
loose mesh to organised bundles during filling, providing tensile strength and structure to the 
bladder wall. After micturition, the elastic fibres pull the bladder into its original resting shape 
(Andersson and McCloskey, 2014). 
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1.1.2.3 INTERSTITIAL CELLS 
The role of interstitial cells (ICs) in the bladder is yet to be fully established. There are two 
distinctly different populations of ICs in the bladder, those which reside in the LP and those of 
the detrusor, where each population may serve different functions. ICs in the LP are vimentin-
containing stellate-shaped cells which are located close to both the urothelium and nerve 
endings in both animals and humans (McCloskey 2013; Wiseman et al. 2003). 
Immnofluorescent staining shows that these IC cells form connections with other nearby IC 
cells, creating an interconnecting cell network, mediated by connexin 43 (Cx43) gap junctions. 
Bladder ICs are also found in the detrusor, which comprise a further two subgroups; stellate-
shaped detrusor ICs, which reside in the interstitial space between muscle bundles, and 
elongated ICs, which are organised in parallel lines on the boundaries of the muscle bundles 
(McCloskey, 2013). Both form close physical connections with detrusor nerves (Davidson and 
McCloskey, 2005). Although our understanding of these cells is currently limited, available 
evidence has indicated a role for LP ICs in coordinating local bladder signalling (Andersson 
and McCloskey, 2014). Of importance, suburothelial interstitial cells (myofibroblasts) form a 
cellular network via expression of connexin 43, in close contact with the sensory nerves (Sui et 
al., 2002; Wiseman et al., 2003) and have been shown to be electrically active and respond to 
ATP, which is released by the urothelium(Sui et al., 2008, 2004; Wu et al., 2004). This would 
allow an interaction with urothelial cells and amplification of “ATP signals”, hence serving as a 
gain of this function. 
1.1.2.4 UROTHELIUM 
The urothelium is the epithelial lining of the lower urinary tract that functions both as a physical 
barrier, separating urine from the underlying tissue, as well as actively participating in bladder 
signalling, as revealed by recent studies (de Groat, 2004). This internal bladder lining is a 
transitional epithelium composed of three cell layers, each with a morphologically distinct cell 
type (Figure 1 - 3).  
 
 
 
 
Figure 1 – 3. Schematic of urinary bladder urothelium. Cross section highlighting the three 
morphologically distinct cellular layers of this transitional epithelial lining. 
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Basal cells are 5-10μm in diameter and lye across the continuous basal lamina. These cells 
are germinal in nature and the fusion of these cells forms intermediate cells, allowing for cell 
replacement and total urothelial turn over (~6 week in mice)(Martin, 1972). These intermediate 
cells are slightly larger, with diameters of 20μm and again fuse to form the large umbrella cells 
that line the bladder lumen, forming a superficial barrier layer. The umbrella cells have a 
diameter between 50-120μm depending on the degree of bladder stretch and function partly to 
prevent equilibration of substances between the urine and blood. In order to achieve this, the 
umbrella cells are coated in hexagonal plaques composed of crystalline proteins termed 
‘uroplakins’, which increase the impermeability of the urothelial barrier. Additionally, the cell 
stratum of the umbrella layer contains tight junctions, impeding the exchange of ions between 
the urine and blood supply (de Groat, 2004). 
1.1.3 MECHANICS OF DETRUSOR CONTRACTION  
Correct voiding of the bladder contents requires contraction of the bladder in synchrony with 
relaxation of the urethra. In order to develop effective therapies for OAB and other urological 
pathologies through manipulation of micturition, we must possess an extensive knowledge of 
the control mechanisms of bladder wall contraction and relaxation, both under physiological 
and pathological conditions. Although the urothelium has in fact recently been found to have a 
vital role in the afferent sensation of bladder fullness and can exert direct effects on detrusor 
function, it is the detrusor that houses the contractile machinery for bladder contraction.  
Detrusor contraction is achieved in a similar manner to other smooth muscle types, where cell 
shortening occurs via interaction between thin (α- and β-actin-containing) and thick (SM1B and 
SM2B myosin-containing)(Martin et al., 2007) filaments. The actin filaments are anchored to 
dense bodies on the cell membrane and provide binding sites for the thick myosin filaments. 
This system is myosin-activated, where upon activation; the myosin sub-units attach and 
cyclically interact with the actin filaments via cross-bridges formed by the myosin head groups. 
Once this interaction is established, the myosin sub-unit rotates in a rowing motion about its 
attached head group allowing the muscle to contract (Holmes, 1995). This interaction requires 
the hydrolysis of MgATP to MgADP and Pi, providing the energy for muscle shortening and 
force generation (Andersson and Arner, 2004).  
The contractile system is myosin-activated and this activation is initiated up-stream by an 
increase in sarcoplasmic Ca2+ concentration, [Ca2+]i (Fry et al., 2010). Contraction is stimulated 
once [Ca2+]i is raised from basal levels of 50-100 nM, where the half-maximal activation has 
been determined to be around 1μM (Wu et al., 1995). This rise in [Ca2+]i is achieved either via 
entry of extracellular Ca2+ into the sarcoplasm through L- and T-type Ca2+ channels 
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(Montgomery & Fry 1992; Sui et al. 2003), or by release of intracellular Ca2+ stores found in the 
sarcoplasmic reticulum (SR). The latter can be triggered either by Ca2+ (Ca2+-induced Ca2+-
release) via ryanodine receptors, or by inositol trisphosphate (IP3) via IP3 receptors (Harriss et 
al., 1995). The resulting increase in [Ca2+]i causes activation of  various Ca
2+-dependent 
proteins such as calmodulin (CaM). Binding of Ca2+ to CaM generates the active Ca2+4-CaM 
complex, which in turn binds and activates myosin light chain kinase (MLCK).  
Activated MLCK is then able to phosphorylate myosin regulatory light chains, activating the 
contractile machinery and permitting bladder smooth muscle contraction (Andersson and 
Arner, 2004)(figure 1-4).  
Figure 1 – 4. Diagram summarising the important nerve-activated signalling 
pathways in detrusor smooth muscle cells.  Here, the M3 and P2X1 receptor pathways are 
shown, both of which result in elevated [Ca
2+
]i levels leading to subsequent detrusor contraction. M3 
receptor activation initiates cleavage of membrane phospholipids (PIP2) to inositol trisphosphate 
(IP3) and diacylglycerol (DAG) via phospholipase-C (PLC) activity. IP3 triggers intracellular Ca
2+
 
release from SR stores, which binds to calmodulin (CaM), in turn activating myosin light chain 
kinase (MLCK), facilitating the binding of myosin to actin for contraction. Active M3 receptors may 
also activate the rho-kinase pathway, which inhibits MLC phosphatase, also promoting contraction. 
P2X1 receptors activated by ATP provide an additional influx pathway for cations including Ca
2+
. 
Ca
2+
 influx through L-type Ca
2+ 
channels is also shown.(Fry et al., 2010) 
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Relaxation of the smooth muscle requires subsequent dephosphorylation of the myosin light 
chain, catalysed by a myosin light chain phosphatase (MLCP). Hence, smooth muscle 
contraction is controlled by phosphorylation of the myosin light chain by MLCK and 
dephosphorylation catalyzed by MLCP. Agonist stimulation of smooth muscle not only activates 
MLCK, but also causes inhibition of MLCP activity resulting in a net increase in MLC 
phosphorylation, culminating in contraction.  
Modulation of MLCK or MLCP activity can therefore attenuate the sensitivity of the contractile 
system. Various intracellular messengers possess the ability to modulate the activity of these 
enzymes and can therefore also alter contractile activity. Phosphorylation of MLCK results in 
decreased activity and a number of responsible kinases have been identified, including CAM 
kinase II, mitogen-activated protein (MAP) kinase, p21-activated kinase and cAMP-dependent 
kinase (PKA) (Yamaguchi, 2004). MLCP activity is also reduced upon phosphorylation, which 
increases the sensitivity of the system to Ca2+. Importantly, Inhibition of MLCP is achieved 
through phosphorylation by rho-associated kinases (ROCK), which in the detrusor are 
activated by the rho-family G proteins ROCK I/II (Kimura et al., 1996)(figure 1-4). One study 
demonstrated attenuated agonist-induced detrusor contractions with several ROCK inhibitors 
(Y-27632, HA-1077), where these had no effect on depolarisation-mediated contractions 
(Durlu-Kandilci and Brading, 2006). This suggests an important role for the rho-kinase pathway 
in regulating bladder contraction.  
1.1.4 SPONTANEOUS DETRUSOR ACTIVITY 
Detrusor smooth muscle in the bladder exhibits involuntary spontaneous contractile activity 
during the filling stage of the micturition cycle (figure 1-5). This activity seems to occur in 
localised areas of the bladder wall within individual muscle bundles and results in small areas 
of the detrusor contracting in isolation, which is unusual for general smooth muscle tissue. This 
spontaneous activity in the bladder allows individual muscle bundles to adjust their length in 
response to filling and maintain muscle tone. To achieve this, spontaneous contractions remain 
low during the filling phase, however they seem to enhance once the bladder becomes 
increasingly full, resulting in a rise in intravesical pressure promoting bladder contraction 
(Brading, 2006). Of pathological significance, upregulation of spontaneous activity may lead to 
uncontrolled whole bladder contractions and contribute to bladder overactivity. 
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There are several hypotheses for this spontaneous activity and whether it is of neurogenic, 
urotheliogenic or myogenic origin remains unclear, with evidence to support each, however it is 
likely a combination. Spontaneous contractions are insensitive to neurotoxins, but are 
attenuated by Mg2+ and Ca2+ extracellular antagonists, suggesting a partly myogenic origin (Fry 
et al., 2004). Of particular interest, spontaneous activity is significantly attenduated in isolated 
detrusor preparations that have been denuded, compared to intact (Gevaert et al., 2007; Kanai 
et al., 2007). This evidence could suggest that the spontaneous activity is generated within the 
interstitial cells of the suburothelium, or from the urothelium itself, and is propagated to the 
detrusor, triggering contractions. Importantly, it has been observed that this activity is increased 
in bladders of patients with detrusor overactivity suggesting that this phenomenon may 
contribute to the overactive bladder syndrome (Mills et al., 2000).  
 
1.1.5 RECEPTORS IN THE BLADDER 
1.1.5.1 MUSCARINIC RECEPTORS 
Muscarinic receptors are G protein-coupled acetylcholine receptors widely expressed 
throughout the body that mediate a range of vital physiological functions depending on location 
and receptor subtype. Five muscarinic receptor subtypes have been characterised (M1, M2, M3, 
M4, M5) and these act through two distinct signal transduction pathways; M1, M3, and M5 are 
coupled to the Gαq/11 second messenger, activating phospholipase C (PLC) and resulting in 
mobilisation of intracellular calcium; in contrast, M2 and M4  signal predominantly though Gi/o  
proteins reducing intracellular cAMP concentration via inactivation of adenylate cyclase 
(Langmead et al., 2008). Both M2 and M3 muscarinic receptors are expressed in the detrusor, 
with M2 expression ranging from three to nine times greater than that of M3 depending on the 
Figure 1 – 5. Examples of spontaneous detrusor activity in isolated bladder strips from rabbit, 
pig and human.(Brading, 2006) 
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species (Wang et al., 1995). Despite this, it is in fact the M3 receptor subtype that is 
responsible for the muscarinic contribution to contraction in normal bladder. In M2 KO mice, no 
significant difference in the normal bladder response to carbachol (CCh), a muscarinic agonist, 
was observed in vivo and in vitro compared to WT (Igawa et al., 2003). Additionally, 
pharmacological studies using muscarinic receptor subtype specific antagonists revealed M3 as 
predominantly responsible for contraction in detrusor samples from stable human bladders 
(Hegde, 2006).  
Within the bladder, the M3 receptor is found both on the smooth muscle and in the sympathetic 
and parasympathetic nerve endings (Somogyi and de Groat, 1999). Upon stimulation, either by 
ligand (ACh) or agonist (CCh) binding, the coupled Gαq/11 protein is able to activate the enzyme 
phospholipase C (PLC), which initiates hydrolysis of membrane phosphoinositides (PIP2) into 
the second messengers inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG)(figure 1-
4). IP3 then proceeds to activate SR bound IP3-Ca
2+ release channels, initiating release of Ca2+ 
from cellular Ca-stores to the cytosol for contraction. Various studies provide evidence to 
support this contractile signalling mechanism; Harris et al. (1995) demonstrated an increase in 
both IP3 production and force upon stimulation of M3 receptors using subtype specific agonists 
in detrusor strips (Harriss et al., 1995); Wu et al. (2002) showed that blocking IP3 receptors, 
using for example heparin, prevents Ca2+ release, confirming the importance of IP3 signalling 
here. DAG, the other substrate of PIP2 hydrolysis, may also play a supplementary role in the 
contractile signalling mechanism, causing an increased Ca2+ sensitivity of the contractile 
system in a similar manner to the ROCK pathway discussed previously. It has been reported 
that DAG may activate PKC, which in turn phosphorylates MLCP causing a decrease in the 
enzymes activity, thus increasing the Ca2+ sensitivity of the contractile system (Wang et al., 
2009). 
M2 receptors signal through Gi-proteins that reduce cAMP production via inhibition of adenylate 
cyclase activity. The more abundant M2 receptor population present in the bladder appears to 
have a key functional role in modulating bladder contractions, through indirect enhancement of 
the contractile response to M3 receptor activation. It has been suggested that this is achieved 
by M2 receptor stimulation opposing sympathetically mediated smooth muscle relaxation, 
mediated by β-adrenoreceptors (Yamanishi et al., 2000). Additionally, muscarinic receptors 
present on parasympathetic nerve terminals at the neuromuscular junction can suppress (via 
M4) or enhance (via M1) transmitter release. Which of these occurs is dependent on the 
intensity of neural firing(Somogyi et al., 1998).  
M2 and M3 receptors have also been identified in the urothelium, again with M2 being the 
predominantly expressed subtype (Chess-Williams, 2002). Several studies have demonstrated 
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release of an unknown urothelium-derived factor capable of inhibiting detrusor contractions, 
upon stimulation of urothelial muscarinic receptors. Additionally, blockade of these urothelial 
muscarinic receptors in bladder mucosa preparations reduces stretch-induced Adenosine 
triphosphate (ATP) release, strongly suggesting a role for these receptors in overall bladder 
function.   
1.1.5.2 ADRENERGIC RECEPTORS 
Direct sympathetic innervation of the detrusor is low and thus has a much lower contribution to 
contraction than parasympathetic activation. It is possible to evoke detrusor contractions using 
drugs stimulating α-adrenoreceptors (ARs) in most species, where those stimulating α1-ARs 
have the greatest effect, although high (possibly not physiologically relevant) concentrations 
are required (Anderson, 1993). In normal human detrusor, small and variable contractions are 
observed when stimulating isolated tissue strips using α-AR selective drugs (Anderson, 1993). 
Various studies have examined the expression of α1-ARs in the human bladder, where the 
conclusive finding was that α1D- and α1A-ARs are expressed at relatively low levels (6.3±1.0 
mol/mg total protein), with no α1B expression (Malloy et al., 1998). However two studies 
attempting to determine the relative expression of these two subtypes found contrasting data, 
where one found a predominance of α1A (Walden et al., 1997) and the other an expression of 
66% α1D and 34% α1A (Malloy et al., 1998).  
Although the importance of α-ARs in normal bladder function is questionable, it is quite 
possible that these receptors are involved in the progression of LUT disorders, possibly due to 
altered subtype expression. For example, in rats displaying detrusor overactivity associated 
with outflow obstruction, α1A-AR density did not change, however upregulation of α1D- ARs was 
observed (Hampel et al., 2002). This could be of potential importance as α1D- ARs have a 10-
100 fold higher affinity for noradrenaline than the other two subtypes expressed, and α1D- ARs 
are the predominantly expressed subtype in human bladders (Malloy et al., 1998). Recent 
studies have identified all α1–receptor subtypes in the urothelium, with evidence in rat to 
suggest α1A-ARs are able to modulate bladder afferent activity during normal and pathological 
bladder states (Yazaki et al. 2011; Kurizaki et al. 2011).  
Interestingly, it is possible for noradrenaline to exert an inhibitory effect on detrusor contraction 
(i.e. relaxation) through activation of adrenergic nerves innervating parasympathetic ganglia, 
resulting in prejunctional inhibition of the parasympathetic nerves responsible for contraction. 
This is imperative for the filling phase of the micturition cycle, allowing urine to be accumulated 
without leakage. Noradrenaline is released upon electrical stimulation of detrusor adrenergic 
nerves. All three β-receptor subtypes are expressed in DSM, where β3 is the most abundant 
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(Yamaguchi, 2002). These receptors are Gs-protein coupled and their activation results in 
elevated smooth muscle cAMP, activating cAMP-dependent PKA, which subsequently 
phosphorylates and inactivates MLC kinase, resulting in detrusor relaxation (Yamaguchi, 
2002). Isolated human detrusor strips where effectively relaxed by β3-AR selective agonists, 
suggesting this subtype may be the most important β-subtype involved in the relaxation of 
human bladder. As the normal detrusor exhibits a greater expression of β-ARs compared to α-
ARs, the physiological response to noradrenaline is relaxation (Anderson, 1993). Evidence 
from many animal studies supports the theory that the sympathetic nervous system contributes 
to bladder storage function through inhibition of the reflex detrusor contraction during bladder 
filling. Therefore there is current research aimed at developing β-AR specific agonists for 
clinical use as a therapy for bladder overactivity (Leon et al., 2008). All β-AR subtypes have 
been identified in the human urothelium and it has been suggested that these receptors are 
able to modulate detrusor activity by inducing the release of a urothelial factor that inhibits the 
β-AR relaxation of human detrusor (Otsuka et al., 2008). 
1.1.5.3 PURINOCEPTORS 
Further to its function as the key cellular energy source, ATP can also act as a potent 
extracellular messenger, eliciting its response via activation of the distinct P2 cell surface 
receptor family (Ralevic and Burnstock, 1998). ATP acting in this manner can be released into 
the extracellular space by nerve terminals or non-neuronal cells (including epithelia and glia), 
where its availability for receptor activation is regulated by ectonucleotidases, which hydrolyse 
ATP into ADP, AMP and adenosine (Zimmermann, 1999). 
The first indications that ATP played a role in transduction of sensory information were 
provided by Holton & Holton (1954), who demonstrated that ATP released from sensory nerves 
in the rabbit ear triggered artery vasodilation, and later showed this vasodilation was 
accompanied by ATP release (Holton & Holton 1954; Holton 1959). Further study indicated that 
ATP, as well as the pyrimidine nucleotide uridine triphosphate (UTP) and dinucleotides 
adenosine diphosphate (ADP) and uridine diphosphate (UDP) act as ligands for this P2 
receptor superfamily (table 1), which together play key roles in tissue functions such as platelet 
homeostasis, pulmonary, auditory and ocular function, neurotransmission and nociception 
(Burnstock and Williams, 2000).  
The involvement of purinoceptor signalling in correct bladder function was first demonstrated 
by Kasakov and Burnstock, who observed a noncholinergic, nonadrenergic, atropine 
(muscarinic antagonist) resistant fraction of the parasympathetic contractile response in the 
detrusor of GPs (Kasakov and Burnstock, 1982). This atropine-resistant component varies 
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among species, with 75% of the contraction being atropine-resistant in GPs, 70% in mice, 60% 
in rabbits and 25% in pigs (Wüst et al. 2002; Brading & Inoue 1991). This, along with numerous 
additional studies has established a role for purinoceptors in bladder signalling, which exist as 
two distinct families; the ligand-gated ionotropic P2X receptors, and the G protein-coupled 
metabotropic P2Y receptors. P2X receptors respond preferentially to ATP, whereas P2Y 
receptors are activated by UTP, UDP, ATP and ADP in a subtype dependent manner (table 1).  
1.1.5.3.1 IONOTROPIC P2X RECEPTORS 
To date, seven functionally active mammalian P2X receptor subtypes (P2X1-7) have been 
identified. These are non-selective cation channels reported to play roles in the transduction of 
sensory signals such as hearing and nociception. P2X receptors have been further subdivided 
into 3 groups based on agonist efficacy and desensitization dynamics (Dubyak et al., 1996). 
P2X1 and P2X3 make up group 1, which have high affinity for ATP (EC50 - 1μM) and are 
rapidly activated/desensitized. Group 2 consists of P2X2, P2X4, P2X5, P2X6 which all have a 
lower affinity for ATP (EC50 - 10μM) with slow desensitization current, and P2X7 makes up 
group 3, with very low ATP affinity (EC50 – 300-400μM) and little desensitization, which can also 
act as a nonselective ion pore. Functional purinoceptors are composed of either three identical 
P2X subunits (homomeric) or three different subunits (heteromeric e.g. P2X2/3) resulting in 
variation in receptor pharmacology and kinetics. 
purinoceptors are expressed in the bladders of a number of species including human (Tempest 
et al., 2004), rat (Lee et al., 2000), guinea pig (Sui et al., 2014) and mouse (Vial and Evans, 
2000), where P2X1 is found on the DSM and P2X2 and P2X3 on the urothelium and 
suburothelial nerve plexi (Elneil et al. 2001; Tempest et al. 2004). With regards to function, 
P2X2 & P2X3 play key roles in mediating the nociceptive action of ATP, where multiple studies 
have blocked pain-related behaviours in animals with chronic neuropathic/inflammatory pain 
using either P2X3 or P2X2/3 specific antagonists or knockout models (McGaraughty et al. 
2003; Honore et al. 2002; Cockayne et al. 2000).  
P2X receptors also play a key role in mechanosensation and transduction of sensory 
information in the bladder. Distension of the urinary bladder stimulates the release of ATP from 
the urothelium (Ferguson et al. 1997; Mochizuki et al. 2009), and intravesically administrated 
ATP or α, β-methylene ATP stimulates bladder hyperactivity. Non selective purinoceptor 
antagonists abolish this hyperactivity induced by administered ATP (Namasivayam S1, Eardley 
I, 2001), and interestingly reverse the bladder overactivity resulting from bladder obstruction 
(BO) in rats (Velasco et al., 2003). As P2X receptors have a much higher affinity for ATP than 
the P2Y receptors identified in the bladder, it is likely these findings result from P2X activation. 
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However, knockout mice have served as an important model to confirm the comparative 
contributions of P2X and P2Y receptors in functional bladder outputs.  
 P2X3 deficient mice display normal stretch-evoked urothelial ATP release, however show 
increased bladder capacity and decreased voiding frequency i.e. bladder hyporeflexia. These 
findings suggest P2X receptors play a key role in bladder afferent function by receiving 
information from urothelially released ATP, allowing communication between tissues 
(Vlaskovska et al. 2001; Cockayne et al. 2000).  A more recent paper revealed expression of 
P2X2 receptors in human bladder urothelium and demonstrated increased expression of both 
this receptor and P2X3 in interstitial cystitis (IC) bladders (Tempest et al., 2004). Although 
under physiological conditions human detrusor contraction is mediated entirely through M3 
receptor activation, it has been shown that a role for P2X receptors in detrusor contraction 
emerges in pathologically overactive bladders (the hypothesis for which is discussed in section 
1.3.2) and indeed, receptor expression is altered. Together, these findings highlight the 
importance of purinoceptor signalling in the normal and pathogenic bladder, suggesting that 
with further understanding, these may serve as useful drug targets.  
1.1.5.3.2 METABOTROPIC P2Y RECEPTORS 
Thus far, eight molecularly distinct and functionally active P2Y receptors have been reported 
(P2Y1, 2, 4, 6, 11, 12, 13, 14), where P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 have been identified in the 
bladder. In contrast to the P2X family, these receptors are heptahelical G protein-coupled 
receptors which respond to UDP, UTP, ATP and ADP (Ralevic and Burnstock, 1998). P2Y2, 
P2Y4 and P2Y6 are sensitive to pyrimidine (uracil) nucleotides (Burnstock and Williams, 2000). 
P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 are coupled to the Gq signalling pathway and therefore 
once activated, induce phospholipase C (PLC) activity liberating intracellular calcium stores, 
resulting in activation of the protein kinase C (PKC) pathway. Interestingly, it is these receptors 
only that have been identified in human tissues (von Kügelgen and Wetter, 2000). P2Y12, P2Y13 
and P2Y14 are coupled with Gi inhibitory proteins, which prevent conversion of ATP to cAMP by 
inhibition of adenylate cyclase.  
P2Y receptor function has been less extensively studied than P2X, however P2Y1, P2Y2, P2Y4 
and P2Y6 have been identified in rat dorsal root ganglia (DRG) by (RT)-PCR, suggesting a role 
for these receptors in peripheral sensory transduction. Studies have demonstrated an increase 
in intracellular calcium (an output of Gq coupled P2Y receptors) with UTP in rat DRG cells 
(Ruan and Burnstock, 2003). ATP liberated calcium from intracellular stores via the IP3 
pathway in mouse DRG cells (confirmed by thapsigargin, an inhibitor of sarco/endoplasmic 
reticulum calcium stores) and this was attributed to 
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 the P2Y6 receptor (Svichar et al., 1997). Calcium release from intracellular stores of 
nociceptive rat DRG cells was also triggered by ADP-β-S and was inhibited by the specific 
P2Y1 antagonist MRS 2179 (Borvendeg et al., 2003). These results imply a role for P2Y 
receptors in sensory nerve signalling and nociception.  
P2Y6 has been identified in the GP urothelium (Sui et al., 2006), and P2Y1, P2Y2 and P2Y4 
have been reported in the feline urothelium, where P2Y2 expression is reduced in cats with 
naturally occurring IC (Birder et al., 2003).  This suggests P2Y2 may play an important role in 
normal bladder function, and this decrease may coincide with the increase in P2X2 receptors 
observed in the human IC study. This highlights the possible importance of relative 
purinoceptor expression in pathogenic bladders, where further evaluation is needed and may 
prove interesting. An important role for P2Y receptors in the release of ATP from the urothelium 
has been demonstrated in rodents, where both UTP and UDP can evoke ATP release from this 
structure (Carneiro et al., 2014; Sui et al., 2014; Timóteo et al., 2014). These findings suggest 
that P2Y2, P2Y4 and P2Y6 are the subtypes responsible for purinoceptor-mediated ATP release 
from the urothelium.  
Expression of P2Y receptors in the DSM has not been definitively shown. However their 
presence, particularly that of P2Y6,  has been strongly inferred by functional experiments using 
nonspecific purinoceptor agonists (Yu et al. 2013; Bolego et al. 1995).  Interestingly, several 
studies have demonstrated a relaxatory effect of ATP and its analogues on rodent bladder 
preparations, suggesting a role for P2Y receptors in bladder relaxation (McMurray et al., 1998; 
Tong et al., 1997).  One group suggested the weak contractile potency of ATP observed in 
muscle preparations is due to the opposing effect of ATP in the bladder (relaxatory on P2Y, 
excitatory on P2X) (Boland et al., 1993). P2Y receptors may also modulate other receptors and 
channels, indirectly influencing nociception and mechanosensation. Multiple studies have 
demonstrated co-localization and co-expression of P2Y1 with both P2X3 and TRPV1, a 
channel that mediates nociception and mechanosensation (Ruan & Burnstock 2003; Gerevich 
et al. 2004). A recent study also identified a functional interaction between P2Y2 and TRPV1 
receptors in cultured neuroblast cells (neuro2a), whereby active P2Y2 receptors can activate 
TRPV1 in the absence of any other stimuli, however the underlying mechanisms are unclear 
(Lakshmi and Joshi, 2005). A more recent myographical study using mouse detrusor muscle 
revealed that activation of P2Y6 by UDP selectively maximises P2X1–mediated contractile 
force through the PLC/IP3 pathway. This culminates in raised intracellular calcium, however the 
mechanism by which calcium enhances P2X1 activity remains unknown (Yu et al., 2013). 
These findings infer that P2Y receptors are able to significantly influence bladder function and 
have the potential to modulate other receptors present in the bladder tissues.    
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Table 1 - Summary of P2 receptors in the bladder to date(Birder et al., 2004, 2003; Burnstock and 
Knight, 2004; Burnstock and Williams, 2000; Chopra et al., 2008; Dunn et al., 2001; Khandelwal et al., 
2009; Ruan et al., 2006; Säve and Persson, 2010; Tempest et al., 2004; Vlaskovska et al., 2001) 
 
 
 
 
1.1.6 NEURAL CONTROL OF BLADDER FUNCTION 
The bladder operates in only two modes: storage and elimination, where it is believed 
suprapontine influences switch the bladders neural control circuits between the two. These 
circuits are located in the brain, spinal cord and peripheral ganglia and together coordinate the 
muscles in the bladder body and bladder outlet to achieve periodic urine storage and voiding 
(figure 1-6). Unlike many other visceral organs, micturition is under voluntary control that relies 
on learned behaviour that develops during infancy. Prior to this, switching between storage and 
elimination phases occurs in a reflex manner, such that voiding occurs involuntarily. Therefore, 
if the CNS becomes damaged due to spinal cord injury or disease, this reflex-type voiding may 
re-emerge in adulthood, and changes in the peripheral innervation of the LUT muscles may 
also result in bladder dysfunction.  
 Subtype Location Rank order of agonist 
activity 
Signal 
transduction 
P2X P2X1 Bladder smooth muscle (human, cat, 
mouse) 
Nerve fibres (rat) 
2-MeSATP>ATP>α,β-
meATP 
INa/K/Ca
2+
 
P2X2 Bladder smooth muscle (cat, mouse) 
Nerve fibres (rat) 
Urothelium (human, cat, mouse) 
2-MeSATP>ATP 
(α,β-meATP inactive) 
INa/K 
P2X3 Urothelium (human, cat 
Nerve fibres (most abundant subtype 
– human, cat, mouse, rat ) 
Bladder smooth muscle (cat, mouse) 
2-MeSATP>ATP>α,β-
meATP 
INa/K/Ca
2+
 
P2X4 Bladder smooth muscle (rat, mouse 
Nerve fibres (rat) 
ATP>2-MeSATP>>α,β-
meATP 
INa/K 
P2X5 Urothelium (cat ) 
 
ATP>2-MeSATP>ADP INa/K/Ca
2+
 
P2X6 Urothelium (cat) 
 
ATP>2-MeSATP>ADP INa/K/Ca
2+
 
P2X7 Bladder smooth muscle (mouse) 
Urothelium (cat, mouse) 
Nerve fibres (rat) 
ATP>2-MeSATP>ADP INa/K  
Pore formation 
P2Y P2Y1 Bladder smooth muscle (rat, mouse) 
Nerve fibres (rat) 
Urothelium (human cell line, cat) 
2-MeSATP>ATP>ADP 
(UTP inactive) 
PLCβ/IP3 Ca
2+ 
P2Y2 Nerve fibres (cat) 
Urothelium (human cell line, cat, rat) 
4-thioUTP>UTP=ATP>> 
2-MeSATP 
PLCβ/IP3 Ca
2+
 
P2Y4 Nerve fibres (cat) 
Urothelium (cat, rat) 
UTP >ATP=ADP PLCβ/IP3 Ca
2+
 
P2Y6 Nerve fibres (most abundant subtype 
- cat) 
Urothelium (human, rat) 
UDP 
Very weak responses, if 
any to UTP>ATP 
PLCβ/IP3 Ca
2+
 
P2Y12 Nerve fibres (cat) ADP Adenylate 
cyclase 
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Afferent signals from the LUT stimulate micturition in normally functioning bladders (Fowler et 
al., 2008). However, it is the coordinated pattern of both afferent and efferent signalling in 
autonomic (parasympathetic [pelvic] & sympathetic [hypogastric]), and somatic (pudendal) 
nervous pathways that allows controlled bladder filling and voiding. These complex pathways 
either hold the bladder in a relaxed state, granting low intravesical pressure for urine collection 
and filling, or initiate voiding by relaxing the bladder outlet and contracting the detrusor.  
The parasympathetic pathways originating from the sacral region (S2-S4 level) of the spinal 
cord mediate both detrusor contraction and outlet relaxation. Parasympathetic nerves from the 
pelvic nerve innervating the urethral smooth muscle in the outflow region provide inhibitory 
input by the release of nitric oxide (NO)(Anderson, 1993; Andersson and Persson, 1995; 
Mumtaz et al., 2000). Postganglionic parasympathetic neurones also from the pelvic nerve 
highly innervate the detrusor and release both cholinergic (ACh) and non-adrenergic, non-
Figure 1 – 6. Innervation of the human lower urinary tract. Coordination between bladder body 
and outlet (urethra, neck , and urethralsphincters) is mediated by autonomic (sympathetic 
[hypogastric] & parasympathetic [pelvic]), and somatic (pudendal) nervous systems. (modified from 
[Wein et al., 2014] using public access images from [Servier Medical, 2015]) 
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cholinergic (NANC) neurotransmitters. In most animal species, it is the co-release of ACh and 
ATP from these parasympathetic nerves that stimulates contraction and this has been 
demonstrated in various studies (Ambache and Zar, 1970; Burnstock et al., 1972; Carpenter, 
1977). However, cholinergic transmission alone is the major excitatory mechanism in normal 
human detrusor (Andersson and Arner, 2004), although some degree of NANC transmission 
can be demonstrated in functionally altered or pathological human bladders (Bayliss et al. 
1999; Andersson & Wein 2004).  
The sympathetic pathways originating from the thoracolumbar region (T10-L2) innervate both 
the bladder body and urethra, travelling through either the pelvic nerve or the hypogastric 
nerve. The main role of the sympathetic drive is to contract the urethra and bladder base, 
however sympathetic innervation also inhibits parasympathetic nerves at the spinal and 
ganglionic level. Additionally, in many animal species, noradrenaline released from sympathetic 
nerves relaxes the bladder detrusor during filling, however this has not been fully established in 
humans (Anderson 1993; Wein et al. 2014).  
Motor drive to the external urethral sphincter is supplied by somatic cholinergic nerves 
originating from the sacral spinal cord (S2-S4) in a region termed Onuf’s nucleus and these 
reach the periphery via the pudendal nerves. The pelvic floor musculature is also innervated by 
nerves supplied by a motor nucleus arising from the same spinal level.  
The afferents most crucial for micturition are myelinated Aδ-fibres and unmyelinated C-fibers 
which convey information from receptors in the bladder wall to the spinal cord via the pelvic 
nerve.  The Aδ-fibres convey information about bladder filling, as they respond to passive 
distension and active contraction (Jänig and Morrison, 1986) with an activation threshold of 5-
15mmHg. This is the intravesical pressure at which humans first report a sensation of bladder 
fullness, which is followed by urge to void once pressures of 20-25 mmHg are reached. 
Discomfort occurs at pressures above 25mmHg and if bladder pressure exceeds 30 mmHg 
(requires prevention of micturition) pain is perceived (Rong et al. 2002; Chancellor MB & 
Yoshimura N 2006). The C-fibers are termed ‘silent’ as they have a high mechanical threshold 
and respond primarily to chemical irritation (Häbler et al., 1990) or cooling (Fall et al., 1990). 
Information regarding volume of urine present in the bladder is continuously conveyed by these 
afferents through spinal-tract neurons that project to the pontine micturition centre (PMC) for 
voluntary bladder control.  
More recently, sensory nerves projecting into the suburothelial layer surrounding the bladder 
neck, and less so throughout the dome, have been identified in both humans and animals 
(Wiseman et al., 2002). These are in close contact with the cells of the urothelium, and growing 
evidence suggests the urothelial cells engage in reciprocal communication with these 
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neighbouring nerves in order to convey sensory information about the physical and chemical 
environment in the bladder (Birder et al., 2001). 
1.1.7 UROTHELIAL FUNCTION 
Communication between the various tissues of the bladder is integral in maintaining proper 
bladder function.  As well as acting as a primary barrier, growing evidence supports the idea 
that through its own specialised sensory and signalling properties, the urothelium is able to 
respond to chemical and mechanical stimuli in its surrounding environment and engage in 
reciprocal chemical communication with the underlying tissues. To support this, numerous 
studies demonstrate the expression of an extensive collection of ‘sensor molecules’ 
(receptors/ion channels) in the urothelium, similar to those observed in nociceptors and 
mechanoreceptors. These include receptors for purines (P2X1-7 and P2Y 1,2,4,), Ach (M1-M5), 
norepinephrine (α and β), adenosine (A1,2a,2b,3), bradykinin (B1 and B2), various neurotrophins 
and oestrogens, and expression of various TRP channels (TRPV1 TRPV2, TRPV4, TRPV8 
and TRPA1) and mechanosensitive epithelial sodium channels (ENaC)(Beckel et al., 2006; 
Birder, 2006; Birder et al., 2003; Carattino et al., 2008; Chopra et al., 2008, 2005; Du et al., 
2007; Kullmann et al., 2009; Taylor and Al-Azzawi, 2000; Yu et al., 2006). These enable the 
urothelium to respond to a range of sensory inputs such as increased stretch during filling 
(mechanical), soluble factors found in the urine (e.g. ATP and growth factors) and chemical 
mediators (transmitters, peptides) released from neighbouring nerves, inflammatory cells and 
blood vessels (Birder, 2010).  
The urothelium is then able to elicit an according response to such stimuli by secreting a 
variety of chemical mediators, further lending to its role in sensory function. These include ATP, 
ACh, NO, cytokines and prostaglandins which can act in a paracrine or autocrine manner, 
either activating, inhibiting or modulating the surrounding tissues (Birder and de Groat, 2007) 
(figure 1–7). Of importance, ATP can activate underlying sensory nerves by acting on P2X3 
receptors and thus contribute to the micturition reflex (Cockayne et al., 2000; Vlaskovska et al., 
2001). These findings, together with the observation that bladder distension induces ATP 
release from the urothelium (Ferguson et al., 1997), provide experimental evidence that ATP is 
a novel sensory mediator for bladder sensation. In addition, ACh released from the urothelium 
can also stimulate the muscles and nerves in underlying tissues, or stimulate the urothelium 
itself via urothelium-associated muscarinic receptors. As previously mentioned, activation of 
these receptors causes an increase in [Ca2+]i, triggering the release of ATP (Kullmann et al., 
2008), which can modulate the activity of bladder afferent nerves (Birder and de Groat, 2007). 
Additionally, evidence suggests that urothelium-derived ATP acting in an autocrine manner can 
induce membrane turnover and enhance stretch induced exo- and endocytosis, regulating 
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Figure 1 – 7. Sensory input & output pathways of the urothelium and communication pathways 
between the various tissues of the bladder. The urothelium receives sensory input in the form of: 
stretch (as bladder fills); signalling molecules released from the urothelium itself [1]; signalling 
molecules released from adjacent afferent/efferent nerves [2]. Activation of receptors expressed by 
the urothelium (on the apical [3] or serosal [4] surface) triggers the release of mediators such as ATP, 
ACh, NO, adenosine and prostaglandins which serve as sensory outputs[5]. Additionally, autocrine 
acting ATP may stimulate umbrella cell membrane turnover at the apical surface (e.g. during filling)[6]. 
ATP is released from the urothelial cells by exocytosis, through conductive pathways and via ATP 
carrier proteins [7]. The ATP and other soluble mediators released by the urothelium act as sensory 
outputs, which can either alter urothelial function [1] or modulate activity of afferent nerves [8] and 
smooth muscle cells [9][Adapted from(Khandelwal et al., 2009)]. Abbreviations: Ad, adenosine; AdR, 
adenosine receptor; αβAR, α,β-adrenergic receptor; ENaC, epithelial sodium channel; McR, 
muscarinic receptor; NcR, nicotinic receptor; NE, norepinephrine; NO, nitric oxide; PGs, 
prostaglandins; TRP, transient receptor potential channel family member. Created using public access 
images from(Servier Medical, 2015). 
apical surface area (important during filling) and receptor number and function (Wang et al., 
2005). Interestingly, removal of the urothelium from detrusor bladder strips significantly 
increases in vitro muscle contractions to Ach, suggesting the release of an inhibitory factor 
from the urothelium (Hawthorn et al., 2000). Although this urothelium-derived inhibitory factor is 
not yet known, studies have ruled out the possible participation of GABA, NO, adenosine,  
prostaglandins and Ca2+/K+ sensitive ion channels (Birder and Andersson, 2013).  
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1.1.7.1 UROTHELIAL STRETCH AND ATP RELEASE 
The phenomenon of stretch-evoked ATP release from the urothelium has been demonstrated 
in many studies using both intact tissue and cultured cells(Birder et al., 2003; Ferguson et al., 
1997; Mochizuki et al., 2009; Sun and Chai, 2006). As previously mentioned urothelial cells 
possess ion channels, some of which resemble the stretch-activated (mechanosensitive) 
channels found on nerves and therefore these channels may be involved in 
mechanotransduction in the bladder. It is likely that these channels are activated by increased 
tension at the apical surface of umbrella cells imposed during bladder filing. Amiloride 
(epithelial Na channel [ENaC] blocker) and Gd3+ (non-specific mechanosensitive channel 
blocker) are capable of suppressing stretch-evoked ATP release in both cultured urothelial 
cells and mucosal tissue strips in rat (Du et al. 2007; Sadananda et al. 2009). The TRP 
receptor family have also been implicated in bladder mechanosensation and the subsequent 
release of urothelial ATP, with both TRPV1 and TRPV4 antagonists and null mice inhibiting 
release of ATP in response to stretch and specific agonists (Gevaert et al., 2007; Mochizuki et 
al., 2009; Sadananda et al., 2009). These findings strongly imply the involvement of some 
mechanosensitive channels in the stretch-evoked release of ATP from the urothelium. 
This ATP is released from both the serosal and apical surfaces of the urothelium (Ferguson et 
al., 1997)(figure 1-7) via several mechanisms including vesicular exocytosis, conductive 
pathways (connexin and pannexin channels) and various transporters (Wang et al. 2005; 
Birder & Ruggieri 2012). The process is therefore multifactorial, where different receptor-
mediated or stretch-related mechanisms may utilize one, or a combination of these possible 
pathways in varying proportions. Using various inhibitors, Wu et al. previously demonstrated 
that basal ATP release from the mucosa is facilitated by both vesicular transport and 
conductive pathways, with an approximate 70% / 30% proportional contribution respectively. 
However, UTP-mediated (purinoceptor-mediated) ATP release from the mucosa was 
dependent on intracellular Ca2+ release, rather than extracellular Ca2+ influx, and did not involve 
vesicular transport, highlighting the variety of pathways available to be utilized for ATP release 
induced by different stimuli (Sui et al., 2014). Interestingly, studies in astrocytes and various 
cell lines have demonstrated that cell-swelling induced ATP release is tightly dependent on 
intracellular calcium elevations(Boudreault & Grygorczyk 2004; Coco et al. 2003), and indeed 
in primary urothelial cell cultures, stretch-evoked ATP release is closely correlated with calcium 
influx (Mochizuki et al., 2009). Therefore it is likely that the mechanism by which ATP is 
released from the urothelium in response to stretch is dependent on intracellular calcium 
elevations.  
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Serosally released ATP acts on both P2X3 and P2X2/3 heterometric receptors found in the 
suburothelial afferent nerve plexus (Rong et al., 2002). It is possible that the degree of afferent 
stimulation may signal the degree of bladder fullness to the central nervous system, eventually 
inducing contraction. Supporting this, P2X3 and P2X2/3 KO mice, still capable of releasing 
ATP, exhibit significantly diminished bladder afferent activation with reduced micturition 
frequencies and increased bladder capacities (Vlaskovska et al., 2001).  
The purpose of apically released ATP is unclear, however it has been shown that both detrusor 
activity and umbrella cell membrane turnover is increased upon exposure of the apical surface 
of the urothelium to exogenous ATP (Brown et al. 1979; Wang et al. 2005). In theory, this ATP 
could bind to purinoceptors expressed on the apical surface, inducing serosal ATP release 
which could in turn act on the P2X receptors mentioned above, increasing afferent nerve 
stimulation and detrusor activity. Therefore apical ATP release could function to amplify the 
original signal through ATP-induced ATP-release (Sun and Chai, 2006). In summary, both 
apically and serosally released ATP can influence and modulate the activity of adjacent 
urothelial cells, interstitial cells, nerves and smooth muscle cells both directly and indirectly, 
and as such, has an important influence on bladder function.   
 
1.2 TRP CHANNELS 
The superfamily of mammalian transient receptor potential (TRP) channels contains 28 
members, divided into 6 distinct subfamilies based on sequence homology; canonical  
(TRPC1-7), vanilloid (TRPV1-6), melastatin (TRPM1-8), muculipin (TRPML1-3), polycystin 
(TRPP1-3) and ankyrin (TRPA1) (Clapham et al., 2005). Bioinformatic searches through 
genome sequencing data banks has suggested that no further mammalian TRP channel 
subtypes remain to be discovered (Ramsey et al., 2006).  TRP channels are cation-permeable 
pores formed from four, six-transmembrane (6TM) polypeptide subunits assembled into a 
tetramer and are sensitive to a wide range of stimuli depending on their homo- or heteromeric 
formation (Clapham et al., 2005). In general, they are ubiquitously expressed throughout the 
body with most cell types expressing several TRP channel proteins. These channels are most 
well-recognised for their functional roles in mechanosensation and nociception, with an 
interesting function in humans being to differentiate between sweet, bitter and umami tastes 
and hot and cold temperatures (Zhang et al. 2003; Clapham 2003).  
The main function of TRP channels is to mediate the flux of cations across the cell membrane, 
resulting in elevated intracellular Ca2+ and Na+  concentrations ([Ca2+]i and [Na
+]i) which in turn, 
depolarise the cell. This is a crucial event underlying many cell processes such as propagation 
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of neuronal action potential and muscle contraction (Hille, 2001). Cellular Ca2+ influx is also an 
important signalling event where the raised [Ca2+]i activates Ca
2+-sensitive effector proteins 
such as calmodulin, regulating a vast collection of cellular processes such as migration and 
proliferation (Berridge et al., 2003). Most TRP channels can be activated by a number of stimuli 
i.e. polymodal activation, such that the physiologically relevant stimulus for a specific TRP 
channel may be governed by its cellular environment, such as cellular lipid content, available 
interacting proteins, concentrations of ligands and importantly, phosphorylation state (Ramsey 
et al., 2006). Acute post translational modifications, including phosphorylation, are capable of 
activating/deactivating TRP channels, with an additional level of TRP channel modulation 
implemented by Ca2+/calmodulin (Strotmann et al., 2003). The number of functional TRP 
channels in a cell is regulated by insertion of TRP-carrying vesicles into the membrane. 
Therefore, it is important to recognise that agents or conditions that alter the number of spare 
channels may effectively desensitize, or indeed sensitize TRP channels to agonist stimulation 
(Ramsey et al., 2006).  TRP channels can be activated by three general mechanisms: receptor 
activation (through GPCR and receptor tyrosine kinase [RTK] modulation); Ligand activation 
(e.g. endogenous lipids) and direct activation (changes in ambient temperature, mechanical 
stimuli, channel phosphorylation, cell swelling) and these will be discussed later in further detail 
specifically for TRPV4.  
1.2.1 TRP CHANNELS IN THE LUT 
Thus far, TRPV1, TRPV2, TRPV4, TRPM8 and TRPA1 have been identified in the bladder, 
with TRPV1 being most extensively investigated. TRPV1 channel expression has been 
demonstrated in both bladder neurons and urothelial cells (Birder et al., 2002), however there 
is conflicting data as to whether urothelial TRPV1 receptors are functional. TRPV1 is a non-
selective cation channel activated by heat, protons, pH<5.9, noxious stimuli, capsaicin and 
endogenous ligands such as anandamide (Tominaga and Tominaga, 2005). These receptors 
are expressed in sensory nerves throughout the body and are generally involved in nociception 
and temperature sensing(Caterina et al., 1997). Current evidence surrounding the function of 
TRPV1 in the human bladder is limited, however intravesical administration of capsaicin results 
in a dose-dependent reduction in pressure threshold for micturition, first desire to void and 
bladder capacity, suggesting the presence of functional TRPV1 receptors that may modulate 
the micturition reflex (Maggi et al., 1989). Interestingly, it seems TRPV1 plays a more 
prominent role in pathological bladders, contributing to overactive bladder and pain, with 
increased mucosal expression in neurogenic detrusor overactive (NDO) bladders (Avelino and 
Cruz, 2006).   Agonist activation of TRPA1 and TRPM8 induce similar phenomena such as 
increased micturition frequency and reduced voiding volume, and it is likely these channels 
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again play a more significant role in bladder pathologies, rather than in normal bladder function 
(Streng et al. 2008; Mukerji et al. 2006). The case for TRPV2 is similar, where the roles of 
these receptors in normally functioning human bladders, if any, remain to be fully established.  
1.2.2 TRPV4 CHANNELS 
The TRPV4 receptor is a non-selective cation channel preferentially permeable to Ca2+, 
permitting influx of this major secondary signalling ion upon activation by a variety of physical 
and chemical stimuli. This channel plays important roles in many different cellular functions 
including osmo- and thermo- regulation, mechanosensation and nociception.  Interestingly, the 
gating properties of this channel depend on the surrounding cellular environment (temperature, 
osmolarity, [Ca2+]i etc), and as such TRPV4 can be defined as a physiological integrator.  
1.2.2.1 STRUCTURE AND TRAFFICKING  
The molecule is composed of 871 amino acids with 6 membrane spanning segments, including 
an intracellular N- and C- terminus, a pore forming loop between S5 and S6 and 6 ankyrin 
domains in the N terminus thought to have involvement in the mechanosensitive ability of the 
receptor (figure 1-8). There are also several putative calmodulin binding sites contained within 
the C terminus, one of which is found between H812-H831 and is involved in Ca2+ dependent 
activation of TRPV4 (Strotmann et al., 2003). The other sites may also enable modulation of 
the receptor resulting in alternate changes to its function. Coexpression studies have thus far 
concluded that TRPV4 preferentially forms homomers, with no evidence for hetreromeric 
assembly with other TRPV molecules (Hellwig et al., 2005).  
Correct maturation of TRPV4 is characterized by complex glycosylation which takes place in 
the Golgi apparatus before the receptor is targeted and inserted into the plasma membrane 
(Lei et al., 2013). Deletion of the full C terminus or specific C terminal sections impedes 
translocation of TRPV4 from the ER to the plasma membrane (Becker et al., 2008). C residues 
are not only required for glycosylation, but are also involved in oligomerization, a process that 
is commonly necessary before translocation of proteins to the plasma membrane can take 
place. As such, the C terminus plays an important role in maturation and correct targeting of 
TRPV4 to the cell membrane. Insertion of TRPV4 into the cell membrane is regulated by 
ubiquitination. Atrophin-interacting protein 4 (AIP4) facilitates this process (Wegierski et al., 
2006), where the degree of ubiquitination influences the fate of the protein.  Once 
ubiquitinated, TRPV4 is available for endocytosis and once internalized, is transported to 
multivesicular bodies, where TRPV4 channels are sorted and or degraded in lysosomes. 
Mono- and multi-ubiquitinated TRPV4 channels occupy vesicles that sit below the plasma 
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membrane forming a reservoir of proteins, ready for incorporation. Poly-ubiquitinated channels 
are degraded and removed from the vesicular traffic (Katzmann et al., 2002). Interestingly, 
overexpression of AIP4 results in increased retention of TRPV4 within these vesicles, 
preventing their incorporation into the cell membrane and therefore reducing basal function 
(Wegierski et al., 2006). This may have implications in disorders involving TRPV4. Protein-
protein interactions are also important for the correct trafficking and function of TRPV4 e.g. 
interaction with pacsin 1 or 2 shift the ratio of membrane bound TRPV4 compared to cytosolic 
in favour of membrane-associated TRPV4. Additionally, pacsin 3 binding modulates 
endocytosis of the channel, affecting its subcellular localization (Cuajungco et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2.2 EXPRESSION & GENERAL FUNCTION  
The TRPV4 receptor is widely expressed and has been detected by northern hybridization in 
the heart, brain, lungs, liver, trachea, pancreas, prostate and endothelium among other tissues 
(Delany et al., 2001). Strong expression has been confirmed in the kidneys within the cortical 
collecting duct cells, where it functions to recognise changes in osmolarity and shear stress. 
Evidence suggests that once activated by luminal flow, TRPV4 triggers K+ secretion and Na+ 
reabsorption in these cells (Wu et al., 2007). TRPV4 is also highly expressed in the airway 
epithelia of the lungs and trachea, with greatest expression observed in the bronchial cilia 
Figure 1 – 8. Schematic model of TRPV4. TRPV4 is composed of an intracellular C terminus with an 
incorporated CaM binding site (orange), six transmembrane domains (blue), a pore forming loop 
(green) and a cytosolic N terminal head containing the ankyrin repeat domain (ARD) which consists of 
six ankyrin (ANK) repeats.  
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where it is thought to play a role in ciliary beating and mucociliar clearance (Lorenzo et al., 
2008). TRPV4 has also been identified in other ciliated epithelia such as that lining the fallopian 
tube, suggesting a role in oocyte transport (Teilmann et al., 2005). TRPV4 can be found 
throughout the cardiovascular system in high abundance in the vascular endothelium, and to a 
lesser extent in the smooth muscle cells of the pulmonary artery, aorta and cerebral arteries 
(Hartmannsgruber et al. 2007; Yang 2006). Many studies have demonstrated the role of 
TRPV4 in both vasodilation in the vascular endothelium and neovascularisation in capillaries 
through its mechanosensitive properties (Hartmannsgruber et al. 2007; Loot et al. 2008). Data 
suggests that TRPV4 detects shear stress in low-resistance arterioles, converting this to a Ca2+ 
signal, resulting in release of endothelial relaxing factors and flow mediated dilation of these 
vessels (Mendoza et al., 2010).  Activation of TRPV4 through shear stress can also stimulate 
proliferation of endothelial cells, in some cases leading to arterial occlusion, implicating TRPV4 
as a promising therapeutic target for prevention of this disorder (Troidl et al., 2009). 
In the brain, expression has been demonstrated in neurons of the circumventricular, vascular 
and subfornical organs, ependymal cells of the choroid plexus and in scattered neurons 
throughout the brain (Benfenati et al. 2007; Liedtke et al. 2000). TRPV4 is also functionally 
expressed in parasympathetic and sympathetic nerves and sensory trigeminal (TG) and dorsal 
root ganglia (DRG) neurons (Delany et al., 2001), and has been suggested to play a role in 
communication between neurons and astrocytes (Dunn et al., 2013). An important function of 
TRPV4 is its role in detecting nociceptive osmotic and mechanical stimuli at the peripheral 
nerve ending in these TG and DRG cells, confirmed by use of TRPV4-/- mice, which 
demonstrated lower sensitivity to these stimuli (Alessandri-Haber et al., 2003). TRPV4 is 
present throughout the inner ear in epithelial cells of the stria vascularis, inner and outer hair 
cells of the organ of corti, and transitional and sensory cells (Takumida et al., 2005), 
suggesting a role for TRPV4 in mechanosensation in the cochlea for response to sound and 
pressure. TRPV4 is also expressed in osteoblasts where it regulates bone remodelling 
(Masuyama et al., 2008) and in epidermal keratinocytes where it plays a role in thermo -
regulation and –sensation (Chung et al., 2004). Finally, TRPV4 has been demonstrated in 
abundance throughout the urothelium of the bladder, where it is functionally expressed on the 
plasma membrane of these urotheial cells (Everaerts, Vriens, et al. 2010; Birder et al. 2007). 
One Immunoprecipitation assay revealed that TRPV4 expressed in the cell membrane has a 
physical connection to adherence junctions via the actin-microfilament network (Janssen et al., 
2011). In this way, TRPV4 is mechanically connected to structural cellular networks, which may 
facilitate its mechanosensitive abilities, in turn enabling TRPV4 to detect bladder stretch.      
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1.2.2.2.1 TRPV4 AND STRETCH-INDUCED ATP RELEASE 
One important functional output of TRPV4 activation is stretch-induced cellular ATP release, 
which has been demonstrated in a number of tissues (Shahidullah et al., 2012) and cell types 
(Egbuniwe et al., 2014; Mihara et al., 2011; Silva and Garvin, 2008), including those of the 
bladder (Gevaert et al., 2007; Mochizuki et al., 2009). The full mechanism by which TRPV4 
facilitates ATP release, either induced by mechanical stretch or agonist-induced, remains to be 
identified. This is a challenging undertaking, as the general mechanisms by which mechanical 
stimuli trigger ATP release from cells in other systems, which are likely similar for TRPV4, are 
still poorly defined. Studies using various hypotonicity, cell-swelling and cell-stretch systems to 
mimic physiological stretch have however identified vesicular transport, exocytosis (Bodin and 
Burnstock, 2001; Boudreault and Grygorczyk, 2002; Maroto and Hamill, 2001) and conductive 
ATP release (Espelt et al. 2013; Cotrina et al. 1998) as the main pathways for this, coinciding 
with those identified for ATP release in the urothelium (Wang et al., 2005). One study also 
demonstrated that cell-swelling induced ATP release is dependent on intracellular Ca2+ 
elevations (Boudreault and Grygorczyk, 2004) and another that purinoceptor-mediated ATP 
release through conductive pathways requires both intracellular Ca2+ mobilization and active Cl- 
channels (Cotrina et al., 1998). With regards to the bladder, stretch-induced ATP release from 
isolated and cultured feline urothelial cells requires vesicular transport, mobilization of 
intracellular Ca2+ and to a lesser extent extracellular Ca2+ entry (Birder et al., 2003). Currently, 
the mechanisms underlying TRPV4-induced ATP release remain unclear. However, a study in 
porcine lens tissue revealed that TRPV4-induced ATP release (by the TRPV4 agonist 
GSK1016790A) was hemichannel-mediated and dependent on extracellular Ca2+ (Shahidullah 
et al., 2012). A more recent study showed that cell swelling in human bronchial epithelial cells 
caused TRPV4-mediated ATP release, which was facilitated entirely through pannexin-1 
channels (Seminario-Vidal et al., 2011).  
1.2.2.3 ACTIVATION AND REGULATION 
1.2.2.3.1 HEAT 
TRPV4 is expressed in the thermosensitive regions of the hypothalamus indicating a role for 
thermosensation in this tissue.  As with TRPV1, 2 and 3, TRPV4 can be activated by heat. 
However, unlike the 3 others, which are activated by temperatures exceeding 40°C up to those 
that are noxious, TRPV4 responds to  temperatures which lie within the physiological range 
(30-35°C)(Watanabe et al., 2002b).  Thus far, the mechanism by which this occurs is unclear, 
however evidence suggests activation occurs indirectly, through production or enhancement of 
a heat-dependent ligand, rather than direct activation by, for example, a conformational change 
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(Nilius et al., 2003). An important finding is that TRPV4 activation by temperature is modulated 
by osmoliarity and vice versa, meaning changes to one may modulate the activation 
parameters for other stimuli, or indeed change the activation mechanism itself (Guler et al. 
2002; Liedtke et al. 2000). It seems temperature is a critical modulator for channel gating of 
TRPV4, as at room temperature, activation by shear stress and hypotonic swelling is slow, but 
once raised to body temperature (37°C), activation by these is rapid.   
1.2.2.3.2 OSMOLARITY 
TRPV4 expression in mammalian tissues involved in osmoregulation (circumventricular 
organs) and exposed to changes in osmolarity (kidney collecting ducts) provided the first 
indication that TRPV4 may be an osmotically sensitive channel. Importantly, changes in cellular 
osmolarity result in both osmotic stimuli due to cell swelling and mechanical stimuli due to 
membrane stretching/shear stress.  
TRPV4 can be activated by changes in extracellular osmolarity or hypotonicity, where a 
reduction in osmolarity stimulates increased [Ca2+]i in endothelial cells (Strotmann et al., 2000). 
Consistent with this, TRPV4-/- mice exhibit defects in osmoregulation (Liedtke and Friedman, 
2003) as well as a loss of the endothelial cell response to hypotonicity (Vriens et al., 2005). The 
underlying mechanisms are again unclear, however as the response to osmo-stimuli are 
relatively slow, it is thought that this type of TRPV4 activation is through an indirect 
mechanism. Some reports suggested that tyrosine kinase-dependent phosphorylation of 
TRPV4 mediates the channels response to hypotonic cell swelling (Xu et al., 2003), however 
further replicative studies failed to confirm this (Vriens et al. 2003; Plant & Strotmann 2007). 
One study revealed that TRPV4 is activated by arachidonic acid breakdown (Watanabe et al., 
2003b). Through various further investigations, Watanabe et al.  suggested that changes in 
osmolarity activate a phospholipase A2 (PLA2) dependent endogenous signalling pathway, 
which results in the breakdown of arachidonic acid (AA) to epoxyeicosatrienoic acid (EET), a 
mechno- and osmotransducing messenger which can activate TRPV4. Despite this, it is still 
unclear whether EETs directly activate TRPV4, or further mediators are involved, however 
there is evidence to support a direct activation (Fernandes et al., 2008). These findings suggest 
that the mechno- and osmo-sensing properties of TRPV4 are mediated through either EET 
binding or PTK-dependent phosphorylation, or indeed both.  
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1.2.2.3.3 MECHANICAL STIMULI  
Mechanosensitivity i.e. membrane stretch/shear stress may be a result of osmotic changes or 
simply the occurrence of the physical stretch of cells. For example, during bladder filling the 
bladder wall stretches to accommodate increasing volumes of urine, or when artery walls 
stretch during the periodic increases of pressure stimulated by each ventricular contraction. 
Both of these physiological events will cause a degree of shear stress, which can be 
recognised by stretch receptors. With regards to TRPV4, one mechanism by which the channel 
can detect shear stress is thought to be similar to that described for osmotic changes. It is likely 
mechanical stimuli, for example those triggered by osmotic pressure, are detected by PLA2, 
triggering downstream signalling to indirectly activate TRPV4, as again, activation of this 
receptor by shear stress is relatively slow. However, evidence regarding the receptors physical 
incorporation into the cell membrane also provides possible means by which the receptor could 
recognise shear stress. TRPV4 mechanosensitivity is significantly impaired upon deletion of 
the N terminal ARD region, partly responsible for correct trafficking (Vriens and Nilius, 
unpublished observations (refer to Everaerts, Nilius, et al. 2010); Liedtke et al. 2000). It is 
postulated that this domain anchors the receptor into the membrane, forming a mechanical link 
for stretch activation and gating. Additionally, immunoprecipitation studies in human and mouse 
urothelial cells observed a molecular connection between TRPV4 and α-catenin, a component 
of adherence junctions, which ultimately forms another physical link between TRPV4 and the 
cells cytoskeleton (Janssen et al., 2011). However, cell-swelling activation models have 
revealed that this process relies on protein-protein interactions e.g. activation of TRPV4 by 
hypotonicity in salivary gland epithelial cells requires binding of aquaporin 5 (Liu et al., 2006), 
and pacsin 3 has also been implicated in this activation mechanism (D’hondt, unpublished 
data, refer to [Sharif-Naeini et al., 2008]). Thus, although there are several lines of evidence for 
direct mechanical activation of TRPV4, the majority would suggest its ability to recognise 
mechanical stimuli is through activation by endogenous openers generated by stretch.  
1.2.2.3.4 LIGAND ACTIVATORS 
Thus far, the identified endogenous activators of TRPV4 come from the endocannabinoid class 
of lipids, including anandamide (AEA) and its related endocannabinoid 2-arachydonyl glycerol 
(2-AG), which are both able to trigger whole-cell currents in TRPV4 expressing cells 
(Watanabe et al., 2003b). These lipids are transported into the cell where they are degraded by 
lipoxygenase, prior to being hydrolysed to arachidonic acid by various hydrolases and lipases. 
Through various pharmacological studies, it seems that EETs (the breakdown product of AA) 
are the final product of this pathway able to activate the plasma membrane-bound portion of 
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TRPV4 receptors, however it is still unclear whether EETs can directly bind to TRPV4 (Vriens 
et al., 2005). As previously described, this is the proposed mechanism by which TRPV4 can 
recognise osmo- and mechno- stimuli.  
Various well-characterized synthetic agonists for TRPV4 have been utilized to examine its 
function, including 4αPDD, 4α-PDH and GSK1016790A. 4αPDD (EC50 200-400nM) is a 
phorbol ester, a group of compounds which bind directly to TRPV4 at a binding pocket formed 
by TM3 and TM4 residues (Vriens et al., 2003). The structurally similar 4α-PDH agonist 
(EC50   70nM) exhibits 5-fold potency of 4αPDD. GSK1016790A was produced through 
screening of small molecule libraries and shows very high efficacy for TRPV4 activation (EC50 
1-10nM) with a 300-fold higher potency than 4αPDD (Thorneloe et al., 2008). 
1.2.2.3.5 MODULATION BY CALCIUM AND PHOSPHORYLATION 
Feedback regulation by Ca2+ on TRPV4 is an important process, which either potentiates or 
inhibits channel activity depending on the [Ca2+]i and in doing so, can also alter the time course 
and dynamics of channel activity. Ca2+ is involved in both the activation phase and the decay 
phase of TRPV4 responses to osmo-, mechano- and ligand stimuli. The decay phase is 
delayed in the absence of extracellular Ca2+, however the negative feedback mechanism for 
this remains unknown. In contrast, onset of the decay phase is accelerated during conditions of 
raised [Ca2+]e. This involves residues in TM6, where a specific mutation in this region causes 
slower inactivation of TRPV4 by this high [Ca2+]e, with unchanged sensitivity to [Ca
2+]i 
(Watanabe et al., 2003a). Increases in  [Ca2+]i first potentiate TRPV4 activity and then result in 
channel inhibition, where the IC50 for  [Ca
2+]i-dependent inactivation of TRPV4 is 400-600nM 
(Watanabe, Vriens, Janssens, et al. 2003; Watanabe, Davis, et al. 2002). A calmodulin (CaM) 
binding site, found to be functional in other TRP channels, has been identified in the 
intracellular C terminus of TRPV4 (Strotmann et al., 2003). Various studies have suggested a 
Ca2+-dependent component of TRPV4 activation; Ca2+ entering through TRPV4 binds CaM 
forming Ca2+-CaM complex, this binds to the C terminal domain of TRPV4 channels, resulting 
in potentiation of TRPV4 activity, increasing both speed and amplitude of the response 
(Strotmann et al., 2003). Interestingly, IP3 has also been shown to sensitize TRPV4 receptors 
to osmotic, mechanical and direct EET stimulation through protein-protein interaction at the 
previously described CaM binding site, coupling membrane TRPV4 receptors to intracellular 
Ca2+ stores (Garcia-Elias et al., 2008). Therefore, elevated [Ca2+]i resulting from other 
physiological processes may be partly responsible for basal/spontaneous activation of TRPV4 
in the absence of stimulatory events, by intrinsic activators such as EETs and those yet to be 
identified.  
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TRPV4 contains two major phosphorylation sites for Src-family tyrosine kinases (SFKs) in the 
N- and C- terminus at Y110 and Y805. Y110 plays an important role in activation of the channel 
by all stimuli, however this site is phosphorylated before activation of TRPV4 and as such 
phosphorylation of this site probably sensitizes the receptor rather than causing direct 
activation (Wegierski et al., 2009). 
As previously stated, phorbol esters such as PMA and 4αPDD are able to activate TRPV4 via 
direct interaction with the channel. However, concentrations of these ligands that only stimulate 
negligible effects at room temperature are much more potent when the temperature is raised to 
that of the body (37°C). This has been found to be dependent on Protein kinase A (PKA), and 
as such phorbol esters can activate TRPV4 via both direct and indirect mechanisms, 
depending on modulation by temperature, highlighting the diversity in activation parameters of 
this channel.  
In summary, TRPV4 is not only capable of recognising multiple stimuli and integrating these 
signals, but its activity can be highly influenced by the cellular environment (e.g. heat, 
osmolarity) and modulated by protein-protein interactions, post-translational modifications and 
indeed mutations. These traits, taken with the fact TRPV4 responds to noxious stimuli, such as 
those encountered in inflammation and tissue obstruction and hypertrophy, mean the activity of 
this receptor can be highly influenced by pathologies, and therefore likely has important 
pathological implications in the bladder. 
1.2.3 TRPV4 IN THE BLADDER 
High TRPV4 expression has been demonstrated in mouse urothelium, localized mainly to the 
basal and intermediate urothelial cell layers, with a uniquely abundant mRNA expression here 
compared to other TRP channels (Gevaert et al., 2007; Janssen et al., 2011; Mochizuki et al., 
2009) and in rat urothelium (Kullmann et al., 2009). TRPV4 positive staining was also reported 
in human urothelial umbrella cells, albeit from  limited samples (Yamada et al., 2009). TRPV4 
expression  has been observed in both the peripheral neurons that innervate the bladder and in 
the bladder smooth muscle (Birder et al. 2007; Thorneloe et al. 2008). Its expression in the 
urothelial lining can be observed throughout the urinary tract (Yamada et al., 2009),.  
TRPV4 was first shown to function in cultured bladder urothelial cells as a Ca2+ influx pathway 
activated by hypotonic cell swelling and the synthetic TRPV4 agonist 4α-phorbol 12,13-
didecanoate (4α-PDD)(Gevaert et al., 2007). In the same study, cystometry in TRPV4 null mice 
revealed lower frequency of overall voiding with an increase bladder capacity, but with a higher 
frequency of non-voiding contractions. This is consistent with the notion that TRPV4 may partly 
facilitate voiding. TRPV4 deficient mice also exhibited a decreased spontaneous activity in 
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isolated bladder strips, indicating that TRPV4 may promote spontaneous bladder contraction, 
which could underlie bladder overactivity (Gevaert et al., 2007). This suggests an important 
role for TRPV4 in regulating correct voiding in vivo, likely through mediating transduction of 
intravesical pressure, owing to the channels previously known characteristics. In the same 
paper, a decreased stretch-induced ATP release in isolated whole bladders of these TRPV4 
deficient mice was reported (Gevaert et al., 2007), although direct measurement of ATP 
release from the urothelium was not made. A more recent in vitro mechanical stretch 
stimulation performed on cultured urothelial cells confirmed that stretch activates TRPV4, 
resulting in increased [Ca2+]i and ATP release (Mochizuki et al., 2009). This finding was also 
shown by Birder et al. who demonstrated functional expression of TRPV4 in cultured rat 
urothelial cells, where again both hypo-osmolarity and the agonist 4α-PDD induced calcium 
influx and ATP release. From this evidence it has been proposed that TRPV4 senses bladder 
distension and communicates the extent of this to primary afferent nerves via an ATP signal for 
correct bladder function during the urine storage phase and voiding initiation. Finally, whole 
animal studies revealed that conscious WT mice exhibit bladder overactivity upon intravesical 
administration of GSK1016790A, with no effect in KO mice. As such, TRPV4 also has 
pathological implications and can contribute to bladder disorders associated with overactivity. 
Additionally, this study provided indirect evidence that TRPV4 receptors present in the DSM 
could contract the muscle, revealing separate roles for TRPV4 in both the urothelium and DSM. 
A major step forward in our understanding of TRPV4 physiology awaits clarification of the 
mode of action for TRPV4 in native urothelium and smooth muscle. 
1.2.4 TRPV4 AND DISEASE 
The most well-characterized group of TRPV4-related pathologies are autosomal dominant 
skeletal dysplasias, such as brachyloma, which are caused by various point and missense 
mutations within TRPV4 resulting in mutant channels. Missense mutations within the TM5 
domain have been associated with kozlowski-type spondylometaphyseal dysplasia, where two 
particular mutations result in increased basal channel activity in vitro (Krakow et al., 2009). The 
involvement of TRPV4 in pathologies of other systems is less well studied, however current 
knowledge suggests it does play a role in the development of neuropathic pain and hypo-
osmotic hyperalgesia (Alessandri-Haber et al., 2006). With regards to bladder disorders, as a 
definitive role for TRPV4 has yet to be fully established, its role in bladder pathologies remains 
unclear. However, Everaerts et al. showed that development of cystitis-induced bladder 
dysfunction is greatly reduced in TRPV4 deficient mice. Additionally, using a potent TRPV4 
antagonist HC-067047 the group demonstrated increased bladder capacity and reduced 
micturition frequency in WT mice and rats (Everaerts et al., 2010c) with cystitis. This not only 
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implicates the involvement of TRPV4 in this bladder disorder, but also presents the channel as 
a promising target for novel drug therapies. Despite the fact little else is known about the role 
TRPV4 may play in bladder pathologies such as overactivity, the evidence supporting an 
important role for this channel in normal bladder function would strongly suggest the 
involvement of this channel in the progression of such disorders.  It is imperative to examine 
the role of TRPV4 in human conditions, hence determining the value of targeting this receptor 
for the treatment of overactivity.  
1.3 BLADDER PATHOLOGIES & THE OVERACTIVE BLADDER SYNDROME  
Bladder dysfunctions are extremely common, with urinary urge incontinence (UUI) affecting up 
to 13.3% of males and 30.3% of females of age 40 and above in western countries, with an 
estimated annual cost of €295 million in the UK (Milsom et al., 2014). Disorders affecting 
control of the bladder can be classed as either disorders of filling/storage or voiding (Wein and 
Rovner, 2000).  Failure in the storage phase of the micturition cycle, leading to incontinence, 
can result from anatomical defects or weakness in the bladder outlet, or from bladder 
overactivity i.e. overactive bladder syndrome (OAB). OAB is defined as urgency, with or without 
urge incontinence, usually with frequency and nocturia and is typically caused by detrusor 
overactivity. Epidemiological studies have revealed an overall prevalence of 17% in Western 
Europe and 16.5% in the US, increasing further still with advancing age (Milsom et al. 2002; 
Stewart et al. 2003). Only 1/3 of patients with OAB exhibit urge incontinence, suggesting that 
the source of the dysfunction may not always be from the bladder itself.  
 
 
 
 
 
 
 
 
 
 
Urothelial  
changes 
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Figure 1 – 9. Contributing mechanisms underlying overactive bladder. Factors influencing 
disruption of the normal voiding reflex resulting in involuntary detrusor contractions. 
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Studies using isolated bladder strips have shown a significant association between OAB and 
increased spontaneous detrusor activity (Fry et al., 2010). Therefore, as with the theories for 
generation of spontaneous contractions, there are three principle factors that may influence the 
generation of overactive bladder: urothelial changes, myogenic changes and/or neurogenic 
changes (figure 1-9). 
Neurogenic changes that may contribute to an overactive state include: an increase in the 
afferent input from the bladder, physical damage to the neurones in the spinal cord innervating 
the bladder, and reduced activity of inhibitory pathways due to disrupted central processing of 
afferent input. It is thought that myogenic OAB arises from superior muscarinic sensitivity and 
increased coupling between DSM cells leading to increased detrusor excitability (Fry et al., 
2004).  
1.3.1 ANTIMUSCARINICS 
Antimuscarinics are the first-line pharmacological treatment for overactive bladder. In a study 
assessing over 7 million patients with diagnosed OAB through a 45 year period, 24.4% were 
treated with antimuscarinics, with the remaining 75.6% staying untreated (Helfand et al., 2010).  
However, these drugs exhibit increased side-effects and low efficacy in many patients meaning 
drug compliance and successful treatment is very low. Antimuscarinic agents selectively block 
muscarinic receptors. During treatment of OAB these agents elicit their therapeutic effect by 
blocking the muscarinic receptors on the DSM, which normally respond to Ach released from 
neighbouring parasympathetic nerves, thereby reducing bladder contractions. However, these 
receptors are widely expressed throughout the body and therefore blockade causes a range of 
side effects including constipation, dry mouth and various cognitive impairments which limits 
their clinical use (Klausner & Steers 2008; Abrams et al. 2006). It is highly likely the commonly 
low efficacy is due to the multimodal nature of this disorder and the emergence of other 
signalling pathways governing contraction that emerge during pathology (discussed below). 
Therefore there is an immediate need to develop both uroselective antimuscarinics and drugs 
aimed at other targets capable of treating OAB.  
1.3.2 ATP AND OVERACTIVE BLADDER – EMERGENCE OF A NANC 
COMPONENT 
In the normal human detrusor, contraction is mediated entirely through binding of acetylcholine 
(ACh) to muscarinic M3 receptors located on the cell membrane (Hegde 2006). This has been 
demonstrated by a complete loss of contraction observed with atropine, implicating ACh as the 
sole activating neurotransmitter. Interestingly however, varying levels of atropine-resistance 
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emerge in detrusor samples from pathologically overactive human bladders, where the 
remaining contractions can be suppressed with alpha beta-methylene-ATP (ABMA), which 
desensitizes P2X receptors (Bayliss et al., 1999). ATP is co-released from parasympathetic 
nerves alongside ACh and it has been hypothesised that under physiological conditions the 
ATP released into the neuromuscular junction is completely broken down by extracellular 
ectoATPases, such that none is able to activate the smooth muscle. During human bladder 
pathologies however, it is possible that either the released ATP is less effectively broken down 
in the junction, or an excess of ATP is released. Previously it has been shown that ectoATPase 
activity is reduced in detrusor samples from human detrusor overactive (DO) bladders, 
supporting the former hypothesis; a lower ectoATPase activity will result in concentrations of 
ATP high enough to activate purinoceptors, thus contributing to contraction and causing the 
observed atropine resistance (Harvey et al., 2002). However, conclusive studies must be 
performed using ectoATPase-inhibitors in normal human bladders to fully evaluate this; if ATP 
is in fact released as a co-transmitter under physiological conditions and the purinoceptors 
present on the nerve terminals are always functional, you would expect inhibition of 
ectoATPase activity to again contribute to contractions if the mechanism stands.  
Studies have also demonstrated an augmented release of ATP from the urothelium during 
bladder pathologies. Using a feline interstitial cystitis model, Birder et al. observed an increase 
in stretch-evoked urothelially derived ATP release and altered purinoceptor profiles in urothelial 
cells (Birder et al., 2003). Chronic spinal cord injury and irritated bladders in rats also causes 
enhanced release of ATP into the bladder lumen (Salas et al. 2007; Girard et al. 2008). Thus 
far this augmented release of ATP has only been linked to enhanced sensation of pain via 
activation of purinergic receptors on nearby sensory fibres. Further investigation is needed to 
evaluate whether this increased ATP release is responsible for or indeed capable of 
contributing to the atropine resistant contractile fraction observed in overactive human 
bladders. However, as it is known that purinoceptor contribution to contraction does emerge in 
the pathologically overactive human bladder, it provides an important potential target for 
reducing the contractions observed with bladder overactivity (BOA). These findings also 
provide an indication as to why the muscarinic antagonists currently used for treatment of 
LUTS only exhibit a moderate efficacy. 
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1.3.3 INFLUENCE OF THE UROTHELIUM IN OVERACTIVE BLADDER 
As the urothelium possesses the ability to alter the excitability of bladder neurons, changes in 
the sensory mechanisms responsible may increase signals of bladder sensation and contribute 
to OAB. One explanation is that there is an increase in M2 and M3 receptors in the pathologic 
state, meaning ACh released from the urothelium will have a more profound effect (Kim et al., 
2008). Another theory is that there is simply increased ACh release from the urothelium during 
the filling phase, again leading to increased sensation. Importantly, advances in our 
understanding of the urothelium have revealed many more receptors and signalling pathways 
able to influence bladder function, which may in turn also malfunction (e.g. in aging) and 
contribute to OAB. Indeed, studies have demonstrated changes in urothelial function during 
pathologies (i.e. augmented ATP release) and importantly changes in purinoceptor profiles in 
urothelial cells, suggesting that urothelial sensor molecules exhibit plasticity to response to 
pathologic conditions (Birder et al. 2003; Sun et al. 2001). Therefore, increasing our 
understanding of the urothelium’s sensory function and how it achieves this (for example, 
through TRPV4 receptors) may expose novel candidates for therapeutic intervention.  
 
1.3.4 THE AGING UROTHELIUM 
Various studies have revealed the sensitivity of the urothelium to, for example inflammation, 
injury, pathological insult and aging, which can damage and alter urothelial properties. Studies 
have shown the urothelium to be sensitive to ischemia and hypoxia (associated with aging and 
overactive bladders)(Christiaansen et al., 2011), urothelial cell degeneration and mucosal 
denudation in the bladders of aged animals (Akram Al-Motabagani, 2005). Additionally, various 
bladder disorders can impact on urothelial integrity and function, such as outlet obstruction, 
painful bladder syndrome and overactive bladder itself. There are therefore many triggers that 
may alter urothelial properties and processes, particularly associated with aging, that may 
result in impaired urothelial function and potentially lead to overactive bladder and other 
disorders. Regulation of urothelial function in aging bladders is an important but understudied 
area. Identification of pathological regulators from the urothelium that predispose the aging 
bladder to overactivity may provide new therapeutic targets for management of bladder 
dysfunction in the elderly. 
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1.4 CURRENT RESEARCH QUESTION 
Previous studies have focused only on cultured urothelial cell preparations, which are subject 
to phenotypic changes (Cross et al., 2005), and stretch as a method of investigating TRPV4, 
which activates many stretch-sensitive processes other than TRPV4 channels; however the 
mode of action of TRPV4 in native tissue, in particular by specific activation of this receptor, 
has not yet been examined. Given the recognition of the urothelium and associated structure 
as a whole functional syncytium, it is crucial to understand the function of TRPV4 in intact 
multicellular preparations. More importantly, the role of TRPV4 in human conditions has not 
been explored, prompting urgent need for this translational investigation. The primary aim of 
this thesis is therefore to characterise the properties of TRPV4 and its contribution to urothelial 
activation, through specific activation of the receptor in physiologically relevant tissue strips 
from both animals and humans. Importantly, the effect of aging on the channels activity will 
also be investigated. These studies will provide crucial evidence and translational information 
about TRPV4 that may reveal the therapeutic potential of this receptor in treatment of 
overactive bladder and other age-related sensory disorders. 
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1.5 HYPOTHESES 
1. TRPV4 channels significantly regulate urothelial function through release of urothelium-
derived ATP.  
2. Changes in the expression and function of TRPV4 channels occur in aging and 
overactive bladders. 
1.5.1 AIMS AND OBJECTIVES 
The overall aim of this project is to understand the physiological role of TRPV4 receptors in 
urothelial and bladder function, demonstrate its pathological significance and explore the 
therapeutic potential of targeting this receptor. 
The project will test the former hypotheses by achieving the following objectives: 
(1) 
 Demonstrate the presence of TRPV4 in the urothelium of human and animal bladders. 
 Determine the relative tissue expression of TRPV4 throughout the bladder. 
 Determine whether TRPV4 receptors are functional regarding urothelial ATP release. 
 Explore the mechanisms underlying TRPV4-mediated urothelial ATP release. 
 Explore the effect of channel antagonists on TRPV4 function to evaluate the therapeutic 
potential of the channel. 
(2) 
 Identify any age-related changes in the levels of expression and tissue localization of 
TRPV4. 
 Identify any age-related changes in the function of TRPV4. 
 Explore the relationship of TRPV4 receptors with urothelial purinoceptors associated 
with ATP release, and whether this is affected by aging. 
 Identify any changes in TRPV4 channel activity that occur in overactive aging human 
bladders.  
The outcomes of this study will identify a novel therapeutic target for management of bladder 
over-activity and other sensory disorders and reveal the role of sensory TRPV4 channels in 
contributing to abnormal bladder activity in older people.  
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2.1 CHEMICALS & SOLUTIONS 
All final solutions and buffers were prepared fresh on the day of experiment unless otherwise 
stated.  
2.1.1 FUNCTIONAL ORGAN BATH EXPERIMENTS 
2.1.1.1 HEPES – BUFFERED TYRODE’S SOLUTION  
Tissue samples were incubated and superfused with a HEPES-buffered Tyrode’s solution 
prepared weekly using dry powders and pre-made stock solutions dissolved in ‘ultra-pure’ 
distilled water (Milli-Q system, Millipore, UK)(Table 2). The pH was adjusted to 7.4±0.05 with 
2M NaOH using a pH meter (Oaktron, acorn series) and stored at +4oC until required.  This 
solution is commonly used as a tissue superfusate for physiological experiments, emulating 
extracellular physiological conditions. 
Table 2 – HEPES-buffered Tyrode’s solution 
 Reagent Final concentration (mM) Supplier 
Stock powders NaCl 132 Sigma Aldrich, UK 
HEPES 10 Merck Millipore, UK 
Glucose 6.1 BDH, UK 
Na Pyruvate 5 BDH, UK 
Stock solutions (1M) KCl 4 - 
MgCl2 1 - 
NaH2PO4 0.4 - 
CaCl2  1.8 BDH, UK 
 
A Ca2+-free modified Tyrode’s solution was prepared by substituting the CaCl2 stock with the 
same concentration of MgCl2  (total MgCl2: 2.8mM) to achieve the same concentration of 
divalent cations and thus avoid any changes to cell membrane potential. The chelating agent 
EGTA (0.1mM, [Sigma, UK]) was added to buffer any residual calcium to pCa of 8 (Sui et al., 
2009).  
2.1.1.2 SODIUM BICARBONATE TYRODE’S SOLUTION 
For the purpose of live-cell calcium imaging, a more commonly used sodium bicarbonate 
version of Tyrode’s was prepared. This was prepared on the experimental day as above (table 
1), where HEPES was omitted and replaced with sodium bicarbonate (NaHCO3) at a final 
concentration of 24mM. The final solution was bubbled with a gas mix of 95% O2 : 5% CO2 
resulting in a final pH of 7.4 ± 0.1 at 37.0°C ± 0.5°C. 
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2.1.2 CALIBRATION SOLUTIONS FOR LIVE-CELL CALCIUM IMAGING 
Both Ca2+-free and high-Ca2+ variations of HEPES-buffered high K+-based intracellular 
solutions were required to mimic the intracellular environment for accurate calibration of the 
Ca2+ imaging setup. The Ca2+-free intracellular solutions contained 120mM KCl, 10mM NaCl, 
1mM MgCl2 with no added CaCl2 and 5mM EGTA. High-Ca
2+ Tyrode’s was prepared to a final 
[Ca2+] of 2.0mM by addition of further CaCl2 stock. The pH of both solutions was adjusted to 
pH7 using 2M NaOH.   
2.1.3 DRUGS & COMPOUNDS 
The drugs and compounds used for interventions during physiological experiments were 
dissolved in either deionised water or DMSO (BDH, UK) and stored at -20oC as stock solutions 
for further dilution on the day of each experiment (Table 3). The experimental concentration of 
agonists was chosen based on preliminary work that demonstrated a reproducible effect 
without causing significant desensitization, being above the EC50 but below the maximal effect. 
Experimental concentrations of antagonists were calculated based on their affinity for receptors 
for predominant blockade, but not too high to generate a non-specific effect; and where 
appropriate, to oppose the concentration of same-receptor agonist used, such that >95% of 
receptors were inhibited.  
2.1.3.1 TRPV4 AGONIST / ANTAGONIST INTERACTION 
The TRPV4 antagonist HC-067047 (HC) was used at a concentration of 1μM for predominant 
blockade (>95%) of TRPV4 receptors (based on previous literature and calculations using the 
equilibration dissociation constant of HC-067047 [KD = 7.8][IUPHAR/BPS 2010; Everaerts, 
Zhen, et al. 2010]). During challenge of tissue with both GSK and HC, it is important to 
consider the activity and interactions between the two that may influence the concentrations 
required to achieve desired blockade of TRPV4. In the presence of agonist, the KD of 
competitive antagonists is altered (as is that of the agonist), such that a higher concentration of 
antagonist is required to achieve desired blockade. The Schild-slope factor equations are used 
for this purpose and in this case, the Kb of HC and GSK (7.7 [IUPHAR/BPS 2007; Thorneloe et 
al. 2008]) would be used (Harvey Motulsky, 2004) to determine the required concentrations. 
However, as previous experiments(Everaerts et al., 2010c) suggest that HC is a non-
competitive antagonist, any TRPV4 agonist should not compete/interfere with the activity (and 
KD) of HC. As such, HC at 1μM should still achieve the same percentage blockade with or 
without GSK. To be sure of this, during simultaneous challenge of tissue with both GSK and 
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HC, the concentration of GSK was lowered to 0.5μM, which has been shown to still elicit 
physiological responses by the literature and experiments in this study.   
2.1.4 LUCIFERIN – LUCIFERASE ASSAY SOLUTIONS 
2.1.4.1 ADENOSINE 5′-TRIPHOSPHATE (ATP) ASSAY MIX (ATP MIX) 
This was purchased as a lyophilised powder (Sigma, UK) and reconstituted with 5mL sterile 
water to minimise the background ATP from bacteria.  The solution was stored at -20oC until 
use for ATP measurement (in conjunction with ATP buffer below).  
2.1.4.2 ATP ASSAY MIX DILUTION BUFFER (ATP BUFFER) 
This compound (Sigma, UK) was reconstituted with 50mL sterile water and aliquoted into 
several vials which were then stored at -20oC until use for ATP measurement. 
2.1.5 IMMUNOHISTOCHEMISTRY & WESTERN BLOTTING 
2.1.5.1 PHOSPHATE BUFFERED SALINE SOLUTION (PBS) AND PBS WITH 1% 
BOVINE SERUM ALBUMIN (1% BSA PBS) 
PBS was prepared by the addition of 1 PBS tablet per 100ml dH2O (Oxoid, UK), where 1% 
BSA PBS also required the addition of 1g BSA powder per 100ml. These solutions were 
prepared in advance and stored at 4°C until use. 
2.1.5.2 RIPA LYSIS BUFFER 
RIPA buffer was chosen to lyse cells for total protein extraction, as this is the most applicable 
buffer for investigating membrane-bound proteins, such as TRPV4. This buffer has the capacity 
to denature samples further than others (e.g. NP-40), liberating any membrane-bound proteins 
of interest for further treatment. This was prepared in advance and stored at room temperature, 
with final concentrations (mM) of 50 Tris-HCl, 150 NaCl, 2 ethylene diamine-tetraacetic acid 
(EDTA), 50 NaF, 1% NP-40, 1% Sodium deoxycholate dissolved in ‘ultra-pure’ distilled water. 
The pH was adjusted to 7.5±0.05 with HCl.  
Protease inhibitors (Pi) were added (‘cOmplete, Mini, EDTA free PI cocktail’ [Roche, UK]) to 
inhibit the endogenous proteolytic enzymes released from subcellular compartments during cell 
lysis that would otherwise degrade proteins of interest, and the final solution was then 
aliquoted (1ml eppendorfs) and stored at -20°C until use. 
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2.1.5.3 SAMPLE LOADING BUFFER 
On the day of experiment, samples (stored in lysis buffer at-20°C) were diluted 3:1 in 4x 
laemmli buffer (277.8 mM Tris-HCl, pH 6.8, 4.4% SDS, 44.4% (w/v) glycerol, 0.02% 
bromophenol blue 10% 2-mercaptoethanol [Bio-Rad, UK]) for loading. The glycerol increases 
sample density for improved layering in sample wells. The SDS acts as the denaturing agent 
and ‘labels’ each protein with a negative charge for electrophoretic size-based separation. The 
2-mercaptoethanol reduces the disulphide bonds and bromophenol blue acts as the ‘dye front’.  
2.1.5.4 TRIS-BUFFERED SALINE (TBS) AND TBS-TWEEN (TBST) 
A 10x TBS solution was prepared weekly and stored at room temperature. This was then 
diluted 10 fold on the day of experiment to provide a solution with final concentrations of 20mM 
Tris-base and 150mM NaCl (pH 7.6). For TBST, 0.1% Tween 20, a detergent that helps 
remove nonspecifically bound material, aiding in clarity of blots, was also added (1ml Tween 20 
: 1L 1x TBS). For blocking and antibody solutions, a 5% milk TBS or TBST solution was 
prepared by adding 5% w/v dry milk powder (Marvel, UK). 
2.1.5.5 ELECTROPHORESIS RUNNING BUFFER 
Pre-prepared 10x running buffer stock solution was diluted to a 1x working solution with dH2O 
for gel electrophoresis. The final 1x solution contained 192mM glycine, 25mM Tris and 0.1% 
w/v SDS dissolved in dH2O with a pH of 8.3 (all reagents purchased from Fisher Scientific 
Chemicals, UK). 
2.1.5.6 TRANSFER BUFFER 
A standard wet-transfer buffer was freshly prepared in dH2O, containing 192mM glycine, 25mM 
Tris and 20% methanol (Sigma, UK). 
2.1.5.7 ANTIBODIES (Abs) 
The Abs listed in table 4 and 5 were stored in aliquots at -20°C to avoid repeated freeze-thaw 
cycles. For the purpose of western blotting, these were diluted in TBST 5% milk on the day of 
experiment and after use were stored in -20°C to be used again. The diluted Abs were used a 
maximum of 3 times before a fresh preparation was made. For Immunohistochemistry, the Abs 
were diluted in 1% BSA/PBS on the day of experiment. 
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2.1.5.8 STRIPPING BUFFER 
Stripping buffer was used to remove any Abs from an already probed membrane to allow re-
probing for further proteins of interest. This allowed for assessment of multiple proteins in the 
same target samples without having to re-run gels, minimizing use of precious samples. A low 
pH (2.5) glycine-HCL (0.1M) buffer was used (Restore™ Stripping buffer, Cat. #21059, Thermo 
Fisher, UK), where the low pH removes Abs by altering their structure such that the binding site 
is no longer active. This is a mild stripping method, which does not remove any protein but in 
some cases may leave traces of Ab. A harsher variation uses heated SDS buffer, however this 
can remove significant amounts of protein. The mild version was successful for the Abs 
employed here.
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Table 3 – List of drugs and compounds employed during physiological organ bath experiments. 
Drug/Compound Stock Solvent Experimental 
concentration 
Effect Company Product 
reference 
GSK1016790A DMSO 0.2-1μM Potent and selective TRPV4 agonist; enhances Ca
2+
 influx in 
human and mouse TRPV4-expressing HEK cells (EC50 = 2.1 nM 
and 18 nM respectively). Has 300-fold higher potency that 4-α-
PDD in activating TRPV4 channels(Thorneloe et al. 2008; Jin et 
al. 2011). Does not affect TRPM8 and TRPA1 channels up to 
concentrations of 20 µM. Suggested by one study to act by 
recruiting previously inactive channels, rather than through 
increasing elevation of basal activity (Sullivan et al., 2012). Others 
suggest the agonist is a true ligand (IUPHAR/BPS 2007; 
Thorneloe et al. 2008). 
Sigma-Aldrich G0798 
HC-067047 DMSO 1μM Selective non-competitive TRPV4 antagonist. Reversibly inhibits 
mouse, human and rat TRPV4 (IC50 = 17, 48, and 133 nM 
respectively in whole cell voltage-gated current measurement). 
Does not inhibit other TRP receptors up to concentrations of 5μM 
(TRPM8 IC50 = 780 nM, little or no activity toward hKv1.3, 
hTRPA1, hTRPC5, hTRPV1/2/3/6, mTRPM7, mTRPV2, or 
rKv1.2)(Everaerts et al., 2010c). 
Sigma-Aldrich SML0143 
      
Uridine 5’-trisphosphate 
trisodium salt dihydrate (UTP)  
 
H2O 100μM Endogenous P2Y receptor agonist. Preferentially activates P2Y2 
and P2Y4, but may agonise P2Y6 to small degree. (Ralevic and 
Burnstock, 1998) 
Sigma-Aldrich 94370 
Uridine 5’-diphosphate 
disodium salt hydrate (UDP) 
H2O 20μM Endogenous P2Y receptor agonist, which preferentially activates 
P2Y6.(Ralevic and Burnstock, 1998) 
Sigma-Aldrich 94330 
MRS2578 DMSO 10-20μM Selective antagonist of P2Y6 nucleotide receptors (IC50 = 37 and 
98 nM in human and rat respectively. Displays no activity at P2Y1, 
P2Y2, P2Y4 and P2Y11 receptors (IC50 > 10 μM). (Mamedova et 
al., 2004) 
TOCRIS 
Biosciences 
2146 
Brefeldin A DMSO 10μM Fungal metabolite which disrupts the structure and function of the 
Golgi apparatus. Inhibits vesicular transport-mediated ATP 
release.(Dinter and Berger, 1998) 
Sigma-Aldrich B7651 
Carbenoxolone H2O 100μM Glucocorticoid that inhibits pannexin and connexin channels. 
Blocks conductive ATP release.(Espelt et al., 2013) 
Sigma-Aldrich C4790 
Genistein DMSO 100μM Inhibitor of tyrosine protein kinase. (Akiyama et al., 1987) Sigma-Aldrich G103 
Autocamtide 2-related 
inhibitory peptide 
H2O 0.5μM Potent inhibitor of calmodulin-depentent protein kinase II. 
Selective over PKC, PKA and CaM kinase IV (IC50 > 
10 μM).(Ishida et al., 1995) 
 
Sigma-Aldrich A4308 
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5-Nitro-2-(3-
phenylpropylamino)benzoic 
acid (NPPB) 
DMSO 100μM Inhibits calcium-sensitive chloride currents.(Keeling et al., 1991) TOCRIS 
Biosciences  
0593 
Carbamoylcholine chloride 
(Carbachol) 
H2O 50μM Non-selective cholinergic agonist. (Yan et al., 1995) Sigma-Aldrich C4382 
Angiotensin II DMSO 0.2-1μM Endogenous AT-1 and AT-2 receptor agonist.(Inagami et al., 
1988) 
Sigma-Aldrich A9525 
Amiloride Hydrochloride Made fresh on 
day in 
Tyrode’s  
1mM Na
+
 channel blocker. Blocks transient receptor potential polycystic 
3 (TRPP3)(Dai et al., 2007), TRPA1 (Nagata et al., 2005), acid 
sensing- (ASIC)(Jetti et al., 2010) and mechanogated membrane-
ion channels (epithelial sodium channels (EnaC])(Ferguson et al., 
1997), urokinase-type plasminogen activator(Vassalli and Belin, 
1987), as well as the Na
+
/H
+
 exchhomoanger(Kleyman & Cragoe 
1988; Rievaj et al. 2013). 
 
Sigma-Aldrich 1019701 
Benzamil H2O 100μM Selective and potent blocker of Na+/Ca2+ exhanger (NCX) (IC50 ~ 
100 nM)(Fischer et al., 2002); TRPP3 channels (IC50 = 1.1 μM for 
inhibition of TRPP3 channel activity)(Dai et al., 2007), non-
selective Deg/ENaC blocker; reduces colonic afferent 
mechanosensitivity. More potent derivative of amiloride. 
TOCRIS 
Biosciences  
0890 
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Table 4 - List of primary Abs employed during immunohistochemistry and western blotting 
 
 
 
 
 
 
 
 
 
Table 5 - List of secondary Abs employed during immunohistochemistry and western blotting 
 
 
 
 
Primary 
Antibody 
Optimised 
Concentration/
dilution  
MW / kDa Host Clonality Supplier Product 
reference 
Anti-TRPV4 
(Alomone) 
2.0μg/ml 
 
98 Rabbit Polyclonal Alomone ACC-034 
Anti-TRPV4 
(ABCAM) 
1.0μg/ml 
 
98 Rabbit Polyclonal ABCAM Ab94868 
β-actin 0.5μg/ml 45 Mouse Monoclonal New  England 
Biolabs 
8H10D10 
Secondary 
Antibody 
Optimised 
Concentration/ 
dilution 
Host Conjugate Excitation/E
mission 
supplier Product 
reference 
Anti-Rabbit 
IgG 
0.1μg/ml 
 
Goat IRDye® 
800CW 
- Li-cor 926-32211 
Anti- Mouse 
IgG 
0.1μg/ml Goat IRDye® 
800CW 
- Li-cor 926-32210 
Anti- Mouse 
IgG 
0.1μg/ml Donkey IRDye® 
680RD 
- Li-cor 926-68072 
Anti- Goat 
IgG 
0.1μg/ml Rabbit IRDye® 
800CW 
- Li-cor 926-32214 
Anti-Rabbit 
IgG Alexa 
568 
1μg/ml Goat Alexa 
Fluor®   
568 
578/603 Life 
Technologies 
A-11011 
To-PRO3 1:5000 / 0.2μg/ml 
 
- Cy®5 642/661 Invitrogen T3605 
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2.2 EXPERIMNETAL MODELS 
2.2.1 GUINEA-PIGS  
Guinea-pigs (GP) have been used extensively as an experimental model in research for the 
study of bladder function under both normal and pathological states, as the physiological 
properties of guinea-pig bladders are similar to those of human bladders. Importantly, 
guinea-pig urothelial and smooth muscle tissues share similarities to human. Many studies 
have identified the fundamental receptor groups in both species (refer to introduction), 
however, important similarities in bladder activity have also been determined. Spontaneous 
and carbachol induced mucosal contractions are observed in both species with a similar 
magnitude, both accompanied by ATP release. In both species, this ATP release increases 
in aging models, and other phenomenon, such as purinoceptor and muscarinic agonist-
induced ATP release have been consistently demonstrated in both species, highlighting 
important similarities in fundamental signalling properties (Sui et al., 2014). Other 
phenomenon conserved between the two species include expression and activity of 
fundamental receptors (Creed et al., 2010; Inoue and Brading, 1991; Shabir et al., 2013), 
contractility parameters (Groen et al., 1994) and similarities in IC populations (Monaghan et 
al., 2012) to name a few.  
In addition, guinea-pig bladders are readily available and provide a homogeneous tissue 
source for detailed investigation of the mechanisms. The size of the animal allows for 
precise surgery under anaesthetic, which is well tolerated, permitting excellent urodynamic 
studies. Precise dissection of the bladder tissue allows clean separation of tissue layers, 
providing tissue uniquely suited to many organ bath and electrophysiological 
techniques(Mostwin et al., 1994). Many pathological bladder models have also been 
developed in the GP, such as partial and progressive bladder outlet obstruction (Mostwin et 
al., 1991).  
 
Laboratory GPs exhibit a median life span of three years until death by natural causes, and 
therefore at this age represent a 70 year old man in western society (Yao et al., 1988). GPs 
between 2 and 5 months old have not yet reached full maturity but are capable of breeding. 
From the age of 18 months GPs begin to exhibit age-related structural and functional 
changes in both general and bladder-specific physiology and therefore represent early old 
age (Fini et al., 2008; Gomez-Pinilla et al., 2007; Karim et al., 1992). Qualitative age-related 
changes observed in humans, such as an increase in prostatic stromal volume, begin to 
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emerge in GPs from 2 years and thereafter, indicating GPs of above this age as a good 
representative model for translational age-related studies (Horsfall et al., 1994; Jones et al., 
2004). In addition, aging GP bladders commonly exhibit detrusor overactivity and as such, 
are a useful model for specific study of pathological bladders associated with aging (Gomez-
Pinilla et al., 2007).  
Generally speaking, larger animals exhibit a closer bladder physiology to humans, however 
research using larger animals is impractical and expensive, especially if it is necessary to 
maintain animals for long periods of time to reach ‘aging’ criteria. The main physiological 
disadvantage of using rodents for bladder research is that they exhibit a certain level of 
atropine resistance, i.e. there is purinoceptor contribution to contraction, whereas in humans 
there is not. This has been shown to be around 50% in GPs (Sibley, 1984). Although under 
physiological conditions human bladder contraction is mediated entirely through muscarinic 
receptor activation, it has been shown that purinoceptor contribution to contraction emerges 
in pathologically overactive bladders. Moreover, the atropine resistance observed in GPs 
stems from the presynaptic release of neurotransmitters, whereas the postsynaptic 
properties of the smooth muscle and the urothelial tissue are similar between GP and 
humans (Inoue and Brading, 1991), which is the focus of the current project. Therefore, the 
GP bladder model is suited for physiological investigation of the current project and also for 
translational pathological studies, despite the atropine resistance, which is not the subject of 
the current project. The advantages listed above make the GP both a useful and practical 
tool in bladder research, where their size also permits cost-effective aging studies.    
Based on this information, young (2-5 months) and aging (24-36 months) male Dunkin-
Hartley guinea-pigs (GPs) were used as the main animal model for this study.  
2.2.2 MICE 
Mice are widely used animal models in biomedical research, with the best-characterised 
genetics and readily available genetically modified models for investigation of molecular 
mechanisms. Of relevance to this project, mice have been extensively used to study the 
mechanisms and treatments of OAB, bladder cancer and the effect of aging on bladder 
function (Chan et al., 2009; Parsons and Drake, n.d.). Despite these small rodents having 
small differences in physiology, the fact that these animals can be bred easily and 
genetically manipulated presents a great advantage and tool for bladder research.  
For the purpose of this project, both wild type (WT) C57BL/6 and P2Y2 knockout (KO) (JAX
® 
laboratories, USA) male mice were used. Young and aged mice were used during this 
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project unless otherwise stated (2-4 months – young, 8-10 months – intermediate age, 24-
28 – aged (Brooks and Faulkner, 1988; Daly et al., 2014).  
2.3 HUMAN SAMPLES  
2.3.1 NORMAL CONTROL (OAB NEGATIVE) 
Mucosal tissue biopsies were obtained by cystoscopy from the bladders of patients with no 
symptoms of OAB during routine surgery to obtain biopsies for diagnostics (table 6). 
Samples were obtained from well informed, consenting patients with the approval of the 
National Research Ethics Committee (South East Coast – Surrey) in accordance with the 
Helsinki declaration. In patients with suspected tumours or cancer, bladder samples were 
taken from macroscopically normal areas. These samples were collected from either Frimley 
Park Hospital (FPH) or The Royal Surrey County Hospital (RSCH) immediately after surgery 
and transported to the laboratory on ice in Tyrode’s solution. These samples were then 
subjected to physiological experimentation (section 2.5.1) using a variety of drug and 
compound interventions, after which they would be snap frozen in liquid nitrogen and stored 
at -80oC for future western blot analysis and immunohistochemistry (IHC). 
Table 6 - List of human tissue biopsies collected for experimentation to date (Muc - mucosa, 
SM - smooth muscle) 
Sample 
# 
Date Hospital Gender Age Diagnosis Tissue Additional 
information 
1 16.11.12 FPH Male 77 Haematuria Muc alone Post-Radical 
Prostatectomy 
2 20.11.12 FPH Male 69 Transitional 
cell carcinoma 
(TCC) 
Muc w/ SM 
attached 
 
3 24.7.13 RSCH Male 83 Suspected 
Tumour 
Muc - very little 
SM 
Unknown 
histology 
4 1.8.13 RSCH Female 25 Suspected 
Cystitis 
Muc w/ little SM 
attached 
 
5 1.8.13 RSCH Male 69 Suspected 
Tumour 
Muc w/ little SM 
attached 
Frozen in OCT 
for IHC 
6 3.9.13 RSCH Male 80 TCC Muc w/ little SM 
attached 
Prior 
Brachytherapy 
7 3.9.13 RSCH Male 64 - Muc - very little 
SM 
Transurethral 
resection of 
prostate 
8 18.11.14 FPH Male 70 TCC Muc - No SM Obstructed 
9 16.12.14 FPH Male 83 TCC Muc w/ little SM 
attached 
Highly obstructed 
w/ chronic 
retention 
10 19.12.14 FPH Male 87 TCC Muc w/ little SM 
attached 
Obstructed 
11 13.1.15 FPH Male 77 Suspected 
tumour 
Muc alone Radiotherapy 
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12 21.1.15 FPH Male 66 Suspected 
tumour 
Muc w/ little SM 
attached 
No/few 
symptoms 
13 13.2.15 FPH Male 74 Suspected 
tumour 
Torn mucosa No/few 
symptoms 
14 5.5.15 FPH Male 64 TCC Muc w/ little SM 
attached 
No/few 
symptoms 
15 27.11.15 FPH Female 58 Urinary tract 
infection 
Muc alone Recurring UTI  
2.3.2 OAB POSITIVE 
Bladder biopsies were again obtained by cystoscopy from well informed, consenting patients 
under the ethics approval of a collaborative research group. These samples were collected 
from Medway Maritime Hospital (MMH) during operations and immediately transported to 
the laboratory. Samples from this cohort of patients were taken from female bladders 
diagnosed with idiopathic detrusor overactivity (IDO) (table 7), for comparison with the 
biopsies from ‘normal’ bladders (no IDO). These samples were then subjected to the same 
physiological experiments as the ‘normal’ biopsies’ and were also then snap frozen in liquid 
nitrogen. 
Table 7 - List of human tissue biopsies collected for experimentation to date (Muc - mucosa, 
SM - smooth muscle) 
 
2.4 ANIMAL TISSUE DISSECTION 
Animals were humanely culled by schedule 1 procedure in accordance with the United 
Kingdom Animals (Scientific Procedures) Act of 1986. All experiments were approved by the 
local ethics committee and followed UK home office regulations.  
The urinary bladders were immediately removed and transported to the laboratory in 
Tyrode’s solution. These were then transferred to a sylgard dissection dish and submerged 
in fresh Tyrode’s. Under a dissection microscope, a longitudinal incision was made from the 
bladder neck to the dome and the full bladder was pinned out as a sheet with the urothelium 
uppermost. Longitudinal strips were then dissected from the bladder. For the purpose of 
Sample # Date Hospital Gender Age Diagnosis Tissue Additional 
information 
1 3.9.15 MMH Female >45 IDO Muc alone - 
2 3.9.15 MMH Female >45 IDO Muc w/ little SM 
attached 
- 
3 17.9.15 MMH Female >45 IDO Large mucosal sheet - 
4 25.9.15 MMH Female >45 IDO Muc, highly vascular, 
no SM 
- 
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thorough investigation, ‘full thickness’, ‘smooth muscle only’ and ‘mucosal’ strips were 
required for experimentation. The mucosa (urothelium and suburothelium) was dissected 
away from the underlying tissue by gentle peeling for mouse tissue and by careful 
microdissection along the natural cleavage plane for GP tissue, using microdissection 
scissors. The various bladder tissue strips were then subjected to further preparation, 
appropriate for either physiological experimentation, immunohistochemistry, or ‘snap-frozen’ 
in liquid nitrogen and stored at -80oC for future investigation. 
 
2.5 TECHNIQUES 
2.5.1 FUNCTIONAL ORGAN BATH EXPERIMENTS 
Longitudinal bladder strips (full-thickness, smooth muscle only, mucosal) dissected from 
animal bladders, or human bladder biopsies, were mounted within an organ bath/perfusion 
trough (Figure 2-2. B) for experiments measuring ATP release and contractile activity. 
Suture thread was used to tie one end of the tissue to a fixed hook and the other to an 
isometric force transducer with micromanipulator, allowing precise orientation of the tissue. 
The full experimental set-up, including trough dimensions, is displayed in figure 2-1. 
Mounting of strips was performed under a dissection microscope to improve accuracy and 
avoid accidental stretch and damage, which can stimulate ATP release and invalidate 
results. A water-jacket system and circulater (Techne C-400, GoIndustry DoveBid, USA) 
was used to encase the solution tubing and perfusion trough to maintain experimental 
solutions and tissue at 37°C. The tissue preparations were superfused with Tyrode’s 
solution at a resting rate of 2ml min-1 for at least 45mins prior to experimentation to allow full 
tissue stabilization. 
In order to monitor and record changes in tissue contractility during experiments, tissue was 
tied at one end to a force-displacement transducer (Model FT03, GRASS, USA) (Figure 2-
2). This instrument enabled detection of changes in isometric force exerted by the tissue in 
response to the specific drug interventions performed, providing a force output in the form of 
volts (V). The force transducer was calibrated to the system using weights of known mass 
(g) to produce a voltage reflection, where the range of weights covered the range of 
isometric force generated by tissue during experiments. This yielded a standard curve of 
force (V) against weight (g), where the voltage output of the bridge amplifier could be used 
to determine force, which was expressed in Newtons from the following relationship, where 
‘F’ is force, ‘m’ is mass and ‘g’ is the accelearation of gravity directed downwards:  
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F = mg (g = 9.8 m.s-2) 
There is a linear relationship between the force and voltage output where the line passes 
through the origin. The signal was amplified using a bridge-amplifier (TBM4M amplifier, WPI, 
USA) and recorded and stored as a digital real-time tracing using AxoScope version 
9.0.2.03 (Axon instruments, USA). To minimise trace interference due to vibration, the set 
up was built on an ‘Active-air vibration control platform’ (Benchmate 2212 series, Kinetic 
Systems, USA). 
For measurement of ATP, samples of solution were taken from the sampling point at 
specified time-points (refer to experimental protocol – figure 2-3) using a micropipette. The 
sampling point was situated downstream of the tissue, such that all ATP released by the 
tissue would be collected and none lost due to solution outflow (Fig. 2.2 C).  The samples 
were later measured for ATP content using the luciferin-luciferase assay (section 2.5.1.2). 
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Figure 2 – 1. An image of full experimental set up. 1. Dissection microscope 2. Isometic force 
transducer 3. Perfusion trough (total of 2 within set up)(dimensions: 4mm [width] x 5mm [depth] x 
30mm [length]) 4. Scaffold housing solution bottles containing Tyrode’s/Tyrode’s + drugs 5. Bottle 
‘position 1’ 6. Bottle ‘position 2’ 7. Bottle ‘position 3’ 8. Water jacket incubating solution tubing at 
37°C 9. Sylgard dissection plate 10. Vibration control platform. Flow rate was adjusted by moving 
Tyrode’s-containing solution bottles between ‘bottle positions’; position 1 – 10ml min
-1
; position 2 – 
5ml
-1
; position 3 – 2ml min
-1
. 
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Figure 2 – 2. Perfusion trough set up. A: Image of two organ baths mounted on vibration control 
platform. B: Close-up image of single organ bath. Dimension: 4mm (width) x 5mm (depth) x30mm 
(length) 1. Isometric force transducer 2. Organ bath #1 3. Organ bath #2 4. Solution tubing 5. 
Fixation hook attached to force transducer 6. Tissue strip 7. Fixation hook 8. Solution inlet C: 
Schematic diagram of perfusion trough. Tyrode’s solution flows from solution bottles through 
insulated tubing and solution inlet over tissue at the desired flow rate. Changes in force exerted by 
tissue are detected by the force transducer, amplified, digitized and recorded as a digital real time 
tracing, observed on a computer monitor.  Samples of solution are taken from the sampling point at 
specified time-points using a pipette and later measured for ATP content. 
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2.5.1.1 EXPERIMENTAL PROTOCOLS 
2.5.1.1.1 STANDARD PROTOCOL 
Tissue trips were mounted and incrementally stretched until exerting approximately 1gram of 
tension. Strips were then left to stabilize in Tyrode’s solution at a constant flow rate of 2ml 
min-1 for between 30-60mins until a stable baseline tension was achieved, after which the 
protocol in figure 2-3 was initiated. The flow rate was then increased to 5ml min-1 and the 
tissue was continuously perfused with Tyrode’s for a specified control period, after which 
superfusate was collected from the sampling point using a micropipette tip and snap frozen 
for later evaluation of ATP content. A sampling volume of 45μl was instated as this allowed 
for duplicate ATP measurement, minimized dilution of the superfusate, and did not 
mechanically disturb the tissue.  
Drug compounds were then introduced via the superfusate and samples taken at 1, 3 and 
5minutes for short observations, followed by sampling at 10min intervals thereafter for 
longer experiments. This was then followed by a post control period using the appropriate 
control solutions (DMSO-containing/normal Tyrode’s) during which further superfusate 
samples were taken. The mean ATP content of pre and post control samples was used as 
the baseline ATP release, and any changes in ATP release stimulated by the drug 
intervention was expressed as a percentage difference from this. Additional samples were 
taken directly from the bottles of prepared solutions (Tyrode’s control, DMSO-containing 
Tyrode’s control, Drug-containing Tyrode’s) for ATP measurement to ensure all observed 
ATP was from tissue release and not from solutions and apparatus.  
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2.5.1.1.2 ANTAGONIST & INTERACTION STUDIES PROTOCOL 
The protocol was then extended for the purpose of interaction and antagonist studies. 
Antagonist studies involved the use of the TRPV4 agonist (GSK1016790A) to trigger ATP 
release, whilst simultaneously inhibiting various signalling molecules and mechanisms to 
observe any effect these may have on this ATP release.  The full procedure is shown in 
figure 2 – 4. The tissue strips were first subjected to the single drug intervention protocol 
(figure 2-3), using GSK. Tissue was then superfused with Tyrode’s at 2ml min-1 for a 
‘recovery period’ of 1 hour to allow the tissue to return to a stable state and for ATP pool 
regeneration. This was followed by a similar protocol, but with the addition of a 10minute 
antagonist step before the GSK, which was maintained throughout the 5minute superfusion 
with GSK and for 10minutes after. The mean ATP release during the 10minute antagonist 
periods were used as control and taken as 100%. This was followed by a further recovery 
period and a repeat intervention of GSK. The GSK intervention was repeated to show that 
activation of TRPV4 is recoverable/reproducible, and allowed any drift in tissue function over 
the period of the full experiment (≈6 hours) to be observed. 
Figure 2 – 3. Single drug intervention protocol. Schematic of protocol used for single drug 
interventions, indicating flow rates, length of superfusion with each solution and timepoints at which 
superfusate was sampled for ATP measurment. For water-soluble drugs, the DMSO control period 
was omitted and a 20min Tyrode’s control was used. For drugs dissolved in DMSO, a 10min 
Tyrode’s control followed by a 20min DMSO control was used. This ensured the effect, if any, of 
DMSO on ATP release and tissue function was monitered.  
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An interaction study was used to determine whether activation of TRPV4  
(1μM GSK) with simultaneous activation of specific purinoceptors (100μM UTP) triggers a 
higher or more sustained ATP release/contraction than their combined individual effects, 
possibly indicating cross-talk of receptor mechanisms. This involved 5 interventions with 1 
hour recovery periods between each. First, tissue was superfused with UTP alone, followed 
by GSK alone (pre-control interventions), and then UTP and GSK in combination to 
determine whether they may amplify the ATP signal when activated in simultaneously. This 
was followed by further post-control interventions of GSK alone and UTP alone. Tissue was 
superfused with Tyrode’s solution for 1hour between each intervention as a recovery period.   
 
Figure 2 – 4. Antagonist studies intervention protocol. Schematic of work flow carried out for 
antagonist studies. Red arrows indicate sampling points, black arrows indicate direction of work 
flow. Tissue was continuously monitored via real-time tracing throughout the protocol to obtain a of 
record all tissue activity and ensure tissue stability. 
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2.5.1.1.3 ASSESSMENT OF MECHANICAL STRETCH-INDUCED ATP RELEASE 
A variation of the antagonist study protocol was designed to investigate the effects of 
mechanical stretch-induced ATP release from GP tissue strips. Instead of the 5minute GSK 
intervention, tissue strips were stretched to 150% of their original length for 30seconds as 
the main intervention. First, tissue was repeatedly stretched in small increments until a 
stable tension was achieved, exerting approximately 9.8mN force. Strips were then 
stretched using the micromanipulator by 150% of their resting length and ATP content of the 
surrounding solution was measured at 30seconds, 1, 2 and 3minutes. These time points 
were chosen from information provided by preliminary optimisation experiments, which 
revealed the stretch-induced ATP release is greatest at 30-60seconds and lost after 
2minutes (refer to figure 3-19). A 30second stretch was chosen as this could be repeated 3 
times (with a 1hour recovery period between each repeat) and still elicit a reproducible ATP 
release with each stretch. A 2minute stretch was also assessed but this was not 
reproducible over 3 repeats. During the first stretch, tissue strips were constantly superfused 
with Tyrode’s. During the second stretch (after a 1hour recovery period) tissue was 
superfused with 1μM HC-067047 (TRPV4 antagonist) for 10minutes prior, during, and 
10minutes after the stretch intervention. This allowed the role of TRPV4 in stretch-induced 
ATP release to be assessed. After stretch, tissue was returned to its original resting tension.  
2.5.1.2 MEASURMENT OF ATP – LUCIFERIN-LUCIFERASE ASSAY 
2.5.1.2.1 EXPERIMENTAL PROTOCOL 
Samples collected during the aforementioned physiological experiments were measured for 
ATP content using the ATP-dependent bioluminescent ‘Luciferin-Luciferase’ assay (Sigma, 
UK). The active working solution was prepared by diluting ‘Sigma ATP assay mix’ with the 
kit buffer according to manufacturer’s guidelines and stabilised at +4oC for 1hour to allow 
any contaminated ATP to breakdown. Samples were then combined in a 1:1 ratio with 
working solution and the luminescence intensity immediately read using an LRB Wallac 
1250 luminometer. Appropriate control readings of reagents and chemicals were also taken 
into account for any background luminescence. The luminometer was calibrated on the day 
of each experiment using an ATP standard of known concentration, as this is an enzyme 
based assay where the enzyme activity will vary slightly between experiments. ATP content 
of samples was determined using a calibration log-log plot of luminescence as a linear 
function of ATP concentration. An example ATP standard curve is provided in figure 2-5, 
with an ‘n=5’ demonstrating the consistency of the assay. 
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2.5.1.2.2 DATA ANALYSIS 
The background luminescence of the working solution was subtracted from the final ATP 
content value to provide a true value of ATP content per sample. The ATP content of the 
control solution sampled directly before and after the drug intervention was averaged, 
providing a mean value for basal ATP release which was used as the control and taken as 
100%. Any ATP released in response to the drug intervention was expressed as a 
percentage change from this. For each individual experiment, ATP release was normalized 
to tissue mass.  
The nonstatic and nonrecirculating experimental setup used for the purpose of ATP 
measurment provides a constant flow, which removes any acumulating metabolites and 
allows any dynamic changes in ATP release to be measured. This also allows controlled 
delivery of intervention chemicals to the tissue through the perfusion system for reliable 
quantification of its effect against basal ATP release. However, it is important to recognise 
that the quantity of ATP release determined is likely an underestimate, as the actual 
quantities released into the tissue microenvironment will be affected by factors such as 
tissue ecto-ATPase activity, the diffusion barrier and the flow imposed by the system. 
Despite this, the setup permits acturate and reproducible determination of the effect of 
chemical interventions on bladder tissue outputs. 
Figure 2 – 5. ATP standard curve. Luminescence emitted by different known concentrations of ATP, 
providing a linear standard curve for determination of sample ATP concentration. Each concentration 
was repeated 5 times, with very little standard deviation, demonstrating the consistency of the assay. 
(n=5).  
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2.5.1.3 MEASURMENT OF ISOMETRIC FORCE 
For appropriate interventions, the magnitude of contraction elicited by the agonist was 
determined. Recorded traces were analysed using ClampFit (version 9.0.2, Axon 
Instruments, USA) and graphical examples of traces were produced using KaleidoGraph 
software (version 3.5, Synergy Software, USA). Traces were imported into Clampfit and the 
baseline tensions at the end of the pre and post control solution periods (Figure 2-6) were 
found. These were averaged and subtracted from the maximal force reached during the 
drug intervention, providing a value of net increase in force of the tissue (contraction) 
evoked by the intervention expressed as force μN/mg tissue. 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 MEASUREMENT OF INTRACELLULAR CALCIUM ([CA2+] I)  
The focus of this thesis is on the function of TRPV4 within the bladder mucosa and the 
mechanisms underlying its physiological outputs. As this receptor is a calcium permeable, 
non-selective cation channel, it is highly likely that the activity of this channel relies 
significantly on entry of extracellular Ca2+ resulting in downstream intracellular Ca2+ 
signalling. Although functional organ bath experiments can and have been designed to 
assess this, measurement of changes in the intracellular Ca2+ concentration in single 
isolated cells using the Ca2+ fluorophore Fura-2 through epifluorescence microscopy grants 
a more direct and conclusive method for this purpose.  
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2.5.2.1 CELL ISOLATION 
Bladders were immediately harvested from culled GPs and placed in a Hepes-buffered 
Tyrode’s solution (described in section 2.1.1.1) to maintain tissue. The mucosa was then 
gently removed using microdissection tools and cells where then dissociated using a 
collagenase type -1 (1.0 mg/ml Worthington Biochemical Corp, Lakewood, NJ, USA) -based 
enzyme mix dissolved in Hepes-buffered Tyrode’s solution with no added CaCl2. The 
collagenase hydrolyses native extracellular collagen fibres releasing the various cell types of 
the mucosa into a single-cell suspension. During the dissociation process, the tissue 
suspension was carefully triturated using a fire-polished glass pipette to further dissociate 
the cells and produce the final cell suspension for loading. Variations of enzyme exposure 
time and incubation temperature were used on the day of each experiment depending on 
tissue size and observations of the cell suspension when triturating and viewing under the 
inverted microscope (Nikon eclipse Ti, UK). Commonly, cells were either incubated in the 
enzyme mix overnight at 4°C, or for 1-1.5 hours at 4°C followed by 2-3 repeats of a 2 minute 
incubation at 37°C with a subsequent 5min incubation at room temperature. These 
optimized methods provide a well-dissociated cell suspension, without damaging the cells 
such that they remain responsive and of high quality. 
2.5.2.2 LOADING OF CELLS WITH THE RATIOMETRIC CALCIUM 
FLUOROPHORE FURA-2 
Fura-2-acetoxymethyl-ester (Fura-2 AM, Molecular Probes®, Thermo fisher Scientific, UK 
Cat# F1201) is a ratiometric fluorescent Ca2+ indicator dye that allows measurement of 
changes in intracellular calcium concentrations. A ratiometric dye is a duel excitation or 
emission indicator that shows a shift in its excitation (or emission) spectra once bound to 
calcium, which can be detected.  Fura-2 is a duel excitation indicator with two excitation 
wavelengths of 340 and 380nm, with an emission wavelength ranging from 410-510nm.  
In the presence of low or 0-Ca2+ the excitation max is 362nm with emission max at 512nm. 
Binding of Ca2+ shifts the excitation max to 335nm and emission to 505nm(Grynkiewicz et 
al., 1985). Therefore, measuring the Ca2+-induced emitted fluorescence (510nm) at both 
340 and 380nm excitation wavelengths allows the Ca2+ concentration to be estimated 
based on the ratio between the 340/380 values. The ratio between the fluorescence 
excitation spectra of Fura-2 is a direct function of the intracellular [Ca2+], as demonstrated 
in figure 2-7. 
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This ratio method minimizes limitations from dye leakage, uneven loading, photobleaching, 
changes in focus, as well as problems associated with varying cell thicknesses in mixed 
populations providing more reliable results.  In Addition, using the ratio to estimate the [Ca2+] 
means the overall dye concentration in the cell will not need to be accounted for. A further 
advantage of Fura-2 is that it is lipophilic and therefore highly cell-permeable. Once in the 
cell the acetoxymethyl group is cleaved off by intracellular esterases, thus containing Fura-2 
within the cell. 
Cells were incubated with 5μM Fura-2 AM at 37°C for 5-10 minutes with an equal volume 
and concentration of pluronic F127 to aid with uptake. The cell suspension was then stored 
in this solution at 4°C under dark conditions for 1-2 hours before loading to the experimental 
set up. Once ready, cells were slightly triturated once more and then pipetted into a 
chamber (10x20x5mm) within a custom-made Perspex dish contained in a water jacket 
heated to 37°C. Cells were then left to settle and attach to the dish in 37°C Tyrode’s solution 
for 20 minutes prior to the experiment.  
Figure 2 – 7. Fluorescence excitation spectra of Fura-2.  This duel excitation dye can be 
excited at both 340 and 380nm wavelengths, emitting at 510nm in both cases. The excitation 
wavelengths at various free Ca
2+ 
concentrations are shown (0-39.8μM in buffer at pH7.1). The 
ratio of light emitted between excitation at 340 and 380nm (dotted lines) is used to estimate the 
concentration of Ca
2+
 within a cell. Image adapted from(Inc., 2015). 
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2.5.2.3 CALCIUM IMAGING SET-UP 
The set-up for detection of calcium in live cells includes; an inverted Nikon Eclipse Ti 
microscope equipped with a xenon arc lamp (Cairn research, UK); an excitation filter wheel 
to supply the required 340nm and 380nm wavelength light; various dichroic mirrors acting as 
beam splitters to filter and direct the desired wavelength light through the necessary light 
path; a cooled charge-coupled device (CCD) camera (LucaEM S, AndorTM Technology, 
UK)(shown in full in figure 2-8) for data acquisition; a Cairn A-D interface to convert the 
analogue signals to digital signals, which are then passed to a PC. The set-up is controlled 
using a PC running WinFluor software for data acquisition. The microscope uses a 10x 
eyepiece with 40x quartz objective lens for imaging, with a numerical aperture exceeding 
1.2. Refer to figure 2-8 for full set up and light path. 
Figure 2 – 8. Schematic of experimental setup for live-cell calcium imaging by 
epifluorescence micrsoscopy.  The xenon arc lamp emits broad spectrum white light which is 
passed through a spun filter wheel, filtering the light to 340nm and 380nm wavelengths. This light is 
then directed to the cell chamber via a 410nm dichroic mirror. Any emitted light is collected by the 
objective and wavelength light of >410nm passes back through the dichroic mirror and is focused 
and directed by a light mirror through a light tube. The light then hits a final 510nm dichroic mirror 
filtering out any >510 wavelength light and delivering the remaining 410-510nm wavelength light to 
the CCD camera. The CCD camera output is processed via a digitizer and is then displayed on a 
computer monitor as a real time trace for 340 and 380nm excitation wavelengths, as well as a trace 
representing the ratio of the two.  The data is captured and stored for later analysis. 
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2.5.2.4 EXPERIMENTAL PROTOCOL 
Once cells had settled they were superfused with a constant flow of oxygenated sodium 
bicarbonate Tyrode’s solution (described in section 2.1.1.2) at approximately 2ml/min-1 
through a water-jacketed tubing system heated to 37°C. This rate of flow ensured cells were 
not dislodged and washed away from the cell chamber, but were still supplied with sufficient 
superfusate to be adequately maintained. Cells were then visualized using the microscope 
white light source and a cell of interest chosen depending on the size, morphology and 
general appearance of the cell (ideally, healthy intermediate urothelial cells). Superfusate 
solutions (sodium bicarbonate Tyrode’s alone, or containing either 100μM UTP or 1μM 
GSK1016790A [same concentrations used for functional organ bath work for comparison]) 
were stored in small gas-bubbled flasks connected to a gravity-fed delivery tube above the 
set-up. Entry of each solution to the delivery tube was controlled by a channel flow switch 
(three-way tap) (figure 2-9). Superfusate solutions flowed through the gravity-fed delivery 
tube and into the cell chamber and waste superfusate removed at the same rate via a 
suction pump (Minipuls 3, Gilson Inc, USA). 
 
Figure 2 – 9. Storage and flow control of superfusate solutions for calcium imaging.  1. Gas 
delivery tubes supplying superfusate solutions with 95% O2 : 5% CO2 2. Solution flasks containing 
superfusate solution and agonist solutions. 3. Channel flow switches controlling entry of solutions 
into final delivery tube 4. Gas control switch 5. Delivery tube flow switch 6. Final solution delivery 
tube. 
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An area of interest was selected to surround the chosen cell and recording initiated. Initially, 
a control period of Tyrode’s superfusate was recorded providing a basal intracellular Ca2+ 
level. Single cells were then challenged with the stated agonists for 5 minutes followed by a 
second control period of Tyrode’s. Throughout the recording period, cells were alternately 
illuminated at 32Hz with 340nm and 380nm excitation wavelength light. Emitted light 
between 410nm and 510nm previously focused and split by dichroic mirrors in the light path 
was then collected by a CCD camera, set at a speed 500 frames per second. The ratio 
between the emitted light intensities of Fura-2 under the two excitation wavelengths was 
converted into intracellular [Ca2+] values and any relative changes to intracellular [Ca2+] were 
recorded and displayed as a real time tracing on a video monitor. The relationship between 
the excitation wavelength ratio (R [340nm/380nm]) and intracellular  [Ca2+] is expressed by 
the equation (Grynkiewicz et al., 1985): 
 
 
Kd (224nM) is the specific dissociation constant of Fura-2 for Ca
2+ in the cytosolic 
environment (determined previously [Grynkiewicz et al., 1985]). β represents the ratio of the 
fluorescence intensity at 380nm between saturating and 0 [Ca2+] conditions and is defined 
by the specific setup used. R is the fluorescence ratio between 340/380nm. The Rmin and 
Rmax refer to the ratio values at saturating and 0 [Ca
2+] conditions and are influenced by the 
optical system, and are thus determined experimentally. For accurate quantification of 
[Ca2+]i,, Rmin and Rmax are determined experimentally using high (1mM) and 0 [Ca
2+] (no 
added CaCl2 plus 1mM EGTA) solutions in vivo, i.e. calibrating the system to R under these 
conditions in live cells, where the cells under investigation are filled directly with the buffered 
[Ca2+]i solutions via patch-clamp technique. This provides a more accurate calibration than 
using an in vitro solution-based method (calibrating to high and 0 Ca2+ solutions only, not in 
live cells) as Fura-2 will behave differently in live cells due to differences in the surrounding 
conditions imposed by the cytosolic environment, such as viscosity.  However, as the aim 
during this study is to simply observe relative changes in [Ca2+]i  in response to specific 
agonists, the system was calibrated using the solution-based method (solutions described in 
section 2.1.2). Here, the calibration solution is a high K+ based saline to mimic the 
intracellular environment. 
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2.5.3 WESTERN BLOTTING 
This technique was used to determine the presence, and or quantity of various proteins of 
interest in the bladders of species used throughout this project. The mucosa and smooth 
muscle were separated and analysed separately to allow comparison of protein expression 
between these tissues.  
2.5.3.1 PREPARATION OF WHOLE TISSUE LYSATES 
Previously snap-frozen mucosal and smooth muscle samples were ground to a fine powder 
in liquid nitrogen using a pre-cooled pestle and mortar. The powder was lysed in an 
appropriate volume of RIPA buffer (depending on the sample weight [for full description see 
section 2.1.5.2]) and sonicated at 100Amp using a VC130PB ultrasonic processor (Sonics & 
Materials Inc, USA) for 30 seconds to release intracellular components. Samples were 
stored at -20°C until required.  
2.5.3.2 PROTEIN QUANTIFICATION 
The protein concentration of whole tissue lysates was determined using a DC™ (detergent 
compatible) colorimetric protein assay kit (DC™ protein assay, BioRad, UK). This was 
performed on the day of whole tissue lysate preparation before samples were frozen down 
to avoid a further freeze-thaw cycle. This particular assay is based on the well-established 
Lowry assay, which relies on the reaction of protein with an alkaline copper tartrate solution 
and folin reagent. The initial reaction between protein and copper, and the subsequent 
reduction of folin results in a blue coloured solution, the intensity of which is proportional to 
the protein content of the sample.  
A serial dilution of known protein concentration ranging from 30.125μg/ml to 1000μg/ml was 
prepared using a stock solution of 1000μg/ml bovine serum albumin (BSA). Samples were 
diluted 1:20 and 1:50 in reverse-osmosis (RO) water and the working solution (alkaline 
copper-tartrate) was prepared as per the manufacturer’s instructions. 50μl of diluted 
samples and standards were reverse-pipetted (in triplicate) into a NUNC 96-well plate, 
followed by 25μl working solution per well. A multi-pipette was then used to add 200μl of the 
folin-containing reagent to each well, initiating the color-producing reaction. After incubation 
for 5 minutes the colour intensity was read at 695nm using a plate reader (multiskan RC 
plate reader, Labsystems, Finland) and recorded using Ascent™ multiskan data acquisition 
software (Thermo-scientific, USA). BSA standards were used to plot a standard curve which 
was used to determine the protein concentration of samples.   
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2.5.3.3 PREPARATION OF LOADING-SAMPLES & GEL ELECTROPHORESIS 
On the day of experiment, frozen samples were rapidly thawed and combined in a 3:1 ratio 
with Laemmli buffer. Samples were then incubated at 95°C for 5 minutes on a hot plate to 
fully resolve the lysate. However, during optimisation of this technique, it was found that this 
level of heating denatured TRPV4 to an extent where it could no longer be detected. 
Therefore, when probing for TRPV4, samples were left at RT for 30 minutes, which resolved 
samples to the optimum degree for TRPV4 detection.  
Precast gels (8–16% Mini-PROTEAN® TGX™ 10 well Gel, BioRad, UK) were clamped in a 
gel cassette and placed in a running tank filled with fresh running buffer. Samples were then 
vortexed before being loaded (30μg/well) in duplicate alongside a pre-stained protein ladder 
(PageRuler Prestained NIR Protein Ladder, Thermo-scientific, USA) which produces 
coloured bands at specified known molecular weights. This allows both visualization of the 
progress of gel electrophoresis and clarification of the size of the protein bands probed from 
samples. The tank was then connected to a powerpack (PowerPac™, BioRad, UK) and run 
at a constant voltage of 120V. A constant voltage was chosen as this insures the current 
does not rise during the run, which can result in band distortion. Using gels that have a 
progressively higher percentage of acrylamide from start to finish means resistance 
increases during the run and thus under a constant voltage, the current slowly drops, 
insuring no damage or distortion occurs. Gel electrophoresis ended once the ‘dye front’ had 
run out from the end of the gel or once the proteins had been adequately separated.  
2.5.3.4 ELECTROPHORETIC TRANSFER 
A nitrocellulose membrane, two sheets of filter paper and two fibre pads were pre-soaked in 
cold transfer buffer. The gel was carefully placed on top of the membrane, which was placed 
centrally between the two sections of filter paper and then the two fibre pads (figure 2-10). A 
roller was used against the filter paper to gently remove any air bubbles from between the 
gel and membrane. The construct was then clamped within a transfer cassette and placed 
within the transfer tank filled with pre-cooled transfer buffer, taking care to orientate the 
cassette correctly such that the proteins would transfer towards the membrane. The transfer 
was run at 300mA for 90 minutes, which ensured full transfer of proteins to the membrane. 
The tank was surrounded by ice and contained a cold pack to maintain low temperatures 
necessary for efficient transfer. An electronic stirrer was also used within the tank to ensure 
a consistent temperature of buffer throughout the tank, as heating may occur at focal points 
close to the electrodes which can cause an uneven transfer.  
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2.5.3.5 IMMUNOBLOTTING 
Once the transfer had completed, the membrane was transferred to a small opaque box and 
rinsed twice in TBS for 5 minutes to remove any residual transfer buffer. All rinsing and 
incubation steps were carried out on a shaker to ensure even coverage of the membrane 
with solutions. The membrane was then incubated for 1 hour at RT in a blocking buffer (5% 
milk TBS) containing a number of proteins, including casein, which bind to the remaining 
surface of the membrane (not occupied by proteins transferred from samples), which 
prevents nonspecific binding of the detection Abs to the membrane in later steps. This 
incubation was followed by the addition of desired primary Abs (diluted in 5% milk TBST) to 
the membrane. Tween20 is introduced to the incubation and washing solutions from this 
point onwards as it is a detergent which also aids in the prevention of nonspecific Ab 
binding. The primary Ab solutions were then decanted into falcon tubes and frozen down at -
20°C for re-use. Membranes were then rinsed once and washed 3 x 5minutes in TBST, 
before addition of the relevant IRDye® – conjugated secondary Ab, also diluted in 5% milk 
TBST. The membranes were incubated for 1 hour at RT in the secondary Ab before a 
further rinse and 2 x 5minute washes in TBST and a final wash in TBS (as tween 20 can 
interfere during signal detection) before visualization. In some cases, once visualized, the 
membrane was stripped of the original Abs using stripping buffer (refer to chemicals and 
solutions) to allow re-probing using different Abs. This was done by washing the membrane 
in 5ml Restore™ stripping buffer for 15minutes, followed by a 5minute wash in TBS, before 
commencing the immunoblotting protocol from the blocking stage. 
 
Figure 2 – 10. Correct arrangement of transfer construct. 1. Black side of transfer cassette 2. 
Fibre pad 3.filter paper 4. Gel 5. Nitrocellulose membrane. Arranging the layers as such ensures the 
current flows from the gel to the membrane, transferring the proteins onto the membrane rather than 
away from it. Transfer of the ladder to the membrane was used as a simple indicator for successful 
transfer. 
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2.5.3.6 SIGNAL DETECTION 
The Odyssey®CLx infrared imaging system (LI-COR, Germany) was used for signal 
detection. Membranes were placed protein-down on the scanning surface in RO water. A 
silicone matt was placed on top and a roller was used to remove any air bubbles. These 
steps ensure the membrane is flat against the imaging surface for optimal signal detection. 
LI-COR® image studio software was used for image acquisition and later analysis.  
2.5.3.6.1 USE OF NEAR-INFRARED (IR) SECONDARY ANTIBODIES 
Various studies have been performed to characterise the sensitivity and variability of IR Abs 
used for western blotting. Use of IR Abs commonly yield a 200-400 fold higher sensitivity 
than classic chemiluminescence, due to a much lower background of membranes in the IR 
range. The most notable advantage, is that IR Abs are directly labelled with a fluorescent 
dye and thus do not involve the enzyme/substrate kinetics indicative of chemiluminescent 
detection. The involvement of enzyme kinetics introduces variation between experiments 
and the need for development and exposure times.  Directly labelled IR Abs avoid these 
limitations, as the fluorescence intensity observed on the final image is emitted directly from 
bound Abs, providing data that is more accurate, reproducible and representative of the 
actual quantity of protein present. To summarise, it has been shown that the IR detection 
method is quantitative, with a wide, consistent linear detection range, compared to 
chemiluminescence, which is only semi-quantitative with an unpredictable, lower linear 
detection range (Schutz-geschwender et al., 2004). Therefore, use of this method provided 
more accurate and reliable data for quantification.  
2.5.3.7 BLOT ANALYSIS 
LI-COR® image studio software was used for this purpose. Rectangular areas of interest of 
identical size were drawn around each band. The software calculates the sum of the 
individual pixel intensities within the rectangle and then subtracts the mean intensity values 
of pixels from the background (taken from the area directly surrounding the rectangle, 
defined by a slightly larger rectangle [figure 2-11]). This provides a final corrected value for 
the ‘signal’ of each band. Raw images were used during analysis, however adjusting the 
contrast/brightness did not affect output values as the software always uses the raw image 
intensity values obtained during acquisition from an ‘image memory’.  
β-actin was used as a loading control to indicate the total protein loaded per well. Initially, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was tested as the reference protein, 
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however this yielded different band strengths between mucosal and smooth muscle samples 
despite similar loading concentrations, due to the increased energy demand of DSM cells 
over urothelial. β-actin is a housekeeping gene that is expressed at similar levels in both 
tissue types and was therefore used as the loading control. The final signal value for the 
band of the target protein was normalized to its corresponding β-actin, accounting for any 
variation in total protein levels. Samples were run in duplicate on the same gel, such that 
duplicate values could be averaged providing a more representative final value of the 
quantity of target protein in each sample. This, as well as vortexing samples prior to loading, 
reduced possible errors due to uneven protein concentrations within samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – 11. Screenshot of example workspace in Image studio®. Inner purple rectangle measures 
total pixel intensity, outer rectangle calculates mean of background pixels, value under each rectangle 
and in ‘signal’ column is total intensity of each band minus surrounding background. The upper bands in 
this example show TRPV4 and the lower bands β-actin. Each TRPV4 signal value would be normalized 
to its corresponding β-actin, providing final values accounting for variation in total protein loaded between 
samples.  
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2.5.4 MEASUREMENT OF REACTIVE OXYGEN SPECIES (ROS) USING 
LUCIGENIN-ENHANCED CHEMILUMINESCENCE 
2.5.4.1 PRE-INCUBATION OF BLADDER TISSUE SECTIONS  
Tissue strips were instantly dissected from a previously harvested GP bladder. Ten GP 
bladders were investigated for the purpose of this experiment. From each bladder two strips 
were taken, one for incubation in Tyrode’s solution to serve as control, and one which was 
incubated in 1μM GSK10166790A (TRPV4 agonist) as the intervention. After dissection, the 
strips were transferred to an Eppendorf containing either the control Tyrode’s solution or 
TRPV4 agonist and incubated at 37°C for 30 minutes in a pre-heated water bath. The strips 
were then removed and instantly snap-frozen in liquid Nitrogen before being stored at -80° 
until further investigation. 
2.5.4.2 PREPARATION OF WHOLE-TISSUE LYSATES 
This was achieved in a similar manner to that described for preparation of lysates for 
western blotting. The previously snap-frozen full-thickness bladder wall samples where 
ground to a fine powder in liquid nitrogen using a pre-cooled pestle and mortar. Each 
sample was re-suspended in 200μl Hanks Balanced Salt Solution (HBSS) and then 
sonicated on ice using a VC130PB ultrasonic processor (Sonics & Materials Inc, USA) for 30 
seconds at 60 AMPs.  
A Bradford assay was then employed to determine protein concentrations of the 
homogenates. The Bradford reagent contains Coomassie Brilliant Blue G-250 dye, which 
once bound to protein, changes colour from red to blue. The absorbance at 595nm is 
proportional to the quantity of blue protein-dye complexes and hence the quantity of protein 
in the solution (Bradford, 1976). 2μl of tissue homogenate was added to 1ml Bio-rad protein 
assay dye (Bio-Rad Bradford protein dye, Bio-Rad, UK) and thoroughly vortexed. The dye-
homogenate solution was transferred to a 1.5ml plastic cuvette and the optical density was 
measured at 595nm using a spectrophotometer (UV1101 Biotech photometer, WPA, 
Cambride, UK). A standard curve was generated using prepared samples of known BSA 
concentrations and this was used to determine the protein concentrations (μg/ml) of 
homogenate samples. 
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2.5.4.3 MEASUREMENT OF ROS USING LUCIGENIN-ENHANCED 
CHEMILUMINESCENCE 
A lucigenin-enhanced chemiluminescence assay was used to determine the NADPH-
dependent superoxide production in bladder wall homogenates. Lucigenin is a 
chemiluminescent probe that is reduced by ROS to an energy-rich dioxetane molecule. This 
process causes dioxetane to emit a photon, which can be detected by a luminometer 
allowing determination of ROS production in samples (Dikalov et al., 2007). The quantity of 
photons collected is expressed as relative light units, or RLUs. 
Following protein determination, 25μl of each sample was reverse-pipetted in duplicate into 
a NUNC 96-well plate. 25μl sample buffer minus tissue was added to 2 wells to serve as the 
blank control. Sample buffer (HBSS, 0.8mM MgCl2, 1.8mM CaCl2) was then added to 
provide a final volume of 140μl in each well. The plate was then placed in a pre-heated 
(37°C) luminometer (BMG Lumistar, Germany) and 40μl lucigenin buffer (25μM lucigenin 
[Sigma, UK] in sample buffer) was sequentially added to each well using the plate reader’s 
auto-dispenser function. Basal superoxide production was then recorded over 11 cycles, 
where the RLU for each well was measured for a 3 second period during each cycle. After 
this basal reading was taken, 20μl of a 1mM NADPH (Sigma, UK) solution in sample buffer 
was manually reverse-pipetted into each well. The plate was then immediately returned to 
the luminometer and RLU recorded over 3 seconds for each well for a further 21 cycles. 
Finally, 2μl of 1M Tiron (Sigma, UK) was manually added to each well and the RLU 
measured over a further 21 cycles as before. Tiron is a preferential cell-permeable 
superoxide radical scavenger (Ledenev et al., 1986; Van Ginkel and Raison, 1980) and thus 
will remove any superoxide from each well, allowing determination of the proportion of 
superoxide present among the other ROS being measured by the luminometer.  Each well 
contained a final volume of 200μl providing final working concentrations of 5μM lucigenin, 
100μM NADPH and 10mM Tiron. A low lucigenin concentration was used to avoid artifactual 
superoxide production through redox cycling of the molecule(Li et al., 1998). The light 
emission was recorded, corrected to the protein concentration of each sample and 
expressed as median arbitrary light units/min (MLU/min). 
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2.5.5 IMMUNOHISTOCHEMISTRY 
2.5.5.1 SAMPLE PREPARATION & SECTIONING 
Following dissection, longitudinal strips of full bladder wall were embedded in optimal cutting 
temperature compound (OCT [Bright Instrument LTD, UK]), snap-frozen in liquid nitrogen 
and stored at -80°C.  These bladder strips were orientated to enable sectioning through the 
transverse plane, ensuring that once sectioned, each specimen contained all three distinct 
tissue layers; the urothelium, suburothelium and detrusor smooth muscle. This enabled 
analysis of molecular structures across the entirety of the bladder.  
Specimens were transported from -80oC in a liquid nitrogen tank to a pre-cooled (-22oC) 
cryostat (Hyrax C25, Zeiss, Germany). Specimens within OCT were fixed to the cryo-chuck 
using further OCT and were sectioned at 10μm thickness before being immediately mounted 
onto poly-L-lysine coated slides (4 sections per slide). Each section was viewed under a 
light microscope to ensure both structural integrity and presence of all tissue types, before 
being stored at -80oC prior to immunostaining. 
2.5.5.2 IMMUNOSTAINING 
On the day of immunostaining, cryosections were fixed in previously cooled methanol for 
5mins at -20oC, before undergoing 3x10min washes in PBS. 1%BSA PBS solution was then 
used to block the sections for 1 hour at room temperate, after which either a diluted primary 
antibody would be added to the sections, or 1% BSA PBS would be reapplied to one as a 
secondary control. This secondary control reveals any unspecific secondary antibody 
binding that could present a false positive stain. Slides were then incubated over night at 
4oC in a humidified chamber. On the following day, slides were again washed 3 times in 
PBS for 10mins, before incubation at room temperature for 1 hour in the appropriate 
secondary antibody. Following another 3x10min PBS washes, each specimen was 
incubated for 10mins in a nuclear stain (To-PRO3® [Molecular Probes, Netherlands]) at 
1:5000 concentration. A further 3x10min PBS washes were performed, after which sections 
were mounted using an antifadent-containing fluorescence mounting medium (AF-1 
[Citifluor, UK]), sealed using clear nail polish and then stored under dark conditions at +4oC 
until imaging. 
Optimal concentrations of antibodies were experimentally determined previously, and all 
antibodies were diluted to this respective concentration in 1% BSA PBS. All procedures and 
incubations involving fluorescent-conjugated antibodies were performed in either complete 
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darkness or dim-light conditions to reduce photo-bleaching. Additionally, diluted secondary 
antibodies were centrifuged at 10,000rpm at 4oC for 4mins to separate any artefacts and 
other particles from the antibody solution to achieve a cleaner final section and thus image.  
2.5.5.3 IMAGING & ANALYSIS 
Immunostained sections were visualized at 40x magnification (oil-emersion lens) using a 
Bio-Rad Radiance 2000 laser-scanning confocal Nikon TE1000 microscope and images 
were subsequently analysed using Axovision LSM 510 Meta software. Appropriate filter 
pathways were employed to omit any autofluorescence and detect only the desired emission 
wavelength of each specific antibody/stain (alexa-568nm [emission 603], To-PRO3 642nm 
[emission 661]). For each animal bladder investigated (‘n number’), 4 sections would be 
used; one for the secondary control, and three positively stained sections to confirm 
expression of the target protein throughout the bladder. For each set (1 secondary control, 3 
positively stained) the gain and contrast was calibrated using the secondary control section, 
such that no fluorescence emitted from the secondary Ab (nonspecific staining) was 
observed. This ensured all staining observed on positive sections is a true representation of 
the presence and localization of the desired target protein. Specificity of immunostaining 
was confirmed in all sets as no or very little fluorescence was displayed in the absence of 
primary antibody (secondary control) and this was further confirmed using a peptide control.  
ImageJ software (NIH, USA) was used to quantify the density of images. Each image was 
converted to an ‘RGB stack’ to isolate each fluorescent channel. For alexa 568 channel, the 
image’s threshold was set to highlight the fluorescent tissue from non-fluorescent tissue and 
background using the ROI manager tool. Highlighted regions of tissues of interest 
(urothelium, suburothelium or smooth muscle) were selected using the ‘region of interest 
selection wand’ tool and the ‘density’ measured (refer to figure 2-12 for example workspace). 
The number of To-PRO3-stained nuclei within this defined area were counted manually 
(using a ‘marker tool’ to prevent miscounting) and the ‘density’ value was divided by this 
number, providing an average density/fluorescence per cell (mean cell fluorescence [MCF]. 
The MCF from the secondary control was subtracted from that of the three positively stained 
sections, which were then averaged, providing a final MCF for the target protein throughout 
the bladder with background removed.  
This method possesses an advantage over western blotting as it allows more precise 
differentiation of receptor expression between tissue layers and cell types. For a list of Abs 
used and their concentrations, refer to tables 3 and 4. 
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2.6 STATISTICAL ANALYSIS 
Data are expressed as medians ± interquartile range (int. range), where n denotes the 
number of bladders assessed, unless otherwise stated. All statistics were performed using 
raw data, unless comparing the relative effects of two different interventions, graphs display 
data normalized to controls (taken as 100%) for quick comparisons. All statistical analysis 
was performed using Microsoft Excel (2010, version 14.1.6) and GraphPad Prism (2011, 
version 6.01, GraphPad Software). All data was tested for normality using D’Agostino-
Pearson omnibus test and all variables were found to have non-Gaussian distribution. As 
such, a Mann-Whitney (unpaired, non-parametric student’s t-test) was used to examine two 
unpaired data sets of unknown distribution. A Wilcoxon matched-pairs signed rank test was 
used to analyse paired data sets, for example comparing two different interventions 
Figure 2 – 12. Example workspace in ImageJ 
software. A: Channel displaying TRPV4 
fluorescence selected in greyscale (for measurement 
purposes), an area of interest selected around 
section of urothelial tissue (yellow selection) and 
’measure’ tool used to determine ‘density’ in this 
selected area, provided in window ‘C’ as integrated 
density. B: Channels switched to that displaying 
nuclear TO-PRO-3 stain on same image for 
counting, area of interest remains to aid in accurate 
measurement. C: results window. 
A B 
C 
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performed on the same bladder strip. The null hypothesis was rejected at p<0.05, with the 
level of significance indicated by *p<0.05, **p<0.01 and ***p<0.001.  When describing 
results in text, the medians with 25% percentile and 75% percentile will be provided as: 
median [25%, 75%]. 
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CHAPTER 3: EXPRESSION AND FUNCTION 
OF TRPV4 RECEPTORS IN THE HUMAN AND 
GUINEA PIG BLADDER 
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3.1 INTRODUCTION 
Since the identification of TRPV4 receptors in the bladder, the role of these channels in 
bladder physiology and pathophysiology has become of increasing interest. It is well 
established that TRPV4 receptors are responsible for many nociceptive and stretch-
mediated responses in various tissues throughout the body, such as the vasculature 
(Alessandri-Haber et al., 2003; Hartmannsgruber et al., 2007; Loot et al., 2008; Mendoza et 
al., 2010). As such, various studies have investigated the role of TRPV4 in stretch-mediated 
ATP release in the bladder in cultured cells and knockout models (Gevaert et al., 2007; 
Mochizuki et al., 2009), however, studies using intact tissue preparations to define the mode 
of action in different tissue layers, especially those from humans, are lacking. Furthermore, 
the mechanisms underlying TRPV4-associated ATP release remain to be elucidated. As a 
purinoceptor-induced component to contraction appears to emerge in various human 
bladder pathologies, the importance of ATP release and signaling in such pathologies is 
heightened(Bayliss et al., 1999). Therefore, TRPV4 receptors and their associated signaling 
may provide novel targets for therapeutic intervention of OAB symptoms.  
3.1.1 RELEVANT STUDIES OF TRPV4 FUNCTION IN THE BLADDER 
For a detailed review of the current knowledge of TRPV4 function in the bladder, please 
refer to section 1.2.3 in the general introduction.  
The role of TRPV4 in normal bladder function has been previously explored by a collection 
of studies in animal bladders.  Gevaert et al. first identified a crucial role for TRPV4, where 
TRPV4-/- mice exhibited reduced voiding frequency and reduced stretch-induced ATP 
release from isolated whole bladders(Gevaert et al., 2007). They suggested that TRPV4 
mediates urothelial transduction of intravesical mechanical pressure via release of an ATP 
signal. In vivo evidence for TRPV4 function was also demonstrated by Everaerts et al. who 
showed increased functional bladder capacity and reduced voiding frequency in WT mice 
upon application of the specific TRPV4 inhibitor HC-067047(Everaerts et al., 2010c). 
However, it was not definitively confirmed whether these altered voiding patterns were due 
to lack of TRPV4 function in the urothelium, or lack or TRPV4 in the DSM, or indeed both. 
Following from this, Thorneloe et al. utilised the selective TRPV4 agonist GSK1016790A 
(used in the current study) to further investigate TRPV4 function in the bladder. GSK 
contracted both intact and denuded DSM strips and induced bladder over-activity in 
TRPV4+/+ mice, both of which were not observed in TRPV4-/- mice. Together with the 
findings from Gevaert et al(Gevaert et al., 2007) and Birder et al(Birder et al., 2007), they 
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proposed that ‘GSK1016790A-induced bladder overactivity in vivo (absent in 
TRPV4−/− mice) is a result of the functional role of TRPV4 in both the urothelium and the 
UBSM, causing a release of ATP from the urothelium, sensitizing bladder afferents and 
direct contraction of UBSM, respectively’(Thorneloe et al., 2008). This study not only 
identified a possible role for TRPV4 in mediating bladder overactivity, but also demonstrated 
the specificity of GSK with regards to TRPV4-mediated bladder outputs. Mochizuki et al. 
then demonstrated a reduced agonist and stretch-induced ATP release from cultured 
primary urothelial cells from mice upon knockout of TRPV4 or with unspecific TRP channel 
blockers(Mochizuki et al., 2009). This evidenced the role for TRPV4 in stretch-induced 
urothelial cell ATP release, although native urothelial tissue was not directly examined. Thus 
specific studies in more physiologically relevant tissue strips, including native urothelial 
tissue are needed to fully establish the role of TRPV4 in sensation of bladder stretch. 
Furthermore, as TRPV4 receptors can be activated by inflammatory conditions without 
stretch, defining the role of TRPV4 receptors in the bladder by selective receptor activation 
without stretch will provide new insight into the physiological role of these receptors with 
pathological implications.  
The studies in this chapter build upon previous work but take a major step forward. Rather 
than using stretch as a means of evoking ATP release, which will activate a myriad of other 
receptors and pathways, the specific TRPV4 agonist GSK1016790A (more potent and 
specific than 4α-PDD [Thorneloe et al., 2008]) is used to directly activate TRPV4 receptors, 
to investigate the functional importance of TRPV4 and the underlying mechanisms in 
physiologically relevant native and intact guinea pig bladder preparations. This will 
overcome the limitations of phenotypic change in cultured cells and also maintain cell-to-cell 
interactions. 
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3.2 SUMMARY 
The objectives for characterizing TRPV4 receptors in both human and guinea pig bladder 
are as follows: 
1. EXPRESSION STUDIES: 
a. Determine the presence and localization of TRPV4 receptors throughout the 
bladder wall using immunohistochemistry. 
 
b. Confirm and quantify the expression of TRPV4 in the mucosa and smooth 
muscle using quantitative western blotting. 
 
2. IN VITRO FUNCTIONAL EXPERIMENTS USING FUNCTIONAL ORGAN 
BATH TECHNIQUE: 
a. Determine the effect of specific TRPV4 activation on ATP release and 
contractile function in various bladder tissue preparations. 
 
b. Explore the mechanisms underlying TRPV4-related ATP release using a 
variety of antagonists and extracellular conditions.  
 
3. FURTHER IN VITRO STUDIES: 
a. Determine the dependence of TRPV4-related ATP release on extracellular 
Ca2+ entry using live-cell calcium imaging. 
 
b. Investigate the effect of TRPV4 activation on production of reactive oxygen 
species in bladder tissue preparations using lucigenin-enhanced 
chemiluminescence. 
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3.3 METHODS 
For a full description of the techniques and protocols used, please refer to the relevant 
methods section (detailed in text or figure legend where applicable). 
3.4 RESULTS 
3.4.1 PHYSIOLOGICAL EXPRESSION OF TRPV4 IN THE BLADDER  
This section of the study was performed to first establish the expression of TRPV4 in the 
bladder tissues of the species used during the investigation to corroborate functional 
findings.  
3.4.1.1 IDENTIFICATION AND TISSUE LOCALIZATION OF TRPV4 IN GP AND 
HUMAN BLADDER TISSUES BY IMMUNOHISTOCHEMISTRY 
The distribution of TRPV4 receptors throughout the bladder was assessed in GP and human 
bladder cryosections and examined using confocal microscopy (figures 3-1 and 3-3). 
Sections were labeled with a specific Ab for TRPV4 (Alomone, Isreal, ACC-034), which was 
in turn labeled with an Alexa Fluor® - 568 fluorescent secondary Ab (em=603nm, Cy3 
channel) of the relevant species, providing a red signal for TRPV4. Sections were also 
labeled with a blue nuclear stain (TO-PRO3®, em=661nm, Cy5 channel) to identify cell 
numbers and provide clearer tissue differentiation for images. Brightfield images were also 
used to examine tissue morphology and integrity and to identify tissue types more clearly 
(Cy2 channel). A peptide control was carried out on sections from 4 GP bladders to confirm 
specificity of the Alomone TRPV4 Ab (figure 3-2). 9 young GP bladders and 4 human 
bladder mucosa biopsies (taken from position of healthy tissue in male patients >65 years of 
age [YOA] with suspected or known tumours) were examined. Representative images for 
each group are shown in figures 3-1 and 3-3. All groups showed clear expression of TRPV4 
in the urothelium and suburothelium. The smooth muscle was assessed in 3 GP bladders 
and 1 human biopsy (which had smooth muscle attached), TRPV4 expression was 
observed in all. TRPV4 staining seems to be more evident in the urothelium, with weaker 
expression in the suburothelium and weaker still in the smooth muscle. To assess this, 
staining was quantified by measuring pixel density of images and calculated per cell, 
providing final values of TRPV4 expression as ‘mean cell fluorescence’  (MCF) for each 
tissue type (figure 3-4).  
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GP urothelium expressed higher levels of TRPV4 compared to the suburothelium in all 9 
bladders examined (MCF - uro; 2393 [1928, 3677], suburo; 1207 [605, 2091], SM; 1624 
[611, 2098]). GP smooth muscle was assessed for 4 of the bladders providing an indication 
of expression levels (similar to that of suburothelium), however accurate quantification was 
not possible. Human TRPV4 expression in the urothelium and suburothelium appears to be 
similar, however only 4 bladders were examined due to limited biopsies (MCF - uro; 2708 
[2263, 3074], suburo; 2019 [1162, 2854]).  
However, quantification using confocal images has many limitations (considered in critique 
of methodology). As such, a more robust western blotting method was also used to examine 
and quantify TRPV4 expression in these tissues, and results from the two methods 
compared to see if the results were in agreement.  
 
103 
 
 
Figure 3 – 1. Representative images demonstrating expression of TRPV4 in young GP bladder 
tissues. Cryo-sections (10μm) of young GP bladder tissues at x40 magnification. TRPV4 is labelled with Alexa 
fluor 568 (red) and nuclei with To-PRO3 (Cy5; blue). Column A: Secondary control; no primary antibody (Ab) 
added, ensuring no unspecific binding of secondary Ab to sample. Column B: Positively stained sections 
depicting expression and distribution of TRPV4 in the urothelium (green bar), suburothelium (pink bar), smooth 
muscle and vasculature. High TRPV4 expression is observed in the urothelium with lower expression in the 
suburothelium. Images from each row (tissue type) were taken from the same ‘area’ of tissue on sections cut 
directly after one another, thus providing a reliable comparison between control and positive staining. These 
images were taken from sections of 1 of 9 young GP bladders examined.  
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Figure 3 – 2. Representative peptide control for Alomone anti-TRPV4 primary antibody. 
Cryo-sections (10μm) of young GP bladder tissues at x40 magnification. TRPV4 is labelled with Alexa 
fluor 568 (red) and nuclei with To-PRO3 (Cy5; blue). A: Brightfield image of peptide control section only, 
demonstrating general morphology and tissue distribution. B: Secondary control; no primary antibody 
(Ab) added, ensuring no unspecific binding of secondary Ab to sample. C: Primary TRPV4 antibody was 
pre-incubated with supplied control peptide for 30min at room temperate before addition to tissue 
section. Any red staining observed here represents unspecific binding of the primary to proteins other 
than TRPV4. D: Positively stained sections displaying expression and distribution of TRPV4 in the 
urothelium and suburothelium. Each image was taken from the same ‘area’ of tissue from serial 
sections, thus providing a reliable comparison between controls and positive staining. Aging GP tissue 
was also examined using a peptide control (total 4 bladders) 
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Figure 3 – 3. Expression of TRPV4 in aging human bladder tissues. 10μm cryo-sections of human 
bladder wall from a male patient (69yo) with a suspected tumour (Sample #5 - methods table 5), examined by 
confocal microscopy at x40 magnification. TRPV4 is labelled with Alexa fluor 568 (red) and nuclei with To-PRO3 
(Cy5; blue). Column A: Secondary control; no primary antibody (Ab) added, ensuring no unspecific binding of 
secondary Ab. Column B: Positively stained sections indicating expression and distribution of TRPV4 in the 
urothelium (green bar), suburothelium (pink bar) and smooth muscle. High TRPV4 expression is observed in the 
urothelium with some expression in the suburothelium. Images from each row (tissue type) were taken from 
the same ‘area’ of tissue on sections cut directly after one another, thus providing a reliable comparison 
between control and positive staining. These images were taken from sections of 1 of 5 aging male patient 
bladders examined. Unfortunately, due to limited samples, evaluation of vessels was not possible.  
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3.4.1.2 IDENTIFICATION AND RELATIVE TISSUE EXPRESSION OF TRPV4 IN 
GP AND HUMAN BLADDER TISSUES BY WESTERN BLOTTING 
TRPV4 expression was confirmed in separated mucosal and smooth muscle bladder whole 
tissue lysates by western blot, run against rat brain lysate (RBL) positive control tissue 
(recommended by Ab suppliers). Both representative blots in Figure 3-5 A and B show clear 
bands at the same molecular weight (kDa) as the positive control, thereby confirming 
presence of TRPV4 in these samples. Two Abs were used as the Alomone Ab was formerly 
used for immunohistochemistry, however optimising use of this Ab for western blotting was 
originally unsuccessful. Therefore, the Abcam Ab was purchased for this purpose and 
yielded positive results. To confirm integrity of the Alomone Ab, western blotting was 
attempted for a second time and successfully optimised. Expression levels were quantified 
by densitometry and relative expression between tissues compared (figure 3-5 C).  
 
 
Figure 3 – 4. Expression levels of TRPV4 in human & young GP bladder tissues quantified from 
confocal microscopy images. Quantitative analysis of TRPV4 fluorescence. The pixel density of an 
area of tissue was measured and divided by the number of cells, providing final values of mean cell 
fluorescence (MCF). TRPV4 expression is significantly higher in the urothelium than the suburothelium 
of young GP tissue. TRPV4 expression in human mucosa seems to be similar in both tissues, however 
only 4 biopsies were assessed, providing an indication of expression levels only. Expression in GP 
smooth muscle was only assessed in 3 bladders, such that this data is also only an indication. Data 
sets expressed as % medians [25%, 75%], GP urothelium and suburothelium; n=9, GP smooth muscle; 
n=3, human urothelium and suburothelium; n=4, ** p ≤0.01. Expression levels between tissues in same 
species compared using Wilcoxon’s, GP urothelium vs. GP suburothelium.  
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Quantification by densitometry revealed a much higher expression of TRPV4 in mucosal 
tissue than smooth muscle when using either primary Ab (Arbitrary units normalized to 
loading control - Abcam; mucosa – 29.1 [17.8, 74.7], smooth muscle – 4.314 [2.7, 19.1] 
Alomone; mucosa – 52.3 [31.1, 78.6], smooth muscle – 17.8 [8.6, 21.6]). Mucosal TRPV4 
expression was approximately 6-fold higher compared to smooth muscle when probed with 
the Abcam Ab and 4-fold higher with Alomone. However, the results obtained using one 
A B 
C 
Figure 3 – 5. Detection and quantification of TRPV4 in young GP bladder using two different 
α-TRPV4 primary antibodies. A: Representative blot of TRPV4 (98kDa) probed using Abcam 
primary Ab B: Representative blot of TRPV4 (98kDa) probed using Alomone primary Ab. β-actin 
loading controls (42kDa) shown in blot below dotted blue line. (RBL: rat brain lysate Muc: mucosa, 
SM: smooth muscle). Membrane was cut at 55kDa (dashed blue line) and each half probed with the 
appropriate Abs. C: Quantified data of TRPV4 expression by densitometry. Each TRPV4 band is 
normalized to its corresponding β-actin loading control.  Samples were run in duplicate and 
averaged. Results for each tissue type are similar when using either primary Ab; mucosal lysates 
have significantly higher TRPV4 expression than in smooth muscle lysates when probed with either 
primary Ab. No significant difference observed between Abs for either tissue type assessed. Data 
sets expressed as % medians [25%, 75%], Abcam; n=5, Alomone; n=8, * p <0.05, Mann-Whitney, 
Alomone vs. Abcam. 
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β-actin  
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primary Ab were not significantly different from the other, both confirming the integrity of Abs 
and providing robust evidence of the presence of TRPV4.  
Once the western protocol was optimised, TRPV4 expression was assessed in human 
mucosal biopsies. Biopsies were very small, therefore it was important the protocol was fully 
optimised before attempting to evaluate these samples, as failures in the process would 
waste large proportions of sample. The exact same RBL positive control was again used for 
these blots, providing reassurance of correct band size. Once again, clear bands can be 
observed at the same molecular weight (kDa) as the positive control for 3 of the 4 mucosal 
lysates assessed, thereby confirming presence of TRPV4 in these samples (figure 3-6).  
Quantification was not necessary, as the purpose of these blots was to simply confirm 
presence of TRPV4 in human biopsies and support the previous findings from 
immunohistochemistry. 
 
 
 
 
 
 
 
Figure 3 – 6. Detection of TRPV4 in human bladder mucosa biopsies. Mucosal bladder biopsies 
from four aging male patients assessed for presence of TRPV4 by western blot. These biopsies were 
taken from a healthy position in the bladder from patients undergoing surgery to collect further biopsies 
from suspected or known tumour sites (sample #11, 12, 13, 14 - methods table 5). The rat brain lysate 
(RBL) sample used as the control here is the exact sample used for GP western blots previously. The 
membrane was first probed for TRPV4 (A), which can be observed as bands at 98kDa. The membrane 
was then stripped and re-probed for β-actin (B) with bands at 42kDa. 3 of the 4 samples assessed have 
a positive band at 98kDa confirming presence of TRPV4. Sample #11 is negative for TRPV4 however 
this is likely due to sample degradation due to reuse.  
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3.4.2 FUNCTIONAL CHARACTERIZATION OF TRPV4 IN THE BLADDER  
It was first important to characterise the functional outputs of TRPV4 in bladder tissues and 
for this purpose, the effect of TRPV4 activation on ATP release and bladder contractions 
were examined, as ATP release from the urothelium and smooth muscle contraction are two 
essential physiological responses critical for correct bladder function.  
3.4.2.1 GSK1016790A – A POTENT AND SELECTIVE TRPV4 AGONIST 
This TRPV4 agonist was used for the majority of experiments in this thesis. As such, it was 
of high importance to select a concentration that was most physiologically relevant (activate 
a proportion of receptors similar to that which would occur in response to a stimuli within the 
body) and provide reproducible results. In current literature, a concentration of 10μM is 
commonly used for infusion of isolated whole mouse bladders to stimulate contractions 
(Thorneloe et al., 2008), and concentrations of 100nM-1μM are used for eliciting Ca2+ influx 
(Egbuniwe et al., 2014; Thorneloe et al., 2008) and 30nM-300nM to induce ATP release in 
various cell types (Mihara et al., 2011; Shahidullah et al., 2012). One study used 300nM 
GSK to generate contractions in intact bladder strips from mice (Thorneloe et al., 2008). This 
study, along with another, demonstrated that GSK is inactive against TRPV1 and TRPM8 
channels up to concentrations of 20μM, demonstrating no modulation of Ca2+ influx in HEK 
cells expressing these channels(Willette et al., 2008). It is suggested to act by recruiting 
previously inactive channels, rather than through increasing elevation of basal 
activity(Sullivan et al., 2012). 
Previous preliminary experiments by the research group had identified 1μM GSK as the 
optimal concentration for eliciting reproducible ATP release and contractions in GP tissue, 
while remaining physiologically relevant (above EC50 , below maximal effect). To reinforce 
this, the effect of 0.3μM, 0.5μM and 1μM GSK on ATP release and contractions in GP 
bladder strips were assessed to determine the most appropriate concentration for 
experiments (figure 3-7). 
All 3 concentrations significantly enhanced ATP release in both mucosal and full thickness 
bladder preparations, with no significant difference between any (refer to table 8). No 
contractions were evoked in mucosal strips by GSK at any concentration. However, 1μM 
evoked a significantly stronger and more reproducible contraction in full thickness tissue 
strips than lower concentrations (proportion of successfully evoked contractions; 0.3μM – 
20%, 0.5μM – 25%, 1μM – 90%). This concentration is within a physiologically relevant 
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range and far below that which may have effects on other receptors, but is capable of 
evoking reproducible ATP release and a contraction in intact tissue strips. Therefore, 1μM 
was chosen for functional experiments.  
Table 8 - Quartiles (median [25%, 75%]) of ATP release and force elicited by various GSK 
concentrations in bladder tissues (referring to figure 3 – 7 graphs). 
 Tissue strip 0.3μM GSK 0.5μM GSK 1μM GSK 
ATP release  
(% of 
averaged 
controls) 
Mucosa 246 [191, 290] 197 [191, 359] 286 [174, 361] 
Full thickness 248 [171, 327] 221 [173, 281] 292 [184, 386] 
Force 
generated 
(μN/mg 
tissue) 
Mucosa 17.8 [12.8, 29.9] 8.5 [4.2, 33.2] 7.3 [0.6, 19.7] 
Full thickness 42.0 [10.1, 138.2] 48.4 [15.6, 216.4] 358.1 [195.3, 576.1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 7. Dose dependent effect of 
GSK1016780A on bladder functional outputs in 
GP. A: Median force of mucosal and full thickness 
contractions generated by range of GSK 
concentrations. No contractions observed in 
mucosa at any concentration, small contractions 
evoked at 0.3 and 0.5μM in full thickness (median 
force: 41.98 and 48.36μN respectively) with 
significantly greater contractions evoked at 1μM 
(median force: 358.1) B: Corresponding median 
ATP release from same bladder strips. All 
concentrations significantly increase ATP release 
from basal levels in both mucosa and full 
thickness. No significant difference in ATP release 
is observed between mucosa and full thickness or 
at different concentrations of GSK (data sets 
compared using Mann-Whitney test). For both 
graphs: data expressed as % medians [25%, 
75%], n=10 (0.3μM), n=8 (0.5μM), n=18 (1μM), 
Wilcoxon’s, graph B *p<0.05, drug intervention vs. 
control (basal levels [BL]). 
A 
B 
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3.4.2.2 TRPV4-INDUCED ATP RELEASE AND CONTRACTIONS IN BLADDER 
TISSUE STRIPS: GUINEA PIG 
The role of TRPV4 in regulation of ATP release and smooth muscle contraction was 
investigated. Separated mucosal and full thickness GP bladder strips were mounted to a 
contraction setup (described in figure 2-1 and 2-2). Both changes in ATP release and force 
were measured as functional outputs in response to specific activation of TRPV4 using 1μM 
GSK1016790A (GSK - TRPV4 agonist) (refer to section 2.5.1).  Superfusate was sampled at 
3 time-points across a 5-minute intervention period (example in figure 3-8 A) and measured 
for ATP content. These values were averaged to provide a median ATP release and 
expressed as a percentage change from basal ATP levels taken as 100%. All data are 
normalized to tissue mass. GSK (1μM) significantly enhanced ATP release (figure  3-8 B) in 
both mucosal (235% [147%, 412%]) and full thickness (256% [217%, 378%]) tissue strips. 
GSK (1μM) also evoked contractions in full thickness strips (force μN/mg tissue: 246 [175, 
669]), which were significantly higher than mucosal sheets (force μN/mg tissue: 0.39 [0, 
3.57]) where no contractions were observed. The contractions evoked in full thickness strips 
were of similar magnitude to those evoked by the gold-standard muscarinic agent carbachol 
(50μM), however GSK was not capable of evoking contractions in mucosal sheets, whereas 
carbachol is(Sui et al., 2014) (figure 3-8 D). As can be seen in figure 3-8 C, TRPV4-derived 
contractions are sustained, usually for between 2-4 hours, unlike transient carbachol 
contractions. The force of GSK-induced bladder contractions did not coincide with the level 
of ATP release as demonstrated in figure 3-9, where data shows a Pearson correlation 
coefficient r value of -0.02963, implying a very weak, non-significant negative correlation. 
This suggests that ATP release and bladder contractions are independent in this model, 
where ATP is not required for or does not significantly modulate contraction. This is 
supported by findings observed with denuded smooth muscle strips (refer to figure 3-10). 
GSK evoked contractions in 70% of denuded smooth muscle strips (median force μN/mg 
tissue: 260 [74, 347], however significant ATP release was lost (103% [96%, 123%) with 
only 16% of strips releasing ATP beyond basal levels. (>120% of basal ATP release). This 
suggests that the majority of released ATP is derived from the urothelium, and also that this 
urothelium-derived ATP is not necessary for smooth muscle contraction.  
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Figure 3 – 8. Effects of TRPV4 activation on young GP bladder. A: Example of mucosal and 
full-thickness (FT) ATP release after exposure to 1μM GSK (TRPV4 agonist) B: Combined data – 
GSK (1μM) increased ATP release. ATP release across the 3 time-points (as seen in A) was 
averaged for each bladder (n=9 bladders) and data presented as % medians [25%, 75%], p value 
shown, Wilcoxon’s, drug intervention vs. control. C: Record of contraction induced by 1μM GSK in 
mucosal and full thickness bladder strips. D: Median values of mucosal and full thickness 
contractions, with record of single 50μM carbachol (CCh) contraction for reference (note Log2 Y 
axis). GSK does not trigger a contraction in mucosa, but does in full thickness. The contractions 
observed in full thickness strips are significantly greater than those observed in mucosa. Data sets 
are expressed as % medians [25%, 75%], n=8, Mann-Whitney, mucosa vs. full thickness.  
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Figure 3 – 9. Relationship between 
GSK1016790A-induced contractions 
and ATP release. No correlation observed 
between the force of contraction and level of 
ATP release in young GP full thickness strips. 
Pearson correlation r value: -0.02963,  n=18. 
Figure 3 – 10. Effect of denuding GP 
bladder strips on GSK1016790A-
induced changes in ATP release and 
force. Shown alongside mucosa and full 
thickness tissue for comparison. A: Median 
force of mucosal, full thickness and 
denuded smooth muscle tissue 
contractions generated by 1μM GSK. No 
significant difference observed between 
force of contraction generated in full 
thickness or denuded smooth muscle 
strips. B: Corresponding median ATP 
release from same bladder strips. Denuded 
smooth muscle tissue does not release 
ATP in response to GSK. Data sets 
expressed as % medians [25%, 75%], 
n=10, * p ≤0.05, Wilcoxon’s, drug 
intervention vs. control. Data sets 
compared using Mann-Whitney, e.g. full 
thickness vs. denuded smooth muscle. 
Protocol: figure 2-3 methods. 
A 
B 
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3.4.2.2.1 ORIGIN OF TRPV4-INDUCED ATP RELEASE 
For this purpose, mucosal, denuded smooth muscle and full thickness strips were 
challenged with 1μM GSK, allowing differentiation between tissues. To determine the 
tissue(s) responsible for the ATP release evoked by GSK, the raw data must be analysed 
(figure 3-11). Observing the ATP release as a relative change from basal levels in the form 
of a percentage (normalized to controls) will mask the relative quantities of ATP being 
released from each tissue preparation. Figure 3-12 shows that significant ATP release is 
evoked by GSK in both mucosa and full thickness tissue, but not denuded (ρMoles ATP/min: 
muc - basal; 55 [43, 172], GSK; 140 [46, 455], denuded - basal; 9 [6, 23], GSK; 16 [6, 37], 
full thick - basal; 12 [5, 34], GSK; 16 [37, 99]). The quantity of ATP released per gram from 
full thickness bladder was significantly less than that from separated mucosa. This indicates 
that the DSM and other underlying tissues in full thickness bladder do not contribute to GSK-
induced ATP release, as normalizing to tissue mass in this tissue preparation significantly 
reduces both basal and agonist-induced ATP release, implying that these tissues are 
redundant regarding ATP release. This and the fact that denuded smooth muscle is 
incapable of releasing ATP in response to GSK, implies that all GSK-induced ATP release is 
from the mucosa.  
Additionally, mucosa released significantly more basal ATP per gram of tissue than both 
denuded smooth muscle and full thickness tissue. This again implies that the majority of 
basal ATP release originates from the mucosa. 
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Figure 3 – 11. GSK1016790A-induced ATP release from different bladder tissue 
preparations: Raw data. Graph of raw data representing ρmoles of ATP released per gram of 
tissue per minute, before normalizing to controls. GSK significantly enhanced ATP release from 
mucosal and full thickness strips, but not from denuded smooth muscle tissue. The GSK-induced 
ATP release from mucosa was significantly greater to that from full thickness (not shown). Basal 
ATP release from mucosa was significantly greater than basal ATP release from both denuded and 
full thickness tissue (not shown). Basal release from full thickness was not different to denuded. ATP 
release expressed as ρmoles/g tissue/min medians [25%, 75%], mucosa and full thickness n=8, 
denuded n=10, p values shown, Wilcoxon’s, drug intervention vs. control. Unpaired data sets 
compared using Mann-Whitney e.g. mucosa vs. full thickness. 
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3.4.2.3 TRPV4-INDUCED ATP RELEASE AND CONTRACTIONS IN BLADDER 
TISSUE STRIPS: HUMAN 
Human mucosal biopsies taken from macroscopically healthy tissue positions in bladders 
from male patients >65 YOA with suspected or known tumours were also investigated. GSK 
(0.3μM and 1μM) significantly enhanced ATP release, however the times after initial 
exposure for onset and maximal ATP release were different for each concentration. 1μM 
GSK did not evoke significant ATP release until 3minutes, with the peak at 10 minutes and 
return to basal levels at 20 minutes. 0.3μM GSK did not evoke significant ATP release until 
5minutes, with the peak at 20 minutes. The peak ATP release for each concentration were 
similar (0.3μM; 20min - 235% [155%, 427%], 1μM; 10min – 190% [149%, 467%]). Despite 
different onset and peak times, ATP release was not significantly different between either 
concentration at any time-point. However, 1μM was used throughout the study as the 
dynamics of ATP release were more consistent and this allowed reliable comparison with 
GP tissue. A noticeable contraction was evoked in 1 of the 11 mucosal sheets (sample #2 in 
methods table 5)(figure 3-12 B(i)1) and it was noted that this mucosal sheet was the only 
biopsy examined with abundant intact smooth muscle attached, confirmed by confocal 
microscopy performed on this sample after physiological experimentation (figure 3-12 B ii). 
All other mucosal sheets remained relaxed (figure 3-12 B2). 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 12. Effect of TRPV4 activation on aging human bladder biopsies.  A: Both 
1μM (light grey bars) and 0.3μM (dark grey bars) GSK significantly enhanced ATP release from 
mucosal bladder biopsies (aging male patients, suspected or known tumours, >65 YOA, biopsy 
taken from macroscopically normal area) over a 20minute period. Times of onset and peak ATP 
release differed between concentrations. Data sets expressed as % medians [25%, 75%],1μM; 
n=10, 0.3μM; n=11, * p ≤0.05, ** p ≤0.01, Wilcoxon’s, drug intervention vs. control. Data sets 
compared using Mann-Whitney, 1μM GSK vs. 0.3μM GSK. B(i): Example trace recordings of tension 
during challenge with 1μM GSK in human mucosal biopsies. B(i)1: Contractile response of a 
mucosal biopsy (smooth muscle attached) to GSK (B(ii) confocal image of SM from biopsy used for 
this tension recording). B(i): 2. Record of common contractile activity of human mucosal biopsies 
during challenge with GSK. 
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3.4.3 MECHANISMS UNDERLYING TRPV4-INDUCED MUCOSAL ATP 
RELEASE  
Antagonists of various receptors and molecules postulated to be involved in the mechanism 
for TRPV4-related ATP release were utilized to explore the potential underlying signalling 
pathways. Refer to methods section, figure 2-4 for detailed description of protocol used for 
the following antagonist studies. 
3.4.3.1 CONTROL EXPERIMENT 
The majority of functional experiments in this thesis require 3 repeated exposures of tissue 
to 1μM GSK, with the second including an antagonist, with ATP release as the focus 
variable. As such, a control experiment was performed to further assess the reproducibility 
of ATP release in response to 3 successive exposures to GSK (figure 3-13), in accordance 
with the protocol used for antagonist studies (refer to figure 2-4), but omitting any 
antagonist. This was used to confirm that during antagonist studies, any observed reduction 
in ATP release is due to effects of antagonist, and not a consequence of an inability of GSK 
to re-evoke ATP release.  
All 3 successive exposures to GSK significantly enhanced ATP release in both mucosal and 
full thickness bladder preparations (refer to table 9), with no significant difference between 
any. This confirmed that successive use of 1μM GSK in accordance with the ‘antagonist 
protocol’ evokes reproducible ATP release. A contraction was evoked with first exposure, 
however following exposures were incapable of eliciting further contractions and this was 
observed throughout all the similar experiments performed in this thesis.  
 
 
 
118 
 
Table 9 - Quartiles (median [25%, 75%]) of ATP release and force elicited by 3 successive 
exposures to 1μM GSK in bladder tissues (referring to figure 3 – 13 graph). 
 Tissue strip Exposure 1 Exposure 2 Exposure 3 
ATP release  
(% of 
averaged 
controls) 
Mucosa 305 [222, 412] 181 [171, 226] 217 [115, 259] 
Full thickness 345 [190, 434] 233 [174, 375] 161 [147, 224] 
Force 
generated 
(μN/mg 
tissue) 
Mucosa 10.7 [2.5, 19.5] 5.6 [2.5, 10.87] 1.1 [0,3.8] 
Full thickness 154.3 [55.9, 187.6] 6.4 [3.5, 8.5] 2.1 [0.9, 13.9] 
 
3.4.3.2 SELECTIVE BLOCKADE OF TRPV4 USING HC-067047 
HC-067047 (HC) was used at a concentration of 1μM for predominant blockade (>95%) of 
TRPV4 receptors. The ATP release triggered by GSK (0.5μM) was significantly reduced by 
HC-067047 to near basal levels in both tissue types (mucosa; GSK con - 221% [164%, 
312%], GSK W/ HC - 105% [94%, 119%], full thick; GSK con - 180% [175%, 182%], GSK 
W/ HC - 113% [102%, 133%]) (figure 3-14). This confirms that all ATP release observed 
when using GSK is a result of specific TRPV4 activation and not unspecific action of GSK 
on other related receptors, such as TRPV1. HC also significantly reduced basal ATP 
release in mucosa but not full thickness strips (mucosa; 92% [61%, 103%], full thick; 80% 
Figure 3 – 13. Effect of repeated 
exposure to GSK1016780A on GP 
bladder functional outputs. A: Median 
force of mucosal and full thickness 
contractions generated by 3 exposures to 
1μM GSK. No contractions observed in 
mucosa at any concentration, a large 
contraction evoked in FT with first 
exposure, which is lost (significantly less) 
with successive exposures. B: 
Corresponding median ATP release from 
same bladder strips. All exposures 
significantly increase ATP release from 
basal levels in both mucosa and full 
thickness to a similar level. No significant 
difference in ATP release is observed 
between mucosa and full thickness or 
during consecutive exposures to GSK. For 
both graphs: data expressed as % medians 
[25%, 75%], n=10, Wilcoxon’s, graph B 
*p<0.05, drug intervention vs. control (basal 
levels [BL]). Protocol: figure 2-4 methods. 
A 
B 
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[65%, 106%] of control). Data from human mucosa indicate that antagonism of TRPV4 
reduces basal ATP release, although it took a longer time for the effect to occur (relative 
change in ATP release from basal levels: 10min; 95% [80%, 130%], 15min; 62% [43%, 
100%], 20min; 74% [37%, 80%]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 14. Effect of TRPV4 antagonist HC-067047 on ATP release in bladder 
strips. A: HC-067047 (1μM) significantly reduces ATP release triggered by GSK (0.5μM) in GP 
tissue. Light grey bars: Averaged ATP release from pre and post control interventions of 0.5μM 
GSK. Dark grey bars: ATP release from middle drug intervention of 1μM GSK with 1μM HC. Data 
sets expressed as % medians [25%, 75%], n=7, p values shown, Wilcoxon’s, GSK averaged 
pre/post control vs. GSK W/ HC-067047. Protocol: figure 2-4 methods. B: (i) 1μM HC-067047 
significantly reduces basal ATP release in GP mucosal strips, but not in GP full thickness strips. 
Data sets expressed as % medians [25%, 75%], n=8, p values shown, Wilcoxon’s, drug 
intervention vs. control. Protocol: figure 2-3 methods. (ii) Raw ATP release data from (i) expressed 
as median release/g tissue/min. C: (i) 1μM HC-067047 reduces basal ATP release in human 
mucosal biopsies after 20min. Data sets expressed as % medians [25%, 75%], n=7, p values 
shown, Wilcoxon’s, drug intervention vs. control. (ii) Raw ATP release data from (i) expressed as 
median release/g tissue/min. 
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3.4.3.3 SPECIFIC PATHWAY FOR TRPV4-INDUCED ATP RELEASE 
The mechanisms for ATP release from tissue including the urothelium are complex and may 
involve several processes including vesicular exocytosis, conductive pathways (connexin 
and pannexin channels) and various transporters(Birder and Ruggieri, 2012). The 
involvement of these processes in the release of ATP specific to TRPV4 activation was 
further explored (figure 3-15). The pannexin /connexin channel inhibitor carbenoxolone 
(100μM) significantly reduced GSK-induced ATP release in both tissue types by 
approximately 90% (mucosa; GSK con - 262% [196%, 443%], GSK W/ Carb - 119% [85%, 
207%], full thick; GSK con - 326% [202%, 208%], GSK W/ Carb - 120% [87%, 153%]). 
Brefeldin A (10μM), an inhibitor of vesicular transport-mediated ATP release, had no effect 
on GSK-induced (TRPV4-activted) ATP release from both tissue types (mucosa; GSK con - 
236% [192%, 357%], GSK W/ Bref A - 228% [94209 264%], full thick; GSK con - 206% 
[149%, 277%], GSK W/ HC - 223% [178%, 276%]). These findings suggest that the 
observed ATP is released via conductive pathways, with little or no involvement of vesicular 
transport.  
 
 
 
 
 
Figure 3 – 15. Effect of inhibitors of various ATP release pathways on GSK1016790A-
stimulated ATP release from GP bladder tissue. A: Carbenoxolone (100μM) significantly reduces 
GSK-induced ATP release in both mucosal and full thickness strips. n=9. B: Brefeldin A (10μM) has 
no effect on GSK-stimulated (TRPV4-activted) ATP release in both mucosa and full thickness strips. 
Data sets expressed as % medians [25%, 75%], n=5, p ≤0.05, Wilcoxon’s, GSK pre/post average 
vs. GSK W/ antagonist. Light grey bars: Averaged ATP release from pre and post control 
interventions of 1μM GSK. Dark grey bars: ATP release from middle drug intervention of 1μM GSK 
with a specific antagonist. 
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3.4.3.4. ROLE OF Ca2+ AND RELATED SIGNALLING IN TRPV4-MEDIATED ATP 
RELEASE  
The dependence of TRPV4-mediated ATP release on influx of extracellular Ca2+ was 
explored (figure 3-16). A Ca2+-free modified Tyrode’s solution was used for this purpose 
(described in methods section 2.1.1.1), providing an extracellular environment free from 
Ca2+. The effect of 1μM GSK on ATP release is abolished in the absence of extracellular 
Ca2+ (mucosa; GSK W/Ca2+ - 202% [153%, 332%], GSK W/O Ca2+- 111% [101%, 125%], 
full thick; GSK con - 198% [175%, 216%], GSK W/ Carb - 129% [93%, 159%])(figure 3-17: 
A). This tight dependence on extracellular Ca2+ demonstrates that  urothelial TRPV4 
functions mainly as a Ca2+ influx pathway, which was also observed in cultured urothelial 
cells under 4α-PDD (non-specific TRPV4 activator) stimulation (Gevaert et al., 2007).  
Various other channels and signalling molecules were investigated in an attempt to 
determine the pathway underlying TRPV4-mediated ATP release. The Ca-activated Cl 
channel (CaCC) blocker NPPB (100μM) was also ineffective in reducing GSK-induced ATP 
release (mucosa; GSK con - 188% [143%, 255%], GSK W/ NPPB - 243% [219%, 345%], full 
thick; GSK con - 241% [191%, 291%], GSK W/ NPPB - 197% [156%, 327%])(figure 3-17: 
B). Genistein (100μM; selective tyrosine protein kinase inhibitor) suppressed GSK-induced 
ATP release to below basal levels in both tissue preparations (mucosa; GSK con - 221% 
[184%, 346%], GSK W/ Gen - 93% [75%, 119%], full thick; GSK con - 221% [191%, 409%], 
GSK W/ Gen - 93% [72%, 140%])(figure 3-16: C), suggesting a role for tyrosine protein 
kinases in either the downstream signalling pathway for TRPV4-mediated ATP release, or in 
the modulation of TRPV4 channels themselves. 
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Figure 3 – 16. Effects of a Ca2+-free 
extracellular environment and inhibitors of 
various signalling molecules and channels 
on GSK1016790A-stimulated ATP release 
from GP bladder tissue. A: Removal of Ca
2+
 
from Tyrode’s superfusate significantly reduces 
GSK-stimulated ATP release, n=8. B: NPPB 
(100μM; inhibits Ca
2+
-sensitive chloride 
currents) has no effect on GSK-induced ATP 
release, n=6. C: Genistein (100μM; selective 
protein tyrosine kinase inhibitor) significantly 
reduces GSK-stimulated ATP release, n=8. All 
data sets expressed as % medians [25%, 
75%], p values shown, * p ≤0.05, Wilcoxon’s, 
GSK pre/post average vs. GSK W/ antagonist 
or Ca
2+
-free Tyrode’s. Light grey bars: 
Averaged ATP release from pre and post 
control interventions of 1μM GSK. Dark grey 
bars: ATP release during middle drug 
intervention of 1μM GSK with a specific 
antagonist/Ca
2+
-free Tyrode’s. 
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 3.4.3.4.1 TRPV4 ACTIVATION RAISES INTRACELLULAR Ca2+  
 
 
 
 
 
 
The ability of TRPV4 receptor activation to cause Ca2+ influx was directly investigated in 
freshly-isolated urothelial cells. Live-cell Ca2+ imaging demonstrated a Ca2+ rise in isolated 
urothelial cells from GP bladders in response to TRPV4 activation (figure 3-16: A). The 
averaged data from 7 bladders revealed that TRPV4 activation (GSK, 1μM) significantly 
raises [Ca2+]i from resting levels (resting Ca
2+; 140.3nM [85.5 nM, 169.0 nM], GSK; 283.2 nM 
[249.4 nM, 356.2 nM]), providing further evidence for the importance of Ca2+ in TRPV4-
mediated signalling (figure 3-16: B). Thus, it is likely that extracellular Ca2+ entry, resulting in 
increased intracellular Ca2+, is involved in TRPV4-mediated ATP release. 
 
 
 
 
 
 
Figure 3 – 17. Effect of GSK on intracellular Ca
2+
 concentration. A. GSK (1μM) generates a Ca
2+
 
transient in a freshly isolated single urothelial cell from GP bladder. B. Averaged data; GSK (1μM) 
evokes a significant rise in [Ca
2+
]i. Data sets expressed as % medians [75%], n=7, p value shown, 
Wilcoxon’s, drug intervention vs. resting control.    
  
A B 
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3.4.3.5 ROLE OF EPITHELIAL SODIUM CHANNELS (ENAC) 
As with TRPV4 channels, previous literature has also demonstrated a reduction in stretch-
evoked ATP release with blockade of mechanosensitive ENaC channels from both the 
mucosa of whole isolated rat bladders and single urothelial cell preparations (Birder et al., 
2003; Du et al., 2007). As such, the possibility of a relationship between the two channels 
was investigated with regard to TRPV4-mediated ATP release. Preliminary experiments 
using amiloride  (1mM) to block ENaC channels during stimulation of ATP release with GSK, 
revealed a substantial release of ATP throughout the exposure of tissue to amiloride. As 
such, the effect of amiloride on basal ATP release was investigated (figure 3-18 A). Indeed, 
amiloride (1mM) significantly increased ATP release, with a delay of between 10-20minutes 
and peak release at 40minutes in both tissue preparations (peak release: mucosa; 287% 
[200%, 441%], full thick; 371% [275, 517])(table 10). Significant ATP release was lost after 
90minutes. The antagonist study protocol was adapted accordingly, with a 90minute pre-
control of amiloride before the 5minute GSK W/amiloride intervention (as opposed to the 
usual 10minute pre-control). This prevented interference from the amiloride-induced ATP 
release, such that any ATP release measured during the GSK W/amiloride period was 
attributable to TRPV4 activation and not due to amiloride.  
Table 10 - Quartiles (median [25%, 75%]) of ATP release elicited by 1mM amiloride in bladder 
tissues (referring to figure 3 – 18 A graph).   
 Tissue 
strip 
Time of exposure to amiloride (1mM) 
5min 10min 20min 40min 60min 90min 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 81 [66, 
134] 
110 [67, 
147] 
230 [148, 
288] 
287 [200, 
441] 
252 [165, 
344] 
153 [111, 
204] 
Full 
thickness 
105 [70, 
139] 
145 [86, 
185] 
233 [171, 
327] 
371 [275, 
517] 
279 [161, 
400] 
177 [126, 
241] 
 
Amiloride (1mM) significantly attenuated, but did not fully suppress GSK-induced ATP 
release in mucosa (45% reduction) and full thickness (25% reduction) strips (mucosa; GSK 
con - 222% [193%, 277%], GSK W/ Ami - 164% [123%, 247%], full thick; GSK con - 224% 
[203%, 245%], GSK W/ Ami - 151% [121%, 227%])(figure 3-18 B). Benzamil, a more potent 
derivative of amiloride, was also used to provide further evidence for these findings (figure 
3-18 C), as the non-specific effects of amiloride have been scrutinized. Preliminary findings 
showed that unlike amiloride, benzamil alone does not increase ATP release and as such, 
comparison of the targets of these two compounds may reveal the receptor/channel 
responsible for the ATP release observed with amiloride. Data suggests however that unlike 
amiloride, benzamil (100μM) does not have a suppressant effect, where a reduction in ATP 
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release was only observed in 2 of the 5 bladders assessed in mucosa and 3 of 5 in full 
thickness strips(figure 3-18 D)(mucosa; GSK con - 197% [153%, 235%], GSK W/ Benz - 
151% [82%, 204%], full thick; GSK con - 196% [149%, 228%], GSK W/ Benz - 145% [107%, 
219%]). Unfortunately, due to time constraints, only 5 bladders were assessed for benzamil, 
such that further repeats are needed to uncover any true trends. These findings suggest that 
ENaC channels may be partly involved in the TRPV4-mediated release of ATP, possibly 
through a cooperation of the two receptors. However, as amiloride and benzamil are non-
selective and block a variety of Na+ channels, the implications of these findings will be 
explored fully in the discussion. 
Figure 3 – 18. Effects of various Na+ channel blockers, employed to inhibit epithelial sodium 
channels (ENaC), on GSK1016790A-stimulated ATP release from GP bladder tissue. A: Amiloride  
(1mM) significantly increases ATP release from both tissue preparations with a 10minute delay, a peak 
release at 40minutes and a decline to near basal levels after 90minutes. Data sets expressed as % 
medians [25%, 75%], n=13, * p ≤0.05, ** p ≤0.01, *** p ≤0.001, Wilcoxon’s, drug intervention vs. control 
(basal levels). B: Amiloride (1mM) attenuates GSK-stimulated (1μM) ATP release. Data sets expressed 
as % medians [25%, 75%], n=13, p values shown, Wilcoxon’s, GSK pre/post average vs. GSK W/ 
amiloride. C: Benzamil (100μM) has no significant effect on GSK-stimulated ATP release, however due 
to time constraints, only 5 bladders were assessed. Paired data is shown in D, revealing individual 
trends of each repeat. For graph C, data sets expressed as % medians [25%, 75%], n=5, p values 
shown, Wilcoxon’s, GSK pre/post average vs. GSK W/ benzamil. Graph B and C; Light grey bars: 
Averaged ATP release from pre and post control interventions of 1μM GSK. Dark grey bars: ATP 
release from middle drug intervention of 1μM GSK with 1mM Na
2+ 
channel blocker.  
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3.4.4 ROLE OF TRPV4 IN STRETCH-EVOKED ATP RELEASE 
The highly specific TRPV4 antagonist HC-067047 was used to investigate the role of 
TRPV4 in stretch-evoked ATP release from the GP mucosa. Mucosal and full-thickness 
tissue strips (5-6mm) were stretched to 150% of their original length for 30seconds, and 
ATP release measured during and after the stretch (these parameters are based on 
preliminary work mentioned in section 2.5.1.1.3). A control experiment was performed to 
assess the viability and reproducibility of this protocol (figure 3-19).  Strips were 
successively stretched in this manner 3 times, with a 1hour recovery period between each 
(refer to 2.5.1.1.3 for full description of protocol). 150% stretch evoked significant release of 
ATP at 30seconds and 1minute after initial stretching, where ATP release subsided after 
2minutes.  
 
 
 
 
Figure 3 – 19. Effect of 3 successive mechanical stretches on ATP release in GP bladder strips. 
Mechnical stretch evokes significant ATP release at 30seconds and 1minute in both tissue types during 
each stretch repeat. The ATP release appears to subside after 2minutes. No signficiant differences 
were observed between the ATP released at 30seconds and 1minute during any of the 3 successive 
stretches (data sets compared using Mann-Whitney, e.g. mucosa; ATP release during stretch #1 
30seconds vs. mucosa; ATP release during stretch #3 30seconds). Data sets expressed as % medians 
[25%, 75%], n=5, p values shown, Wilcoxon’s, time after stretch vs. control.  
 
 
127 
These dynamics of ATP release were reproducible for a second and third stretch. This 
experiment was repeated for 5 bladders, such that statistics yielding significant differences 
are not possible. However, as is shown, the ATP release at 30seconds and 1minute in both 
tissue strips during all 3 stretches have a p value of 0.0625 compared to controls. This 
information was sufficient to begin experiments using antagonists to assess the role of 
TRPV4 in stretch-induced ATP release. 
To assess the involvement of TRPV4 in stretch-evoked ATP release, the same protocol 
used for the control experiment was followed, however TRPV4 was antagonised using HC-
067057 (1μM) during the second stretch. Tissue stretch during inhibition of TRPV4 with HC-
067047 still significantly raises ATP release from basal levels in both tissue preparations at 
30seconds and 1minute (mucosa; 30sec - 197% [145%, 233%], 1min - 202% [150%, 214%], 
full thick; 30sec - 218% [174%, 221%], 1min - 127% [102%, 200%]) (figure 3-20 A). 
However, the stretch-evoked ATP release during TRPV4-inhibition is in fact significantly less 
than that evoked without inhibition at 30seconds in both tissue preparations and at 1minute 
also in full thickness (mucosa; stretch con 30sec - 361% [294%, 517%], Stretch W/ HC - 
197% [145%, 233%], stretch con 1min - 292% [209%, 343%], Stretch W/ HC - 202% [150%, 
214%], full thick; stretch con 30sec - 331% [244%, 489%], Stretch W/ HC - 218% [174%, 
221%], stretch con 1min - 194% [137%, 255%], Stretch W/ HC - 127% [102%, 200%])(figure 
3-20 B).  These values translate to approximately a 50% reduction in the stretch-evoked 
ATP release when inhibiting TRPV4 (mucosa; 30sec - 61% reduction, 1min - 46% reduction, 
full thick; 30s - 49% reduction, 1min - 70% reduction). This suggests that TRPV4 is partly 
responsible for the stretch-induced ATP release from the bladder mucosa. 
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Figure 3 – 20. Effect of TRPV4 antagonist HC-067047 on mechanical stretch-induced ATP 
release in GP bladder strips. A: Stretch-induced ATP release during inhibition of TRPV4 receptors 
with HC-067047 (second stretch during protocol). Mechanical stretch stimulates significant ATP 
release during TRPV4 receptor inhibition. Data sets expressed as % medians [25%, 75%], n=11, * p 
≤0.05, Wilcoxon’s, time after stretch vs. control. B: Stretch-induced ATP release with (dark grey 
bars) or without (light grey bars) inhibition of TRPV4 (HC-067047; 1μM). Inhibition of TRPV4 
receptors significantly attenuates stretch-induced ATP release in both tissue types 30seconds and 
1minute after mechanical stimulation. At 2 and 3 minutes ATP release is close to basal control 
levels, with or without TRPV4 blockade. Data sets expressed as % medians [25%, 75%], n=11, p 
values shown, Wilcoxon’s, stretch W/O HC pre/post average vs. stretch W/ HC. Light grey bars: 
Averaged ATP release from pre and post stretch interventions. Dark grey bars: ATP release from 
middle stretch intervention with 1μM HC-067047. Refer to section 2.5.1.1.3 for protocol. 
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3.4.5 INFLUENCE OF TRPV4 ON BLADDER ROS PRODUCTION 
Superoxide (O2
−) production was measured in young GP full thickness bladder strips treated 
with either control Tyrode’s solution or 1μM GSK for 30minutes at 37°C, assessed using 
lucigenin chemiluminescence. In the absence of added agents, basal ROS production in full 
thickness tissue lysates was minimal and did not differ between control and treated (1μM 
GSK) groups (MLU: Tyr con - 35 [30%, 55%], GSK - 46 [39%, 122%])(figure 3-21). Addition 
of NADPH (100μM) significantly raised ROS production from basal levels in both groups, 
however no significance between groups was observed (MLU: Tyr con - 165 [118%, 222%], 
GSK - 270 [162%, 360%]). After addition of Tiron (10mM) ROS production was significantly 
supressed from the NADPH treatment, but was still significantly greater than that of basal 
levels (MLU: Tyr con - 86 [57%, 154%], GSK - 88 [129%, 211%]). No difference between the 
control and treated group was observed after addition of Tiron.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 21. Measurement of reactive oxygen species (ROS): Effect of pre-treatment with 1μM 
GSK1016790A on ROS production in young GP bladder. A: Kinetics of ROS
 
production over 
experimental time-course. 0-15minutes; basal ROS production, 15-30minutes; ROS production after 
additions of 100μM NADPH, 30-45minutes; ROS production after addition of 5mM tiron (O2
− 
scavenger). Data expressed as % medians [25%, 75%], control n=10, GSK n=10. B: Median light units 
(MLU) averaged across the 15minute period of each treatment. No significant difference in ROS 
production was observed between groups during any treatment. NADPH (100μM) significantly 
enhanced ROS production from basal levels in both tissues (**). ROS production in presence of Tiron 
was significantly less than during NADPH treatment (††), but still significantly greater than basal levels 
(**). Data sets expressed as % medians [25%, 75%], control n=10, GSK n=10, * p ≤0.05, **/†† p ≤0.01, 
Wilcoxon’s, control tissue basal vs. control tissue NADPH.  
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Addition of Tiron (superoxide [O2
-] scavenger) enabled the proportion of ROS composed of 
O2
- to be calculated. This revealed that activation of TRPV4 receptors by pre-treatment with 
GSK significantly enhances O2
- production in bladder tissue lysates (percentage increase 
from control: 136% [114%, 317%])(figure 3-22). TRPV4-induced O2
- production may effect 
bladder signalling and alter oxidative stress levels with further downstream implications. 
 
 
  
 
 
 
 
 
Figure 3 – 22. Measurement of reactive oxygen species (ROS): Effect of pre-treatment with 1μM 
GSK1016790A on ROS production in young GP bladder. A: Paired data - shows difference in O2
− 
production between control and GSK-treated full thickness bladder strips from each bladder 
investigated. n=10. B: Normalized data - O2
− 
production in control tissue from each bladder is 
normalized to 100% and O2
− 
production in GSK-treated strips expressed as % change from control. 
Pre-treatment with 1μM GSK as opposed to control Tyrode’s solution stimulates significantly greater 
O2
− 
production. Data expressed as % medians [25%, 75%], n=10, * p ≤0.05, Wilcoxon’s, pre-treatment 
1μM GSK vs. pre-treatment control Tyrode’s. 
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3.5 DISCUSSION 
This chapter identified the presence and expression of TRPV4 in the bladder and explored 
the effects of specific TRPV4 activation on mucosal ATP release and bladder contractility. 
Using the specific agonist GSK1016790A, the study has demonstrated a reproducible 
TRPV4-induced ATP release from the mucosa, but not from denuded smooth muscle, 
indicating the source of ATP and functional importance of this receptor in the bladder. In 
addition, the basic pathway underlying TRPV4-induced ATP release has been elucidated 
and further potential consequences of TRPV4 activation have been explored.  
 
3.5.1 IDENTIFICATION AND TISSUE LOCALIZATION OF TRPV4  
TRPV4 has previously been shown in urothelial tissue sections from mice and rats (Gevaert 
et al., 2007) by immunohistochemistry, and in the mouse mucosa and DSM by western 
blotting (Thorneloe et al., 2008; Yamada et al., 2009). The receptor has also been reported 
in isolated urothelial cells from human bladders in a small number of samples (Janssen et 
al., 2011). In GP bladder however, TRPV4 expression has only been suggested by using 
functional experiments by observations of TRPV4 agonist-induced whole-cell currents in 
isolated urothelial cells, where no conclusive studies using western blotting and IHC exist in 
current literature (Xu et al., 2009). In addition, detailed tissue distribution of this receptor in 
the bladder remains unclear. In this study, TRPV4 expression was demonstrated by IHC 
and western blotting in both human mucosa and GP bladder tissues with detailed 
information on tissue distribution.  
Immunohistochemistry demonstrated TRPV4 expression in the urothelium, suburothelium 
and DSM of GP bladder tissue, with highest expression in urothelium. Results from western 
blotting provides further proof for TRPV4 expression in both mucosa and DSM, with 
significantly higher expression in the mucosa. Together, these data identify the urothelium 
as the predominant site of TRPV4 expression in the bladder. To our knowledge, this is the 
first study to show expression of TRPV4 in GP bladder using these techniques, also 
indicating the tissue localization. TRPV4 expression in human mucosal biopsies was also 
confirmed using these techniques, corroborated by evidence from the aforementioned 
literature.  
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3.5.2 FUNCTIONAL CHARACTERIZATION OF TRPV4 IN THE BLADDER 
ATP release induced by specific TRPV4 activation has been previously demonstrated in a 
variety of intact tissues (Shahidullah et al., 2012) and isolated cell types (Egbuniwe et al., 
2014; Mihara et al., 2011; Silva and Garvin, 2008), as well as in cultured urothelial cells 
(Kullmann et al., 2009). TRPV4 has also been strongly implicated in stretch-induced ATP 
release from the bladder mucosa by previous studies observing either a reduced stretch-
induced ATP release from TRPV4-/- whole isolated bladders (Gevaert et al., 2007), or 
abolished stretch-induced ATP release from isolated urothelial cells using a broad TRP 
channel blocker (ruthenium red)(Mochizuki et al., 2009). TRPV4-induced bladder 
contractions have also been demonstrated in tissue strips and whole perfused bladders from 
mice using specific TRPV4 agonists (Birder et al., 2007; Gevaert et al., 2007; Thorneloe et 
al., 2008). However, the effect of specific activation of TRPV4 on ATP release using more 
physiologically relevant bladder preparations, especially in native urothelium and urothelium-
intact bladder tissue remains to be assessed.  
3.5.2.1 SELECTIVE ACTIVATION OF TRPV4 
Specific activation of TRPV4 by GSK1016790A evokes a reproducible, significant ATP 
release from the bladder mucosa. In GP full thickness bladder strips, the ATP release is 
accompanied by a strong contraction during first exposure to GSK, however this contractile 
phenomenon is non-reproducible with subsequent exposures.  
There is no correlation between the quantity of ATP release and magnitude of contraction, 
implying the two phenomena are relatively independent. This is supported by TRPV4 
activation in denuded smooth muscle strips, where no ATP release is observed but a 
contraction of similar magnitude to that in full thickness strips is still evoked. This provides 
evidence for functional expression of TRPV4 receptors in the detrusor smooth muscle 
(DSM), which are able to elicit contractions through a mechanism independent of urothelilal 
TRPV4 receptors and ATP release. This is supported by previous literature, which 
demonstrates separate functional roles for TRPV4 in both the urothelium (inducing ATP 
release [Birder et al., 2007; Gevaert et al., 2007]) and the DSM (direct contraction of smooth 
muscle [Thorneloe et al., 2008]), which have been shown to induce bladder overactivity in 
vivo. All observations together suggest that GSK-induced contractions result mainly from 
direct action on the DSM and not an indirect consequence of GSK-induced ATP release. 
Our findings also suggest that the majority of released ATP originates from the mucosa, as 
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no ATP release is observed in denuded DSM strips. However, communication between the 
mucosa and DSM may be necessary for ATP release from sources other than the mucosa.  
Shown both here and in a previous study, contractions stimulated by GSK are of similar 
magnitude to those induced by carbachol and are sustained over a period of a few hours 
(Thorneloe et al., 2008). This shows that by its large magnitude and sustained contraction 
TRPV4 is a potent inotropic regulator. On the other hand, unlike GSK-induced ATP release, 
contractions cannot be generated for a second time after a recovery period of 1 hour. Again, 
this can probably be attributed to the independent effects of GSK on the mucosa (ATP 
release) and directly on the DSM (contraction). It may be that the TRPV4 receptors involved 
in ATP release have transient dynamics, defined by the specific cellular environment and 
signalling pathways involved, such that they are returned to a resting state in less than 1 
hour. However, it is likely that TRPV4 receptors responsible for direct contraction of the 
DSM remain in an activated long openstate for longer in order to achieve the sustained 
contraction observed, resulting in refractory state and hence an inability to elicit a second 
contraction in the timeframe defined by this study. TRPV4 receptors have indeed been 
shown to elicit the sustained proinflammatory effects of other receptors such as proteolytic-
activated receptor 2 in DRG neurones(Poole et al., 2013). Desensitisation is another 
possibility. 
GSK was also successful in evoking ATP release from human bladder biopsies of healthy 
mucosal tissue from aging (>65YOA) male patients. Out of the 10 biopsies assessed, only 
one showed a contraction in response to TRPV4 activation, where this was the only biopsy 
with fully-intact smooth muscle (full thickness strip). This behaviour of intact human bladder 
provides a strong indication that, with the reproducible ATP release, human bladder 
responds to GSK in the same way as GP tissue, supporting use of GP tissue as a relevant 
and translatable additional model for investigation of TRPV4 in this study.  
3.5.2.2 SELECTIVE BLOCKADE OF TRPV4 
Antagonism of TRPV4 reduced intrinsic ATP release from unstimulated mucosal sheets, 
supporting a role for this receptor in maintaining basal release of ATP from the urothelium. 
This observation suggests that TRPV4 channels are opened under resting conditions, likely 
by endogenous activators such as mediators, temperature, pH changes and even small 
degree of stretch. This effect was only observed in separated mucosal sheets and not in 
intact full thickness tissue, thus indicating a urothelium-specific phenomenon. This finding 
lends weight to the physiological importance of this receptor in urothelial function. 
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Antagonism of TRPV4 in human mucosal biopsies also reduces basal ATP release, despite 
following a longer superfusion. This supports human relevance of this phenomenon.  
These initial experiments confirm the presence of TRPV4 and establish a functional role for 
these receptors in both urothelial ATP release and direct DSM contraction in the models 
used for this study.   
3.5.2.3 IMPLICATIONS OF TRPV4-MEDIATED ATP RELEASE 
As previously described, ATP is a critical signalling molecule in the bladder and as such, 
has a strong influence on correct bladder function. Not only can ATP influence bladder 
contraction through sensitization of bladder afferents (Rong et al., 2002), but it can also alter 
urothelial function and modulate interstitial and smooth muscle cells through purinoceptors 
(Elneil et al., 2001; Liu et al., 2009; Vlaskovska et al., 2001). It is well documented that 
TRPV4 may be involved in stretch-induced ATP release from the mucosa and therefore 
likely plays an important role in physiological bladder function. However, studies have 
identified an augmented basal ATP release from aging bladder mucosa (Sui et al., 2014) 
and augmented stretch-induced ATP release from the urothelium of pathological rat (Birder 
et al., 2003) and human (Yan Sun et al., 2001) bladders with interstitial cystitis. This 
augmented release has been shown to enhance sensation of pain through purinoceptor 
activation, however the responsible mechanism underlying this enhanced ATP release has 
not been identified. As this ATP is indeed capable of activating nociceptive purinergic 
recpetors under these conditions, it is feasible to assume this ATP is just as capable of 
modulating purinoceptors present on downstream effectors that also express these 
receptors. It has indeed been shown that ATP released from the urothelium can affect DSM 
contraction in a paracrine manner, suggesting urothelially derived ATP release is sufficient 
to reach and influence activity of deep effector tissues including smooth muscle, sensory 
nerve endings and interstitial cells, contributing to sensory modulation (Sui et al., 2014). 
TRPV4 activity is therefore exceptionally important, as the receptor has the ability to 
significantly influence bladder function through ATP release. As such, it is also possible that 
TRPV4 may contribute to the augmented ATP release observed during bladder pathologies 
and aging, and in doing so influence the progression of bladders into such pathological 
states. This highlights the importance of further investigation of this receptor, as modulation 
of TRPV4 and its associated signalling may provide a novel tool for regulating bladder 
pathologies and sustaining correct bladder function in older individuals.   
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3.5.3 ORIGIN OF TRPV4-INDUCED ATP RELEASE 
The mucosa was identified as the main source of TRPV4-induced ATP release. Denuded 
smooth muscle does not release ATP in response to TRPV4 activation, at least not without 
an intact mucosa, as synergy between the two tissues in full thickness bladder may grant 
smooth muscle-derived ATP release through various inter-tissue signalling. Raw data 
revealed that the quantity of ATP released in response to specific TRPV4 activation from 
mucosa was significantly greater per gram than full thickness bladder preparations. This 
implies the smooth muscle tissue in the full thickness strips is effectively redundant 
regarding ATP release, as when present, it reduces the ATP release per gram tissue. 
Together, these results provide strong evidence to suggest that the vast majority of ATP 
released in response to TRPV4 activation originates from the mucosa. As such, the ATP 
release observed from full thickness tissue shown in the figures of this study can also be 
attributed to the mucosa, without contribution from the underlying tissues. However, if there 
were a significant difference between the release of ATP from the mucosa and the release 
of ATP from full thickness tissue in response to a specific stimulant, this would imply the 
underlying tissues in the full thickness strip are influencing ATP release. That being said, no 
differences were observed between mucosal and full thickness strips in this study.  
Basal ATP release from denuded smooth muscle was negligible. Mucosa and full thickness 
tissue released ATP without stimulation, where per gram, basal release from mucosa alone 
was significantly higher than intact full thickness tissue. These findings imply that the 
mucosa is the source of intrinsic basal ATP release. 
3.5.4 PATHWAY FOR ATP RELEASE AND THE UNDERLYING SIGNALLING 
Stretch-induced ATP release from the urothelium is facilitated by a variety of pathways 
including vesicular exocytosis, conductive pathways (connexin and pannexin channels) and 
various ATP carrier proteins (Wang et al., 2005). General stretch-induced ATP release from 
isolated urothelial cells requires mobilization of intracellular Ca2+ and to a lesser extent 
extracellular Ca2+ entry, and is facilitated by vesicular transport (Birder et al., 2003). 
Mochizuki et al. also demonstrated that ATP release from isolated cells induced specifically 
by TRPV4 is also tightly dependent on extracellular Ca2+ entry. TRPV4-induced ATP release 
in other tissues also requires extracellular Ca2+ influx and is hemichannel-mediated 
(Shahidullah et al., 2012), with one study specifically identifying pannexin-1 as the 
responsible channel (Seminario-Vidal et al., 2011) and as such, these may also underlie the 
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TRPV4-induced ATP release in bladder mucosa. Currently however, the full pathway 
underlying TRPV4-induced ATP release remains unclear.  
3.5.4.1 VESICULAR OR CONDUCTIVE RELEASE & THE ROLE OF Ca2+ 
Results suggest that TRPV4-induced ATP release from the mucosa is facilitated by 
conductive pathways, as demonstrated by a near-complete abolition of ATP release (90% 
reduction) by the connexin/pannexin inhibitor carbenoxolone, with no significant reduction by 
the vesicular transport inhibitor brefeldin A. Removal of extracellular Ca2+ also abolished any 
observed ATP release and live-cell calcium imaging revealed a significant rise in intracellular 
Ca2+ upon activation of TRPV4 with GSK, both of which suggest that TRPV-induced ATP 
release is Ca2+-dependent, relying on extracellular Ca2+ influx. This is expected, as TRPV4 is 
a Ca2+ influx pathway. However, various studies provide evidence that Ca2+-dependent ATP 
release is facilitated by vesicular transport (Boudreault and Grygorczyk, 2004; Coco et al., 
2003) and another that ATP release through conductive pathways occurs under low 
[Ca2+](Stout et al., 2002), conflicting with this finding. These studies may be of little 
relevance here, as they were performed using astrocyte cells in culture, however they are 
currently the only studies to have investigated the underlying mechanisms of cell-swelling 
induced Ca2+-dependent ATP release. The results from this study are however, supported 
by others, which show that TRPV4-mediated ATP release from intact porcine lens 
epithelium requires extracellular Ca2+ influx and is hemichannel-mediated (Shahidullah et 
al., 2012), with another study in airway epithelial cells specifically identifying pannexin-1 as 
the responsible channel (Seminario-Vidal et al., 2011). These studies are therefore of 
greater relevance as they were performed in both whole tissue and cells from epithelia 
closely related to bladder epithelia, and assessed TRPV4-induced ATP release specifically. 
As such, taken together with results from this study, there is strong evidence supporting a 
Ca2+-dependent (extracellular influx), hemichannel-mediated mechanism for TRPV4-induced 
ATP release from the urothelium. A very recent and interesting study indicated that 
pannexin-1 hemichannels facilitate P2Y6 receptor-mediated ATP release from the rat 
urothelium in vivo, and confirmed urothelial pannexin-1 expression by confocal microscopy 
(Timóteo et al., 2014). These pannexin-1 channels may therefore also be utilized in the 
pathway underlying TRPV4-induced ATP release.  
3.5.4.2 Ca2+-ACTIVATED CHLORIDE CHANNELS 
To follow from this, various other signalling molecules and channels postulated to be 
involved in the underlying pathway were assessed. The CaCC blocker NPPB was used to 
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evaluate the possible role for these channels, as limited previous literature suggests that 
ATP release through hemichannels is associated with activation of Cl- channels (Cotrina et 
al., 1998). Blockade of CaCCs had no suppressive effect on TRPV4-induced ATP release, 
providing reassuring evidence that these channels are not involved in the pathway.  
3.4.5.3 ROLE FOR PROTEIN TYROSINE KINASES 
The potential role of protein tyrosine kinases was also evaluated using the inhibiter 
genistein, as again, these enzymes have been implicated in the modulation of both TRPV4 
and ATP release. The first report of TRPV4 regulation by PTK was by Xu et al. who 
elegantly demonstrated that hypotonic stress results in rapid phosphorylation of TRPV4 by 
src-family tyrosine kinases (SFKs) at the tyr-253 residue (Xu et al., 2003). This residue is 
conserved across all species and in the same study, was shown to be vital for hypotonicity-
induced TRPV4 channel activity. A further study demonstrated a crucial role for a newly 
identified N-terminal tyrosine residue in the activation of TRPV4 by mechanical stress and 
hypotonic cell swelling, but not for activation by the synthetic ligand 4αPDD. Again, SFK-
mediated phosphorylation of this site was induced by such stimuli and was a necessary 
initial step before TRPV4 could elicit its specific responses (Wegierski et al., 2009). Yet 
another study showed that hypotonic stress-induced ATP release from aortic endothelial 
cells requires PTK-mediated phosphorylation of an unidentified protein of 110kDa. TRPV4 
has a molecular weight of 98kDa and phosphorylation commonly shifts this by about 6kDa 
(Winkler et al., 1993), meaning the responsible protein could indeed be TRPV4, which has 
been identified in aortic endothelium (Watanabe et al., 2002b), however, this is simply a 
logical stipulation that requires much further investigation. Taken together, these studies 
provide strong evidence that mechanical stress first induces PTK-mediated phosphorylation 
of TRPV4, which is a necessary prerequisite for channel activity in response to such stimuli. 
The mechanisms by which PTKs recognise hypotonic and mechanical stress remain 
unclear, however it is well documented that mechanical stress up-regulates expression of 
PTKs (Zheng et al., 2004) and these kinases are involved in the hypotonic-stress response 
in many cell types (Edwards and Kapadia, 2000; Lepple-Wienhues, 1998; Xu et al., 2003), 
eliciting efflux of various solutes from the cell as a result (Musch et al., 1999). 
Indeed, our findings indicate that PTK activity is necessary for agonist-induced TRPV4-
mediated ATP release from the mucosa. Although phosphorylation is not necessary for 
TRPV4 activation by 4αPDD (Wegierski et al., 2009), the mechanism by which GSK 
activates TRPV4 to cause ATP release remains unclear and as such, the necessity for PTK-
mediated phosphorylation for GSK-induced channel activity is possible. In aggregate, our 
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findings with those of others provide substantial evidence that PTK-mediated 
phosphorylation is an important initial step for TRPV4-mediated responses. This reveals 
another step in the pathway underlying TRPV4-induced ATP release.  
3.4.5.4 INTERACTION WITH ENAC CHANNELS 
For some time, mechanosensitive epithelial sodium channels (ENaC) have been implicated 
in stretch-evoked ATP release in the bladder. Previous studies have demonstrated 
suppression of urothelially-derived, stretch-evoked ATP release using the ENaC channel 
blocker amiloride, by as much as 100% in one study (Du et al., 2007) and 70% (by 
hypotonic swelling) in another (Birder et al., 2003). As such, we investigated the possible 
interplay between TRPV4 and ENaC channels in TRPV4-mediated ATP release, as it is 
possible that TRPV4 may elicit a proportion of its effect through secondary activation of 
ENaC channels. Amiloride was successful in supressing GSK-induced ATP release in both 
mucosal and full thickness strips, providing evidence for this cross-talk. However, this was 
not replicated by the more potent derivative of amiloride, benzamil, and although only 5 
bladders were assessed, no obvious trend was observed in individual data sets, where GSK 
still evoked ATP release in the presence of benzamil in 60% of bladders assessed. As 
benzamil is more potent, it can be used at lower concentrations, activating target molecules 
with higher specificity. Indeed, at the concentrations used in this study, benzamil has been 
shown to reduce mechanosensitivity, indicating a specific effect on ENaC and degenerin 
channels (Deg, also mechanosensitive)(Page et al., 2007), as its other targets are not 
mechanosensitive. As the concentrations required for amiloride to efficiently block ENaC 
channels affect such a variety of other channels (TRPP3, TRPA1, ASIC, Na+/H+ exchanger, 
non-selectively inhibits mechanogated membrane-ion channels, urokinase-type 
plasminogen activator [see methods table 2 for citations]), conclusions drawn from 
amiloride-based experiments cannot be confidently specific to ENaC channels. Of these 
additional targets, TRPA1 and ASIC channels are expressed in the urothelium (shown in 
rat(Streng et al., 2008) and human and rat(Kullmann et al., 2009; Sánchez-Freire et al., 
2011) respectively). Evidence suggests that TRPA1 channels in the urothelium act to sense 
toxic and irritant substances, with no reported function in mechanosensation or ATP release 
to date. However, ASIC channels are implicated in both mechanosensation in the colon 
(Page et al., 2005) and ATP release from the rat urothelium (Sadananda et al., 2009). This 
suggests that in this case, the target for amiloride could be either ENaC or ASIC channels, 
as both appear to play roles in mechanosensation and ATP release. As such, assessing the 
effect of benzamil in additional bladders and investigating the effect of ASIC channel 
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blockers (e.g. gadolinium) may allow the responsible receptor to be determined. Our results 
have successfully identified that a proportion of TRPV4-induced ATP release requires the 
activity of another unknown receptor that is blocked by amiloride, with likely candidates 
being ENaC and ASIC channels. Previous literature (mentioned at the beginning of this 
segment) has suggested ENaC channels for this role and as such, ENaC channels are 
currently the more likely candidate. If such a cross-talk exists, where ENaC channels are 
responsible for a proportion of the ATP release elicited by TRPV4 activity, it may be possible 
to modulate urothelial ATP release with higher control, manipulating only a portion of the 
ATP release. In this way, symptoms of OAB could be controlled, with little interference on 
normal bladder function.  
Superfusion with amiloride alone generated significant release of ATP from both the mucosa 
and full thickness bladder, with a 10minute delay, peak release at 40minutes and return to 
basal levels after 60-90minutes. This agrees with findings in previous literature (Ferguson et 
al., 1997). Again, benzamil had no such effect and as such, the responsible molecule may 
be identified by comparison of the targets of each drug. However, the ATP release 
generated by amiloride may be multifactorial, owing to the multiple targets of amiloride  or it 
may be that the high concentration of amiloride used (1mM) activates a greater proportion of 
ENaC channels than benzamil at 100μM, eliciting an unknown effect, factors all of which 
need careful consideration. In summary, amiloride seems to evoke ATP release when used 
alone, however attenuates the ATP release evoked by stretch or TRPV4 activation, effects 
likely elicited through ENaC channel blockade. As such, direct inhibition of ENaC channels 
could indeed exacerbate symptoms of OAB through amplified ATP release, however careful 
manipulation of the signalling underlying its stretch-related function could provide some level 
of pharmacological control. This provides evidence that TRPV4 and its related signalling 
may be a more suitable and reliable target for intervention of OAB symptoms.  
3.4.6 STRETCH-INDUCED ATP RELEASE: A PROPORTION MEDIATED BY 
TRPV4 
Various studies have provided strong evidence to suggest that TRPV4 plays a pivotal role in 
stretch-dependent ATP release. A decreased stretch-evoked ATP release has been 
demonstrated in whole isolated bladders from TRPV4-null mice, however this model cannot 
confirm the tissue source of ATP release (Gevaert et al., 2007). Mochizuki et al. provided 
further evidence with suppression of stretch-evoked ATP release from single cultured  
urothelial cells using a TRPV4 knockout model and broad TRP antagonists (Mochizuki et al., 
2009). This study endeavoured to provide data of more physiological relevance, and as 
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such, to further investigate the channels responsible for physiological stretch-induced ATP 
release and the proportional roles each plays, the effect of specific TRPV4 antagonism on in 
vivo stretch-induced ATP release was investigated. A mechanical stretch of mucosal and full 
thickness strips to 150% of their original length for 30seconds generated significant release 
of ATP 30s and 1minute after initial stretch. This effect was significantly attenuated by 
inhibition of TRPV4 using the highly specific antagonist HC-067047. However, the stretch-
induced ATP release was still significant in the presence of HC-067047, with an 
approximate 50% suppression. This provides novel evidence for the role of TRPV4 in 
stretch-evoked ATP release, also indicating the involvement of one or more other stretch-
sensitive receptors. As ENaC channels have been strongly implicated in stretch-evoked ATP 
release, it would be interesting to assess the effect of ENaC channel blockade, and more so 
the effect of simultaneous TRPV4/ENaC channel blockade using this stretch model on 
stretch-evoked ATP release. This may reveal the proportional contributions of the various 
mechnosensative channels implicated in this role.  
3.4.7 TRPV4-INDUCED ATP RELEASE – A POSSIBLE MECHANISM  
The experiments performed have revealed a substantial proportion of the signalling pathway 
underlying TRPV4-induced ATP release and taken with previous findings, provided sufficient 
evidence to confidently postulate a comprehensive underlying mechanism. For full 
deliberation, differences between the agonist-induced and the more physiologically relevant 
stretch-induced pathways must be considered. The postulated mechanism for stretch-
induced ATP release mediated by TRPV4 activation is as follows; 1. Mechanical stretch 
activates SFKs, which phosphorylate TRPV4 at tyr-253, permitting channel activity 2. 
TRPV4 mediates Ca2+ influx, raising intracellular [Ca2+]; Ca2+ directly activates pannexin-1 
channels, which mediate both the serosal and apical release of ATP 3. ATP activates P2Y 
receptors on neighbouring urothelial cells, in turn activating further pannexin-1 channels via 
Ca2+ entry, propagating and amplifying ATP release throughout the urothelium 4. Serosally 
released ATP is available to stimulate downstream effector tissues such as smooth muscle, 
interstitial and suburothelial cells and sensory nerve endings expressing purinergic/purine 
receptors, possibly resulting in sensory modulation (figure 3-23). ENaC channels have been 
included in this mechanism, as preliminary evidence suggests they may mediate a small 
proportion of TRPV4-induced ATP release. Although the underlying mechanisms remain 
unknown, it is an appealing thought that the SFKs that activate TRPV4 also activate ENaC 
channels, however ENaC channels are predominantly activated by serine proteases, so this 
is unlikely (Rossier and Stutts, 2009). 
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As previously described, this study and others provides strong evidence for steps 1, 2 and 4. 
Pannexin channel activity and evidence supporting its viability as the key facilitator of ATP 
release in this pathway has only been documented in very recent years. Our study 
demonstrated abolition of TRPV4-induced ATP release with carbenoxolone, implying a 
connexin or pannexin hemichannel as the pathway for ATP release. Connexin expression in 
the bladder has been previously described, with Cx26 localized to the urothelium, Cx43 to 
the lamina propria and strong expression of both Cx43 and Cx45 in the DSM (Ikeda et al., 
2007). This narrows the possibilities down to Cx26 or a pannexin channel, however Cx26 is 
closed by cytoplasmic Ca2+ (Lopez et al., 2013) and is not modulated by phosphorylation like 
other connexins (Lampe and Lau, 2004; Traub, 1989). As such, the Ca2+ influx facilitated by 
TRPV4 will neither directly nor indirectly (for example, through calmodulin and CaMKII 
signalling) activate Cx26 allowing ATP release from urothelial cells. Novel evidence 
supporting a role for pannexin-1 channels in ATP release from various cell types and indeed 
the urothelium has recently been published (Iglesias et al., 2009; Locovei et al., 2006a). 
Timóteo et al. identified pannexin-1 channels in the urothelium and showed them to be 
functional, facilitating P2Y6-receptor induced ATP release and that this is responsible for 
UDP (specific P2Y6 agonist)-induced OAB (Timóteo et al., 2014). Interestingly, they found 
that pannexin-1 is expressed throughout the urothelium and is not limited to one cell layer, a 
pattern similarly identified for TRPV4 in the current study, suggesting possible cooperation 
between these receptors.  Further studies have revealed that pannexin-1 can be activated 
by Ca2+ and that this is likely a direct effect of the ion, rather than intermediate Ca2+ 
signalling (Locovei et al., 2006b). Evidence also suggests that Ca2+ activation of pannexin-1 
is a result of raised intracellular Ca2+, as the channel does not respond to extracellular Ca2+ 
(Bruzzone et al., 2005). Unlike connexins, pannexin-1 therefore presents a novel calcium-
activated conductive ATP release pathway, meaning Ca2+-dependent ATP release does not 
need to be exclusive to vesicular release, as previously thought. This is in line with our 
findings, where previous studies and ours show decreased (Ca2+-dependent) ATP release 
with the pannexin/connexin channel blocker carbenoxolone. Finally, a study in primary 
airway epithelial cells provided evidence that TRPV4-mediated ATP release induced by 
membrane stretch is achieved through pannexin-1 channels, directly linking the 
two(Seminario-Vidal et al., 2011). Taken together, the current evidence supports a role for 
pannexin-1 channels in facilitating Ca2+-dependent, stretch-evoked ATP release from the 
urothelium, mediated by TRPV4.  
The pathway for specific GSK-induced (agonist-induced) ATP release, as opposed to 
stretch-induced, would follow the same steps, varying only in the initial stage. GSK is 
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thought to activate TRPV4 either by direct activation, acting as a synthetic ligand, or by 
recruiting previously inactive receptors.  In either case, the mechanism would bypass the 
SFK stage, where GSK would activate TRPV4, either directly or through recruitment of new 
receptors, in both cases eliciting Ca2+ influx thereby initiating the ATP release mechanism. 
However, findings from this study indicated that PTK activity is still necessary for GSK-
induced ATP release. As discussed, TRPV4 phosphorylation by SFKs appears to be a 
necessary prerequisite for channel activity. If all PTKs are inhibited, as was done in this 
study, the proportion of basal phosphorylated TRPV4 receptors able to be activated may be 
reduced, resulting in the reduced agonist effect observed. Therefore, although the agonist-
induced ATP release pathway for TRPV4 may not involve the same initial SFK step 
described for the stretch-induced pathway, it may still require a basal level of SFK activity to 
prime the receptors (through phosphorylation) for activation by GSK. It is highly likely the 
direct contractile effect of GSK on the DSM is elicited simply by Ca2+ influx, activating the 
contractile machinery through the common Ca2+-dependent mechanism.  
The summarised findings from this study, taken with those from supporting literature, define 
a plausible and highly evidenced mechanism for stretch-evoked, TRPV4-mediated ATP 
release. This provides a variety of targets and possibilities for controlling stretch-evoked 
ATP release during bladder filling, which may contribute to OAB syndrome and thus, 
pharmacological intervention of this pathway may serve useful in alleviation of OAB 
symptoms. Pannexin-1 channel inhibitors may be the most promising targets, as these 
channels seem to be the prominent pathway for both stretch (TRPV4)-induced and 
purinoceptor-induced ATP release from the urothelium. These would supress any NANC-
mediated contractions that emerge during various pathological bladder states, also 
alleviating ATP-related pain, while leaving the physiological muscarinic contractile 
component fully intact for normal bladder function. Pannexin-1 expression has been 
demonstrated in the urothelium of rats (Beckel et al., 2015), however there is currently no 
report of its expression in other bladder tissues or in human bladders. If indeed, pannexin-1 
is localized to the urothelium in human bladders, this would not only make targeting 
pharmacological agents simple, but also reduce side effects, making pannexin-1 channels 
highly appealing candidates for therapeutic intervention of OAB. 
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Figure 3 – 23. Postulated mechanism for stretch-induced, TRPV4-mediated ATP release from 
the urothelium. The urothelium receives sensory input in the form of stretch (as bladder fills) and this 
activates Src-family tyrosine kinases (SFKs)[1], which phosphorylate TRPV4 at tyr-253, permitting 
channel activity. Active TRPV4 mediates Ca
2+
 influx [2], raising intracellular [Ca
2+
]; Ca
2+
 directly 
activates pannexin-1 channels [3], which mediate both the serosal and apical release of ATP. Both 
serosally and apically [5] released ATP activates P2Y receptors on neighbouring urothelial cells 
(autocrine action), in turn activating further pannexin-1 channels, propagating and amplifying ATP 
release throughout the urothelium [4]. Serosally released ATP is available to stimulate downstream 
effector tissues such as smooth muscle, interstitial and suburothelial cells and sensory nerve endings 
expressing purinoceptors (paracrine action)[6], possibly resulting in sensory modulation. ENaC 
channels  responsible for a small proportion of TRPV4-induced ATP release are activated by an 
unknown mechanism, triggering subsequent ATP release [7]. Agonist-induced ATP release by GSK 
bypasses stage [1], directly activating TRPV4, intiating the downstream pathway by eliciting Ca
2+
-
influx [2]. Created using public access images from(Servier Medical, 2015) 
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3.4.8 INFLUENCE OF TRPV4 ON BLADDER ROS PRODUCTION 
ROS production in the bladder has previously been linked to detrusor overactivity, through 
modulation of the cyclooxygenase pathway in C-fibre afferents in rats (Chien et al., 2003; 
Masuda et al., 2008). Interestingly, TRPV4 has been linked to ROS production, where 
receptor activation in human coronary artery strips increased the mitochondrial production of 
superoxide for physiological vasodilation (Bubolz et al., 2012). As such, lucigenin-enhanced 
chemiluminescence was employed to assess the potential of TRPV4 to produce ROS in the 
GP bladder. TRPV4 activation in full thickness bladder strips significantly enhanced 
superoxide production to 136% of control. As ROS production was enhanced upon addition 
of NADPH, this suggests an NADPH-oxidase (NOX) enzyme is responsible. TRPV4 
activation induced Ca2+ influx and as NOX-5 is the only subtype activated by Ca2+ this is the 
likely subtype mediating TRPV4-induced ROS production (Bánfi et al., 2004). As both 
receptors are localized to the cell membrane, it is possible local increases in [Ca2+] could 
activate NOX5 receptors in close proximity to activated TRPV4. NOX5 expression has not 
yet been confirmed in the GP bladder and as such, evaluation of this is necessary before 
postulations can be made and may provide interesting novel data. This increase in oxidative 
stress may result in bladder inflammation, detrusor overactivity through hyperactive bladder 
afferent signalling, or indeed contribute to the aging bladder phenotype. Wegierski et al. also 
showed that ROS significantly up-regulate the phosphorylation of TRPV4 in the presence of 
SFKs, possibly enhancing the activity of TRPV4 further (Wegierski et al., 2009). TRPV4 
channels may therefore contribute to overactive bladder not only though ATP release, but 
also through stimulation of afferent signalling via ROS, indicating that TRPV4 has the 
potential to significantly influence pathological bladder states.    
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CHAPTER 4: TRPV4 RECEPTOR 
EXPRESSION AND FUNCTION IN THE AGING 
BLADDER  
 
 
 
 
 
 
 
 
 
146 
4.1 INTRODUCTION 
It is well-known that bladder dysfunction increases markedly with age, with urinary urge 
incontinence affecting up to 13.3% of males and 30.3% of females of age 40 and above in 
western countries, accompanied by a huge financial cost (Milsom et al., 2014). Despite this, 
the underlying mechanisms have yet to be fully established, as they appear to be highly 
complex and multifactorial. Many studies have endeavoured to investigate this 
phenomenon, where the emergence of a NANC-component to contraction (Bayliss et al., 
1999), changes in the purinoceptor signalling and afferent pathways controlling bladder 
function (Daly et al., 2014), and increased basal and stretch-evoked ATP release (Kumar et 
al., 2010; Sui et al., 2014) are some of the factors identified in aging bladders associated 
with the progression of overactive bladder.  
The previous chapter identified an important functional role for TRPV4 receptors in ATP 
release from the mucosa of both GP and native human bladders, elucidated the underlying 
mechanisms and revealed their potential to influence ROS production. Both of these outputs 
have the potential to directly alter bladder function and as such, any changes in the 
behaviour of TRPV4 that may result from aging may contribute, in part, to overactive 
bladder.  Previous studies in humans have revealed the cellular localization of urothelial 
TRPV4 (Janssen et al., 2011), however the only functional studies associated with humans 
that exist used heterologously expressed human TRPV4 in cultured HEK cells (Everaerts et 
al., 2010c). As such, the aim of this study was to investigate any changes in the expression 
and function of TRPV4 receptors that occur with aging in bladder strips from both humans 
and GPs, providing more physiologically relevant findings. Any changes observed may 
reveal that this receptor is not only important for physiological bladder function, but may also 
be involved in mediating overactive bladder and promoting other age-related bladder 
pathologies.  
In addition, as purinoceptors have previously been shown to both mediate ATP release from 
the mucosa (Sui et al., 2014) and display altered receptor expression with aging/pathology 
(Daly et al., 2014; Moore et al., 2001; Tempest et al., 2004), the effect of aging on 
purinoceptor-mediated ATP release and their potential to influence TRPV4 mediated ATP 
release was also investigated.  
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4.2 SUMMARY 
The objectives for investigating the possible changes to TRPV4 receptor expression and 
function associated with aging are as follows: 
1. EXPRESSION STUDIES: 
a. Compare the expression levels of TRPV4 receptors in the urothelium and 
suburothelium between young and aging GP bladders using quantitative 
immunohistochemistry. 
 
b. Compare the expression levels of TRPV4 in separated mucosa and smooth 
muscle between young and aging GP bladders using quantitative western 
blotting, identifying any tissue-specific changes. 
 
2. IN VITRO FUNCTIONAL EXPERIMENTS USING FUNCTIONAL ORGAN 
BATH TECHNIQUE: 
a. Compare the effect of TRPV4 activation on ATP release and bladder 
contractions in young and aging GP bladder preparations. 
 
b. Investigate the effect of co-activation of TRPV4 and P2Y receptors on ATP 
release and bladder contractions in young and aging GP bladder 
preparations. 
 
c. Investigate the effect of objective 2b on both normal and overactive human 
bladder biopsies. 
 
3. FURTHER IN VITRO STUDIES: 
a. Use P2Y2 knockout mice to identify the purinoceptor subtypes responsible for 
any co-dependent effects observed during objective 2.  
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4.3 METHODS 
The functional experiments performed in this chapter followed the protocols described in 
section 2.5.1 of methods. For a full description of other techniques used, please refer to the 
relevant methods section (detailed in text or figure legend where applicable). 
4.3.1 EFFECT OF PRE-ACTIVATION OF ONE RECEPTOR GROUP ON 
ACTIVITY OF THE OTHER 
The following experiments were designed to examine the relationship between TRPV4 and 
P2Y receptors in section 4.4.2.2.6 of this chapter. The concept of experiments (referring to 
step 2 in figure 4-1) was to first activate one receptor group (e.g. TRPV4), then also activate 
a second group (e.g. P2Y2/P2Y4) to determine whether the second can raise ATP release 
beyond that already being stimulated by the first. In this way it is possible to determine the 
dynamics of the relationship between two receptor types regarding ability to release ATP i.e. 
do they use the same mechanism. The ‘antagonist studies’ protocol was followed (figure 2-
4), where the antagonist step was replaced with either of the agonists, for example when 
assessing pre-treatment with GSK the protocol was as follows (figure 4-1): 
 
 
 
 
 
 
 
 
 
For example, if UTP can stimulate ATP release during step 1 and 3, but pre-activation of 
tissue with GSK prevents this UTP-induced ATP release, this implies some shared 
mechanism for ATP release, allowing the relationship between the two receptors to be 
deliberated.   
Figure 4 – 1. Receptor relationship studies protocol. Schematic of work flow carried out for receptor-
relationship studies. The ‘antagonist studies’ protocol was followed, where the antagonist step was replaced with 
an agonist (step 2, GSK). Then a second agonist (UTP) was introduced to determine whether activation of a 
second receptor group could enhance ATP release beyond that of the first agonist. ATP release was measured 
throughout the protocol in the same manner as the antagonist studies. Steps 1 and 3 act as control to ensure 
tissue is responsive (regarding ATP release) to the agonist under investigation 
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4.4 RESULTS  
4.4.1 ALTERED EXPRESSION OF TRPV4 IN THE AGING BLADDER  
This section of the study was performed to determine whether aging affects the tissue 
localization or overall expression levels of TRPV4 in the bladder. IHC allowed observations 
between the urothelium and suburothelium to be made, while western blotting provided a 
more robust method of quantification, but only between separate mucosa and smooth 
muscle tissue.  
4.4.1.1 EFFECT OF AGING ON TISSUE LOCALIZATION OF TRPV4 IN GP AND 
HUMAN BLADDER TISSUES BY IHC 
The distribution of TRPV4 receptors throughout the bladder was assessed in young and 
aging GP full thickness and human mucosal cryosections and examined using confocal 
microscopy in the same manner as described in the previous chapter (section 3.4.1.1). 9 
young GP bladders, 7 aging GP bladders and 4 human bladder mucosa biopsies (taken 
from position of healthy tissue in male patients >65 years old with suspected or known 
tumours) were examined. Representative images for aging GP are shown in figure 4-2 and 
those for young GP and human are shown in the previous chapter. All groups showed clear 
expression of TRPV4 in the urothelium and suburothelium. The smooth muscle was 
assessed in 3 young and 3 aging GP bladders and 1 human biopsy (which had smooth 
muscle attached), TRPV4 expression was observed in all. TRPV4 staining seems to be 
more evident in the urothelium, with weaker expression in the suburothelium and weaker still 
in the smooth muscle. To assess this, staining was quantified by measuring pixel density of 
images and calculated per cell, providing final values of TRPV4 expression as ‘mean cell 
fluorescence’ (MCF) for each tissue type. The median values for mean cell fluorescence 
represented in figure 4-3 are shown in table 11. 
Higher TRPV4 expression was observed in the urothelium compared to the suburothelium in 
all 7 aging GP bladders and 8 of the 9 young GP bladders. TRPV4 expression was similar 
between the urothelium and suburothelium in healthy, aging human tissue. The difference in 
expression levels between the two tissues seems to be greater in aging than young GP 
bladder, with a greater significant difference, suggesting there may be a shift in expression 
with age in favour of the urothelium.  This method allowed differences between the urothelial 
and suburothelial expression to be identified, which is not possible with western blotting. 
However, comparison between age groups using this technique was not possible as some 
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sections of each group were examined on different days under different conditions, such 
that expression on different tissue sections on the same slide could be compared, but those 
examined on different days could not. Therefore, a protocol using western blotting was 
performed allowing comparison of TRPV4 tissue expression between age groups.  
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Figure 4 – 2. Representative images demonstrating expression of TRPV4 in aging GP bladder 
tissues. Cryo-sections (10μm) of aging GP bladder tissues at x40 magnification. TRPV4 is labelled with Alexa 
fluor 568 (red) and nuclei with To-PRO3 (Cy5; blue). Column A: Brightfield images demonstrating general 
morphology and tissue distribution. Column B: Secondary control; no primary antibody (Ab) added, ensuring no 
unspecific binding of secondary Ab to sample. Column C: Positively stained sections depicting expression and 
distribution of TRPV4 in the urothelium (green bar), suburothelium (pink bar), smooth muscle and vasculature. 
High TRPV4 expression is observed in the urothelium with some expression in the suburothelium. Images from 
each row (tissue type) were taken from the same ‘area’ of tissue on sections cut directly after one another, 
thus providing a reliable comparison between control and positive staining. These images were taken from 
sections of 1 of 7 aging GP bladders examined.  
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Table 11 - Quartiles (median [25%, 75%]) of MCF of TRPV4 in various tissues (referring to 
figure 4 – 3 graph). 
 
 
 
 
 
 
Tissues type Young GP Aging GP Human 
Urothelium 2393 [1928, 2393] 2789 [2318, 4865] 2708 [2263, 3074] 
Suburothelium 1207 [605, 2091] 489 [290, 873] 2019 [1162, 2854] 
Smooth muscle 1624 [611, 2098] 1665 [1258, 2098] 1347 
Figure 4 – 3. Expression levels of TRPV4 in young & aging GP & human bladder tissues 
quantified from confocal microscopy images. Quantitative analysis of TRPV4 fluorescence. The 
pixel density of an area of tissue was measured and divided by the number of cells, providing final 
values of mean cell fluorescence (MCF). TRPV4 expression is significantly less in the suburothelium 
than the urothelium in both young and aging GP but not human. Smooth muscle was only assessed in 3 
young and 3 aging GP bladders and 1 human such that this data provides only an indication. 
Expression between groups was non-comparable, as experiments were performed on different days 
under different conditions. Data sets expressed as % medians [25%, 75%], aging GP urothelium and 
suburothelium; n=7, young GP urothelium and suburothelium; n=9, aging and young GP smooth 
muscle; n=3, human  urothelium and suburothelium; n=4, human smooth muscle; n=1, *p<0.05, ** p 
≤0.01, *** p ≤0.001, wilcoxon’s, Young GP urothelium vs. Young GP suburothelium. 
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4.4.1.2 EFFECT OF AGING ON RELATIVE TISSUE EXPRESSION OF TRPV4 IN 
GP BLADDER TISSUES BY WESTERN BLOTTING 
The effect of aging on TRPV4 expression was assessed in separated mucosal and smooth 
muscle bladder whole-tissue lysates by western blot, run against rat brain lysate (RBL) 
positive control tissue (recommended by Ab suppliers). The representative blot in Figure 4-4 
A shows clear bands at the same molecular weight (kDa) as the positive control, thereby 
confirming bands correctly represent TRPV4 in these samples. At first glance, it is clear the 
expression of TRPV4 is greater in aging tissue than young. To reliably confirm this, 
expression levels were quantified by densitometry and relative expression between tissues 
of each age group compared (figure 4-4 B).  
 
 
 
 
 
 
  
A 
TRPV4 
(98 kDa) 
RBL  
β-actin  
(42 kDa) 
Muc SM Muc SM  kDa 
Young GP  Aging GP  
34 
250 
130 
95 
70 
55 
43 
B 
Figure 4 – 4. Detection and 
quantification of TRPV4 in 
young & aging GP bladder. A: 
Representative blot of TRPV4 
(98kDa, probed using Abcam 
primary Ab) and β-actin loading 
control (42kDa) (RBL: rat brain 
lysate Muc: mucosa, SM: smooth 
muscle). Membrane was cut at 
55kDa (dashed blue line) and each 
half probed with the appropriate 
Abs. B: Quantified data of TRPV4 
expression by densitometry. Each 
TRPV4 band is normalized to its 
corresponding β-actin loading 
control. Samples run in duplicate 
and averaged. Aging tissues have 
significantly higher TRPV4 
expression than young. Aging 
mucosa has significantly greater 
expression than aging smooth 
muscle, young tissue does not. 
Data sets are expressed as % 
medians [25%, 75%], n=5, ** p 
≤0.01, Mann-Whitney, Young vs. 
Aging or Aging vs. Aging. 
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Quantification of relative band intensity by densitometry revealed a significantly greater 
median TRPV4 expression (8 fold) in aging mucosa than young (arbitrary units normalised 
to loading control - aging; 42.9 [25.7, 75.6], young; 5.8 [2.1, 14.3]) and (16 fold) in smooth 
muscle (aging; 13.5 [10.1, 28.3], young; 0.8 [0.6, 3.4]). Additionally, TRPV4 expression in 
the mucosa was significantly greater compared to smooth muscle in aging but not in young 
bladders. 
Taken with the confocal data, it appears that TRPV4 expression is drastically altered with 
age. Western blotting showed a distinct increase in TRPV4 expression in the mucosa and 
smooth muscle of aging bladders, and confocal images revealed that the higher TRPV4 
expression observed in the urothelium compared to the suburothelium was even greater and 
more profound in aging tissue. These results suggest that TRPV4 expression is increased in 
the urothelium and smooth muscle, but not the suburothelium with age.  
4.4.2 ALTERED FUNCTION OF TRPV4 AND PURINOCEPTORS IN THE AGING 
BLADDER 
As aging drastically alters the expression of TRPV4 in the bladder, their function may also 
be affected, changes in which could contribute to age-related bladder dysfunctions. 
purinoceptors have also previously been shown to mediate ATP release from the mucosa 
(Sui et al., 2014) and display altered receptor expression with aging/pathology (Daly et al., 
2014; Moore et al., 2001; Tempest et al., 2004). As such, the effect of aging on both TRPV4 
and P2Y receptor-mediated ATP release and bladder contraction was assessed. The effect 
of activating both receptors simultaneously was also investigated to determine whether they 
have a synergistic role in mucosal ATP release and whether this is also affected with aging. 
For this purpose, a carefully designed protocol was followed (section 2.5.1.1.2 – interaction 
protocol) where each n represents a tissue strip that was mounted within the organ bath and 
subjected to 5 drug interventions with a 1hour recovery period between each. 
4.4.2.1 EFFECT OF PURINOCEPTOR AND TRPV4 ACTIVATION ON 
FUNCTIONAL OUTPUTS IN THE GP BLADDER 
4.4.2.1.1 YOUNG GP MODEL 
UTP (100μM) was used for purinoceptor activation as this agonist specifically activates P2Y2 
and P2Y4 at this concentration and has previously been shown to induce reproducible ATP 
release from the GP mucosa (Sui et al., 2014). Very weak mucosal contractions were 
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observed in 33% of strips examined when challenged with UTP and none with GSK. GSK 
(1μM) evoked a large contraction in full thickness tissue which was significantly greater than 
that evoked by UTP (Force μN/mg tissue - GSK; 246.2 [175.1, 668.8], UTP; 3.6 [2.2, 4.0])( 
median data figure 4-5 A, example traces figure 4-6). Subsequent drug interventions were 
not capable of eliciting a further contraction for reasons previously discussed when 
assessing reproducibility of GSK-induced contractions using control experiments (section 
3.4.3.1). Significant ATP release was generated by all interventions from both tissue 
preparations (see table 12), aside from the post-GSK and post-UTP interventions in full 
thickness where significant release was lost (figure 4-5 B). This is likely attributable to drift in 
tissue function over the period of the experiment, where these post-interventions were 
performed to identify this. ATP release generated by UTP was not significantly different to 
GSK. ATP release generated by mucosa was not significantly different to full thickness 
tissue with any intervention. ATP release generated by UTP+GSK was significantly greater 
than that by GSK or UTP in mucosa and greater than GSK (but not UTP) in full thickness. 
This data will be compared to that from aging GP tissue and further analysed later. 
 
Table 12 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in young GP bladder tissues (referring to figure 4 – 5 B graph). 
 
 
 
 
 
 
 
 
 
 
 
 
 Tissue 
strip 
100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 323 [223, 388] 235 [147, 412] 440 [343, 727] 234 [118, 330] 168 [120, 361] 
Full 
thickness 
321 [210, 595] 256 [173, 378] 502 [241, 727] 191 [81, 331] 442 [158, 616] 
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Figure 4 – 5. Effect of UTP and GSK1016780A on bladder functional outputs in young GP 
bladder. Young GP bladder strips challenged with stated drug interventions in sequence from left to 
right (for full protocol refer to sections 2.5.1.1.1 and 2.5.1.1.2). A: Median force of mucosal and full 
thickness (FT) contractions generated by drug interventions. No contractions observed in mucosa with 
any agonist (confirmed by traces), a large contraction evoked in FT with the first exposure to GSK, 
where this contractile effect was lost (significantly less) in the following two exposures, including the 
joint intervention (UTP+GSK). The contraction generated by 1μM GSK (TRPV4 activation) was 
significantly greater than 100μM UTP (P2Y agonist). Note Log2 Y axis for clear visualization. B: 
Corresponding median ATP release from same bladder strips. All drug interventions significantly 
increase ATP release from basal levels in both mucosa and FT, apart from in FT during post controls. 
No significant difference in ATP release is observed between mucosa and FT for any drug 
intervention. In mucosa, the joint intervention (UTP+GSK) triggered significantly more ATP release 
than individual pre-UTP or pre-GSK interventions (significance not shown on graph).  Additionally, 
ATP release triggered from FT by the joint intervention was significantly higher than the individual pre-
GSK intervention (not shown).  For both graphs: data expressed as % medians [25%, 75%], n=9 (pre 
UTP, pre GSK, UTP+GSK), n=8 (post UTP, post GSK), Wilcoxon’s, graph B *p<0.05, drug 
intervention vs. control (basal levels). 
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4.4.2.1.2 AGING GP MODEL 
Small contractions were observed in 35% of the mucosal strips examined when challenged 
with UTP and in 50% when challenged with GSK. GSK (1μM) evoked a large contraction in 
full thickness tissue which was significantly greater than that evoked by UTP (Force μN/mg 
tissue - GSK; 485.4 [252.6, 814.4], UTP; 7.9 [2.5, 34.87])(figure 4-7 A). Interestingly, the 
subsequent drug intervention of UTP+GSK was capable of eliciting further contractions in 
65% of the full thickness strips, although these were weaker (UTP+GSK; 22.25.4 [1.5, 
174.5). Significant ATP release was generated by all interventions from both tissue 
preparations (see table 13), however, as with young GP, no significant ATP release was 
observed in full thickness during post GSK and UTP interventions (figure 4-7 B). ATP 
release generated by UTP was not significantly different to GSK, nor was the ATP release 
generated by these interventions different between mucosa or full thickness tissue. 
However, the ATP release generated by UTP+GSK was significantly greater in mucosa than 
full thickness. ATP release generated by UTP+GSK was significantly greater than that by 
GSK or UTP in mucosa and greater than GSK (but not UTP) in full thickness. 
Table 13 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in aging GP bladder tissues (referring to figure 4 – 7 B graph).  
 Tissue 
strip 
100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 218 [204, 385] 156 [106, 346] 886 [309, 
1050] 
171 [93, 282] 260 [147, 358] 
Full 
thickness 
329 [185, 531] 307 [115, 333] 543 [361, 612] 220 [102, 327] 317 [153, 531] 
 
Figure 4 – 6. Contractile responses of GP tissue strips to GSK and UTP. Record of 
contraction induced by 1μM GSK (A) and 100μM UTP (B) in mucosal and full thickness bladder 
strips. GSK evokes a strong, sustained contraction in full thickness tissue, compared to the 
weaker, transient contractions evoked by UTP. Agonists evoked negligible contractions in mucosal 
strips. 
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Figure 4 – 7. Effect of UTP and GSK1016780A on bladder functional outputs in aging GP 
bladder. Aging GP bladder strips challenged with stated drug interventions in sequence from left 
to right (for full protocol refer to sections 2.5.1.1.1 and 2.5.1.1.2).  A: Median force of mucosal and 
full thickness (FT) contractions generated by drug interventions. Agonists generated negligible 
contractions in mucosa (confirmed by traces). First exposure to GSK generated a large contraction 
in FT, where this effect was weakened (significantly less, not shown) in the following two 
exposures, including the joint intervention (UTP W/ GSK). Note Log2 Y axis for clear visualization. 
B: Corresponding median ATP release from same bladder strips. All drug interventions 
significantly increase ATP release from basal levels in both mucosa and FT to a similar level, apart 
from in FT during post controls. The joint intervention (UTP+GSK) triggered significantly more ATP 
release from the mucosa than from FT. The ATP release triggered from mucosa by the joint 
intervention was significantly higher than the individual pre-UTP or pre-GSK interventions 
(significance not shown on graph). Additionally, the ATP release triggered from FT by the joint 
intervention was significantly higher than the individual pre-GSK intervention. For both graphs: 
data expressed as % medians [25%, 75%], n=11 (pre UTP, pre GSK, UTP+GSK), n=7 (post UTP, 
post GSK), Wilcoxon’s, graph B *p<0.05, drug intervention vs. control (basal levels). 
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4.4.2.1.3 ORIGIN OF UTP-INDUCED ATP RELEASE 
In the previous chapter the mucosa was identified as the origin of TRPV4-induced ATP 
release, supported by strong evidence. Figure 4-8 displays raw data of ATP release induced 
by UTP in the form of ρMoles released per gram tissue per minute, from the experiments in 
this section (refer to figure 4-7 B ‘pre-100M UTP’ for normalized data). This allows the 
actual quantities of ATP released from each tissue preparation to be compared, providing an 
indication of the origin of ATP release. UTP significantly increased ATP release from 
mucosa and full thickness strips, as shown previously with normalized data (ρmoles/g 
tissue/min: mucosa - con; 88 [47, 162], UTP; 253 [185, 492], full thick - con; 16 [13, 37], 
UTP; 88 [45, 172]). Here we observe significantly greater ATP release per gram from 
mucosa compared to full thickness strips (significance not shown in figure). As with GSK, 
this implies that the DSM and other underlying tissues present in the full thickness strip add 
no further ATP release to that produced by the mucosa, as normalizing to tissue mass 
effectively reduces ATP release per gram of tissue, indicating these underlying tissues are 
redundant regarding ATP release. As such, data suggests that UTP-induced ATP release 
also originates from the mucosa. This implies that all UTP and GSK-induced ATP release 
observed in these experiments is from the mucosa, with no contribution from underlying 
tissues.   
 
 
 
 
 
 
 
 
 
  
 
Figure 4 – 8. UTP-induced ATP release from young GP mucosa and full thickness bladder 
preparations: Raw data. Graph of raw data representing ρmoles of ATP released per gram tissue per 
minute. UTP significantly enhanced ATP release from mucosal and full thickness young GP bladder 
strips. The UTP-induced ATP release from mucosa was significantly greater per gram than that from 
full thickness (not shown). Basal ATP release per gram was also significantly greater from mucosa 
than full thicknesss (not shown). ATP release expressed as ρmoles/g tissue/min medians [25%, 75%], 
young GP n=8, aging GP n=11, p values shown, Wilcoxon’s, drug intervention vs. control. Mucosa 
compared to full thickness using Mann-Whitney. 
 
159 
4.4.2.1.4 COMPARISON OF YOUNG AND AGING BLADDER OUTPUTS: 
CONTRACTILITY 
UTP evoked minimal contractions in full thickness tissue, whereas GSK evoked strong 
contractions of similar magnitude in both age groups (Force μN/mg tissue – young FT; 246.2 
[175.1, 668.8], aging FT; 485.4 [252.6, 814.4]). Interestingly, second exposure to GSK 
(during the joint UTP+GSK intervention) generated contractions in 65% of aging full 
thickness strips, where half of these were strong (>100μN/mg tissue) and half weaker 
(>20μN/mg tissue), compared to 9% in young tissue, which were all weak (aging; 22.1 [1.5, 
174.5], young; 1.6 [0.4, 2.2])(figure 4-9). Again, this is likely attributable to the higher 
expression of TRPV4 in the smooth muscle of aging bladder and a direct effect of GSK on 
the abundant receptor population in this tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 9. Contractions generated by UTP and GSK1016790A in young and aging full 
thickness bladder strips.  This data is taken from the previous young and aging contraction graphs 
(graphs A in figures 4-5 and 4-7) and organised to allow clear comparison between age groups. Note 
Log2 Y axis for clear visualization. No difference between contractions generated by pre-UTP, pre-
GSK, post-GSK or post-UTP. The GSK+UTP intervention generated significantly greater contractions 
in aging GP FT strips than young. Young; pre-UTP, pre-GSK, UTP+GSK n=9, post-GSK, post-UTP 
n=8. Aging; pre-UTP, pre-GSK, UTP+GSK n=11, post-GSK, post-UTP n=7. Data sets expressed as % 
medians [25%, 75%], * p ≤0.05, Mann-Whitney, young GP vs. aging GP. 
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4.4.2.1.5 COMPARISON OF YOUNG AND AGING BLADDER OUTPUTS: ATP 
RELEASE 
There was no significant difference in the quantities of ATP released from the mucosa per 
gram of tissue in response to TRPV4 activation between age groups (ρmoles/g tissue/min: 
mucosa - con; 47 [37, 63], GSK; 105 [45, 379], full thick - con; 50 [27, 155], GSK; 88 [59, 
217])(figure 4-10). Basal ATP release was also similar. 
 
There was no significant difference in ATP release observed between age groups for any 
intervention in either mucosal or full thickness tissue (figure 4-11). However, to assess 
whether TRPV4 and purinoceptors interact to alter the ATP release in some way, the data 
was analysed further. The ATP released during the pre-UTP intervention was averaged with 
that of the post-UTP intervention. This provides values that take the drift in tissue function 
over the course of the experiment into account, allowing comparison of this intervention with 
the GSK and UTP+GSK intervention. Without this, a decrease in ATP release observed 
during the third intervention could be wrongly interpreted as an effect of the intervention, 
Figure 4 – 10. GSK-induced ATP release from young and aging GP mucosa: Raw data. Graph of 
raw data representing ρmoles of ATP released per gram tissue per minute. GSK significantly 
enhanced ATP release from mucosal strips in both age groups. The quantity of ATP released per 
gram was similar between groups for both basal and GSK-induced release. ATP release expressed as 
ρmoles/g tissue/min medians [25%, 75%], young GP n=8, aging GP n=11, p values shown, 
Wilcoxon’s, drug intervention vs. control. Mucosa compared to full thickness using Mann-Whitney. 
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rather than due to the drift in tissue function.  This was also applied to the pre and post-GSK 
interventions. Finally, the ATP released during the averaged UTP intervention was manually 
combined with that of the GSK interventions and compared to the UTP+GSK intervention 
(figure 4-12). 
 
 
 
 
Figure 4 – 11. Effect of UTP and GSK1016780A on ATP release from young compared to aging 
GP bladder tissues. These graphs allow for clear comparison of ATP release between young and 
aging bladder mucosa and full thickness (FT) strips triggered by the stated drug interventions (data is 
taken from ATP release graphs (B) in figures 4-5 and 4-7 but arranged for comparative purposes). A: 
Pre-100μM UTP intervention – increased ATP release in both mucosa and FT from both age groups. 
No difference between age groups (n=9 young, n=11 aging). B: Pre-1μM GSK intervention – increased 
ATP release in both mucosa and FT in both age groups. No difference between age groups (n=9 
young, n=11 aging). C: 100μM UTP + 1μM GSK intervention – increased ATP release in both mucosa 
and FT in both age groups. No difference between age groups (n=9 young, n=11 aging). D: Post-1μM 
GSK intervention – increased ATP release in mucosa but not FT in both age groups. No difference 
between age groups (n=8 young, n=7 aging). E: Post-100μM UTP intervention – increased ATP release 
in mucosa but not FT in both age groups. No difference between age groups (n=8 young, n=7 aging). 
For all graphs: data expressed as % medians [25%, 75%], data sets compared to control (basal ATP 
levels) using Wilcoxon’s, *p<0.05, young compared to aging using Mann-Whitney test. 
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In young GP mucosa, activating TRPV4 and P2Y2/P2Y4 simultaneously, evokes the same 
proportional increase in ATP release as activating them individually and combining the two 
(manually combined individual activations: 482% [415%, 633%], simultaneous activation: 
440% [343%, 727%]). This implies their joint effect is additive, suggesting they have no 
interaction and mediate ATP release via different mechanisms. However in the aging 
mucosa, activating the receptors simultaneously evokes significantly higher levels of ATP 
release, than the combined release from separate activation, implying their joint effect is 
potentiative here (manually combined individual activations: 468% [358%, 606%], 
simultaneous activation: 886% [309%, 1050%]). This suggests that some underlying 
interaction between the two receptor types emerges in the aging group, causing 
amplification of the ATP signal beyond that of their combined separate effects. It could be 
that a novel synergistic effect between these two receptors activates another ATP release 
pathway, or it may be that one receptor is now capable of sensitizing the other, rendering it 
more active or indeed activating it in a secondary manner. The fact that this phenomenon 
was not observed in full thickness tissue indicates the site of interaction was at mucosa but 
not smooth muscle. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 12. Additive or potentiating effect of co-stimulation of ATP release using UTP 
(100μM) and GSK1016790A (1μM) in young and aging GP bladder tissue.  Light grey bars: ATP 
release from Pre and post control interventions (figures 4-5 and 4-7) of UTP (and GSK separately) 
were averaged, then this average for UTP-induced ATP release was manually combined with that 
of GSK. This represents the total (sum of) ATP release evoked by these mechanisms when 
activated separately. Dark grey bars: represent the total ATP released when UTP and GSK are 
used simultaneously. In young GP tissues and aging FT, the combined ATP release is very similar 
to simultaneous, with no significant difference between the two, suggesting the effect of 
simultaneous stimulation is additive. In contrast, simultaneous activation in aging GP mucosa 
generated significantly more ATP release than combined ATP release from independent activation 
with these agonists. This suggests the effect of simultaneous stimulation is potentiating in aging GP 
mucosa. Data sets expressed as % medians [25%, 75%], p value shown, data sets compared using 
Mann-Whitney. 
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4.4.2.2 EFFECT OF PURINOCEPTOR AND TRPV4 ACTIVATION ON 
FUNCTIONAL OUTPUTS IN VARIOUS MOUSE MODELS 
In order to identify the responsible purinoceptor subtype/s and dynamics underlying the 
apparent relationship between purinoceptor signalling and TRPV4 in the aging GP mucosa, 
young WT, young P2Y2 knockout (P2Y2KO) and aging P2Y2KO mouse bladders were 
subjected to the same experimentation as above. As transgenic GPs are not permitted, 
these transgenic mice provide robust models for investigating the responsible subtypes.  
TRPV4 expression was not evaluated in these mice as it has been well established in 
previous literature (Gevaert et al., 2007; Mochizuki et al., 2009; Yamada et al., 2009).  
Confirmation that knockout mice were void of P2Y2 receptors was performed prior to the 
commencement of this study.  
 
4.4.2.2.1 YOUNG WT MOUSE BLADDER 
No contractions were observed in mucosa during any intervention. Both UTP (100μM) and 
GSK (1μM) evoked contractions in full thickness tissue, where those of GSK were 
significantly greater (Force μN/mg tissue - GSK; 193.5 [105.5, 607.5], UTP; 62.74 [25.12, 
148.1])(figure 4-13 A). The post UTP intervention was also capable of evoking a contraction 
of similar magnitude to that of pre UTP (Post UTP; 56.2 [7.9, 118.7]), however post GSK 
was not (Post GSK; 3.8 [-0.5, 14.04]). The joint intervention evoked contractions of similar 
magnitude to pre and post UTP (UTP+GSK; 81.84 [2.3, 239.3], and as post GSK could not 
simulate a contraction, the contractions observed during the joint intervention are likely 
attributable to the effect of UTP. Significant ATP release was generated by all interventions 
from both tissue preparations (see table 14), aside from post-UTP in both tissue 
preparations (figure 4-13 B). As with GP tissue, this is likely attributable to drift in tissue 
function over the period of the experiment. ATP release generated by UTP was not 
significantly different to GSK. ATP release generated by mucosa was not significantly 
different to full thickness tissue with any intervention. ATP release generated by UTP+GSK 
was significantly greater than that by GSK or UTP in mucosa and full thickness. This data 
will be compared to that from young P2Y2KO and aging P2Y2KO tissue and further analysed 
later. 
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Table 14 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in young WT mouse bladder tissues (referring to figure 4 – 13 B graph). 
 Tissue 
strip 
100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 277 [184, 752] 269 [143, 340] 652 [505, 
1039] 
180 [134, 238] 210 [129, 263] 
Full 
thickness 
276 [177, 334] 229 [202, 278] 481 [425, 660] 172 [138, 220] 257 [93, 605] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 13. Effect of UTP and GSK1016780A on bladder functional outputs in young WT 
mouse bladder. WT mouse bladder strips challenged with stated drug interventions in sequence from 
left to right (for full protocol refer to sections 2.5.1.1.1 and 2.5.1.1.2).  A: Median force of mucosal and 
full thickness (FT) contractions generated by drug interventions. No contractions observed in mucosa 
with any agonist (confirmed by traces). All interventions (except post-GSK) generated contractions in 
FT tissue, where that generated by 1μM GSK (TRPV4 agonist) was significantly greater than 100μM 
UTP (P2Y agonist). The contractions generated by pre- and post-UTP and UTP+GSK were all of similar 
magnitudes. B: Corresponding median ATP release from same bladder strips. All drug interventions 
significantly increase ATP release from basal levels in both mucosa and FT to a similar level, apart from 
post-UTP. The joint intervention (UTP+GSK) generates significantly higher ATP release than pre-UTP 
or pre-GSK alone in both mucosa (shown on graph) and FT (not shown). No significant difference in 
ATP release is observed between mucosa and FT. For both graphs: data expressed as % medians 
[25%, 75%], n=8, Wilcoxon’s, graph B *p<0.05, drug intervention vs. control (basal levels). 
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4.4.2.2.2 YOUNG P2Y2KO MOUSE BLADDER 
As with WT mouse, no contractions were observed in mucosa during any intervention. Both 
UTP (100μM) and GSK (1μM) evoked contractions in full thickness tissue, where those of 
GSK were significantly greater (Force μN/mg tissue - GSK; 167.2 [86.5, 198.6], UTP; 47.4 
[27.2, 75.9])(figure 4-14 A). The post UTP intervention was also capable of evoking a 
contraction of similar magnitude to that of pre UTP (Post UTP; 28.2 [6.9, 84.9]), however 
post GSK only evoked a contraction in 2 of the 8 strips (Post GSK; 9.1 [3.0, 47.7]). The joint 
intervention evoked contractions of similar magnitude to pre and post UTP (UTP+GSK; 56.9 
[25.5, 139.9]), and as post GSK only stimulated a contraction in 25% of strips, these 
contractions are likely attributable to the effect of UTP. Significant ATP release was 
generated by all interventions from both tissue preparations (see table 15 and figure 4-14 
B). ATP release generated by UTP was not significantly different to GSK. Unlike WT mouse, 
ATP released in response to the joint intervention (UTP+GSK) was not significantly different 
from those triggered by pre UTP or pre GSK, where all interventions generated a similar 
median release. ATP release generated by mucosa was not significantly different to full 
thickness tissue with any intervention. This data will be compared to that from young 
P2Y2KO and aging P2Y2KO tissue and further analysed later. 
 
Table 15 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in young P2Y2KO mouse bladder tissues (referring to figure 4 – 14 B graph). 
 Tissue 
strip 
100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 373 [274, 399] 309 [248, 356] 301 [190, 351] 142 [122, 239] 300 [173, 445] 
Full 
thickness 
407 [381, 518] 310 [187, 429] 402 [235, 460] 185 [149, 202] 469 [145, 853] 
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Figure 4 – 14. Effect of UTP and GSK1016780A on bladder functional outputs in young P2Y2 
KO mouse bladder. Young P2Y2 mouse bladder strips challenged with stated drug interventions 
in sequence from left to right (for full protocol refer to sections 2.5.1.1.1 and 2.5.1.1.2).  A: Median 
force of mucosal and full thickness (FT) contractions generated by drug interventions. No 
contractions observed in mucosa with any agonist (confirmed by traces). All interventions 
generated contractions in FT tissue, where that generated by 1μM GSK (TRPV4 agonist) was 
significantly greater than 100μM UTP (P2Y agonist). The contractions generated by pre- and post-
UTP and UTP+GSK were all of similar magnitudes B: Corresponding median ATP release from 
same bladder strips. All drug interventions significantly increase ATP release from basal levels in 
both mucosa and FT to a similar level, with no loss of effect in post-interventions. No significant 
difference in ATP release is observed between mucosa and FT or between different drug 
interventions. For both graphs: data expressed as % medians [25%, 75%], n=8, Wilcoxon’s, graph 
B *p<0.05, drug intervention vs. control (basal levels). 
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4.4.2.2.3 AGING P2Y2KO MOUSE BLADDER 
Unfortunately, it was only possible to maintain 5 P2Y2KO mice for the time necessary to 
reach ‘aging’ criteria (>10 months old), however these 5 provided an initial indication of any 
age-dependent changes to TRPV4 and purinoceptor-mediated bladder outputs. 
Again, no contractions were observed in mucosa during any intervention. Both UTP (100μM) 
and GSK (1μM) evoked contractions in full thickness tissue, however these were not 
significantly different, unlike with the other 2 groups where GSK-evoked strong contractions 
(Force μN/mg tissue - GSK; 123.9 [35.61, 146.0], UTP; 55.3 [41.3, 62.9])(figure 4-15 A). 
Post UTP evoked weak contractions (Force μN/mg tissue >25, <80) in 3 of the 5 full 
thickness strips assessed; with lower magnitudes to those of pre UTP (Post UTP; 25.3 [2.8, 
63.3]) and post GSK also only evoked contractions in 3 of the 5 strips, and these were 
weaker still  (>15, <40)(Post GSK; 15.7 [2.0, 34.4]). The joint intervention evoked 
contractions of similar magnitude to pre and post UTP (UTP+GSK; 36.5 [9.4, 50.6]), and as 
such, these contractions are likely attributable to the effect of UTP. ATP release was 
generated by all interventions from both tissue preparations (see table 16 and figure 4-15 
B), where an increase in ATP release from basal levels was observed in at least 4 of the 5 
strips assessed for each intervention. Only 5 bladders were assessed, such that statistics 
are weak and therefore, these results only provide an indication of trends. As with young 
P2Y2KO, median ATP release appears to be similar during all interventions, however the 
variations in ATP release are much larger here. As with all mouse models investigated, 
relative ATP release between mucosa and full thickness are also similar. 
 
Table 16 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in Aging P2Y2KO mouse bladder tissues (referring to figure 4 – 15 B graph). 
 Tissue 
strip 
100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Mucosa 365 [280, 804] 306 [190, 334] 385 [366, 
1274] 
323 [194, 543] 122 [62.6, 377] 
Full 
thickness 
330 [317, 787] 248 [194, 292] 434 [294, 
1342] 
202 [157, 390] 301 [92.5, 509] 
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Figure 4 – 15. Effect of UTP and GSK1016780A on bladder functional outputs in aging P2Y2 
KO mouse bladder. Aging P2Y2 mouse bladder strips challenged with stated drug interventions in 
sequence from left to right (for full protocol refer to sections 2.5.1.1.1 and 2.5.1.1.2).  A: Median 
force of mucosal and full thickness (FT) contractions generated by drug interventions. No 
contractions observed in mucosa with any agonist (confirmed by traces). All interventions 
generated weak contractions in FT tissue. Note, Y-axis for figures 4-13, 4-14 and 4-15 have the 
same scale for quick comparisons. B: Corresponding median ATP release from same bladder 
strips. All drug interventions stimulated ATP release from the tissue with a p value of 0.0625, 
therefore indicating significance would likely be reached with further n numbers. These data 
provide an indication of these functional outputs in aging mice for comparison with the other two 
previous groups. For both graphs: data expressed as % medians [25%, 75%], n=5, Wilcoxon’s, 
drug intervention vs. control (basal levels). 
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4.4.2.2.4 COMPARISON OF BLADDER OUTPUTS BETWEEN MOUSE GROUPS: 
CONTRACTILITY 
Mucosal contractions were not evoked by any intervention in any of the mouse groups 
investigated and as such, no comparison is necessary. However, contractions of varying 
magnitude were elicited by drug interventions in full thickness strips from each group (figure 
4-16). Those evoked by pre UTP (100μM) were of similar magnitude for all groups (median 
force ≈60μN/mg tissue). The contractions evoked by pre GSK (1μM) were not significantly 
different between groups, however these appear to be weaker in aging P2Y2KO mice. The 
contractions evoked by UTP+GSK were similar in all groups, where UTP is the agent 
responsible for these contractions (discussed previously for each group). Post GSK evoked 
negligible contractions and post UTP evoked contractions of similar magnitude to other UTP 
interventions and these were not dissimilar between groups.  
 
 
 
 
 
 
 
 
 
 
Figure 4 – 16. Contractions generated by UTP and GSK1016790A in young WT, young P2Y2 
KO & aging P2Y2 KO mouse full thickness bladder strips.  This data is taken from the previous 
contraction graphs from the various mouse models (graphs A in figures 4-13, 4-14 and 4-15) and 
organised to allow clear comparison between groups. No difference observed between groups for 
contractions generated by drug interventions. However, WT tissue seems to contract with greater 
magnitude during drug interventions than P2Y2 mice and the aging P2Y2 tissue seems to only be 
capable of weak contractions. Young WT; n=8, Young P2Y2 KO n=8, Aging P2Y2 KO n=7. Data sets 
are expressed as % medians [25%, 75%], * p ≤0.05, compared using Mann-Whitney. 
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4.4.2.2.5 COMPARISON OF BLADDER OUTPUTS BETWEEN MOUSE GROUPS: 
ATP RELEASE 
There was no significant difference in ATP release observed between mouse models for any 
intervention in either mucosal or full thickness tissue, apart from during the joint intervention 
(figure 4-17). UTP+GSK evoked significantly higher ATP release in young WT than in young 
P2Y2KO mucosa and full thickness tissue, highlighting this as the key difference between 
these 2 groups (relative ATP release during UTP+GSK - WT mucosa; 652% [505%, 
1039%], P2Y2KO mucosa - 301% [190%, 351%], WT full thick; 481% [425%, 660%], 
P2Y2KO full thick - 402% [235%, 460%]). The data was then analysed in the same way as 
for the GP comparison (see section 4.4.2.1.5), where the ATP released during the joint 
intervention (UTP+GSK) is compared to the manually combined ATP release from the 
separate UTP and GSK interventions.  
As with young GP mucosa, the effect of activating TRPV4 and P2Y2/P2Y4 simultaneously in 
young WT mouse mucosa, evokes the same proportional increase in ATP release as 
activating them individually and combining the two (manually combined individual 
activations: 533% [473%, 659%], simultaneous activation: 652% [505%, 1039%])(figure 4-
18). Again, this implies the effect of activating these receptors simultaneously is additive, 
suggesting they have no interaction and mediate ATP release via different mechanisms. 
This was also observed in young WT mouse full thickness tissue. However, knockdown of 
P2Y2 in young mouse mucosa causes this additive effect to be lost, where the ATP released 
during simultaneous activation is significantly less than that of the manually combined 
releases, and is similar to that of each individual UTP or GSK intervention (manually 
combined individual activations: 538% [467%, 691%], simultaneous activation: 301% [190%, 
351%], averaged pre/post UTP interventions: 347% [300%, 446%], averaged pre/post GSK 
interventions: 235% [176%, 250%]). This effect caused by knockdown of P2Y2 was also 
observed in young P2Y2KO full thickness tissue (manually combined individual activations: 
1017% [935%, 1538%], simultaneous activation: 402% [235%, 460%], averaged pre/post 
UTP interventions: 538% [350%, 747%], averaged pre/post GSK interventions: 264% 
[185%, 333%]).  
As P2Y2 is absent, these results imply that P2Y4 and TRPV4 mediate ATP release via the 
same mechanism and therefore when activated simultaneously, their signalling pathways 
compete for this mechanism and as such, can only elicit an ATP release equalling that of 
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either of their individual effects only. The ATP release in aging P2Y2 tissue is highly variable, 
a phenomenon previously observed in aging GP tissue also(Sui et al., 2014), and with the 
low n numbers, this makes comparisons and conclusions difficult here. Due to these 
variations, many additional aging P2Y2KO bladders must be assessed before reliable 
conclusions can be drawn, as currently the data is insufficient to reveal any trend.  These 
results suggest that P2Y2 is necessary for the additive ATP release observed with 
simultaneous P2Y and TRPV4 activation. The large variations in the ability to release ATP in 
individual mice in older age group may reflect the ageing process. 
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Figure 4 – 17. Effect of UTP and GSK1016780A on ATP release from various mouse models. 
These graphs allow for clear comparison of ATP release between young WT, young P2Y2 KO and aging 
P2Y2 KO mouse bladder mucosa and full thickness (FT) strips, triggered by the stated drug 
interventions (data is taken from ATP release graphs (B) in figures 4-13, 4-14 and 4-15, but arranged 
for comparative purposes). A: Pre-100μM UTP intervention – increased ATP release in both mucosa 
and FT from young WT (YWT), young P2Y2 KO (YP2Y2) and aging P2Y2 KO (AP2Y2) bladders. No 
difference between groups. B: Pre-1μM GSK intervention – increased ATP release in mucosa and FT 
from all groups. No difference between groups. C: 100μM UTP + 1μM GSK intervention – increased 
ATP release in both mucosa and FT from all groups. This simultaneous drug intervention generated 
significantly greater ATP release from YWT mucosa and FT than YP2Y2 (data sets compared using 
Mann-Whitney test, p value shown). D: Post-1μM GSK intervention – increased ATP release in mucosa 
and FT from all groups. No difference between groups. E: Post-100μM UTP intervention – increased 
ATP release in mucosa and FT in YP2Y2 tissue only. No difference between age groups. Significance 
was not reached in AP2Y2 for any intervention as it was only possible to assess 5 bladders. all graphs: 
data expressed as % medians [25%, 75%], (WT young; n=8, P2Y2 KO young; n=8, P2Y2 KO aging; 
n=5) Wilcoxon’s, *p<0.05, drug intervention vs. control (basal levels). All age groups compared using 
Mann-Whitney test e.g. WT mouse – young vs. P2Y2 mouse – aging.  
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Figure 4 – 18. Additive or potentiating effect of co-stimulation of ATP release with UTP 
(100μM) and GSK1016790A (1μM) in young WT, young P2Y2 KO & aging P2Y2 KO mouse 
bladder tissues.  Light grey bars: ATP release from Pre and post control interventions (figures 4-
13, 4-15 and 4-15) of UTP (and GSK separately) were averaged, then this average for UTP-
induced ATP release was manually combined with that of GSK. This represents the total (sum of) 
ATP release evoked by these mechanisms when activated separately. Dark grey bars: represent 
the total ATP released when UTP and GSK are used simultaneously. In young WT and aging 
P2Y2KO tissues, the combined ATP release is similar to simultaneous in both tissue preparations, 
with no significant difference between the two, suggesting the effect of simultaneous activation is 
additive. In contrast, simultaneous activation in young P2Y2KO tissues generated significantly 
lower ATP release than combined ATP release from independent activation of these receptors. 
This suggests the mechanism underlying the ATP release pathway triggered by TRPV4 or P2Y 
activation in this model may be shared. Young WT; n=8, Young P2Y2 KO n=8, Aging P2Y2 KO 
n=7. Data sets are expressed as % medians [25%, 75%], data sets compared using Wilcoxon’s, p 
value shown. 
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4.4.2.2.6 EFFECT OF PRE-ACTIVATION OF ONE RECEPTOR GROUP ON 
ACTIVITY OF THE OTHER 
The following experiments were designed to further examine the relationship between 
TRPV4 and P2Y receptors and identify the nature of their cooperative properties that allow 
modulation of ATP release during simultaneous activation. The experimental design is 
described in section 4.3.1 of this chapter.  
4.4.2.2.6.1 EFFECT OF PRE-ACTIVATION OF P2Y RECEPTORS ON TRPV4-
MEDIATED ATP RELEASE: WILD TYPE MOUSE 
Both pre and post controls of GSK significantly enhanced ATP release from mucosa and full 
thickness strips (figure 4-19). After 1hour recovery, UTP significantly enhanced ATP release, 
after which GSK was also introduced, which significantly enhanced ATP release above that 
generated by UTP, and when GSK was removed leaving only UTP, ATP release dropped 
significantly to similar levels during initial UTP (% ATP from basal control: mucosa – UTP 
pre-activation; 291 [214, 437], UTP+GSK; 446 [410, 508], UTP post-activation; 258 [193, 
339], full thick; - UTP pre-activation; 317 [237, 433], UTP+GSK; 502 [422, 666] UTP post-
activation; 351 [324, 401]). This suggests that TRPV4 and P2Y2/P2Y4 receptors can mediate 
ATP release independent of the activity of the other in WT bladder.  
4.4.2.2.6.2 EFFECT OF PRE-ACTIVATION OF P2Y RECEPTORS ON TRPV4-
MEDIATED ATP RELEASE: P2Y2KO MOUSE 
It was only possible to asses 5 bladders here, and as such data provide good initial 
inferences. As with WT mouse, both pre and post controls of GSK enhanced ATP release 
from mucosa and full thickness strips (figure 4-20). Again, after 1hour recovery, UTP 
enhanced ATP release, after which GSK was also introduced. However in this case, GSK 
did not raise ATP release beyond that already generated by UTP in either tissue preparation 
(% ATP from basal control: mucosa - UTP pre-activation; 492 [351, 549], UTP+GSK; 619 
[321, 684], full thick; UTP pre-activation; 649 [311, 1100], UTP+GSK; 619 [337, 1338]. This 
suggests that TRPV4 relies on the same mechanism as P2Y4 receptors for ATP release, as 
P2Y2 is knocked down here. Despite only 5 bladders being assessed, all interventions 
enhanced ATP release from control levels in all 5 bladders (where direct calculation of the 
probability gives significant p values of 0.0313), and GSK only raised ATP beyond that of 
UTP in 40% of bladders here, compared to 90% in WT, providing strong evidence for this 
conclusion. 
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4.4.2.2.6.3 EFFECT OF PRE-ACTIVATION OF TRPV4 RECEPTORS ON P2Y-
MEDIATED ATP RELEASE: P2Y2KO MOUSE 
To confirm the above finding, the same protocol was followed but the order of agonists was 
switched, such that TRPV4 receptors were pre-activated, followed by subsequent, additional 
activation of P2Y4. This determines whether P2Y4 receptors solely rely on the same 
mechanism as TRPV4 for ATP release, or are able to utilize a second mechanism when 
their favoured, original mechanism is already being utilized by TRPV4 signalling. These 
experiments were performed in bladder strips taken from the same 5 P2Y2KO mice as used 
for the previous experiment. 
Both pre and post controls of UTP enhanced ATP release from mucosa and full thickness 
strips (figure 4-21). Following 1hour recovery, GSK enhanced ATP release, after which UTP 
was also introduced. As with the previous experiment, UTP was incapable of raising ATP 
release beyond that already generated by GSK in either tissue preparation (% ATP from 
basal control: mucosa - UTP pre-activation; 302 [227, 372], UTP+GSK; 348 [229, 455], full 
thick; - UTP pre-activation; 206 [213, 342], UTP+GSK; 225 [209, 480]. This suggests that 
TRPV4 and P2Y4 receptors rely solely on the one mechanism for ATP release.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 19. Effect of GSK (TRPV4 
agonist) on ATP release after pre-
treatment with UTP (P2Y agonist) in 
young WT mouse bladder. A: Mucosal 
tissue strips. B: Full thickness tissue 
strips. Both pre- and post-control 
interventions of 1μM GSK increased ATP 
release from basal levels (control). 
During the middle ‘intervention’ period, 
100μM UTP increased ATP release from 
control; introduction of GSK within this 
period caused a significant rise in ATP 
release above that already stimulated by 
UTP, followed by a significant decrease 
of ATP upon removal of GSK 
(‘UTP+GSK’ compared to ‘UTP’ using 
Wilcoxon’s).  Data expressed as % 
Medians [25%, 75%], n=8, Wilcoxon’s, 
*p<0.05, **p<0.01, drug intervention vs. 
control (basal levels). 
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Figure 4 – 20. Effect of GSK (TRPV4 
agonist) on ATP release after pre-
treatment with UTP (P2Y agonist) in 
young P2Y2 KO mouse bladder. A: 
Mucosal tissue strips. B: Full thickness 
tissue strips. Both pre- and post-control 
interventions of 1μM GSK increased ATP 
release from basal levels (control). 
During the ‘intervention’ period, 100μM 
UTP increased ATP release from control; 
however introduction of GSK within this 
period did not cause a significant rise in 
ATP release above that already 
stimulated by UTP (‘UTP+GSK’ 
compared to ‘UTP’ using Wilcoxon’s).  
Data expressed as % Medians [25%, 
75%], n=5, Wilcoxon’s, drug intervention 
vs. control (basal levels). 
Figure 4 – 21. Effect of UTP (P2Y 
agonist) on ATP release after pre-
treatment with GSK (TRPV4 agonist) in 
young P2Y2 KO mouse bladder. A: 
Mucosal tissue strips. B: Full thickness 
tissue strips. Both pre- and post-control 
interventions of 100μM UTP increased 
ATP release from basal levels (control). 
During the ‘intervention’ period, 1μM GSK 
increased ATP release; however 
introduction of UTP within this period did 
not cause a significant rise in ATP 
release above that already stimulated by 
GSK (‘GSK+UTP’ compared to ‘GSK’ 
using Wilcoxon’s).  Data expressed as % 
Medians [25%, 75%], n=5, Wilcoxon’s, 
drug intervention vs. control (basal 
levels). 
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4.4.2.2.7 P2Y6 ACTIVITY IN THE MOUSE BLADDER  
In order to further dissect the pathways and receptor subtypes responsible for mucosal ATP 
release, the role of P2Y6 was investigated.  The P2Y6 agonist UDP (20M) evoked ATP 
release from mucosal and full thickness strips from WT mouse bladders with similar 
effectiveness to UTP (% increase in ATP release from basal levels: mucosa – UTP; 426 
[300, 638], UDP; 334 [208, 573] full thick – UTP; 458 [265, 944], UDP; 256 [185, 521])(figure 
4-22 B). UTP evoked contractions in full thickness tissue whereas UDP did not (force μN/mg 
tissue: UTP; 63 [23, 217], UDP; 5 [1, 21])(figure 4-22 A). Neither agonist evoked contractions 
in mucosa (force μN/mg tissue: UTP; 29 [15, 36], UDP; 9 [6, 19].  This suggests a functional 
role for P2Y6 in urothelial ATP release.  
To confirm the P2Y receptor subtypes activated by UTP, the effect of P2Y6 blockade on 
UTP-mediated ATP release was evaluated using the P2Y6 specific antagonist MRS2578 
(MRS)(figure 4-23). MRS (10M) had no effect on UTP-mediated ATP release (% increase 
in ATP release from basal levels: mucosa – UTP; 417 [283, 480], UTP W/ MRS; 342 [166, 
641] full thick – UTP; 323 [253, 664], UTP W/ MRS; 250 [173, 386]). This indicated that 
none of the ATP release evoked by UTP is mediated by P2Y6, confirming the effect of UTP 
is likely attributable to P2Y2 and P2Y4 only. 
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Figure 4 – 22. Effect of purinoceptor agonists on ATP release and contractile activity in WT 
mouse bladder tissues. A: Median force of mucosal and full thickness (FT) contractions generated by 
either UTP (P2Y2/P2Y4 agonist, 100M) or UDP (P2Y6 agonist, 20M). Agonists generated negligible 
contractions in mucosa (confirmed by traces). UTP evoked contractions in full thickness tissue whereas 
UDP did not. B: Both UTP and UDP evoked significant ATP release from mucosa and full thickness 
tissue with similar effectiveness. For both graphs: data expressed as % medians [25%, 75%], n=7, 
Wilcoxon’s, *p<0.05, **p<0.01, drug intervention vs. control (basal levels). Effect of UTP compared to 
effect of UDP using Mann-Whitney.  
 
 
Figure 4 – 23. Effect of P2Y6 blockade on UTP-mediated ATP release from WT mouse bladder 
tissues. Blockade of P2Y6 receptors using MRS2578 (10M) had no effect on UTP-mediated ATP 
release from mucosa or full thickness tissue strips. For both graphs: data expressed as % medians 
[25%, 75%], n=7, Wilcoxon’s, *p<0.05, **p<0.01, UTP pre/post average vs. UTP W/ MRS.  
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4.4.2.3 EFFECT OF TRPV4 AND PURINOCEPTOR ACTIVATION ON 
FUNCTIONAL OUTPUTS IN THE NORMAL AND OVERACTIVE AGING HUMAN 
BLADDER 
The previous experiments assessing the individual and joint effects of P2Y and TRPV4 
receptor activation on bladder ATP release were also applied to both normal and overactive 
human bladder mucosa from older patients (normal: Male, >65, OAB: Female >45). 
Unfortunately, only 4 OAB biopsies were collected and as such, these results provide only 
an indication of mucosal behaviour in overactive bladders.  
4.4.2.3.1 BASAL ATP RELEASE 
Interestingly, a higher basal ATP release was observed in mucosa from overactive bladders. 
Figure 4-24 shows the basal ATP release during the first 3 interventions performed on each 
biopsy. This was approximately 10-fold higher in OAB positive samples during the first 
intervention (ρmolar ATP release: OAB -ve; 48 [109, 23], OAB +ve; 463 [448, 808]), and 15-
fold higher during the second 2 (ρmolar ATP release: intervention 2 - OAB -ve; 34 [17, 64], 
OAB +ve; 778 [612, 1174] intervention 3 - OAB -ve; 28 [14, 55], OAB +ve; 778 [296, 969]), 
presumably due to activation of tissue by the first intervention. As physiological basal ATP 
release in human tissue is minimal, a ten-fold increase in basal ATP release could have 
profound effects on bladder function and may be partly responsible for the overactive 
phenotype. 
4.4.2.3.2 TRPV4-INDUCED ATP RELEASE 
The effect of TRPV4 activation on ATP release was characterised in both cohorts. Figure 4-
25 A shows comparison of the effect of GSK (1μM) on ATP release from normal and 
overactive bladder mucosa. Significant ATP release is generated with a delay in normal 
aging bladder mucosa, with onset at 3 minutes, rising until a peak at 10minutes, after which 
the effect is lost. Comparatively, GSK appears to elicit ATP release after only 1minute from 
OAB positive mucosa, where the effect is lost after 3 minutes. Specifically, GSK enhanced 
ATP release from basal levels in all 4 OAB samples at 1 and 3 minutes and at 5 minutes in 
3 of the 4 samples. However, the median values for peak ATP release are lower in OAB 
samples (% ATP release from basal levels: OAB -ve - 1min; 132 [70, 157], 3min; 173 [132, 
319], 5min; 214 [126,441], 10min; 276 [149, 467], 20min; 134 [97,236], OAB +ve - 1min; 197 
[193, 217], 3min; 179 [132,228], 5min; 170 [105, 208], 10min; 135 [119, 137], 20min; 151 
[118, 182]). Therefore, these data indicate that TRPV4 is able to elicit ATP release from 
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mucosa of both normal and overactive human bladder mucosa, however the dynamics of 
release may differ slightly, with an earlier but diminished release in OAB samples. 
Expressing the data in this way (as a percentage increase from basal levels) indicates the 
proportionate drug effect of GSK on ATP release is similar in both cohorts. However, 
expressing ATP release as ρmoles/g tissue/min revealed that, like basal ATP release, the 
quantity of TRPV4-induced ATP release was much higher from the mucosa of overactive 
bladders (ρmolar ATP release: OAB –ve – basal; 35 [24, 40], GSK; 320 [241, 433], OAB +ve 
- basal; 656 [479, 1254], GSK; 1072 [735, 1854])(figure 4-25 B).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 24. Basal ATP release levels in human bladder mucosa biopsies. Mucosal biopsies 
from overactive bladders release significantly higher basal levels of ATP than bladders without OAB 
symptoms. Basal ATP was measured during the Tyrode’s pre and post control for the first 3 
interventions on the day of each experiment and averaged, providing the values represented by bars. 
ATP release expressed as ρmoles/g tissue/min medians [25%, 75%], OAB negative; n=11, OAB 
positive; n=4, Mann-Whitney, p values shown, OAB positive vs. OAB negative. 
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Figure 4 – 25. Effects of TRPV4 activation on aging human bladder biopsies with or without 
OAB symptoms. A: Effect of 1μM GSK on ATP release from mucosal bladder biopsies from 
patients without OAB symptoms (male, >65, n=10, light grey bars) compared to mucosal bladder 
biopsies with OAB symptoms (female, >45, n=4, dark grey bars). Only 4 OAB bladders were 
assessed such that significant statistics are not possible from this cohort (p values stated). 
However, data indicates significantly higher ATP release from non-OAB patients at 10minutes. 
Data sets expressed as % medians [25%, 75%], OAB negative; n=10, OAB positive; n=4, * p 
≤0.05, ** p ≤0.01, or p value stated, Wilcoxon’s, drug intervention vs. control. Data sets compared 
using Mann-Whitney, OAB negative vs. OAB positive. B: Effect of 1μM GSK on mucosal ATP 
release expressed as ρmoles/g tissue/min as opposed to a percentage increase from basal levels. 
ATP release across the 20minute period of exposure to GSK was averaged. Data indicates that 
GSK-induced ATP release is higher in the mucosa from patients with overactive bladders 
compared to those without overactive bladders. As only 4 OAB patients were assessed, data 
provide only an indication of trend, where significance is not yet possible. ATP release expressed 
as ρmoles/g tissue/min medians [25%, 75%], OAB negative; n=10, OAB positive; n=4, Wilcoxon’s, 
p values shown, Basal vs. GSK. Comparison between groups is not possible due to low n 
numbers. 
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4.4.2.3.3 CO-ACTIVATION OF TRPV4 AND PURINOCEPTORS 
The protocol designed to assess the effect of joint activation of P2Y and TRPV4 receptors 
was then applied (section 2.5.1.1.2 – interaction protocol). No contractions were observed, 
as these biopsies were composed of mucosal tissue only (small tears of smooth muscle 
were attached to a small number of biopsies, however this was not enough to elicit 
contractions) and as such, no graph of contractility is shown.   Significant ATP release was 
generated by all interventions from normal mucosa (see table 17), however, due to low n 
numbers, ATP release from OAB samples was not significant (figure 4-26). However, ATP 
was elevated by all interventions in the OAB samples in all 4 of the biopsies, resulting in the 
p value of 0.125 shown. The ATP releases generated by different interventions were not 
significantly different from one another. 
Table 17 - Quartiles (median [25%, 75%]) of ATP release and force elicited by stated 
interventions in aging GP bladder tissues (referring to figure 4 – 26 graph).  
 Cohort 100μM UTP 
(pre) 
1μM GSK     
(pre) 
100μM UTP + 
1μM GSK 
1μM GSK    
(post) 
100μM UTP 
(post) 
ATP 
release  
(% of 
averaged 
controls) 
Normal 431 [229, 499] 202 [134, 303] 595 [331, 
1504] 
143 [137, 254] 108 [41, 400] 
OAB 200 [180, 228] 181 [163, 200] 322 [209, 437] 126 [109, 157] 136 [52, 230] 
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This data was then analysed in the same way as for the animal models, comparing the 
combined, separate effects of UTP and GSK with the simultaneous effect (figure 4-27). 
Referring to figure 4-27 B, in normal (OAB negative) human mucosa, activating TRPV4 and 
P2Y2/P2Y4 simultaneously evokes the same proportional increase in ATP release as 
activating them individually and combining the two (manually combined individual 
activations: 509% [402%, 760%], simultaneous activation: 595% [331%, 1504%]). This was 
also observed in young GP and young WT mouse models and implies the effect of 
simultaneous receptor activation is additive, suggesting they have no interaction and 
mediate ATP release via different mechanisms. This was also observed in the 4 OAB 
positive biopsies assessed thus far (manually combined individual activations: 335% [244%, 
378%], simultaneous activation: 322% [209%, 437%]). Interestingly, when observing the 
individual trends for each individual experiment (figure 4-27 A), 2 of the 11 normal biopsies 
examined showed a considerable increase in ATP release when the receptor groups were 
Figure 4 – 26. Effect of UTP and GSK1016780A on ATP release from human bladder mucosa 
biopsies. Biopsies from 2 cohorts of patients were challenged with stated drug interventions in 
succession from left to right. OAB negative cohort; 9 male patients with suspected or known 
tomours, >65 years of age. OAB positive cohort; 4 female patients with OAB symptoms, >45 years 
of age. All interventions stimulated significant ATP release from OAB negative patients excluding 
final UTP intervention. Due to low number of OAB positive samples assessed significant statistics 
are not possible for this cohort (p values shown). No significant difference in ATP release observed 
between cohorts. Data expressed as % medians [25%, 75%], Wilcoxon’s, *p<0.05, ** p ≤0.01 or as 
stated, drug intervention vs. control (basal levels). Data sets compared using Mann-Whitney, OAB 
negative vs. OAB positive.  
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activated together, similar to that of the aging GP. It is possible therefore, that these aging 
human bladders had similar properties to those of the aging GP, resulting in potentiated 
ATP release during simultaneous activation.   This may identify a further age-related change 
in bladder properties that may result in altered function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 27. Effect of co-stimulation of ATP release with UTP (100μM) and GSK1016790A (1μM) 
in human bladder mucosa biopsies. For all graphs: UTP+GSK groups: ATP release from Pre and 
post control interventions (from figure 4-26) of UTP were averaged, then this average for UTP-induced 
ATP release was manually combined with the average of GSK. This represents the total (sum of) ATP 
release evoked by both of these mechanisms when activated separately. UTP W/ GSK groups: 
represent the total ATP released when UTP and GSK are used simultaneously. A: Individual paired 
data from each mucosal biopsy revealing the individual trend of each experiment.  B: Averaged ATP 
release. No significant difference between ATP released from simultaneous drug intervention compared 
to combined single-drug interventions. OAB negative cohort; 9 male patients with suspected or known 
tomours, >65 years of age. OAB positive cohort; 4 female patients with OAB symptoms, >45 years of 
age. Data expressed as % medians [25%, 75%], Wilcoxon’s, *p<0.05, simultaneous drug intervention 
vs. combined single-drug interventions.  
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4.5 DISCUSSION 
The purpose of this chapter was to identify any age-related changes in the expression or 
function of TRPV4 receptors in the bladder. Findings revealed that not only is TRPV4 
expression up-regulated in the aging bladder, but a novel relationship with P2Y receptors 
appears to emerge, where co-activation generates an amplified ATP release from the 
mucosa.   
4.5.1 TRPV4 RECEPTOR EXPRESSION IS INCREASED WITH AGING 
Results from IHC of young and aging GP bladder revealed similar expression profiles in 
both age groups, with highest TRPV4 expression in the urothelium and lower levels in both 
the suburothelium and DSM. The bladder sections investigated for this purpose were 
examined on different days across a period of months, where confocal imaging settings 
were optimised for each set of sections (per bladder; 1x secondary control, 3x positive). As 
such, comparison of TRPV4 expression levels between age groups is not possible, as 
settings were altered to account for background and secondary control fluorescence. 
However, this technique provides important information regarding the tissue specific 
expression of TRPV4 across the bladder wall, which is not possible with other techniques 
such as western blotting. Following from this, western blotting was employed to reliably 
confirm any differences in the expression levels of TRPV4 between age groups. Indeed, 
results revealed a 8-fold higher expression in separated mucosa and 16-fold higher in DSM. 
Taken together, and with findings from the previous chapter, these results indicate that; 1. 
the relative expression of TRPV4 between tissues remains similar with aging (IHC; 
urothelium > suburothelium and DSM, western; mucosa > smooth muscle) 2. However, the 
overall expression levels are greatly increased. Other studies have identified plasticity in the 
expression of other key receptors in the bladder that occur with both age and pathology. 
Changes in expression of bradykinin and muscarinic receptors and connexin and Ca2+-
activated K and Cl channels have been identified in overactive and obstructed bladders, 
pathologies both strongly associated with age (Chopra et al., 2005; Haefliger et al., 2002; Li 
et al., 2008; Somogyi and de Groat, 1999). In addition, IC has been shown to increase the 
expression of purinoceptors in the feline (Birder et al., 2004) and human bladders (Tempest 
et al., 2004), where patients suffering from IC also exhibit augmented stretch evoked ATP 
release (Sun and Chai, 2006). A further study demonstrated changes in purinoceptor and 
muscarinic receptor expression (between 2-6 fold reduction) and altered urothelial and DSM 
function as a direct result of aging in the mouse bladder (Daly et al., 2014). These findings 
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highlight how sensitive the mucosa is to pathology and aging with respect to expression of 
key receptors. As such, the findings in this chapter are in agreement with this and provide 
further important evidence, reporting for the first time a significant increase in TRPV4 
expression as a direct result of aging.   
4.5.2 CO-ACTIVATION OF TRPV4 AND P2Y RECEPTORS – EMERGENCE OF 
A FUNCTIONAL LINK 
4.5.2.1 YOUNG AND AGING GP MODELS 
There is good evidence to suggest that the urothelium is the principal source of ATP in the 
bladder, the release of which is primarily induced by stretch during bladder filling (Ferguson 
et al., 1997; Kumar et al., 2010, 2004; Sui et al., 2014).  This process is crucial for 
physiological bladder function and relies on a multitude of receptors and pathways. Both 
TRPV4 and P2Y receptors, among others, have been strongly implicated in this process. 
UTP-induced ATP release has been previously demonstrated in GP mucosal sheets (Sui et 
al., 2014) and from urothelial cell lines (Chopra et al., 2008; Mansfield and Hughes, 2014), 
and TRPV4-associated ATP release has been extensively evidenced both in the previous 
chapter and in the literature. Owing to the apparent importance of these receptors in 
urothelial ATP release, it was hypothesised that a functional relationship may exist between 
the two receptor groups, capable of influencing the properties of urothelial ATP release. As 
such, the effect of co-activation of these receptors was investigated in both young and aging 
bladders. 
4.5.2.1.1 PURINOCEPTOR AND TRPV4 MEDIATED ATP RELEASE 
Both GSK (TRPV4 agonist) and UTP (P2Y2/P2Y4 agonist) evoked ATP release from the 
bladder, the main source of which was identified as the mucosa. Aging had no effect on the 
ATP released from bladder tissues in response to either GSK or UTP individually, where the 
quantities of ATP released were similar. In both mucosa and full thickness tissue from young 
GP, co-activation of these receptors generated an additive ATP release (i.e. quantity of ATP 
released by co-activation = separate TRPV4-induced ATP + P2Y-induced ATP). This implies 
that both receptor groups utilize unrelated pathways for ATP release (figure 4-29 B), as 
there is no less ATP release than the combined individual releases, which would imply 
competition of the ATP release pathway, or no more ATP release beyond the combined, 
which would imply a co-dependent amplification of ATP release signal. Additionally, levels of 
ATP released through P2Y activation were similar to that of TRPV4, possibly implying the 
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actual mechanisms for release are similar for each receptor group, even if the pathways are 
mutually exclusive.  
Co-activation in aging mucosa resulted in an amplified or potentiated ATP release, beyond 
that of the combined individual effects. This amplified release during co-activation was only 
observed in the mucosa, where the effect was additive in aging full thickness tissue. The 
difference between co-activated release and the combined individual releases was 
completely attributable to a markedly higher ATP release during the co-activation 
intervention and not due to lower ATP release from either of the individual interventions 
(confirmed by a significantly higher release during the co-activation/joint intervention in 
mucosa compared to full thickness). Co-activation also generated a higher ATP release in 
the majority of aging mucosal strips compared to young mucosal strips (figure 4-28). These 
results show that the individual or combined effects of P2Y and TRPV4 receptor activation 
are similar in aging and young GP bladder tissue, apart from when the receptors are 
activated together in separated aging GP mucosa, where a much higher ATP release is 
observed, identifying this particular situation as the trigger for amplified ATP release. This 
co-activated amplification of ATP release only occurred in aging tissue, implying the need 
for an age-dependent change in tissue function, possibly in the form of a functional 
interaction between the two receptor groups that emerges with aging. The amplified ATP 
signal was not observed in full thickness aging tissue, implying that the tissues underlying 
the mucosa possess some modulatory control over ATP release from the mucosa. A 
negative feedback mechanism for limitation of urothelial ATP release must exist in some 
form, as ATP can evoke further ATP release via P2Y receptors (ATP-induced ATP release) 
and therefore without negative feedback ATP release would be continually amplified. 
Indeed, AMP and adenosine, breakdown products of ATP, have both been shown to inhibit 
mucosal ATP release, suggesting this as the primary negative feedback mechanism 
(Dunning-Davies et al., 2013; Mansfield and Hughes, 2014). This feedback is therefore 
highly influenced by the ectonucleotidases responsible for breakdown of ATP to AMP and 
adenosine. Eight members of the ectonucleoside triphosphate diphosphohydrolase 
(NTPDase) family have been identified in the mouse bladder, where their expression is 
highly cell specific.  NTPD1, NTPD2, NTPD3, NTPD8 and NT5E subtypes catalyze the step-
wise conversion of extracellular ATP to adenosine. However, expression is not ubiquitous; 
NTPD1 in cells of the lamina propria and DSM, NTPD2 in lamina propria cells adjacent to 
the DSM, NTPD3 and 8 in the urothelium only, and NT5E exclusively in the DSM, with the 
localization of others unidentified (Yu et al., 2011). As such, coordination between these 
enzymes governs the availability of nucleotide ligands for purinoceptors. The activity of 
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these enzymes will therefore influence AMP and adenosine-mediated inhibition of ATP 
release. Perhaps ectonucleotidase expression and function is altered with age, as indeed a 
reduced econucleotidase activity has been demonstrated in human DO bladders (Harvey et 
al., 2002). In the young GP the subtypes present in the mucosa may be sufficient to 
modulate ATP release via breakdown of ATP to AMP and adenosine in the absence of 
underlying tissues. However, ectonucleotidase activity and expression may be altered in the 
aging GP, such that the subtypes present in the mucosa cannot produce the AMP and 
adenosine necessary for negative feedback of mucosal ATP release. This would result in 
the augmented ATP release observed in aging GP mucosa when the underlying tissues 
have been removed. However in-depth examination of the expression of enzyme subtypes 
in aging bladders is needed to support his hypothesis.   
In aggregate, these findings suggest that a mechanism for excessive ATP release mediated 
by co-activation of P2Y and TRPV4 receptors develops in the aging bladder, which has the 
potential to come into effect if regulatory mechanisms, likely in the form of negative 
feedback pathways imposed by the underlying tissues, are disrupted. As previously 
discussed, the urothelium is highly susceptible to age-related factors such as inflammation, 
injury, pathological insult, hypoxia and ischemia, all of which can damage and alter urotheial 
signalling properties. As such, it is not unreasonable to presume that some of these age-
related factors are capable of causing a malfunction in bladder signalling that would permit 
this exaggerated ATP release, possibly through altered ectonucleotidase activity, which 
would in turn have considerable consequences on bladder function. A potential mechanism 
is discussed in section 4.5.2.4.1 after the effects in mouse models have been considered. 
 
 
 
 
 
 
 
 
Figure 4 – 28. ATP release evoked by co-activation of TRPV4 and P2Y receptors in young and 
aging GP mucosa. Dot plot showing individual ATP release values for each young and aging bladder 
assessed. A greater proportion of aging bladders released higher levels of ATP in response to co-
activation than their younger counterparts, reflected by a higher median (black bars). Data expressed 
as individual data points with % medians (black bars). 
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4.5.2.1.2 PURINOCEPTOR AND TRPV4 MEDIATED CONTRACTIONS 
Weak contractions were generated by UTP in approximately 35% of mucosal strips 
examined in both young and aging GP. A contractile effect has previously been 
demonstrated by UTP on mucosa and this was attributed to suburothelial myofibroblasts, 
which contain contractile proteins and express P2Y2 receptors, thus enabling them to 
mediate contraction (Sui et al., 2014). If P2Y2 is indeed the responsible subtype, results 
suggest P2Y2 function in these cells is unaltered by age. TRPV4 agonist GSK was unable to 
evoke contractions in young mucosal strips, however generated weak contractions in 50% 
of aging mucosal strips. It is possible that TRPV4 expression is also up-regulated in 
suburothelial myofibroblasts with age and this results in emergence of a contractile function. 
TRPV4 is indeed expressed by myofibroblasts in the lungs and activity of these receptors is 
up-regulated under pathological conditions (pulmonary fibrosis), supporting this finding 
(Rahaman et al., 2014).  
UTP is a weak agonist for P2X1 & P2X3 receptors and therefore any small contractions 
observed in full thickness tissue are likely in part due to direct activation of DSM via these 
receptors (Chen et al., 1995; Robertson et al., 1996). However, P2Y activation by UTP only 
evoked minimal contractions in full thickness bladder strips from young or aging GP 
bladders. It is likely a proportion of this is due to direct action of UTP on DSM and the 
remainder possibly due to a weak paracrine effect of UTP-induced urothlium-derived ATP, 
as agonist-induced urothelial ATP has been shown to be capable of eliciting a paracrine 
effect on DSM contractions (Sui et al., 2014). The contractions evoked by GSK are a result 
of direct action on DSM as previously discussed, possibly with a small contribution from the 
paracrine action of GSK-induced mucosal ATP. It is also important to consider that the 
urothelium may release further currently unidentified neurotransmitters that could also 
contribute in part to DSM contraction.  
GSK evoked contractions of similar magnitude upon first exposure in both young and aging 
full thickness tissue. In young tissue, further exposures were incapable of evoking 
contractions. Interestingly however, second and third exposures to GSK in aging tissue 
evoked further, weaker contractions in the majority of strips. This is likely a consequence of 
the considerably higher expression of TRPV4. These surplus receptors may already be 
incorporated into the membrane, where a proportion remains inactivated by the first GSK 
intervention of enough numbers to elicit a second contraction upon second exposure to 
GSK. Alternatively, these excess receptors may be housed in vesicles beneath the 
membrane, as per their normal trafficking process (Everaerts et al., 2010a; Schwartzberg, 
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1998; Wegierski et al., 2006), and as such a greater number are available for rapid 
incorporation into the membrane for subsequent activation. This identifies a functional 
change in TRPV4 receptors in aging tissue, likely as a consequence of TRPV4 
overexpression, which has the potential to directly alter DSM contractile responses.  This 
increased population of TRPV4 receptors is therefore capable of eliciting contractions in 
quicker succession and this could indeed contribute to overactive bladder activity.  
4.5.2.2 MOUSE MODELS  
4.5.2.2.1 PURINOCEPTOR AND TRPV4 MEDIATED ATP RELEASE  
Co-activation of TRPV4 and P2Y receptors was investigated further using young wild type, 
young P2Y2KO and aging P2Y2KO mice, allowing the involvement of P2Y2 and P2Y4 to be 
determined.  Both GSK (TRPV4 agonist) and UTP (P2Y2/P2Y4 agonist) evoked ATP release 
from the mucosa and full thickness strips in all models. Co-activation in young WT mice 
generated an additive ATP release reflecting that observed in the young GP. However, 
knockdown of P2Y2 significantly reduced the co-activated ATP release to levels reflecting 
those observed during separate challenge with either GSK or UTP, meaning the co-
activation effect was significantly less than additive. The effect of co-activation was 
investigated in 5 aging P2Y2KO mice, however these exhibited high variations in ATP 
release thus preventing any rational conclusions from being drawn.  
The levels of ATP release evoked by UTP were similar in all models (~400% increase), as 
were those by GSK (~300% increase). However, co-activation in P2Y2KO elicited 
significantly less ATP than in WT, highlighting this intervention as the determining factor 
accounting for the less-than additive effect observed. This implies that here, P2Y4 and 
TRPV4 may share the same mechanism for ATP release; during co-activation the receptors 
compete for a shared pathway, which becomes fully saturated, preventing ATP release 
beyond that of the individual effect of one receptor type (figure 4-29 B). As the WT model 
exhibits an additive effect in the presence of P2Y2, this implies that P2Y2 either utilizes a 
different mechanism all together, or is capable of utilizing an additional pathway once the 
first (utilized by TRPV4 and P2Y4) becomes saturated.  
If it is indeed the case that TRPV4 and P2Y4 share a mechanism for ATP release and P2Y2 
utilizes an alternative, it might be expected that UTP-induced ATP release would be greater 
in WT than P2Y2KO mice. However, our data show the levels of ATP release to be similar in 
both models, with no significant difference between the two (data values shown in table 18).  
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Table 18 - Values (median [25%, 75%]) of ATP release as ρmoles / g tissue / min evoked by 
100μM UTP in WT and P2Y2KO mouse mucosa (graph not shown). 
 WT P2Y2KO 
N number 8 10 
Minimum 38.33 82.28 
25% Percentile 156.5 165.2 
Median 373.5 235.1 
75% Percentile 654.5 798.3 
Maximum 1491 1015 
   
Mean 477.3 409.5 
Std. Deviation 460.6 346.2 
Std. Error of Mean 162.8 109.5 
 
It may be that P2Y2 and P2Y4 mediate ATP release cooperatively to prevent release 
exceeding physiological levels, or a purinoceptor-specific feedback pathway mediates a 
balanced release between the two receptors, despite each using a different pathway. 
purinoceptors also display high plasticity in expression under varying conditions in many 
tissues (Dubyak et al., 1996), as well as the bladder (previously discussed). It may be that 
expression of functional P2Y4 receptors is up-regulated in the P2Y2KO mouse, sustaining 
the levels released in WT, however competition for the pathway by TRPV4 prevents any 
additive release during co-activation.  
The involvement of P2Y6 receptors in this mechanism was eliminated as blockade of these 
receptors had no effect on UTP-mediated ATP release. However, P2Y6 activation by the 
agonist UDP did evoke ATP release from the mucosa. This has been demonstrated 
previously in anaesthetized rats, where the ATP release was mediated by pannexin-1 
channels and indirectly increased voiding frequency via P2X3 receptors on suburothelial 
afferent nerves (Carneiro et al., 2014; Timóteo et al., 2014). As such, current findings 
suggest that P2Y2, P2Y4 and P2Y6 are the purinoceptor subtypes responsible for urothelial 
ATP release. The involvement of additional P2Y subtypes is unlikely as there is currently no 
report of expression of other P2Y subtypes in the urothelium, aside from P2Y1, which does 
not respond to UTP and does not evoke ATP release from the urothelium when activated 
(Mansfield and Hughes, 2014). Currently, P2X receptors are also not believed to contribute 
to urothelial ATP release and this is supported by findings from multiple studies (Mansfield 
and Hughes, 2014; Sui et al., 2014, 2006).  
As P2Y2 and P2Y4 respond to ATP, it is likely they mediate ATP-induced ATP release from 
the urothelium. Results from this study imply that P2Y4 is primarily responsible for ATP/UTP 
induced ATP release, and P2Y2 functions as an alternate pathway for additional ATP 
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release once others become saturated. As P2Y6 preferentially responds to UDP only, the 
physiological function of P2Y6-mediated ATP release is less clear, as unlike ATP, it is yet to 
be established whether UTP and UDP are released from the bladder tissues for 
physiological function. However, findings from one study did support the endogenous 
release of UTP and UDP from the bladder and that this modulated the micturition reflex via 
P2Y6 (Carneiro et al., 2014). Additionally, physiologically relevant levels of nucleosides and 
nucleotides, including UTP and UDP have recently been identified in human urine samples 
and as such, P2Y6 may be activated by endogenous UDP, contributing to urothelial ATP 
release (Contreras-Sanz et al., 2012). 
P2X receptors respond preferentially to ATP, and P2Y1 receptors to adenine nucleotides. As 
these are the only other purinoceptor subtypes present in the urothelium, the effects of UTP 
and UDP observed in this study can be attributed to P2Y2, P2Y4 and P2Y6 with confidence. 
However, the agonists used (UTP, UDP) do lack subtype specificity to some degree, where 
the EC50 values have been determined in cultured cells exhibiting different purinoceptor 
phenotypes to the cells present in the bladder preparations examined here. As such, there 
may be some crossover of effects of UTP and UDP on these subtypes that cannot be 
determined, making it difficult to definitively identify the receptor subtypes responsible for the 
respective observations. A novel P2Y6 agonist PSB0474 (3-phenacyl-UDP) has recently 
been developed, which has a higher selectivity for the receptor than UDP (EC50=70nm, 
>500 fold selectivity)(El-Tayeb et al., 2006). This UDP derivative could be used in future 
studies for more definitive results.   
4.5.2.2.2 PURINOCEPTOR AND TRPV4 MEDIATED CONTRACTIONS 
Unlike GP bladders, no mucosal contractions were observed in any mouse model when 
challenged with UTP. For the WT, this is likely due to species differences, where subtype-
specific expression levels and functional responsibilities of purinoceptors differ between the 
two animals. UTP-induced mucosal contractions would not be expected in P2Y2KO 
bladders, as it was suggested that these contractions were mediated by P2Y2 expressing 
myofibroblasts As with young GP, no contractions were generated by GSK in either of the 
young mouse models. Unlike aging GP however, no contractions were observed in aging 
mice, however only 5 bladders were assessed. It may be that further n numbers would 
reveal contractions in a similar proportion of bladders as observed in aging GP, or it may be 
that TRPV4 expression is not altered with age in mice and as such, this needs further 
investigation.  
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Contractions of similar magnitude were generated by UTP in full thickness strips from all 3 
models. As discussed for GP tissue, this is likely in part due to direct action of UTP on DSM 
P2X3 receptors with a small contribution from a paracrine effect of mucosal ATP release. 
GSK evoked contractions in full thickness strips from all mouse models in a similar fashion 
to that observed in GP tissue. However, in the 5 aging mouse bladders examined there was 
no reproducible effect of GSK like that observed in aging GP and again, this may be due to 
an unchanged TRPV4 expression in aging mice.  
4.5.2.3 FURTHER MOUSE STUDIES: DOES TRPV4 ACTIVITY LIMIT THAT OF 
P2Y RECEPTORS AND VICE VERSA?  
The apparent interplay between TRPV4 and P2Y receptor signalling for ATP release was 
investigated. As discussed, it was hypothesised that TRPV4 and P2Y4 share a mechanism 
for ATP release, and P2Y2 is either able to utilize a further mechanism once the first 
becomes saturated, or indeed utilizes a different mechanism all together. Using P2Y2KO 
mice, it was found that if ATP release was induced by P2Y4 receptors slightly in advance of 
TRPV4, TRPV4 could not mediate additional ATP release above that already being 
generated by P2Y4. This was also found if TRPV4 receptors were activated in advance of 
P2Y4. Interestingly, if P2Y2 and P2Y4 were activated in advance of TRPV4 in WT bladders, 
TRPV4 was then capable of generating additional ATP release. This supports the previous 
hypothesis that P2Y2 is the subtype required to mediate additional ATP release, accounting 
for the additive effect observed in WT models.  
4.5.2.4 SUMMARISED FINDINGS AND IMPLICATIONS FROM ANIMAL 
STUDIES 
In aggregate, the substantial collection of findings from these animal studies permits reliable 
postulation of the changes that occur during aging that underlie the observed shift from 
additive to potentiated mucosal ATP release. TRPV4 and P2Y2/P2Y4 activation induced ATP 
release in both species, highlighting the similarity in basic receptor functions between these 
two models. TRPV4-induced contractions were again similar between species, however 
contractile responses to purinoceptor activation varied slightly, with strong contractions in 
mouse and minimal contractions in GP, indicating the presence of some differences that 
may need to be considered when using these models.  
 
 
194 
4.5.2.4.1 CO-ACTIVATION OF TRPV4 WITH PURINOCEPTORS ELICITS 
ADDITIVE OR POTENTIATIVE ATP RELEASE  
Co-activation of TRPV4 and P2Y receptors in both young GP and WT mice generates an 
additive ATP release, the total of which reflects that of the sum of ATP release generated by 
each receptor group individually. This can imply that the two receptor groups utilize different, 
mutually exclusive mechanisms for ATP release, however in this case there appears to be a 
more complex relationship. Mouse studies identified the importance of P2Y2 receptors in this 
observed additive ATP release in young WT animals. Results suggest that TRPV4 and P2Y4 
can generate ATP release independently; however P2Y2 is necessary for co-activated 
additive ATP release. Without P2Y2, co-activation results in a level of ATP release reflecting 
that of only one of the individual agonists, not the sum of both, with multiple experiments 
evidencing this phenomenon. This implies that TRPV4 and P2Y4 share the same 
mechanism for ATP release, and when activated simultaneously, compete for this, such that 
the total ATP release still reflects that of only one receptor group (figure 4-29 B).  Following 
from this, a few possible theories for the additive and potentiated ATP release observed in 
other models can be drawn. Activation of TRPV4 generates ATP release via raised [Ca2+]i,  
likely mediated by pannexin-1 channels as described in the previous chapter. Activation of 
P2Y4 alone generates ATP release via an unknown mechanism. It is possible this is partly 
mediated via pannexin-1 channels, as P2Y6 receptors have been shown to induce pannexin-
1 mediated ATP release from the urothelium (Timóteo et al., 2014), likely via internal Ca2+ 
release via the IP3 / PLC signalling pathway (Iglesias et al., 2009), the standard signalling 
transduction for P2Y2, P2Y4 and P2Y6 receptors. Interestingly, activation of P2Y2 and P2Y4 
generates similar levels of ATP release to P2Y4 alone. This implies either a negative 
feedback mechanism is in place (likely via inhibitory action of AMP and adenosine), or the 
receptors cooperate to mediate a balanced ATP release, either of which would prevent 
purinoceptor-induced ATP release beyond a certain level. Indeed in other systems, multiple 
P2Y subtypes function together to achieve a balanced output, where certain subtypes are 
necessary for function and others only contribute. This relative contribution can shift 
depending on the chemical environment or stimulatory factors, as is the case for platelet 
function (Daniel et al., 1998; Hechler et al., 1998). In this case therefore, it may be that P2Y4 
is the predominant subtype responsible for UTP-mediated ATP release and P2Y2 may only 
contribute to a certain controlled level, if at all. However, once TRPV4-mediated ATP 
release is also initiated, the mechanism utilized by both TRPV4 and P2Y4 will become 
saturated and this may trigger a shift in the balance between P2Y2 and P2Y4 mediated ATP 
release in favour of P2Y2, utilizing a further mechanism and in doing so permitting the 
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additive ATP release observed (figure 4-29 A). Put simply, it may be that P2Y4 is 
responsible for principal purinoceptor-associated release of ATP and P2Y2 is necessary for 
additional release (amplification).  
However, another possible theory is that in WT animals, P2Y2 is the predominant subtype 
for purinoceptor-induced ATP release and utilizes a different, mutually exclusive mechanism 
to TRPV4, allowing additive release during simultaneous activation. However, knockout of 
P2Y2 may induce purinoceptor plasticity, up-regulating functional expression of P2Y4 
receptors capable of inducing ATP release, to compensate for the lack of functional P2Y2 
receptors. However, these P2Y4 receptors utilize the same ATP release mechanism as 
TRPV4, thus preventing additive ATP release during co-activation. As plasticity of 
purinoceptors and balance between subtypes for a shared function appears to be such an 
important characteristic of these receptors, this possibility cannot be ruled out. As such, 
comparative expression levels of P2Y2 and P2Y4 in both WT and P2Y2KO mice must be 
determined for firm conclusions to be drawn.  
Possibly the most interesting finding from these studies was the emergence of a potentiated 
ATP release from the aging GP mucosa during co-activation of P2Y and TRPV4 receptors. It 
is likely the mechanics underlying this phenomenon are highly complex, as it depends on 
both an unknown change that occurs with aging and separation from underlying tissues. 
Presence of the underlying tissues prevents this augmented ATP release and as previously 
discussed, this suggests the existence of a regulatory feedback mechanism originating from 
these supportive tissues, preventing augmented ATP release, even when a change or 
dysregulation in the mucosa emerges.  The urothelium is susceptible to a variety of harmful 
age-related factors such as inflammation and pathological insult, all of which can have a 
dramatic impact on urothelial function. As such, it is highly likely that regulatory mechanisms 
exist in the supporting tissues as a safe-guard to correct any malfunctions resulting from 
such transformative factors. Therefore, it is possible that aging may disrupt these safe-
guards also, resulting in uncontrolled release of ATP.  
The mechanisms underlying the observed age-dependent enhancement of TRPV4/P2Y co-
mediated ATP release are unclear. If the purinoceptor-mediated components identified in 
mouse are translated in GP it is likely that TRPV4 and P2Y2 coordinate this enhanced ATP 
release through some synergistic functional interaction that develops in aging. A link 
between TRPV4 and P2Y4 is less likely as findings suggest these receptors already share a 
limited mechanism, making a synergistic amplification unlikely. A functional interaction 
between P2Y2 and the closely related TRPV1 channel has been previously described, 
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where co-expression of P2Y2 and TRPV1 was identified and functional activation of TRPV1 
was induced by ATP via P2Y2 receptors in the absence of any other stimuli (Lakshmi and 
Joshi, 2005; Moriyama et al., 2003). This identified a functional interaction between the two 
receptors, permitting activation of TRPV1 via P2Y2. As such, it is possible a similar 
interaction develops between P2Y2 and TRPV4 in the aging mucosa, possibly mediated by 
the considerable increase in TRPV4 expression and high plasticity of purinoceptors. If 
TRPV4 receptors are functionally linked to P2Y2 receptors, this could enable utilization of 
multiple ATP release pathways during co-activation, permitting excessive ATP release 
beyond physiological levels.  
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Figure 4  – 29. Postulated mechanisms 
for ATP release from urothelial cells 
evoked by simultaneous activation of 
TRPV4/P2Y2/P2Y4 in various animal 
models.  A: Mechanism in young WT 
mice and GPs. Activation of TRPV4 alone 
(synthetic by GSK or physiological by 
stretch) induces ATP release mechanism 
‘1’, likely mediated by ↑[Ca
2+
]i  resulting in 
opening of pannexin-1 channels. 
Activation of P2Y receptors alone 
(synthetic by UTP, physiological by ATP 
[ATP-induced ATP release, pathological 
states etc]) induces ATP release via 
mechanism ‘1’ also, possibly with a 
balance between the two subtypes in 
favour of P2Y4. Simoltaneous activation of 
all 3 receptor types induces an additive 
ATP release (the sum of TRPV4 activation 
alone + P2Y activation alone). Once 
shared mechanism ‘1’ utilized by both 
TRPV4 and P2Y4 becomes saturated, 
purinoceptor functional balance shifts to 
P2Y2, which utilizes additional pannexin-1 
channels or an additional ATP release 
mechanism altogether (2), permitting 
additional ATP release. B: Mechanism in 
P2Y2 KO mice. Separate activation of 
either TRPV4 of P2Y4 evokes ATP release 
of similar proportions via shared 
mechanism ‘1’. As such, simultaneous 
activation saturates this shared 
mechanism and in this case, P2Y2 is 
absent preventing additional ATP release. 
C: Mechanism in aging WT GP. A 
functional interaction between TRPV4 and 
P2Y2 emerges. Separate activation of 
receptors generates ATP release via 
mechanism ‘1’ in the same way as young 
GPs. Simultaneous activation also evokes 
ATP as in young GPs, however here the 
functional interaction between a proportion 
of TRPV4 and P2Y2 receptors grants 
augmented ATP release possibly by 
heightened stimulation of current ATP 
release mechanisms (2, 3 - ⊕) or via 
activation of a novel unknown pathway (4) 
that emerges with aging.  These 
postulations are evidenced by the findings 
from this study. Created using public 
access images from(Servier Medical, 
2015). 
 
 
198 
The results suggest a mechanism where only a proportion of the TRPV4 receptors are 
functionally linked to P2Y2 receptors, where activation of both is required for induction of 
additional ATP release pathways, granting excess release. A postulated mechanism is 
described in figure 4-29 C. However, as previously discussed it may simply be that 
ectonucleotidase expression patterns are altered in the aging bladder, such that subtypes 
critical for full degradation of ATP to AMP and adenosine are only expressed in the 
underlying tissues. Removal of the underlying tissues in aging bladders would therefore 
disrupt the negative feedback mechanism mediated by AMP and adenosine on ATP 
release, possibly resulting in the amplified ATP release observed. However, if this is the 
case, an augmented ATP release would also be expected with UTP alone, which was not 
observed, unless an additional purinoceptor-specific feedback mechanism is also present. 
As such, it is more likely the augmented ATP release observed in aging GP mucosa is 
attributable to a novel functional interaction between TRPV4 and purinoceptor signalling, 
however altered ectonucleotidase activity may contribute to some degree. However, 
evaluation of the expression and distribution of ectonucleotidase subtypes between the 
tissues of young and aging bladders may still prove interesting. 
Simultaneous activation of TRPV4 and P2Y receptors can be achieved physiologically, 
where stretch activates TRPV4 and endogenous ATP will activate P2Y receptors. ATP can 
be supplied by parasympathetic nerves  or from the urothelium itself and augmented basal 
and stretch-induced ATP release has been demonstrated in aging and pathological bladders 
(Birder et al., 2003; Sui et al., 2014; Yan Sun et al., 2001). It may be that this age/pathology-
dependent increase in basal ATP release over-stimulates the purinoceptors, such that 
subsequent TRPV4 activation by stretch results in augmented ATP release, or it may be that 
the age/pathology-dependent augmented ATP release described in the literature is a result 
of the co-activated phenomenon identified in this study. Either way, the amplified ATP 
release identified in the current study will be capable of disrupting bladder function and 
promoting an overactive bladder state. 
The hypothetical underlying mechanisms described here are based on the findings from this 
study and recent literature only. However, despite the mechanisms not being fully 
understood, this study has identified an age-dependent augmented mucosal ATP release 
associated with purine and stretch-detecting receptors. This phenomenon may be a 
significant contributing factor in the generation of overactive bladder and associated 
pathologies. As such, this may be an important area for further investigation, as gaining a 
full understanding of this phenomenon may reveal novel methods for therapeutic 
intervention.  
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4.5.2.5 CO-ACTIVATION IN HUMAN MUCOSAL BIOPSIES FROM PATIENTS 
WITH OR WITHOUT OVERACTIVE BLADDER 
An important finding from human studies was that basal ATP release from the mucosa is 
considerably increased in patients diagnosed with overactive bladder. This is in agreement 
with a previous study that found increased basal and stretch-induced ATP release from 
mucosal bladder strips from patients with idiopathic detrusor overactivity (IDO), but similar 
levels in patients with neurogenic overactivity (NDO)(Kumar et al., 2010). Previous studies 
have demonstrated a decreased muscarinic (Datta et al., 2010) and increased P2X receptor 
expression (O’reilly et al., 2002) in overactive human bladders, which may influence this 
augmented basal ATP release. However currently, no studies have examined P2Y receptor 
expression in overactive human bladders, which may be of high importance as they are 
strongly associated with mucosal ATP release (Sui et al., 2014; Timóteo et al., 2014). 
TRPV4 activation by GSK evoked ATP release from both normal and overactive mucosal 
sheets. The proportional increase in ATP release from basal levels was similar between 
cohorts, indicating the drug effect of GSK was similar. However, actual quantities of both 
basal and TRPV4-induced ATP release were much higher in mucosa from overactive 
bladders. It is likely therefore, that TRPV4 contributes in part to the amplified stretch-induced 
ATP release observed in mucosal strips from IDO bladders (Kumar et al., 2010). In addition, 
the onset, peak and offset of ATP release occurred more rapidly in mucosa from overactive 
bladders. This implies that TRPV4 receptors may be more responsive in OAB mucosa. If like 
in the GP, TRPV4 expression is increased in aging human mucosa, perhaps a greater 
proportion of receptors are sensitized prior to activation, for example, by PTKs, increasing 
their sensitivity and responsiveness to stimuli. This could contribute to the increased voiding 
frequency observed during OAB. 
The effect of TRPV4/P2Y co-activation on ATP release was additive in both cohorts. 
However, there was greater variation in the normal aging cohort, with 20% of bladders 
showing an amplified ATP release similar to that observed in the aging GP. The effect was 
additive in the 4 overactive bladders assessed. However, these patients were younger (45-
55) than the normal cohort (>65). This phenomenon may only occur in a low proportion of 
human aging bladders, however it may still be a significant factor in the progression of 
pathologies in such bladders. Further n numbers in both groups are needed to fully assess 
this. However, as this phenomenon was not observed in any of the 4 overactive bladders 
examined, it is unlikely this is a leading factor in overactive bladder, although it may 
contribute to or support the disorder in bladders that exhibit overactivity due to other causes.   
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To summarise, this study has established similarities in the mechanisms and receptor 
subtypes responsible for mucosal ATP release between rodents and humans and identified 
age-dependent changes in both the expression and behaviour of TRPV4. Both P2Y2/P2Y4 
and TRPV4 activation evoke ATP release from the mucosa of GPs, mice and humans, 
demonstrating common functional characteristics between species. P2Y4 can evoke ATP 
release from mouse bladders independently, however P2Y2 appears to be necessary for 
amplification of ATP release beyond that of the apparent principal pathways. P2Y6 activation 
also evokes ATP release, meaning the urothelium can also respond to endogenous UDP, 
however the physiological relevance of this remains unclear. This indicates that different 
purinoceptor subtypes have different roles, which integrate in a complex manner to achieve 
an overall purinoceptor-mediated function in ATP release. A functional interaction between 
purinoceptors and TRPV4 appears to emerge with aging, characterized by an augmented 
mucosal ATP release upon co-activation of these receptors, which is not observed in 
younger animals. This may in part result from the significant increase in TRPV4 expression 
identified in aging bladders, promoting the development of a functional link between TRPV4 
and purinoceptors. However, age-dependent changes in ectonucleotidase activity could also 
facilitate an augmented ATP release and must therefore be considered. This could provide 
an interesting area for future research.  
The age-dependent changes in expression and function of receptors critical for bladder 
function identified here add to the growing number of age-related changes already identified 
in the urothelium. As bladder pathologies are strongly associated with age, it is evident that 
these changes contribute to age-related bladder dysfunction and may have profound 
implications on physiology and pathophysiology of the aging bladder. Equally, identifying the 
underlying mechanisms responsible for such changes may provide novel approaches for 
therapeutic intervention of bladder disorders.  
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CHAPTER 5. GENERAL DISCUSSION 
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5.1 SUMMARY AND INTERPRETATION OF PRINCIPAL FINDINGS 
The primary aim of this project was to characterise the activity of TRPV4 in both 
physiological and pathophysiological/aging bladders and determine the therapeutic potential 
of this channel for OAB syndrome. For this purpose, two hypotheses were tested; TRPV4 
significantly regulates urothelial function through urothelial ATP release; changes in TRPV4 
channel activity occur in aging/overactive bladders that contribute to abnormal bladder 
function. This builds upon the work of previous studies that have identified the importance of 
TRPV4 in bladder function (Everaerts et al., 2010c; Gevaert et al., 2007; Janssen et al., 
2011; Mochizuki et al., 2009; Thorneloe et al., 2008). The current studies clarified the mode 
of action of TRPV4 in native urothelium, elucidated the underlying mechanisms and 
identified age-dependent changes in channel function and expression. 
5.1.1 CHARACTERIZATION OF TRPV4 RECEPTORS IN THE BLADDER 
5.1.1.1 EXPRESSION OF TRPV4 
TRPV4 expression has been previously identified by immunostaining and western blotting in 
the urothelium and DSM from mouse and rat (Gevaert et al., 2007; Janssen et al., 2011; 
Thorneloe et al., 2008; Yamada et al., 2009). TRPV4 expression has also been 
demonstrated by immunostaining in isolated human urothelial (Janssen et al., 2011). 
However, information regarding the specific expression profile of TRPV4 throughout the 
bladder tissues is lacking. In the current study, findings from immunostaining and western 
blotting in GP bladders revealed a predominant expression of TRPV4 in the urothelium. 
TRPV4 expression was also confirmed in 3 human mucosal biopsies by western blotting 
and in 4 by immunostaining; more importantly, in-vitro experiments demonstrated functional 
expression of TRPV4 in all biopsies examined. The effect of aging on TRPV4 expression 
was profound, where findings indicated that TRPV4 expression was up-regulated in the 
urothelium and DSM, but not the suburothelium of aging bladders.  This is an important 
novel finding, as altered expression may alter the overall behaviour of TRPV4 in aging 
bladders, possibly impacting on bladder function. As such, TRPV4 expression in young and 
aging human mucosa should be assessed, as this may reveal a critical age-dependent 
change that could influence the age-related pathologies observed in human bladders. 
The role of TRPV4 in normal bladder function has been previously explored by a collection 
of studies in animal bladders (Everaerts et al., 2010c; Gevaert et al., 2007; Mochizuki et al., 
2009; Thorneloe et al., 2008). The collective findings from these provide direct evidence for 
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TRPV4 mediated ATP release from cultured urothelial cells and indirect evidence for this 
role in bladder function from in vivo TRPV4 knockout mice. These studies provide initial 
evidence for the importance of TRPV4 in bladder function and pathology. The present 
studies built upon this collection of research to establish the physiological role of this 
receptor using native urothelium and bladder tissue from both animal models and humans to 
determine the underlying mechanisms of TRPV4 function in the bladder.   
5.1.1.2 TRPV4-MEDIATED UROTHELIAL ATP RELEASE 
Multiple lines of evidence from the current study established a functional role for TRPV4 in 
urothelial ATP release. Selective activation of TRPV4 evoked a significant and reproducible 
release of ATP from the mucosa of human, guinea pig and mouse bladders, demonstrating 
common functionality of TRPV4 between species. As such, this serves as evidence that the 
TRPV4 activity observed in these animal models can be translated to humans with 
confidence. Mucosal strips released far greater quantities of ATP per gram of tissue than full 
thickness strips, suggesting the majority of ATP released by the bladder in response to 
TRPV4 activation originates form the urothelium. Removal of the mucosa resulted in near 
complete loss of GSK/TRPV4-induced ATP release, further indicating that the urothelium is 
the source of ATP release.  
5.1.1.2.1 SELECTIVE BLOCKADE OF TRPV4 
Antagonism of TRPV4 with HC-067047 completely abolished any GSK-induced ATP 
release, confirming selectivity of GSK regarding activity in the bladder. Additionally, 
antagonism with HC-067047 reduced basal ATP release in both young GP and human 
mucosa. This implies TRPV4 has a function in maintaining basal ATP release and is 
therefore activated by an endogenous ligand.  Currently, EETs are the only endogenous 
activators of TRPV4 identified (Vriens et al., 2005; Watanabe et al., 2003b). EETs are 
mechano- and osmotransducing messengers thought to mediate the channels responses to 
such stimuli. However, EETs are involved in numerous other biological processes such as 
angiogenesis (Michaelis et al., 2005) and cell-cell communication (Popp et al., 2002), 
importantly between endothelial cells and smooth muscle cells (Fleming, 2001). As such, it 
is likely that EETs are still bioavailable in the bladder in the absence of mechanical/osmotic 
stimuli due to these other important processes and can therefore contribute to the basal 
TRPV4 activity observed.  However, TRPV4 channel activity can also be enhanced by Ca2+-
CaM complex and IP3, which couple the membrane-bound receptor to intracellular Ca
2+ 
stores (Garcia-Elias et al., 2008; Strotmann et al., 2003). As such, it has been postulated 
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that rises in [Ca2+]i resulting from other physiological processes can also contribute to 
basal/spontaneous channel activity. SFKs can also sensitize TRPV4 channel activity and 
are also thought to mediate the channels responses to mechanical/hypotonic stimuli 
(Wegierski et al., 2009; Xu et al., 2003). SFKs are ubiquitously expressed and regulate a 
vast number of cellular processes such as cell motility, responses to extracellular growth 
factors, specialized cellular responses such as platelet aggregation and responses to 
oxidative stress (reviewed elsewhere [Parsons and Parsons, 1997; Schwartzberg, 1998]). 
As such, it is also likely that these are available for basal TRPV4 activation, possibly 
sensitizing the receptor for lower level stimulation. A role for urothelial TRPV4 in 
spontaneous bladder contractility has been previously demonstrated (Gevaert et al., 2007). 
Removal of the urothelium and knockout of TRPV4 resulted in reduced spontaneous 
activity, suggesting urothelial TRPV4 was responsible for this spontaneous activity, and not 
TRPV4 expressed in the DSM. The findings here support this, identifying a role for TRPV4 in 
basal ATP release form the urothelium, that may be involved in this TRPV4-dependent 
spontaneous activity observed previously. 
5.1.1.2.2 FUNCTIONAL CONTRIBUTION OF TRPV4 TO STRETCH-INDUCED ATP 
RELEASE 
Mechanical stretch also evoked a reproducible ATP release from the mucosa. The findings 
here demonstrated a 50% reduction in stretch-induced ATP release with TRPV4 blockade. 
This is not entirely in agreement with the literature, where previous studies showed a 90% 
reduction in stretch-evoked ATP release from freshly isolated urothelial cells (Birder et al., 
2003) and a 100% reduction from rat tissue strips (using a protocol identical to the one in 
the current study)(Du et al., 2007) with the ENaC blocker amiloride. It is not feasible that 
ENaC channels are solely responsible for stretch-induced ATP release, as there is an 
extensive collection of studies evidencing a role for TRPV4 in this process. It is likely that 
both mechanosensitive channels contribute a proportion of this ATP release, where the 
respective contributions could be determined by individual and simultaneous blockade of 
each receptor. This could also identify proportional contributions from further 
mechanosensitive receptors yet to be identified in this process; for example, the stretch-
activated channels which have been identified in urothelial cells (Wu et al., 2011). The 
mechanisms by which stretch activates TRPV4 channels have been studied previously and 
it is currently thought that the process requires activation of TRPV4 by EETs (possibly direct 
[Fernandes et al., 2008]) generated by the PLA2 dependent endogenous signalling pathway 
(Watanabe et al., 2003b), or phosphorylation by SFKs (Wegierski et al., 2009; Xu et al., 
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2003), or indeed both. However, the possibility of direct activation by mechanical force has 
not been excluded (Christensen and Corey, 2007) and therefore it is clear that further 
research is required to fully establish the mechanisms underlying stretch activation of 
TRPV4.  
5.1.1.2.3 PATHWAYS FOR TRPV4-MEDIATED ATP RELEASE 
The downstream mechanisms underlying TRPV4-induced ATP release were partly 
elucidated here. PTK activity was required for GSK-induced ATP release. This was not 
observed in a similar study using the TRPV4 agonist 4αPDD, however this is likely due to 
different activation mechanisms for each agonist. Activation by 4αPDD and heat both rely on 
tyrosine residue 555, which is not required for activation by cell-swelling and EETs, which 
rely on the PLA2 pathway (Vriens et al., 2003). This highlights the various distinct 
mechanisms needed for activation of TRPV4 by different stimuli and therefore, it is possible 
that unlike 4αPDD,  activation by GSK requires phosphorylation by SFKs, possibly sharing 
the same mechanism as activation by stretch.  
This study found that GSK/TRPV4-induced ATP release is mediated majoritively by 
conductive pathways (90%), with little or no contribution from vesicular transport.   The 
process was also tightly dependent on extracellular Ca2+ entry, the main action mediated by 
TRPV4 channels. This was further evidenced by live-cell calcium imaging, which identified a 
rise in [Ca2+]i upon TRPV4 activation in freshly isolated GP urothelial cells. Blockers of Ca
2+-
activated chloride channels had no effect on GSK-induced ATP release, excluding them 
from the mechanism. The collective findings, supported by those from previous studies, 
suggest a mechanism whereby; stretch activates TRPV4 receptors via SFK-mediated 
phosphorylation of the channel; TRPV4 mediates Ca2+ influx raising [Ca2+]i; this activates a 
Ca2+-dependent, hemichannel-mediated ATP release mechanism, likely through pannexin-1 
channels (refer to section 3.4.7 for a more detailed discussion).  
5.1.1.2.4 IMPLICATIONS OF TRPV4-MEDIATED ATP RELEASE: ROLES IN 
PHYSIOLOGY AND PATHOPHYSIOLOGY 
The ATP release mediated by TRPV4 can influence the physiology of the bladder. It is 
currently thought that TRPV4 senses distension in the bladder during filling and 
communicates this to the underlying tissues as an ATP signal. This may be a fundamental 
process in the bladders overall ability to sense fullness, whereby the extent of bladder 
distention (equating to urine volume) is relayed to underlying afferent nerves via an ATP 
signal generated, in part, by TRPV4. These nerves continuously convey information 
regarding urine volume to the PMC for voluntary bladder control and perception of bladder 
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fullness, initiating urges to void at appropriate volumes (20-25mmHg[Häbler et al., 1990]), 
permitting correct periodic storage and voiding of urine. Interestingly, pain is perceived once 
certain harmful volumes are reached (30-50mmHg[Häbler et al., 1990]), mediated via ATP 
through P2X3 and P2X2/3 receptors on suburothelial sensory nerves (Burnstock, 1999; 
Cockayne et al., 2000; Vlaskovska et al., 2001). As such, urothelial TRPV4 may not only 
mediate volume-dependent pain perception in the bladder under physiological conditions, 
but may also induce pain and respond to inflammatory stimuli as a result of various 
pathologies and inflamed bladders. Not only this, but changes in the expression and function 
of TRPV4 that result from aging or pathology that have indeed been identified, may 
influence painful bladder. TRPV4-mediated nociception in the rat has been shown to be 
enhanced by PGE2, a hyperalgesic inflammatory mediator (Alessandri-Haber et al., 2003). 
As such, inflamed bladders could enhance TRPV4 mediated nociception in the same 
manner, implicating TRPV4 in painful bladder pathologies. A fundamental role for TRPV4 in 
urothelial transduction of sensory information regarding bladder distension has therefore 
been identified, which may also have implications in bladder overactivity and pain.  
5.1.1.3 TRPV4-MEDIATED DSM CONTRACTIONS 
A role for TRPV4 expressed in the DSM has been identified both here and in previous 
studies (Thorneloe et al., 2008). TRPV4 activation evoked sustained contractions in intact 
bladder strips of similar magnitude to those evoked by the gold standard muscarinic agonist 
carbachol. These contractions were also observed in denuded DSM strips and therefore, it 
was concluded that direct activation of TRPV4 receptors in the DSM can cause DSM 
contractions, although additional small contractions could result from an indirect effect of 
ATP release. This supports findings from previous studies, identifying the presence of 
functional TRPV4 receptors in the DSM and highlighting the ability of TRPV4 to directly 
contract bladder muscle with a force equalling that of muscarinic activation, however the 
physiological significance of this remains to be established (Thorneloe et al., 2008). Whether 
these channels directly mediate physiological bladder contraction or not, these findings 
reveal the potential they have to do so, and as such, TRPV4 activity could indeed influence 
bladder pathologies associated with over-activity. Although nerve-mediated contractions in 
humans are mediated entirely through M3 receptors under physiological conditions, with the 
possible emergence of a purinergic component in DO bladders, TRPV4 in the DSM may still 
influence bladder contractile activity. They provide a direct Ca2+ entry channel into smooth 
muscle cells specialized to respond to raised Ca2+ by eliciting contraction. Despite this, the 
study by Thorneloe et al found that Nifedipine supressed, but did not abolish, GSK-induced 
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DSM contractions, indicating the involvement of L-type Ca2+ channels in TRPV4-mediated 
contractions (Thorneloe et al., 2008). The results suggested that TRPV4 activation 
depolarises the membrane potential, activating L-type Ca2+ channels, which supply further 
Ca2+ for contraction, where the direct supply of initial Ca2+ through TRPV4 channels 
contributes to initial contraction. Additionally, TRPV4-/- had no effect on DSM contractile 
responses to electrical field stimulation (EFS) in vitro, indicating they do not contribute to 
nerve-mediated contractions and only possibly play a modulatory role on DSM contractile 
behaviour during normal micturition. The data from the present study takes it further from the 
findings in mice, and demonstrates that TRPV4 in the DSM is capable of evoking strong 
contractions across all major species, including human, proving that this receptor is a 
fundamental regulator of the DSM. However, its primary role in the DSM seems to be 
modulating smooth muscle contractility, possibly responding to bladder distension during 
filling, owing to its mechanosensitivity. As a role for TRPV4 receptors in basal ATP release 
has been identified here, it is possible they play a basal role in DSM also.  These receptors 
may be activated at a basal level in the same way as described previously, for example, by 
raised [Ca2+]i resulting from other physiological processes, initiating low level contractile 
activity in isolated muscle bundles to maintain bladder tone during filling. They may also 
recognise stretch and initiate contractions in these isolated muscle fascicles during higher 
pressures of bladder filling to continue to provide tone until voiding. Despite the fact DSM 
TRPV4 receptors seem to only play a small modulatory role on DSM contractility under 
physiological conditions , the ability of such receptors to evoke cholinergic-like contractions 
has been identified. As such, these receptors have the potential to strongly influence 
bladder contractility if their function is altered, for example by over-stimulation or increased 
functional expression. More importantly, inflamed bladders may generate inflammatory 
mediators such as prostaglandins, change of pH and temperature that can activate TRPV4 
receptors, highlighting one way in which these receptors may become overstimulated during 
pathology, influencing their function and therefore, potentially influencing bladder 
contractility. 
Indeed, TRPV4 receptors have the potential to cause or influence bladder overactivity. 
Infusion of GSK into the bladders of WT mice induces bladder overactivity, believed to be 
mediated by both distinct roles of TRPV4, by causing urothelial ATP release, which 
sensitizes bladder afferents, and by directly contracting DSM (Thorneloe et al., 2008). The 
concentrations used were high (10M) and therefore may not be physiologically relevant, 
however, the results again indicate the potential importance of TRPV4 in bladder 
overactivity.  
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5.1.1.4 TRPV4-MEDIATED ROS PRODUCTION 
The current study identified a further, potentially pathologic output of TRPV4, where TRPV4 
activation appears to increase bladder superoxide (O2
-) production. O2
- plays physiological 
roles in cellular signalling, for example in cell growth, where low levels stimulate cell 
proliferation (Pimentel et al., 2001). Stretch increases ROS production in cardiac myocytes 
(Pimentel et al., 2001) and selective TRPV4 activation initiates mitochondrial ROS 
production in human coronary artery strips for vasodilation (Bubolz et al., 2012). Our novel 
findings suggest that TRPV4 activation, possibly by stretch, induces ROS production for 
ROS-mediated physiological processes. However, ROS production in the bladder has 
previously been linked to detrusor overactivity, through modulation of C-fibre afferents in 
rats (Chien et al., 2003; Masuda et al., 2008). In addition, ROS significantly up-regulate the 
phosphorylation of TRPV4 by SFKs (Wegierski et al., 2009), presenting a positive feedback 
on TRPV4, where TRPV4-mediated ROS production enhances the receptors activity. A fine 
balance must therefore be achieved between the multitude of stimuli able to regulate the 
receptors activity (heat, osmolarity, mechanical stress, ligand activators, regulation by Ca2+ 
and phosphorylation, ROS) for correct physiological function of the receptor. ROS 
overproduction is an important pathological process in inflammation, many chronic diseases 
and ageing. As such, any imbalance in these processes may alter receptor activity, and lead 
to increased ROS production which can aggravate bladder ageing and overactivity.  
Collectively, current findings indicate a multifactorial role for TRPV4 in overactive bladder, 
where the channel can potentially enhance ATP release and ROS production and directly 
contract DSM, all of which can significantly influence bladder overactivity and also pain.   
5.1.2 A ROLE FOR PURINOCEPTORS IN UROTHELIAL ATP RELEASE 
A role for various purinoceptor subtypes in urothelial ATP release has previously been 
described by the research group in humans and GPs (Sui et al., 2014) and by other studies 
in rats (Carneiro et al., 2014). Purinoceptor-mediated mucosal ATP release was identified in 
the present study, where different subtypes appear to have different roles, providing an 
overall purinoceptor-mediated function. UTP-induced ATP release was conserved across all 
species examined, highlighting common functional characteristics between the animal and 
human urothelium. P2Y4 appears to be the subtype responsible for principal purinoceptor-
mediated ATP release, demonstrated with P2Y2 KO, where P2Y2 appears to function as a 
secondary pathway once others become saturated. Our findings from animal studies 
suggest that TRPV4 and P2Y4 share an ATP release pathway and P2Y2 utilizes an 
alternative. As such, P2Y4 cannot contribute to ATP-induced ATP release during TRPV4 
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activation, as the pathway is already utilized (by TRPV4) and therefore P2Y2 may function 
here to allow ATP-induced ATP release via an alternative pathway during TRPV4 activation. 
P2Y6 is also capable of evoking ATP release from the mucosa, however as this subtype 
responds primarily to UDP, its physiological roles regarding ATP release are limited by 
endogenous UDP availability. The suggested roles are therefore as follows: 
 P2Y4  Principal subtype for purinoceptor-mediated ATP release in response to  
endogenous ATP/UTP 
 ATP-induced ATP release, aside from when TRPV4 is activated 
 
 P2Y2    Utilizes a different release pathway to P2Y4     
              ATP-induced ATP release        
              Provides secondary route for purinoceptor-mediated ATP release once  
  P2Y4 pathway becomes saturated 
 
 P2Y6    Endogenous UDP-mediated ATP release. 
 
For a full dissection of the results and the subsequent interpretations, please refer to the 
detailed discussion in chapter 4. 
5.1.3 THE EFFECT OF AGING ON TRPV4 ACTIVITY  
It is well established that bladder pathologies are highly associated with increasing age. As 
TRPV4 receptors have the potential to contribute to overactive bladder in a multifactorial 
manner, the current study explored the effects of aging on TRPV4 activity to determine if 
any association exists between age and altered channel behaviour, which may contribute to 
age-related bladder pathology. An increase in TRPV4 expression was identified in the 
mucosa (8 fold) and DSM (16 fold) of aging GPs compared to tissues of their younger 
counterparts. Despite this, TRPV4-mediated ATP release and DSM contractions were 
similar between age groups, indicating that although expression is increased, basic function 
of the receptor appears to be conserved. Unfortunately, it was not determined whether the 
increased number of TRPV4 receptors are functionally located to the cell membrane, or are 
held in vesicles below the surface in an inactive state, ready for incorporation into the 
membrane. The contractile effect of GSK was more reproducible in aging tissue compared 
to young. This suggests that at least a proportion of the surplus TRPV4 is held in vesicles, 
permitting a more rapid incorporation of fresh receptors into the membrane following first 
stimulation, allowing subsequent contractions to be generated more rapidly. However, this is 
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only applicable to the DSM and the location of surplus TRPV4 receptors in the urothelium 
remains to be determined. In addition, UTP- (P2Y2/P2Y4-) mediated ATP release was also 
similar between age groups. However, co-activation of P2Y2/P2Y4 with TRPV4 generated an 
augmented ATP release from mucosal strips that was only observed in aging bladders. The 
situation in aging full thickness tissue may be more complicated and presence of the 
underlying tissues may impose additional regulatory mechanisms on urothelial ATP release, 
or affect its breakdown. As the phenomenon was only observed in aging mucosa, it appears 
that a functional interaction between TRPV4 and P2Y receptors emerges with aging, 
generating augmented ATP release when activated simultaneously. As TRPV4 expression 
is greatly increased with age, and purinoceptor plasticity is such a common phenomenon 
induced by physiological processes, various pathologies and aging, it is possible a 
functional link between the two receptors develops as a result of these circumstances. To 
investigate this further, immunoprecipitation assays should be performed to determine 
whether the two receptors are co-expressed in the aging urothelium. This phenomenon was 
only observed in 20% of normal aging human bladders assessed and was not observed in 
any of the 4 overactive bladders. As such, this interaction is not a necessary prerequisite for 
overactive bladder, however it may emerge in a small proportion of aging human bladders 
and could therefore exacerbate, or contribute to the overactive bladder phenotype. Despite 
the mechanics underlying this phenomenon remaining elusive, this study has successfully 
identified the age-dependent emergence of an augmented ATP release mediated by a novel 
receptor interaction.  This, together with the increase in expression, reveals yet another way 
in which TRPV4 can mediate bladder overactivity.  
An increased basal and TRPV4-mediated ATP release was identified in overactive human 
mucosa. This is the first report that TRPV4-mediated ATP release is enhanced in overactive 
bladders. This provides strong evidence that the overactivity results, at least in part, from a 
considerably increased mucosal ATP release, and that all forms of ATP release, whether it 
be basal, receptor-mediated, or indeed stretch-mediated (Kumar et al., 2010) are increased 
during this pathology.   
In summary, the studies here and others have revealed the fundamental physiological role 
of TRPV4 in urothelial ATP release, as well as potential roles in direct modulation of DSM 
contractility and ROS production. These studies have also revealed the immense potential 
TRPV4 has to mediate bladder overactivity, whether that be through increased functional 
expression, augmented urothelial ATP release, modulation of DSM contractility, ROS 
production, or through age-induced functional interactions with other receptors involved in 
urothelial ATP release.   
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5.1.4 NOVEL TARGETS FOR TREATMENT OF OVERACTIVE BLADDER 
OAB is one of the most prevalent pathologies of the bladder, however currently, it is also 
one of the least understood and understudied. A large study evaluating a cohort of over 7 
million patients  diagnosed with OAB syndrome over a 45 year period found that 24.4% 
were treated with antimuscarinics and the remainder went untreatead (Helfand et al., 2010). 
The poor efficacy and range of side-effects of current therapies including antimuscarinics, 
results in low patient compliance and presents an immediate need for novel therapeutics 
against the disorder. 
5.1.4.1 TRPV4 AS A NOVEL TARGET AGAINST OVERACTIVE BLADDER 
Various studies have demonstrated an increased functional bladder capacity and decreased 
frequency of voiding contractions by either pharmacological intervention or genetic 
disruption of TRPV4 in mice (Everaerts et al., 2010c; Gevaert et al., 2007). The study by 
Gevaert et al. also demonstrated reduced spontaneous contractions in explanted bladder 
strips from TRPV4-/- mice and this was attributed to the basal function of TRPV4 in the 
urothelium and not the DSM . As OAB is highly associated with an increase in spontaneous 
bladder contractions, this finding, with the others, first indicated that TRPV4 may be a 
promising target for OAB. Our findings provide the first evidence that TRPV4 receptors in 
the bladder are universal functional regulators across animals and humans, and in particular 
identifies a role for TRPV4 in stretch-evoked urothelial ATP release in physiologically 
relevant bladder strips and reveals age-dependent changes that may influence OAB, 
highlighting the multifactorial potential of TRPV4 to contribute to OAB. Importantly, reduced 
basal ATP release was achieved with selective blockade of TRPV4, further indicating the 
potential of this receptor as a drug target.  
However, TRPV4 is widely expressed and is responsible for many important functions such 
as vasodilation in the vascular epithelia, regulation of ion exchange in the kidneys, ciliary 
beating in the airway epithelia, mechanosensation in the cochlea, neuronal communication 
and bone remodelling to name a few. As such, un-targeted blockade of these receptors by 
pharmaceutical agents may induce severe and wide spread side-effects.  However, novel 
drug delivery systems (DDSs) targeting drugs to the bladder are currently under 
development, which appear promising (reviewed here [Zacche et al., 2015]). Systemic and 
oral administration of drugs requires large doses to achieve therapeutic concentration at the 
desired tissue target, increasing the likelihood of undesired side-effects through widespread 
effects of the drug.  The anatomy of the bladder permits simple and direct delivery of drugs 
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through a catheter under cytoscopy, which is relatively non-invasive and allows drugs to be 
easily targeted to the bladder, reducing possible side-effects. However, the continually 
changing urine volume and periodic voiding present difficulties, as these factors cause drugs 
to become diluted and periodically washed away. Additionally, the low permeability of the 
urothelium prevents efficacious diffusion of drugs into the bladder wall. Current treatment for 
OAB in cases where antimuscarinics are ineffective involves intradetrusorial injection of 
botox and this is routine practice in many clinics (Kuo and Kuo, 2013). Repeated 
catheterization for this purpose is less well-tolerated by patients than for example, systemic 
or oral administration and therefore, novel DDSs are in development. These include 
nanocarriers, polymeric hydrogels and biodegradable and nondegradable intravesical 
devises. Nanocarriers can be formulated from lipids, proteins, polymers and metals and 
allow site-specific delivery of drugs to desired targets (Singh and Lillard, 2009). Liposomal 
delivery of drugs and uptake by the urothelium has been successfully demonstrated in the 
bladder (Rajaganapathy et al., 2015). A more bladder-specific method involves application 
of drug-containing polymeric hydrogels to the bladder wall, which allow sustained released 
of drugs for up to 24hours and are not removed by voiding (Tyagi et al., 2004). Intravesically 
administered drug delivery devices are also in development, which are inserted and remain 
in the bladder, allowing controlled and extended delivery of drugs over periods of days to 
weeks (Haupt et al., 2013; Tobias et al., 2010; Von Walter et al., 2009). These novel and 
viable DDSs highlight the ways in which drugs can be specifically targeted to the bladder 
and could therefore be applied to TRPV4 antagonists, avoiding the possible side-effects 
associated with widespread application of such drugs.  
As TRPV4 receptors involved in bladder function are predominantly expressed in the 
urothelium, intravesicular delivery of drugs to this site would be more easily targetable, 
compared to targeting to the DSM, which would require diffusion of drugs over a greater 
distance and through many diffusion barriers. Our findings suggest TRPV4 is responsible for 
50% of the stretch-induced ATP release involved in communication of intravesical pressure, 
a process fundamental for correct dynamics of bladder filling and voiding. Furthermore, 
blocking the receptor has no effect on nerve-mediated contractions, and hence normal 
miciturtion reflexes. Therefore, normal bladder function would be preserved. TRPV4 also 
appears to contribute to spontaneous bladder contractions during filling (Gevaert et al., 
2007) and indeed, blockade of this receptor has been shown to increase functional bladder 
volume. Additionally, results suggest that TRPV4 in the DSM regulates membrane potential, 
with little contribution to voiding contractions under physiological conditions, however, this 
DSM TRPV4 is very capable of eliciting overactivity and therefore likely contributes to the 
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disorder during pathology. Therefore, inhibition of this receptor for therapeutic purposes 
would likely reverse any pathological effects presented by DSM TRPV4 with little 
interference on other normal bladder processes.  Overall, our current understanding of 
TRPV4 suggests that specific blockade could alleviate symptoms of OAB, while retaining 
physiological functioning of the bladder. This would be effective whether altered TRPV4 
activity is partly responsible for the observed bladder overactivity or not. These points make 
TRPV4 an attractive novel target for treatment of OAB. However, the TRPV4-/- mice studied 
by Gevaert et al. exhibited an incontinent phenotype, with increased non-voiding 
contractions resulting in increased urine spotting, despite reduced frequency of full voiding. 
Therefore, it appears that both complete knockout of TRPV4 function and  greatly enhanced 
TRPV4 activity (Thorneloe et al., 2008) can both induce LUTS. As such, manipulating the 
degree of TRPV4 activity through controlled dosing of antagonists may permit precise 
modulation of bladder function.  Combined with novel approaches to drug targeting, careful 
and controlled pharmaceutical modulation of TRPV4 activity appears to be a very promising 
novel approach for treatment of bladder overactivity.  
5.1.4.2 PANNEXIN-1 CHANNELS: A FURTHER POTENTIAL TARGET 
Very recent research has demonstrated a role for pannexin-1 channels in mediating both 
purinoceptor and TRPV4-induced ATP release in epithelial cells (Seminario-Vidal et al., 
2011; Shahidullah et al., 2012), where the former has been demonstrated in the urothelium 
(Beckel et al., 2015; Timóteo et al., 2014). These proteins have only recently been identified 
and appear to play a role in cell-cell communication and passage of large molecules by 
forming active hemi-channels, which are closed by common gap-junction blockers (Locovei 
et al., 2006a). As such, our finding that carbenoxolone prevents TRPV4-mediated ATP 
release suggests the involvement of these channels here. These channels are widely 
expressed and have been identified in the eye, thyroid, prostate, kidney, bladder, brain and 
spinal cord of rats, where the most studied functions are formation of neuronal circuits and 
ATP release (reviewed elsewhere [Barbe et al., 2006]). As these channels appear to 
mediate many forms of urothelial-ATP release including that induced by both stretch and 
activation of multiple receptors, these may provide a further novel approach for treatment of 
overactive bladder through control of urothelial ATP release. They are expressed throughout 
the urothelium, however their expression in DSM has not yet been explored (Timóteo et al., 
2014). If they are expressed exclusively in the urothelium, this will make the channels easily 
targetable and remove the possibility of other bladder-related side-effects, lending further 
positive features of these channels regarding pharmacologic modulation. 
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5.2 CRITIQUE OF METHODOLOGY 
5.2.1 SPECIES EXAMINED AND TISSUE AVAILABILITY 
The studies in this thesis were performed on both animal and human tissue, allowing 
comparison of the similarities and differences between native tissue and that from animals 
and providing human relevance.  
A strength of this study was the use of GPs as the main animal model for research. These 
animals provide an excellent model for age-related translation studies as they exhibit many 
qualitative age-related changes also observed in humans. The bladders of these animals 
share more similarities to those of humans than other rodents and commonly exhibit 
overactivity with aging, lending them as useful tools for study of the bladder (discussed fully 
in methods section 2.2.1). However, the micturition patterns were not assessed in the GPs 
used, which could have been used to identify those with or without overactive bladder 
phenotypes. This may have been useful when interpreting the data, where overactivity may 
have been responsible for some of the higher variations in ATP release observed in aging 
bladders. This should be performed in future experiments. 
Transgenic mice were also used as they offer an important research tool that other species 
cannot and as such, findings from these knockout animals were used to supplement the 
data from other models. Despite this, rodents do exhibit some important differences in 
bladder physiology to humans, such as a NANC component to contraction, and as such, 
findings from these studies should be interpreted with care, as any deviation from humans 
will have a reduced degree of relevance. Nonetheless, many similarities were observed 
between species, particularly for urothelial ATP release and detrusor smooth muscle 
contractions, the two key physiological functions of the bladder wall, where the drug effects 
of GSK and UTP were similar in humans, mice and GPs. This provides evidence that many 
of the regulatory mechanisms and functional characteristics of the urothelium are conserved 
between these species, justifying use of these animals to provide translatable information 
regarding bladder function.  
Human samples provide direct information on any function under investigation and were 
hence included in this study. Evidences gained from the collected samples have permitted 
the first ever characterisation of basic mode of action of TRPV4 receptors in native human 
urothelial tissues. Unfortunately, a lower number of human biopsies were obtained than 
anticipated, especially for the OAB group, due to unforeseen circumstances out of the 
control of the research group. As such, data from the OAB group only provide indications of 
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behaviour of this tissue for comparison to the normal group, although observed differences, 
particularly in basal and TRPV4-mediated levels of ATP release, provide very interesting 
initial findings. It is expected that further n numbers will provide statistically significant 
conclusive findings. Low numbers of biopsies also meant that n numbers for IHC and 
western blotting analysis were limited. Once these techniques had been fully optimized, the 
available biopsies were split between techniques to provide as much data as possible 
regarding expression of TRPV4. Optimizing techniques first reduced the risk of failed 
experiments using these precious samples. Despite this, expression was confirmed in 3 of 
the 4 biopsies assessed using western blotting and relative tissue expression was examined 
in 4, providing sufficient data. With more samples, it would be interesting to compare TRPV4 
expression levels between normal and overactive human bladders. 
5.2.2 TECHNIQUE-SPECIFIC STRENGTHS AND WEAKNESSES 
5.2.2.1 IHC AND WESTERN BLOTTING 
These techniques were used in conjunction to provide a comprehensive expression profile 
for TRPV4, both within the tissues of the bladder and between young and aging bladders. 
Using both techniques allowed the limitations of each to be overcome. IHC allows specific 
expression between different tissue layers and the location of the receptors of interest to be 
examined and compared, which is not possible with western blotting. However, the confocal 
microscopy stage of IHC requires settings to be optimised per set of sections and an 
extensive number of sections were examined over a long period of time, making comparison 
of expression between age groups highly unreliable. Therefore, quantification of this 
technique only allows differences in relative expression to be evaluated within each section. 
For example, TRPV4 expression was significantly greater in the urothelium compared to the 
suburothlium in both young and aging GP bladders, however comparison between age 
groups was not possible due to the aforementioned varying parameters required to correctly 
examine each set of sections.  This was overcome by using western blotting, where young 
GP tissues were run alongside aging GP tissues on the same gel, allowing relative levels of 
TRPV4 to be compared reliably. As age-groups were always run simultaneously, any 
experiment-specific changes in conditions would apply to both, meaning relative differences 
in expression were always reliable.  
TRPV4 Abs have a reputation for low specificity, presenting another possible limitation. An 
anti-TRPV4 primary Ab supplied by Alomone Labs was used for IHC, and peptide controls 
demonstrated specificity. This Ab was also employed for western blotting and results were 
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then replicated using a further TRPV4 Ab from a different company, reinforcing any 
observations.   
During western blotting, expression levels of the housekeeping protein GAPDH were initially 
used as loading control, which is typically recommended for this purpose due to its 
commonly consistent ubiquitous expression. However, levels were consistently higher in 
separated DSM lysates than mucosal lysates. This was quickly identified and attributed to 
the fact that tissues with increased energy demand (including smooth muscle) exhibit higher 
GAPDH expression,  owing to the enzymes role in the glycolytic pathway (Barber et al., 
2005). As such, β-actin was used for loading controls thereafter.  
5.2.2.2 FUNCTIONAL ORGAN BATH EXPERIMENTS 
The majority of work in this thesis was produced using the well-established organ bath 
technique, which has been extensively used to accurately measure contractility and ATP 
release from urinary bladder preparations (Burnstock et al., 1978; Ferguson et al., 1997; Sui 
et al., 2014).  
Physiological outputs exhibit a high degree of variation between individuals, which is to be 
expected, even between animals of the same species. This was accounted for when 
measuring ATP, where each strip served as its own internal control. Expressing data as a 
relative change from control revealed drug effects had low variability between animals, 
although the actual quantities of ATP released per gram may vary to a greater degree. To 
maximise data output from each animal bladder, the maximum number of experiments 
(determined by quantity of tissue available) were performed in succession directly after 
sacrifice. This meant that experiments were commonly performed over a 24hour period and 
as such, tissue integrity and drift in function over the experimental period is a factor that 
needed consideration.  For animals, fresh strips were mounted for each set of interventions. 
Preliminary control experiments performed by the research group found that tissue function 
with regards to contraction and ATP release remains fairly unchanged even after 2 days 
incubation at 4C. However, repeated challenge of tissue with drugs during each experiment 
(commonly 3-5 separate drug interventions) will have an effect on tissue function. This was 
controlled for by performing pre and post drug controls for each individual intervention, 
allowing drift in tissue function to be accounted for. During some of the longer experiments, 
where strips were challenged with 5 separate interventions, significant ATP release was lost 
during the fifth, and sometimes fourth intervention, highlighting the importance of these 
controls. Internal controls also eliminated the possibility that ATP release was a direct result 
of tissue damage and not drug intervention, however this could be definitively confirmed by 
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assessing lactate dehydrogenase activity, a marker of tissue damage. In some cases, to 
confirm tissue integrity at the end of experiments a hypotonic 70% Tyrode’s : 30% H2O 
solution was used to evoke contraction and ATP release, indicating that the tissue remained 
responsive. However, the majority of interventions performed in this study were successful 
in evoking ATP release, in itself confirming tissue activity throughout the experimental 
period. For the purpose of comparing actual quantities of ATP release per gram of tissue, 
only experiments performed as the first intervention after sacrifice were included, to reduce 
differences in ATP release resulting from time-dependent tissue drift and repeated exposure 
to interventions.  
Human biopsies were collected from clinics approximately 2 hours from the laboratory and 
as such, it was essential to confirm integrity of these samples before commencing extended 
periods of experiments. For this purpose, mucosal strips were initially challenged with 
carbachol, which evokes highly reproducible ATP release. If ATP release was confirmed, 
subsequent experiments were performed. Carbachol is a strong contractile agent and 
therefore if contractions were observed, this would confirm presence of underlying DSM, 
providing further information regarding the biopsy.  
Initially, superfusate samples were frozen immediately after sampling for later evaluation of 
ATP content. However, variations in the time taken to freeze these samples could result in 
variations in data due to rapid hydrolysis of ATP. Additionally, this method required thawing 
of samples before ATP measurement could be performed, meaning samples measured later 
on in the procedure would have been thawed for longer, providing another source of error. 
As such, the protocol was improved early on, by measuring ATP content directly after 
sampling, eliminating any time-dependent variations. 
It should be noted that the ATP release measured using this system is likely an 
underestimation due to the flow imposed by the setup and uncontrollable factors imposed by 
the tissue, such as ectonucleotidase activity and diffusion barriers, all of which will reduce 
the observed ATP release. However, this setup was used as it allows dynamic changes in 
ATP release in response to various interventions to be accurately measured.  
5.2.2.2.1 MECHANICAL STRETCH EXPERIMENTS 
For this purpose, tissue strips were mechanically stretched to 150% of their original length 
by careful adjustment of the force transducer fixation hooks. This magnitude of stretch could 
damage tissue strips, such that the ATP release attributed to stretch may be generated by 
tissue damage. Once again, tissue integrity should have been confirmed by measuring 
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lactate dehydrogenase activity, as this will have even greater implications on conclusions 
here than for the previously mentioned experiments.  
5.2.2.3 MEASUREMENT OF ROS PRODUCTION  
A method requiring low-temperature crushing of tissue in liquid nitrogen was used for this 
purpose. This is essentially the physical destruction of cells, a process necessary for 
isolation of subcellular organelles. This can damage organelles and will disrupt many 
cellular signalling processes, although crushing at these low temperatures will preserve 
enzymatic activities, which are heat liable. Literature on this topic is scarce, however this is a 
widely used and accepted technique for cell lysis, where custom made scientific pestle and 
mortars have been designed for the purpose. In this study, intact tissue  samples were 
incubated in agonist for 30minutes at 37C, such that cellular signalling was retained, and 
the samples were then snap frozen in this state. Samples were then crushed in liquid 
nitrogen to retain enzymatic activity, thawed and ROS production in treated samples was 
compared to control samples. An increased ROS production was observed in treated 
samples, and the use of control tissue suggests this is a true phenomenon. However, this 
technique relies on the enzymes that are activated by TRPV4 and that are responsible for 
the increased ROS, remaining active throughout the experimental time course, making the 
findings dubious. Other methods for ROS detection exist, permitting changes in ROS to be 
observed in tissue sections and cell preparations using fluorescence microscopy (briefly 
described here [Bubolz et al., 2012]). These preparations can be incubated in agonist in the 
same way as before, with the addition of fluorescent dyes that probe for ROS. These 
techniques would allow measurement of TRPV4-induced ROS production, whilst retaining 
cellular signalling functions and thus the functional link between TRPV4 and the enzyme 
responsible for the ROS production. Incubation with various antagonists could also be 
employed to elucidate the underlying mechanisms. As such, our findings provide a 
preliminary indication of a role for TRPV4 in ROS production, where improved methods are 
needed to further evidence this.   
5.2.3 SPECIFICITY OF TRPV4 RELATED DRUG COMPOUNDS 
Agonists were used at concentrations that provide physiologically relevant responses, whilst 
maintaining a high level of specificity. The selectivity of GSK for TRPV4 was also 
experimentally demonstrated here. The specificity of HC-067047 has been previously 
demonstrated, with no effect on other TRP receptors up to concentrations of 5M (Everaerts 
et al., 2010c), where the IC50 (140nM) was determined in mouse urothelial cells, making this 
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value relevant and applicable to this study (Everaerts et al., 2010c). As such, the 
conclusions drawn using these compounds are reliable.  
In summary, all possible appropriate measures were taken to provide data of the highest 
accuracy, representing the true functional output as closely as possible. The main limitation 
of this study was lack of human samples, however data from those provided has indicated 
important differences between normal and overactive bladders that will likely be confirmed 
with further biopsies.      
 
5.3 CONCLUSIONS  
The studies within this thesis have provided novel information about the functional roles of 
TRPV4 within the bladder and the underlying mechanisms. Changes in the receptors 
expression, activity and interactions with other fundamental receptors have also been 
identified. Key conclusions are listed below: 
 TRPV4 is predominantly expressed in the urothelium, with lower level expression in 
the suburothelium and DSM.  
 Selective TRPV4 activation evokes mucosal ATP release that is: 
o tightly dependent on extracellular Ca2+ entry. 
o mediated by conductive pathways, likely via pannexin-1 channels. 
o dependent on PTK activity. 
 Selective blockade of TRPV4 reduces basal ATP release and a proportion of stretch-
evoked ATP release from the mucosa. 
 Selective TRPV4 activation evokes strong and sustained contractions via direct 
action on DSM. 
 Expression is significantly increased in both the mucosa and DSM in aging bladders. 
 The ATP release evoked by co-activation of TRPV4 with P2Y2/P2Y4 is augmented in 
aging mucosa. 
 Basal and TRPV4-mediated ATP release is higher in human mucosa from overactive 
bladders than from normal bladders. 
Importantly, the results demonstrate the multifactorial means by which TRPV4 activity can 
potentially influence overactivity and thus, provide further rationale for therapeutic 
intervention of OAB through the pharmacological modulation this receptor.  
Therefore, careful pharmacological modulation of this receptor may be a promising novel 
approach in the treatment of OAB syndrome, however further in vivo research is required. 
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5.4 FUTURE DIRECTION 
5.4.1 MECHANISM UNDERLYING TRPV4-MEDIATED ATP RELEASE 
The first results chapter of this thesis identified a role for TRPV4 in mucosal ATP release 
and partly elucidated the underlying mechanism. However, further experiments are required 
to establish the full mechanism.  
It was proposed that pannexin-1 channels facilitate the ATP release, based on our finding 
using carbenoxolone (broad connexin/pannexin blocker) and the current literature. 
Therefore, assessing the effect of a pannexin-1 specific inhibitor, such as pannexin-1 
mimetic inhibitory peptide (10Panx) on TRPV4-mediated ATP release would confirm this. 
Patch clamp technique could then be used to determine whether Ca2+ directly activates 
pannexin-1 channels, which has been suggested, or if it is through an indirect second 
messenger. This would provide a fully comprehensive mechanism for TRPV-mediated ATP 
release.  
5.4.2 CHANNELS RESPONSIBLE FOR STRETCH-INDUCED ATP RELEASE 
Stretch experiments revealed that TRPV4 is partly responsible for stretch-evoked ATP 
release with a 50% contribution. Current literature using amiloride suggests ENaC channels 
are responsible for 90-100% of the stretch-evoked ATP release. To confirm the relative 
contributions definitively, the effect of benzamil, a more potent ENaC channel blocker and 
HC-067047 on stretch-evoked ATP release should be assessed individually and in 
combination. This may also indicate the involvement of other receptors not yet identified.  
5.4.3 TRPV4-MEDIATED ROS PRODUCTION 
An increased ROS production was identified in bladder tissue after challenge with GSK. This 
should be confirmed using whole tissue and single cell techniques by fluorescence 
microscopy, which retain cell signaling functions. The role of NOX5 in this ROS production 
should also be assessed by first determining the expression of NOX5 in the bladder and 
then through inhibition of the enzyme.  
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5.4.4 A ROLE FOR TRPV4 IN BASAL ATP RELEASE 
A reduced basal ATP release was observed upon blockade of TRPV4.  Further experiments 
could identify the endogenous activator responsible for basal TRPV4 activity, for example 
through blockade of likely candidates including EETs, Ca2+-CaM and IP3.  
5.4.5 TRPV4 EXPRESSION IN AGNIG AND PATHOLOGICAL BLADDERS 
The second results chapter of this thesis identified an increased TRPV4 expression in aging 
GPs. This should also be examined in young and aging human bladders, which will be 
performed once further samples for each group have been obtained. It would also be 
interesting to compare the expression of TRPV4 in normal and overactive human bladders, 
which again will be done with further samples.  
5.4.6 A FUNCTIONAL LINK BETWEEN TRPV4 AND P2Y RECEPTORS 
The study also identified an increased mucosal ATP release in aging animals during co-
activation of TRPV4 with P2Y2/P2Y4, suggesting a functional interaction. Co-precipitation 
assays should be performed to confirm a physical link between the two receptors and also 
identify the responsible purinoceptor subtype.  
The most important future work for this project is to continue to examine the effects of OAB 
on TRPV4 expression and TRPV4-mediated ATP release in human tissue.   
 
 
 
 
 
 
 
 
 
 
 
 
222 
REFERENCES 
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, 
W.A., 2002. The standardisation of terminology of lower urinary tract function: report 
from the Standardisation Sub-committee of the International Continence Society. 
Neurourol Urodyn. 2, 167–178. doi:10.1002/nau.10052 
Abrams, P., Andersson, K.-E., Buccafusco, J.J., Chapple, C., de Groat, W.C., Fryer, A.D., 
Kay, G., Laties, A., Nathanson, N.M., Pasricha, P.J., Wein, A.J., 2006. Muscarinic 
receptors: their distribution and function in body systems, and the implications for 
treating overactive bladder. Br. J. Pharmacol. 148, 565–78. doi:10.1038/sj.bjp.0706780 
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., 
Fukami, Y., 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. 
Biol. Chem. 262, 5592–5. 
Akram Al-Motabagani, M., 2005. Age-Related Changes in the Urinary Bladder of the Female 
Albino Rats. Int. J. Morphol. 23. doi:10.4067/S0717-95022005000400005 
Alessandri-Haber, N., Dina, O.A., Joseph, E.K., Reichling, D., Levine, J.D., 2006. A transient 
receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by 
concerted action of inflammatory mediators. J. Neurosci. 26, 3864–74. 
doi:10.1523/JNEUROSCI.5385-05.2006 
Alessandri-Haber, N., Yeh, J.J., Boyd, A.E., Parada, C.A., Chen, X., Reichling, D.B., Levine, 
J.D., 2003. Hypotonicity Induces TRPV4-Mediated Nociception in Rat. Neuron 39, 497–
511. doi:10.1016/S0896-6273(03)00462-8 
Ambache, N., Zar, M.A., 1970. Non-cholinergic transmission by post-ganglionic motor 
neurones in the mammalian bladder. J. Physiol. 210, 761–783. 
doi:10.1113/jphysiol.1970.sp009240 
Anderson, K.E., 1993. Pharmacology of lower urinary tract smooth muscles and penile 
erectile tissues. Pharmacol. Rev. 45, 253–308. 
Andersson, K., Wein, A., 2004. Pharmacology of the lower urinary tract: basis for current 
and future treatments of urinary incontinence. Pharmacol. Rev. 56, 581–631. 
doi:10.1124/pr.56.4.4.581 
Andersson, K.-E., Arner, A., 2004. Urinary bladder contraction and relaxation: physiology 
and pathophysiology. Physiol. Rev. 84, 935–86. doi:10.1152/physrev.00038.2003 
Andersson, K.E., McCloskey, K.D., 2014. Lamina propria: the functional center of the 
bladder? Neurourol. Urodyn. 33, 9–16. doi:10.1002/nau.22465 
Andersson, K.E., Persson, K., 1995. Nitric oxide synthase and the lower urinary tract: 
possible implications for physiology and pathophysiology. Scand. J. Urol. Nephrol. 
 
223 
Suppl. 175, 43–53. 
Avelino, A., Cruz, F., 2006. TRPV1 (vanilloid receptor) in the urinary tract: expression, 
function and clinical applications. Naunyn. Schmiedebergs. Arch. Pharmacol. 373, 
287–99. doi:10.1007/s00210-006-0073-2 
Bánfi, B., Tirone, F., Durussel, I., Knisz, J., Moskwa, P., Molnár, G.Z., Krause, K.-H., Cox, 
J.A., 2004. Mechanism of Ca2+ activation of the NADPH oxidase 5 (NOX5). J. Biol. 
Chem. 279, 18583–91. doi:10.1074/jbc.M310268200 
Barbe, M.T., Monyer, H., Bruzzone, R., 2006. Cell-cell communication beyond connexins: 
the pannexin channels. Physiology (Bethesda). 21, 103–14. 
doi:10.1152/physiol.00048.2005 
Barber, R.D., Harmer, D.W., Coleman, R.A., Clark, B.J., 2005. GAPDH as a housekeeping 
gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol. 
Genomics 21, 389–95. doi:10.1152/physiolgenomics.00025.2005 
Bayliss, M., Wu, C., Newgreen, D., Mundy, A.R., Fry, C.H., 1999. A quantitative study of 
atropine-resistant contractile responses in human detrusor smooth muscle, from stable, 
unstable and obstructed bladders. J. Urol. 162, 1833–1839. doi:10.1016/S0022-
5347(05)68247-X 
Beckel, J.M., Daugherty, S.L., Tyagi, P., Wolf-Johnston, A.S., Birder, L.A., Mitchell, C.H., de 
Groat, W.C., 2015. Pannexin 1 channels mediate the release of ATP into the lumen of 
the rat urinary bladder. J. Physiol. 593, 1857–71. doi:10.1113/jphysiol.2014.283119 
Beckel, J.M., Kanai, A., Lee, S.-J., de Groat, W.C., Birder, L.A., 2006. Expression of 
functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am. J. 
Physiol. Renal Physiol. 290, F103–10. doi:10.1152/ajprenal.00098.2005 
Becker, D., Müller, M., Leuner, K., Jendrach, M., 2008. The C-terminal domain of TRPV4 is 
essential for plasma membrane localization. Mol. Membr. Biol. 25, 139–51. 
doi:10.1080/09687680701635237 
Benfenati, V., Amiry-Moghaddam, M., Caprini, M., Mylonakou, M.N., Rapisarda, C., 
Ottersen, O.P., Ferroni, S., 2007. Expression and functional characterization of 
transient receptor potential vanilloid-related channel 4 (TRPV4) in rat cortical 
astrocytes. Neuroscience 148, 876–92. doi:10.1016/j.neuroscience.2007.06.039 
Berridge, M.J., Bootman, M.D., Roderick, H.L., 2003. Calcium signalling: dynamics, 
homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 4, 517–29. 
doi:10.1038/nrm1155 
Birder, L. a, 2010. Urothelial signaling. Auton. Neurosci. 153, 33–40. 
doi:10.1016/j.autneu.2009.07.005 
Birder, L. a, de Groat, W.C., 2007. Mechanisms of disease: involvement of the urothelium in 
 
224 
bladder dysfunction. Nat. Clin. Pract. Urol. 4, 46–54. doi:10.1038/ncpuro0672 
Birder, L., Andersson, K.-E., 2013. Urothelial signaling. Physiol. Rev. 93, 653–80. 
doi:10.1152/physrev.00030.2012 
Birder, L., Kullmann, F.A., Lee, H., Barrick, S., de Groat, W., Kanai, A., Caterina, M., 2007. 
Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-
didecanoate contributes to altered bladder reflexes in the rat. J. Pharmacol. Exp. Ther. 
323, 227–35. doi:10.1124/jpet.107.125435 
Birder, L., Ruggieri, M., 2012. How does the urothelium affect bladder function in health and 
disease? Neurourol. … 299, 293–299. doi:10.1002/nau 
Birder, L.A., 2006. Urinary bladder urothelium: molecular sensors of 
chemical/thermal/mechanical stimuli. Vascul. Pharmacol. 45, 221–6. 
doi:10.1016/j.vph.2005.08.027 
Birder, L.A., Barrick, S.R., Roppolo, J.R., Kanai, A.J., de Groat, W.C., Kiss, S., Buffington, 
C.A., 2003. Feline interstitial cystitis results in mechanical hypersensitivity and altered 
ATP release from bladder urothelium. Am. J. Physiol. Renal Physiol. 285, F423–9. 
doi:10.1152/ajprenal.00056.2003 
Birder, L.A., Kanai, A.J., de Groat, W.C., Kiss, S., Nealen, M.L., Burke, N.E., Dineley, K.E., 
Watkins, S., Reynolds, I.J., Caterina, M.J., 2001. Vanilloid receptor expression 
suggests a sensory role for urinary bladder epithelial cells. Proc. Natl. Acad. Sci. U. S. 
A. 98, 13396–401. doi:10.1073/pnas.231243698 
Birder, L.A., Nakamura, Y., Kiss, S., Nealen, M.L., Barrick, S., Kanai, A.J., Wang, E., Ruiz, 
G., De Groat, W.C., Apodaca, G., Watkins, S., Caterina, M.J., 2002. Altered urinary 
bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci. 5, 856–
60. doi:10.1038/nn902 
Birder, L.A., Ruan, H.Z., Chopra, B., Xiang, Z., Barrick, S., Buffington, C.A., Roppolo, J.R., 
Ford, A.P.D.W., Groat, W.C. De, Burnstock, G., 2004. Alterations in P2X and P2Y 
purinergic receptor expression in urinary bladder from normal cats and cats with 
interstitial cystitis. Am J Physiol Ren. Physiol 15261, 1084–1091. 
doi:10.1152/ajprenal.00118.2004. 
Bodin, P., Burnstock, G., 2001. Evidence that release of adenosine triphosphate from 
endothelial cells during increased shear stress is vesicular. J. Cardiovasc. Pharmacol. 
38, 900–8. 
Boland, B., Himpens, B., Paques, C., Casteels, R., Gillis, J.M., 1993. ATP induced-
relaxation in the mouse bladder smooth muscle. Br. J. Pharmacol. 108, 749–53. 
Bolego, C., Pinna, C., Abbracchio, M.P., Cattabeni, F., Puglisi, L., 1995. The biphasic 
response of rat vesical smooth muscle to ATP. Br. J. Pharmacol. 114, 1557–62. 
 
225 
Borvendeg, S.J., Gerevich, Z., Gillen, C., Illes, P., 2003. P2Y receptor-mediated inhibition of 
voltage-dependent Ca2+ channels in rat dorsal root ganglion neurons. Synapse 47, 
159–61. doi:10.1002/syn.10156 
Boudreault, F., Grygorczyk, R., 2004. Cell swelling-induced ATP release is tightly dependent 
on intracellular calcium elevations. J. Physiol. 561, 499–513. 
doi:10.1113/jphysiol.2004.072306 
Boudreault, F., Grygorczyk, R., 2002. Cell swelling-induced ATP release and gadolinium-
sensitive channels. Am. J. Physiol. Cell Physiol. 282, C219–26. 
doi:10.1152/ajpcell.00317.2001 
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 
248–54. 
Brading, A.F., 2006. Spontaneous activity of lower urinary tract smooth muscles: correlation 
between ion channels and tissue function. J. Physiol. 570, 13–22. 
doi:10.1113/jphysiol.2005.097311 
Brading, A.F., Inoue, R., 1991. Ion channels and excitatory transmission in the smooth 
muscle of the urinary bladder. Z. Kardiol. 80 Suppl 7, 47–53. 
Brooks, S. V, Faulkner, J.A., 1988. Contractile properties of skeletal muscles from young, 
adult and aged mice. J. Physiol. 404, 71–82. 
Brown, C., Burnstock, G., Cocks, T., 1979. Effects of adenosine 5’-triphosphate (ATP) and 
beta-gamma-methylene ATP on the rat urinary bladder. Br. J. Pharmacol. 65, 97–102. 
Bruzzone, R., Barbe, M.T., Jakob, N.J., Monyer, H., 2005. Pharmacological properties of 
homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J. 
Neurochem. 92, 1033–43. doi:10.1111/j.1471-4159.2004.02947.x 
Bubolz, A.H., Mendoza, S.A., Zheng, X., Zinkevich, N.S., Li, R., Gutterman, D.D., Zhang, 
D.X., 2012. Activation of endothelial TRPV4 channels mediates flow-induced dilation in 
human coronary arterioles: role of Ca2+ entry and mitochondrial ROS signaling. Am. J. 
Physiol. Heart Circ. Physiol. 302, H634–42. doi:10.1152/ajpheart.00717.2011 
Burnstock, G., 1999. Release of vasoactive substances from endothelial cells by shear 
stress and purinergic mechanosensory transduction. J. Anat. 194, 335–42. 
Burnstock, G., Cocks, T., Crowe, R., Kasakov, L., 1978. Purinergic innervation of the 
guinea-pig urinary bladder. Br. J. Pharmacol. 63, 125–38. 
Burnstock, G., Dumsday, B., Smythe, A., 1972. Atropine resistant excitation of the urinary 
bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br. J. 
Pharmacol. 44, 451–461. doi:10.1111/j.1476-5381.1972.tb07283.x 
Burnstock, G., Knight, G.E., 2004. Cellular distribution and functions of P2 receptor 
 
226 
subtypes in different systems. Int. Rev. Cytol. 240, 31–304. doi:10.1016/S0074-
7696(04)40002-3 
Burnstock, G., Williams, M., 2000. P2 Purinergic Receptors: Modulation of Cell Function and 
Therapeutic Potential. J. Pharmacol. Exp. Ther. 295, 862–869. 
Carattino, M.D., Passero, C.J., Steren, C.A., Maarouf, A.B., Pilewski, J.M., Myerburg, M.M., 
Hughey, R.P., Kleyman, T.R., 2008. Defining an inhibitory domain in the alpha-subunit 
of the epithelial sodium channel. Am. J. Physiol. Renal Physiol. 294, F47–52. 
doi:10.1152/ajprenal.00399.2007 
Carneiro, I., Timóteo, M.A., Silva, I., Vieira, C., Baldaia, C., Ferreirinha, F., Silva-Ramos, M., 
Correia-de-Sá, P., 2014. Activation of P2Y6 receptors increases the voiding frequency 
in anaesthetized rats by releasing ATP from the bladder urothelium. Br. J. Pharmacol. 
171, 3404–19. doi:10.1111/bph.12711 
Carpenter, F.G., 1977. Atropine resistance and muscarinic receptors in the rat urinary 
bladder. Br. J. Pharmacol. 59, 43–49. doi:10.1111/j.1476-5381.1977.tb06975.x 
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., Julius, D., 
1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 
389, 816–24. doi:10.1038/39807 
Chan, E., Patel, A., Heston, W., Larchian, W., 2009. Mouse orthotopic models for bladder 
cancer research. BJU Int. 104, 1286–91. doi:10.1111/j.1464-410X.2009.08577.x 
Chan, L., 2005. What Is a Urinary Tract Infection (UTI)? [WWW Document]. URL 
http://www.publichealthwatchdog.com/what-is-a-urinary-tract-infection-uti/ (accessed 
9.13.13). 
Chancellor MB, Yoshimura N, 2006. Campbell-walsh urology: Physiology and pharmacology 
of the bladder and urethra, 9th ed. Elsevier Health Sciences, Philadelphia, PA, USA. 
Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G., Wood, J.N., 1995. A 
P2X purinoceptor expressed by a subset of sensory neurons. Nature 377, 428–31. 
doi:10.1038/377428a0 
Chess-Williams, R., 2002. Muscarinic receptors of the urinary bladder: detrusor, urothelial 
and prejunctional. Auton. Autacoid Pharmacol. 22, 133–45. 
Chien, C.-T., Yu, H.-J., Lin, T.-B., Lai, M.-K., Hsu, S.-M., 2003. Substance P via NK1 
receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am. J. 
Physiol. Renal Physiol. 284, F840–51. doi:10.1152/ajprenal.00187.2002 
Chopra, B., Barrick, S.R., Meyers, S., Beckel, J.M., Zeidel, M.L., Ford, A.P.D.W., de Groat, 
W.C., Birder, L.A., 2005. Expression and function of bradykinin B1 and B2 receptors in 
normal and inflamed rat urinary bladder urothelium. J. Physiol. 562, 859–71. 
doi:10.1113/jphysiol.2004.071159 
 
227 
Chopra, B., Gever, J., Barrick, S.R., Hanna-Mitchell, A.T., Beckel, J.M., Ford, A.P.D.W., 
Birder, L.A., 2008. Expression and function of rat urothelial P2Y receptors. Am. J. 
Physiol. Renal Physiol. 294, F821–9. doi:10.1152/ajprenal.00321.2006 
Christensen, A.P., Corey, D.P., 2007. TRP channels in mechanosensation: direct or indirect 
activation? Nat. Rev. Neurosci. 8, 510–21. doi:10.1038/nrn2149 
Christiaansen, C.E., Sun, Y., Hsu, Y.-C., Chai, T.C., 2011. Alterations in expression of HIF-
1α, HIF-2α, and VEGF by idiopathic overactive bladder urothelial cells during stretch 
suggest role for hypoxia. Urology 77, 1266.e7–11. doi:10.1016/j.urology.2010.12.041 
Chung, M.-K., Lee, H., Mizuno, A., Suzuki, M., Caterina, M.J., 2004. TRPV3 and TRPV4 
mediate warmth-evoked currents in primary mouse keratinocytes. J. Biol. Chem. 279, 
21569–75. doi:10.1074/jbc.M401872200 
Clapham, D.E., 2003. TRP channels as cellular sensors. Nature 426, 517–24. 
doi:10.1038/nature02196 
Clapham, D.E., Julius, D., Montell, C., Schultz, G., 2005. International Union of 
Pharmacology. XLIX. Nomenclature and structure-function relationships of transient 
receptor potential channels. Pharmacol. Rev. 57, 427–50. doi:10.1124/pr.57.4.6 
Cockayne, D.A., Hamilton, S.G., Zhu, Q.M., Dunn, P.M., Zhong, Y., Novakovic, S., 
Malmberg, A.B., Cain, G., Berson, A., Kassotakis, L., Hedley, L., Lachnit, W.G., 
Burnstock, G., McMahon, S.B., Ford, A.P., 2000. Urinary bladder hyporeflexia and 
reduced pain-related behaviour in P2X3-deficient mice. Nature 407, 1011–5. 
doi:10.1038/35039519 
Coco, S., Calegari, F., Pravettoni, E., Pozzi, D., Taverna, E., Rosa, P., Matteoli, M., 
Verderio, C., 2003. Storage and release of ATP from astrocytes in culture. J. Biol. 
Chem. 278, 1354–62. doi:10.1074/jbc.M209454200 
Contreras-Sanz, A., Scott-Ward, T.S., Gill, H.S., Jacoby, J.C., Birch, R.E., Malone-Lee, J., 
Taylor, K.M.G., Peppiatt-Wildman, C.M., Wildman, S.S.P., 2012. Simultaneous 
quantification of 12 different nucleotides and nucleosides released from renal 
epithelium and in human urine samples using ion-pair reversed-phase HPLC. 
Purinergic Signal. 8, 741–51. doi:10.1007/s11302-012-9321-8 
Cotrina, M.L., Lin, J.H.-C., Alves-Rodrigues, A., Liu, S., Li, J., Azmi-Ghadimi, H., Kang, J., 
Naus, C.C.G., Nedergaard, M., 1998. Connexins regulate calcium signaling by 
controlling ATP release. Proc. Natl. Acad. Sci. U. S. A. 95, 15735–40. 
doi:10.1073/pnas.95.26.15735 
Creed, K.E., Loxley, R.A., Phillips, J.K., 2010. Functional expression of muscarinic and 
purinoceptors in the urinary bladder of male and female rats and guinea pigs. J. 
Smooth Muscle Res. 46, 201–15. 
Cross, W.R., Eardley, I., Leese, H.J., Southgate, J., 2005. A biomimetic tissue from cultured 
 
228 
normal human urothelial cells: analysis of physiological function. Am. J. Physiol. Renal 
Physiol. 289, F459–68. doi:10.1152/ajprenal.00040.2005 
Cuajungco, M.P., Grimm, C., Oshima, K., D’hoedt, D., Nilius, B., Mensenkamp, A.R., 
Bindels, R.J.M., Plomann, M., Heller, S., 2006. PACSINs bind to the TRPV4 cation 
channel. PACSIN 3 modulates the subcellular localization of TRPV4. J. Biol. Chem. 
281, 18753–62. doi:10.1074/jbc.M602452200 
Dai, X.-Q., Ramji, A., Liu, Y., Li, Q., Karpinski, E., Chen, X.-Z., 2007. Inhibition of TRPP3 
channel by amiloride and analogs. Mol. Pharmacol. 72, 1576–85. 
doi:10.1124/mol.107.037150 
Daly, D.M., Nocchi, L., Liaskos, M., McKay, N.G., Chapple, C., Grundy, D., 2014. Age-
related changes in afferent pathways and urothelial function in the male mouse 
bladder. J. Physiol. 592, 537–49. doi:10.1113/jphysiol.2013.262634 
Daniel, J.L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J.B., Kunapuli, S.P., 1998. Molecular 
basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors 
on human platelets. J. Biol. Chem. 273, 2024–9. 
Datta, S.N., Roosen, A., Pullen, A., Popat, R., Rosenbaum, T.P., Elneil, S., Dasgupta, P., 
Fowler, C.J., Apostolidis, A., 2010. Immunohistochemical expression of muscarinic 
receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive 
human bladders, and changes with botulinum neurotoxin administration. J. Urol. 184, 
2578–85. doi:10.1016/j.juro.2010.07.034 
Davidson, R.A., McCloskey, K.D., 2005. Morphology and localization of interstitial cells in 
the guinea pig bladder: structural relationships with smooth muscle and neurons. J. 
Urol. 173, 1385–90. doi:10.1097/01.ju.0000146272.80848.37 
de Groat, W.C., 2004. The urothelium in overactive bladder: passive bystander or active 
participant? Urology 64, 7–11. doi:10.1016/j.urology.2004.08.063 
Deen, S., Ball, R.Y., 1994. Basement membrane and extracellular interstitial matrix 
components in bladder neoplasia? Evidence of angiogenesis. Histopathology 25, 475–
481. doi:10.1111/j.1365-2559.1994.tb00010.x 
DeLancey, J., Gosling, J., Creed, K., Dixon, J., Delmas, V., Landon, D., 2002. Gross 
Anatomy and Cell Biology of the Lower Urinary Tract. Incontinence, Second Int. 
Consult. Incontinence 17–82. 
Delany, N.S., Hurle, M., Facer, P., Alnadaf, T., Plumpton, C., Kinghorn, I., See, C.G., 
Costigan, M., Anand, P., Woolf, C.J., Crowther, D., Sanseau, P., Tate, S.N., 2001. 
Identification and characterization of a novel human vanilloid receptor-like protein, VRL-
2. Physiol Genomics 4, 165–174. 
Dikalov, S., Griendling, K.K., Harrison, D.G., 2007. Measurement of reactive oxygen species 
in cardiovascular studies. Hypertension 49, 717–27. 
 
229 
doi:10.1161/01.HYP.0000258594.87211.6b 
Dinter, A., Berger, E.G., 1998. Golgi-disturbing agents. Histochem. Cell Biol. 109, 571–90. 
Drake, M.J., Mills, I.W., Gillespie, J.I., 2001. Model of peripheral autonomous modules and a 
myovesical plexus in normal and overactive bladder function. Lancet 358, 401–3. 
Du, S., Araki, I., Mikami, Y., Zakoji, H., Beppu, M., Yoshiyama, M., Takeda, M., 2007. 
Amiloride-sensitive ion channels in urinary bladder epithelium involved in 
mechanosensory transduction by modulating stretch-evoked adenosine triphosphate 
release. Urology 69, 590–5. doi:10.1016/j.urology.2007.01.039 
Dubyak, G.R., Clifford, E.E., Humphreys, B.D., Kertesy, S.B., Martin, K.A., 1996. Expression 
of multiple ATP receptor subtypes during the differentiation and inflammatory activation 
of myeloid leukocytes. Drug Dev. Res. 39, 269–278. doi:10.1002/(SICI)1098-
2299(199611/12)39:3/4<269::AID-DDR6>3.0.CO;2-P 
Dunn, K.M., Hill-Eubanks, D.C., Liedtke, W.B., Nelson, M.T., 2013. TRPV4 channels 
stimulate Ca2+-induced Ca2+ release in astrocytic endfeet and amplify neurovascular 
coupling responses. Proc. Natl. Acad. Sci. U. S. A. 110, 6157–62. 
doi:10.1073/pnas.1216514110 
Dunn, P.M., Zhong, Y., Burnstock, G., 2001. P2X receptors in peripheral neurons. Prog. 
Neurobiol. 65, 107–134. doi:10.1016/S0301-0082(01)00005-3 
Dunning-Davies, B.M., Fry, C.H., Mansour, D., Ferguson, D.R., 2013. The regulation of ATP 
release from the urothelium by adenosine and transepithelial potential. BJU Int. 111, 
505–13. doi:10.1111/j.1464-410X.2012.11421.x 
Durlu-Kandilci, N.T., Brading, A.F., 2006. Involvement of Rho kinase and protein kinase C in 
carbachol-induced calcium sensitization in beta-escin skinned rat and guinea-pig 
bladders. Br. J. Pharmacol. 148, 376–84. doi:10.1038/sj.bjp.0706723 
Edwards, J.C., Kapadia, S., 2000. Regulation of the bovine kidney microsomal chloride 
channel p64 by p59fyn, a Src family tyrosine kinase. J. Biol. Chem. 275, 31826–32. 
doi:10.1074/jbc.M005275200 
Egbuniwe, O., Grover, S., Duggal, A.K., Mavroudis, A., Yazdi, M., Renton, T., Di Silvio, L., 
Grant, A.D., 2014. TRPA1 and TRPV4 activation in human odontoblasts stimulates 
ATP release. J. Dent. Res. 93, 911–7. doi:10.1177/0022034514544507 
Elneil, S., Skepper, J.N., Kidd, E.J., Williamson, J.G., Ferguson, D.R., 2001. Distribution of 
P2X1 and P2X3 receptors in the rat and human urinary bladder. Pharmacology. 
El-Tayeb, A., Qi, A., Müller, C.E., 2006. Synthesis and structure-activity relationships of 
uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and 
P2Y6 receptors. J. Med. Chem. 49, 7076–87. doi:10.1021/jm060848j 
Espelt, M. V, de Tezanos Pinto, F., Alvarez, C.L., Alberti, G.S., Incicco, J., Leal Denis, M.F., 
 
230 
Davio, C., Schwarzbaum, P.J., 2013. On the role of ATP release, ectoATPase activity, 
and extracellular ADP in the regulatory volume decrease of Huh-7 human hepatoma 
cells. Am. J. Physiol. Cell Physiol. 304, C1013–26. doi:10.1152/ajpcell.00254.2012 
Everaerts, W., Nilius, B., Owsianik, G., 2010a. The vanilloid transient receptor potential 
channel TRPV4: from structure to disease. Prog. Biophys. Mol. Biol. 103, 2–17. 
doi:10.1016/j.pbiomolbio.2009.10.002 
Everaerts, W., Vriens, J., Owsianik, G., Appendino, G., Voets, T., De Ridder, D., Nilius, B., 
2010b. Functional characterization of transient receptor potential channels in mouse 
urothelial cells. Am. J. Physiol. Renal Physiol. 298, F692–701. 
doi:10.1152/ajprenal.00599.2009 
Everaerts, W., Zhen, X., Ghosh, D., Vriens, J., Gevaert, T., Gilbert, J.P., Hayward, N.J., 
McNamara, C.R., Xue, F., Moran, M.M., Strassmaier, T., Uykal, E., Owsianik, G., 
Vennekens, R., De Ridder, D., Nilius, B., Fanger, C.M., Voets, T., 2010c. Inhibition of 
the cation channel TRPV4 improves bladder function in mice and rats with 
cyclophosphamide-induced cystitis. Proc. Natl. Acad. Sci. U. S. A. 107, 19084–9. 
doi:10.1073/pnas.1005333107 
Fall, M., Lindström, S., Mazières, L., 1990. A bladder-to-bladder cooling reflex in the cat. J. 
Physiol. 427, 281–300. 
Ferguson, D.R., Kennedy, I., Burton, T.J., 1997. ATP is released from rabbit urinary bladder 
epithelial cells by hydrostatic pressure changes--a possible sensory mechanism? J. 
Physiol. 505 ( Pt 2, 503–11. 
Fernandes, J., Lorenzo, I.M., Andrade, Y.N., Garcia-Elias, A., Serra, S.A., Fernández-
Fernández, J.M., Valverde, M.A., 2008. IP3 sensitizes TRPV4 channel to the mechano- 
and osmotransducing messenger 5’-6'-epoxyeicosatrienoic acid. J. Cell Biol. 181, 143–
55. doi:10.1083/jcb.200712058 
Fini, M., Torricelli, P., Giavaresi, G., Aldini, N.N., Cavani, F., Setti, S., Nicolini, A., Carpi, A., 
Giardino, R., 2008. Effect of pulsed electromagnetic field stimulation on knee cartilage, 
subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs. 
Biomed. Pharmacother. 62, 709–15. doi:10.1016/j.biopha.2007.03.001 
Fischer, K.-G., Jonas, N., Poschenrieder, F., Cohen, C., Kretzler, M., Greiber, S., 
Pavenstädt, H., 2002. Characterization of a Na(+)-Ca(2+) exchanger in podocytes. 
Nephrol. Dial. Transplant 17, 1742–50. 
Fleming, I., 2001. Cytochrome p450 and vascular homeostasis. Circ. Res. 89, 753–62. 
Fowler, C.J., Griffiths, D., de Groat, W.C., 2008. The neural control of micturition. Nat. Rev. 
Neurosci. 9, 453–66. doi:10.1038/nrn2401 
Fry, C.H., Meng, E., Young, J.S., 2010. The physiological function of lower urinary tract 
smooth muscle. Auton. Neurosci. 154, 3–13. doi:10.1016/j.autneu.2009.10.006 
 
231 
Fry, C.H., Sui, G.-P., Severs, N.J., Wu, C., 2004. Spontaneous activity and electrical 
coupling in human detrusor smooth muscle: implications for detrusor overactivity? 
Urology 63, 3–10. doi:10.1016/j.urology.2003.11.005 
Garcia-Elias, A., Lorenzo, I.M., Vicente, R., Valverde, M.A., 2008. IP3 receptor binds to and 
sensitizes TRPV4 channel to osmotic stimuli via a calmodulin-binding site. J. Biol. 
Chem. 283, 31284–8. doi:10.1074/jbc.C800184200 
Gerevich, Z., Borvendeg, S.J., Schröder, W., Franke, H., Wirkner, K., Nörenberg, W., Fürst, 
S., Gillen, C., Illes, P., 2004. Inhibition of N-type voltage-activated calcium channels in 
rat dorsal root ganglion neurons by P2Y receptors is a possible mechanism of ADP-
induced analgesia. J. Neurosci. 24, 797–807. doi:10.1523/JNEUROSCI.4019-03.2004 
Gevaert, T., Vriens, J., Segal, A., Everaerts, W., Roskams, T., Talavera, K., Owsianik, G., 
Liedtke, W., Daelemans, D., Dewachter, I., Van Leuven, F., Voets, T., De Ridder, D., 
Nilius, B., 2007. Deletion of the transient receptor potential cation channel TRPV4 
impairs murine bladder voiding. J. Clin. Invest. 117, 3453–62. doi:10.1172/JCI31766 
Girard, B.M., Wolf-Johnston, A., Braas, K.M., Birder, L.A., May, V., Vizzard, M.A., 2008. 
PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and 
receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis. 
J. Mol. Neurosci. 36, 310–20. doi:10.1007/s12031-008-9104-4 
Gomez-Pinilla, P.J., Gomez, M.F., Hedlund, P., Swärd, K., Hellstrand, P., Camello, P.J., 
Pozo, M.J., Andersson, K.-E., 2007. Effect of melatonin on age associated changes in 
Guinea pig bladder function. J. Urol. 177, 1558–61. doi:10.1016/j.juro.2006.11.071 
Groen, J., van Mastrigt, R., van Asselt, E., van Koeveringe, G.A., Bosch, R., 1994. 
Contractility parameters of the guinea pig bladder in situ: similarity to human bladder 
contractility. J. Urol. 151, 1405–10. 
Grynkiewicz, G., Poenie, M., Tsien, R., 1985. A new generation of Ca2+ indicators with 
greatly improved fluorescence properties. J. Biol. Chem. 260, 3440–3450. 
Guler, A.D., Lee, H., Iida, T., Shimizu, I., Tominaga, M., Caterina, M., 2002. Heat-Evoked 
Activation of the Ion Channel, TRPV4. J. Neurosci. 22, 6408–6414. 
Häbler, H.J., Jänig, W., Koltzenburg, M., 1990. Activation of unmyelinated afferent fibres by 
mechanical stimuli and inflammation of the urinary bladder in the cat. J. Physiol. 425, 
545–62. 
Haefliger, J.-A., Tissières, P., Tawadros, T., Formenton, A., Bény, J.-L., Nicod, P., Frey, P., 
Meda, P., 2002. Connexins 43 and 26 are differentially increased after rat bladder 
outlet obstruction. Exp. Cell Res. 274, 216–25. doi:10.1006/excr.2001.5465 
Hampel, C., Dolber, P.C., Smith, M.P., Savic, S.L., Th roff, J.W., Thor, K.B., Schwinn, D.A., 
2002. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder 
outlet obstruction. J. Urol. 167, 1513–21. 
 
232 
Harriss, D.R., Marsh, K. a, Birmingham,  a T., Hill, S.J., 1995. Expression of muscarinic M3-
receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured 
smooth muscle cells. J. Urol. 154, 1241–5. 
Hartmannsgruber, V., Heyken, W.-T., Kacik, M., Kaistha, A., Grgic, I., Harteneck, C., 
Liedtke, W., Hoyer, J., Köhler, R., 2007. Arterial Response to Shear Stress Critically 
Depends on Endothelial TRPV4 Expression. PLoS One 2, e827. 
doi:10.1371/journal.pone.0000827 
Harvey Motulsky, A.C., 2004. Fitting Models to Biological Data Using Linear and Nonlinear 
Regression: A Practical Guide to Curve Fitting, 1st ed. Oxford University Press, USA. 
Harvey, R.A., Skennerton, D.E., Newgreen, D., Fry, C.H., 2002. The contractile potency of 
adenosine triphosphate and ecto-adenosine triphosphatase activity in guinea pig 
detrusor and detrusor from patients with a stable, unstable or obstructed bladder. J. 
Urol. 168, 1235–9. doi:10.1097/01.ju.0000024391.74486.f1 
Haupt, M., Thommes, M., Heidenreich, A., Breitkreutz, J., 2013. Lipid-based intravesical 
drug delivery systems with controlled release of trospium chloride for the urinary 
bladder. J. Control. Release 170, 161–6. doi:10.1016/j.jconrel.2013.05.018 
Hawthorn, M.H., Chapple, C.R., Cock, M., Chess-Williams, R., 2000. Urothelium-derived 
inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br. J. Pharmacol. 
129, 416–9. doi:10.1038/sj.bjp.0703068 
Hechler, B., Eckly, A., Ohlmann, P., Cazenave, J.-P., Gachet, C., 1998. The P2Y1 receptor, 
necessary but not sufficient to support full ADP-induced platelet aggregation, is not the 
target of the drug clopidogrel. Br. J. Haematol. 103, 858–866. doi:10.1046/j.1365-
2141.1998.01056.x 
Hegde, S.S., 2006. Muscarinic receptors in the bladder: from basic research to therapeutics. 
Br. J. Pharmacol. 147, S80–7. doi:10.1038/sj.bjp.0706560 
Helfand, B.T., Evans, R.M., McVary, K.T., 2010. A comparison of the frequencies of medical 
therapies for overactive bladder in men and women: analysis of more than 7.2 million 
aging patients. Eur. Urol. 57, 586–91. doi:10.1016/j.eururo.2009.12.025 
Hellwig, N., Albrecht, N., Harteneck, C., Schultz, G., Schaefer, M., 2005. Homo- and 
heteromeric assembly of TRPV channel subunits. J. Cell Sci. 118, 917–28. 
doi:10.1242/jcs.01675 
Hille, B., 2001. Ion Channels of Excitable Membranes, 4th ed. Sinauer, Sunderland, MA. 
Holmes, K.C., 1995. The actomyosin interaction and its control by tropomyosin. Biophys. J. 
68, 2S–5S; discussion 6S–7S. 
Holton, F.A., Holton, P., 1954. The capillary dilator substances in dry powders of spinal 
roots; a possible role of adenosine triphosphate in chemical transmission from nerve 
 
233 
endings. J. Physiol. 126, 124–40. 
Holton, P., 1959. The liberation of adenosine triphosphate on antidromic stimulation of 
sensory nerves. J. Physiol. 145, 494–504. 
Honore, P., Kage, K., Mikusa, J., Watt, A.T., Johnston, J.F., Wyatt, J.R., Faltynek, C.R., 
Jarvis, M.F., Lynch, K., 2002. Analgesic profile of intrathecal P2X(3) antisense 
oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. 
Pain 99, 11–9. 
Horsfall, D., Mayne, K., Ricciardelli, C., Rao, M., Skinner, J., Henderson, D., Marshall, V., 
Tilley, W., 1994. Age-related changes in guinea pig prostatic stroma. Lab Invest. 70, 
753–63. 
Igawa, Y., Zhang, X., Umeda, M., 2003. In vivo and in vitro functional changes of the urinary 
bladder in mice lacking muscarinic M2 or M3 receptors. Neurourol. … 14–15. 
Iglesias, R., Dahl, G., Qiu, F., Spray, D.C., Scemes, E., 2009. Pannexin 1: the molecular 
substrate of astrocyte “hemichannels”. J. Neurosci. 29, 7092–7. 
doi:10.1523/JNEUROSCI.6062-08.2009 
Ikeda, Y., Fry, C., Hayashi, F., Stolz, D., Griffiths, D., Kanai, A., 2007. Role of gap junctions 
in spontaneous activity of the rat bladder. Am. J. Physiol. Renal Physiol. 293, F1018–
25. doi:10.1152/ajprenal.00183.2007 
Inagami, T., Mizuno, K., Nakamaru, M., Pandey, K.N., Naruse, M., Naruse, K., Misono, K., 
Okamura, T., Kawamura, M., Higashimori, K., 1988. The renin-angiotensin system: an 
overview of its intracellular function. Cardiovasc. Drugs Ther. 2, 453–8. 
Inc., T.F.S., 2015. Fura-2 Calcium Indicator [WWW Document]. URL 
https://www.thermofisher.com/uk/en/home/life-science/drug-discovery/target-and-lead-
identification-and-validation/g-protein-coupled-html/cell-based-second-messenger-
assays/fura-2-calcium-indicator.html (accessed 10.15.15). 
Inoue, R., Brading, A.F., 1991. Human, pig and guinea-pig bladder smooth muscle cells 
generate similar inward currents in response to purinoceptor activation. Br. J. 
Pharmacol. 103, 1840–1. 
Ishida, A., Kameshita, I., Okuno, S., Kitani, T., Fujisawa, H., 1995. A novel highly specific 
and potent inhibitor of calmodulin-dependent protein kinase II. Biochem. Biophys. Res. 
Commun. 212, 806–12. doi:10.1006/bbrc.1995.2040 
IUPHAR/BPS, 2010. HC067047 - Biological Activity [WWW Document]. URL 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligand
Id=4213 (accessed 10.20.15). 
IUPHAR/BPS, 2007. GSK1016790A - Biological Activity [WWW Document]. URL 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligand
 
234 
Id=4205 (accessed 10.20.15). 
Jänig, W., Morrison, J.F., 1986. Functional properties of spinal visceral afferents supplying 
abdominal and pelvic organs, with special emphasis on visceral nociception. Prog. 
Brain Res. 67, 87–114. 
Janssen, D.A.W., Hoenderop, J.G., Jansen, K.C.F.J., Kemp, A.W., Heesakkers, J.P.F.A., 
Schalken, J.A., 2011. The mechanoreceptor TRPV4 is localized in adherence junctions 
of the human bladder urothelium: a morphological study. J. Urol. 186, 1121–7. 
doi:10.1016/j.juro.2011.04.107 
Jetti, S.K., Swain, S.M., Majumder, S., Chatterjee, S., Poornima, V., Bera, A.K., 2010. 
Evaluation of the role of nitric oxide in acid sensing ion channel mediated cell death. 
Nitric Oxide 22, 213–219. doi:10.1016/j.niox.2009.12.006 
Jin, M., Wu, Z., Chen, L., Jaimes, J., Collins, D., Walters, E.T., O’Neil, R.G., 2011. 
Determinants of TRPV4 activity following selective activation by small molecule agonist 
GSK1016790A. PLoS One 6, e16713. doi:10.1371/journal.pone.0016713 
Jones, S. a, Lancaster, M.K., Boyett, M.R., 2004. Ageing-related changes of connexins and 
conduction within the sinoatrial node. J. Physiol. 560, 429–37. 
doi:10.1113/jphysiol.2004.072108 
Kanai, A., Roppolo, J., Ikeda, Y., Zabbarova, I., Tai, C., Birder, L., Griffiths, D., de Groat, W., 
Fry, C., 2007. Origin of spontaneous activity in neonatal and adult rat bladders and its 
enhancement by stretch and muscarinic agonists. Am. J. Physiol. Renal Physiol. 292, 
F1065–72. doi:10.1152/ajprenal.00229.2006 
Karim, O.M., Seki, N., Pienta, K.J., Mostwin, J.L., 1992. The effect of age on the response of 
the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin 
matrix. J. Cell. Biochem. 48, 373–84. doi:10.1002/jcb.240480406 
Kasakov, L., Burnstock, G., 1982. The use of the slowly degradable analog, alpha, beta-
methylene ATP, to produce desensitisation of the P2-purinoceptor: effect on non-
adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. Eur. J. 
Pharmacol. 86, 291–4. 
Katzmann, D.J., Odorizzi, G., Emr, S.D., 2002. Receptor downregulation and multivesicular-
body sorting. Nat. Rev. Mol. Cell Biol. 3, 893–905. doi:10.1038/nrm973 
Keeling, D.J., Taylor, A.G., Smith, P.L., 1991. Effects of NPPB (5-nitro-2-(3-
phenylpropylamino)benzoic acid) on chloride transport in intestinal tissues and the T84 
cell line. Biochim. Biophys. Acta 1115, 42–8. 
Khandelwal, P., Abraham, S.N., Apodaca, G., 2009. Cell biology and physiology of the 
uroepithelium. Am. J. Physiol. Renal Physiol. 297, F1477–501. 
doi:10.1152/ajprenal.00327.2009 
 
235 
Kim, J.C., Yoo, J.S., Park, E.Y., Hong, S.H., Seo, S. Il, Hwang, T.-K., 2008. Muscarinic and 
purinergic receptor expression in the urothelium of rats with detrusor overactivity 
induced by bladder outlet obstruction. BJU Int. 101, 371–5. doi:10.1111/j.1464-
410X.2007.07251.x 
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, 
J., Nakano, T., Okawa, K., Iwamatsu, A., Kaibuchi, K., 1996. Regulation of myosin 
phosphatase by Rho and Rho-associated kinase (Rho-kinase) - Abstract - Europe 
PubMed Central. Science 273, 245–8. 
Klausner, A.P., Steers, W.D., 2008. Antimuscarinics for the treatment of overactive bladder: 
A review of central nervous system effects. Curr. Bladder Dysfunct. Rep. 3, 161–167. 
doi:10.1007/s11884-008-0024-5 
Kleyman, T.R., Cragoe, E.J., 1988. Amiloride and its analogs as tools in the study of ion 
transport. J. Membr. Biol. 105, 1–21. 
Krakow, D., Vriens, J., Camacho, N., Luong, P., Deixler, H., Funari, T.L., Bacino, C.A., Irons, 
M.B., Holm, I.A., Sadler, L., Okenfuss, E.B., Janssens, A., Voets, T., Rimoin, D.L., 
Lachman, R.S., Nilius, B., Cohn, D.H., 2009. Mutations in the gene encoding the 
calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, 
Kozlowski type and metatropic dysplasia. Am. J. Hum. Genet. 84, 307–15. 
doi:10.1016/j.ajhg.2009.01.021 
Kullmann, F.A., Artim, D., Beckel, J., Barrick, S., de Groat, W.C., Birder, L.A., 2008. 
Heterogeneity of muscarinic receptor-mediated Ca2+ responses in cultured urothelial 
cells from rat. Am. J. Physiol. Renal Physiol. 294, F971–81. 
doi:10.1152/ajprenal.00313.2007 
Kullmann, F.A., Shah, M.A., Birder, L.A., de Groat, W.C., 2009. Functional TRP and ASIC-
like channels in cultured urothelial cells from the rat. Am. J. Physiol. Renal Physiol. 
296, F892–901. doi:10.1152/ajprenal.90718.2008 
Kumar, V., Chapple, C.C., Chess-Williams, R., 2004. Characteristics of adenosine 
triphosphate [corrected] release from porcine and human normal bladder. J. Urol. 172, 
744–7. 
Kumar, V., Chapple, C.R., Rosario, D., Tophill, P.R., Chess-Williams, R., 2010. In vitro 
release of adenosine triphosphate from the urothelium of human bladders with detrusor 
overactivity, both neurogenic and idiopathic. Eur. Urol. 57, 1087–92. 
doi:10.1016/j.eururo.2009.11.042 
Kuo, Y.-C., Kuo, H.-C., 2013. Botulinum toxin injection for lower urinary tract dysfunction. Int. 
J. Urol. 20, 40–55. doi:10.1111/j.1442-2042.2012.03035.x 
Kurizaki, Y., Ishizuka, O., Imamura, T., Ichino, M., Ogawa, T., Igawa, Y., Nishizawa, O., 
Andersson, K.-E., 2011. Relation between expression of α(1)-adrenoceptor mRNAs in 
bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. 
 
236 
Scand. J. Urol. Nephrol. 45, 15–9. doi:10.3109/00365599.2010.515611 
Lakshmi, S., Joshi, P.G., 2005. Co-activation of P2Y2 receptor and TRPV channel by ATP: 
implications for ATP induced pain. Cell. Mol. Neurobiol. 25, 819–32. 
doi:10.1007/s10571-005-4936-8 
Lampe, P.D., Lau, A.F., 2004. The effects of connexin phosphorylation on gap junctional 
communication. Int. J. Biochem. Cell Biol. 36, 1171–86. doi:10.1016/S1357-
2725(03)00264-4 
Langmead, C.J., Watson, J., Reavill, C., 2008. Muscarinic acetylcholine receptors as CNS 
drug targets. Pharmacol. Ther. 117, 232–43. doi:10.1016/j.pharmthera.2007.09.009 
Ledenev, A.N., Konstantinov, A.A., Popova, E., Ruuge, E.K., 1986. A simple assay of the 
superoxide generation rate with Tiron as an EPR-visible radical scavenger. Biochem. 
Int. 13, 391–6. 
Lee, H.Y., Bardini, M., Burnstock, G., 2000. Distribution of P2X receptors in the urinary 
bladder and the ureter of the rat. J. Urol. 163, 2002–7. 
Lei, L., Cao, X., Yang, F., Shi, D.-J., Tang, Y.-Q., Zheng, J., Wang, K., 2013. A TRPV4 
channel C-terminal folding recognition domain critical for trafficking and function. J. 
Biol. Chem. 288, 10427–39. doi:10.1074/jbc.M113.457291 
Leon, L.A., Hoffman, B.E., Gardner, S.D., Laping, N.J., Evans, C., Lashinger, E.S.R., Su, X., 
2008. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-
316243) on bladder micturition reflex in spontaneously hypertensive rats. J. Pharmacol. 
Exp. Ther. 326, 178–85. doi:10.1124/jpet.108.138651 
Lepple-Wienhues, A., 1998. The Tyrosine Kinase p56lck Mediates Activation of Swelling-
induced Chloride Channels in Lymphocytes. J. Cell Biol. 141, 281–286. 
doi:10.1083/jcb.141.1.281 
Li, L., Jiang, C., Song, B., Yan, J., Pan, J., 2008. Altered expression of calcium-activated K 
and Cl channels in detrusor overactivity of rats with partial bladder outlet obstruction. 
BJU Int. 101, 1588–94. doi:10.1111/j.1464-410X.2008.07522.x 
Li, Y., Zhu, H., Kuppusamy, P., Roubaud, V., Zweier, J.L., Trush, M.A., 1998. Validation of 
Lucigenin (Bis-N-methylacridinium) as a Chemilumigenic Probe for Detecting 
Superoxide Anion Radical Production by Enzymatic and Cellular Systems. J. Biol. 
Chem. 273, 2015–2023. doi:10.1074/jbc.273.4.2015 
Liedtke, W., Choe, Y., Martí-Renom, M.A., Bell, A.M., Denis, C.S., Sali, A., Hudspeth, A.J., 
Friedman, J.M., Heller, S., 2000. Vanilloid receptor-related osmotically activated 
channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 103, 525–35. 
Liedtke, W., Friedman, J.M., 2003. Abnormal osmotic regulation in trpv4-/- mice. Proc. Natl. 
 
237 
Acad. Sci. U. S. A. 100, 13698–703. doi:10.1073/pnas.1735416100 
Liu, F., Takahashi, N., Yamaguchi, O., 2009. Expression of P2X3 purinoceptors in 
suburothelial myofibroblasts of the normal human urinary bladder. Int. J. Urol. 16, 570–
5. doi:10.1111/j.1442-2042.2009.02307.x 
Liu, X., Bandyopadhyay, B., Nakamoto, T., Singh, B., Liedtke, W., Melvin, J., Ambudkar, I., 
2006. A role for AQP5 in activation of TRPV4 by hypotonicity: concerted involvement of 
AQP5 and TRPV4 in regulation of cell volume recovery. J. Biol. Chem. 281, 15485–95. 
doi:10.1074/jbc.M600549200 
Locovei, S., Bao, L., Dahl, G., 2006a. Pannexin 1 in erythrocytes: function without a gap. 
Proc. Natl. Acad. Sci. U. S. A. 103, 7655–9. doi:10.1073/pnas.0601037103 
Locovei, S., Wang, J., Dahl, G., 2006b. Activation of pannexin 1 channels by ATP through 
P2Y receptors and by cytoplasmic calcium. FEBS Lett. 580, 239–44. 
doi:10.1016/j.febslet.2005.12.004 
Loot, A.E., Popp, R., Fisslthaler, B., Vriens, J., Nilius, B., Fleming, I., 2008. Role of 
cytochrome P450-dependent transient receptor potential V4 activation in flow-induced 
vasodilatation. Cardiovasc. Res. 80, 445–52. doi:10.1093/cvr/cvn207 
Lopez, W., Gonzalez, J., Liu, Y., Harris, A.L., Contreras, J.E., 2013. Insights on the 
mechanisms of Ca(2+) regulation of connexin26 hemichannels revealed by human 
pathogenic mutations (D50N/Y). J. Gen. Physiol. 142, 23–35. 
doi:10.1085/jgp.201210893 
Lorenzo, I.M., Liedtke, W., Sanderson, M.J., Valverde, M.A., 2008. TRPV4 channel 
participates in receptor-operated calcium entry and ciliary beat frequency regulation in 
mouse airway epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 105, 12611–6. 
doi:10.1073/pnas.0803970105 
Maggi, C.A., Barbanti, G., Santicioli, P., Beneforti, P., Misuri, D., Meli, A., Turini, D., 1989. 
Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of 
micturition reflex in humans. J. Urol. 142, 150–4. 
Malloy, B.J., Price, D.T., Price, R.R., Bienstock, A.M., Dole, M.K., Funk, B.L., Rudner, X.L., 
Richardson, C.D., Donatucci, C.F., Schwinn, D.A., 1998. alpha1-adrenergic receptor 
subtypes in human detrusor. J. Urol. 160, 937–943. doi:10.1016/S0022-
5347(01)62836-2 
Mamedova, L.K., Joshi, B. V, Gao, Z.-G., von Kügelgen, I., Jacobson, K.A., 2004. 
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide 
receptors. Biochem. Pharmacol. 67, 1763–70. doi:10.1016/j.bcp.2004.01.011 
Mansfield, K.J., Hughes, J.R., 2014. P2Y receptor modulation of ATP release in the 
urothelium. Biomed Res. Int. 2014, 830374. doi:10.1155/2014/830374 
 
238 
Maroto, R., Hamill, O.P., 2001. Brefeldin A block of integrin-dependent mechanosensitive 
ATP release from Xenopus oocytes reveals a novel mechanism of 
mechanotransduction. J. Biol. Chem. 276, 23867–72. doi:10.1074/jbc.M101500200 
Martin, A.F., Bhatti, S., Pyne-geithman, G.J., Farjah, M., Walker, L., Franks, R., Strauch, 
A.R., Paul, R.J., Manaves, V., 2007. Expression and function of COOH-terminal myosin 
heavy chain isoforms in mouse smooth muscle Expression and function of COOH-
terminal myosin heavy chain isoforms in mouse smooth muscle. Am J Physiol Cell 
Physiol. 1, 238–245. doi:10.1152/ajpcell.00567.2006 
Martin, B.F., 1972. Cell replacement and differentiation in transitional epithelium: a 
histological and autoradiographic study of the guinea-pig bladder and ureter. J. Anat. 
112, 433–55. 
Masuda, H., Kihara, K., Saito, K., Matsuoka, Y., Yoshida, S., Chancellor, M.B., de Groat, 
W.C., Yoshimura, N., 2008. Reactive oxygen species mediate detrusor overactivity via 
sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 101, 
775–80. doi:10.1111/j.1464-410X.2007.07310.x 
Masuyama, R., Vriens, J., Voets, T., Karashima, Y., Owsianik, G., Vennekens, R., Lieben, 
L., Torrekens, S., Moermans, K., Vanden Bosch, A., Bouillon, R., Nilius, B., Carmeliet, 
G., 2008. TRPV4-mediated calcium influx regulates terminal differentiation of 
osteoclasts. Cell Metab. 8, 257–65. doi:10.1016/j.cmet.2008.08.002 
McCloskey, K.D., 2013. Bladder interstitial cells: an updated review of current knowledge. 
Acta Physiol. (Oxf). 207, 7–15. doi:10.1111/apha.12009 
McGaraughty, S., Wismer, C.T., Zhu, C.Z., Mikusa, J., Honore, P., Chu, K.L., Lee, C.-H., 
Faltynek, C.R., Jarvis, M.F., 2003. Effects of A-317491, a novel and selective 
P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic 
nociception following intrathecal and intraplantar administration. Br. J. Pharmacol. 140, 
1381–8. doi:10.1038/sj.bjp.0705574 
McMurray, G., Dass, N., Brading, A.F., 1998. Purinoceptor subtypes mediating contraction 
and relaxation of marmoset urinary bladder smooth muscle. Br. J. Pharmacol. 123, 
1579–86. doi:10.1038/sj.bjp.0701774 
Mendoza, S.A., Fang, J., Gutterman, D.D., Wilcox, D.A., Bubolz, A.H., Li, R., Suzuki, M., 
Zhang, D.X., 2010. TRPV4-mediated endothelial Ca2+ influx and vasodilation in 
response to shear stress. Am. J. Physiol. Heart Circ. Physiol. 298, H466–76. 
doi:10.1152/ajpheart.00854.2009 
Michaelis, U.R., Falck, J.R., Schmidt, R., Busse, R., Fleming, I., 2005. Cytochrome 
P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-
2 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25, 321–6. 
doi:10.1161/01.ATV.0000151648.58516.eb 
Mihara, H., Boudaka, A., Sugiyama, T., Moriyama, Y., Tominaga, M., 2011. Transient 
 
239 
receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in 
mouse oesophageal keratinocytes. J. Physiol. 589, 3471–82. 
doi:10.1113/jphysiol.2011.207829 
Mills, I.W., Greenland, J.E., Mcmurray, G., Mccoy, R., Ho, K.M.T., Noble, J.G., Brading, 
A.F., 2000. Studies of the pathophysiology of idiopathic detrusor instability: the 
physiological properties of the detrusor smooth muscle and its pattern of innervation. J. 
Urol. 163, 646–651. doi:10.1016/S0022-5347(05)67951-7 
Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thüroff, J., Wein, A.J., 2002. How 
widespread are the symptoms of an overactive bladder and how are they managed? A 
population-based prevalence study. BJU Int. 87, 760–766. doi:10.1046/j.1464-
410x.2001.02228.x 
Milsom, I., Coyne, K.S., Nicholson, S., Kvasz, M., Chen, C.-I., Wein, A.J., 2014. Global 
prevalence and economic burden of urgency urinary incontinence: a systematic review. 
Eur. Urol. 65, 79–95. doi:10.1016/j.eururo.2013.08.031 
Mochizuki, T., Sokabe, T., Araki, I., Fujishita, K., Shibasaki, K., Uchida, K., Naruse, K., 
Koizumi, S., Takeda, M., Tominaga, M., 2009. The TRPV4 cation channel mediates 
stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J. Biol. 
Chem. 284, 21257–64. doi:10.1074/jbc.M109.020206 
Monaghan, K.P., Johnston, L., McCloskey, K.D., 2012. Identification of PDGFRα Positive 
Populations of Interstitial Cells in Human and Guinea Pig Bladders. J. Urol. 188, 639–
647. doi:10.1016/j.juro.2012.03.117 
Montgomery, B.S., Fry, C.H., 1992. The action potential and net membrane currents in 
isolated human detrusor smooth muscle cells. J. Urol. 147, 176–84. 
Moore, K.H., Ray, F.R., Barden, J.A., 2001. Loss of purinergic P2X(3) and P2X(5) receptor 
innervation in human detrusor from adults with urge incontinence. J. Neurosci. 21, 
RC166. 
Moriyama, T., Iida, T., Kobayashi, K., Higashi, T., Fukuoka, T., Tsumura, H., Leon, C., 
Suzuki, N., Inoue, K., Gachet, C., Noguchi, K., Tominaga, M., 2003. Possible 
involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor 
potential vanilloid receptor 1-mediated thermal hypersensitivity. J. Neurosci. 23, 6058–
62. 
Mostwin, J.L., Karim, O.M., van Koeveringe, G., Brooks, E.L., 1991. The guinea pig as a 
model of gradual urethral obstruction. J. Urol. 145, 854–8. 
Mostwin, J.L., Karim, O.M.A., Van Koeveringe, G., Seki, N., 1994. Guinea pig as an animal 
model for the study of urinary bladder function in the normal and obstructed state. 
Neurourol. Urodyn. 13, 137–145. doi:10.1002/nau.1930130206 
Mukerji, G., Yiangou, Y., Corcoran, S.L., Selmer, I.S., Smith, G.D., Benham, C.D., Bountra, 
 
240 
C., Agarwal, S.K., Anand, P., 2006. Cool and menthol receptor TRPM8 in human 
urinary bladder disorders and clinical correlations. BMC Urol. 6, 6. doi:10.1186/1471-
2490-6-6 
Mumtaz, F.H., Khan, M.A., Thompson, C.S., Morgan, R.J., Mikhailidis, D.P., 2000. Nitric 
oxide in the lower urinary tract: physiological and pathological implications. BJU Int. 85, 
567–78. 
Musch, M.W., Hubert, E.M., Goldstein, L., 1999. Volume Expansion Stimulates p72syk and 
p56lyn in Skate Erythrocytes. J. Biol. Chem. 274, 7923–7928. 
doi:10.1074/jbc.274.12.7923 
Nagata, K., Duggan, A., Kumar, G., García-Añoveros, J., 2005. Nociceptor and hair cell 
transducer properties of TRPA1, a channel for pain and hearing. J. Neurosci. 25, 4052–
61. doi:10.1523/JNEUROSCI.0013-05.2005 
Namasivayam S1, Eardley I, M.J., 2001. Purinergic sensory neurotransmission in the urinary 
bladder: an in vitro study in the rat. BJU Int. 84, 854–860. doi:10.1046/j.1464-
410x.1999.00310.x 
Nilius, B., Watanabe, H., Vriens, J., 2003. The TRPV4 channel: structure-function 
relationship and promiscuous gating behaviour. Pflugers Arch. 446, 298–303. 
doi:10.1007/s00424-003-1028-9 
O’reilly, B.A., Kosaka, A.H., Knight, G.F., Chang, T.K., Ford, A.P.D.W., Rymer, J.M., Popert, 
R., Burnstock, G., Mcmahon, S.B., 2002. P2X receptors and their role in female 
idiopathic detrusor instability. J. Urol. 167, 157–164. doi:10.1016/S0022-
5347(05)65403-1 
Otsuka, A., Shinbo, H., Matsumoto, R., Kurita, Y., Ozono, S., 2008. Expression and 
functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 377, 473–81. doi:10.1007/s00210-008-0274-y 
Page, A.J., Brierley, S.M., Martin, C.M., Hughes, P.A., Blackshaw, A.L., 2007. Acid sensing 
ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. 
Pain 133, 150–160. doi:10.1016/j.pain.2007.03.019 
Page, A.J., Brierley, S.M., Martin, C.M., Price, M.P., Symonds, E., Butler, R., Wemmie, J.A., 
Blackshaw, L.A., 2005. Different contributions of ASIC channels 1a, 2, and 3 in 
gastrointestinal mechanosensory function. Gut 54, 1408–15. 
doi:10.1136/gut.2005.071084 
Parsons, B.A., Drake, M.J., n.d. Animal Models in Overactive Bladder Research. 
doi:10.1007/978-3-642-16499-6_2 
Parsons, J.T., Parsons, S.J., 1997. Src family protein tyrosine kinases: cooperating with 
growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol. 9, 187–192. 
doi:10.1016/S0955-0674(97)80062-2 
 
241 
Pimentel, D.R., Amin, J.K., Xiao, L., Miller, T., Viereck, J., Oliver-Krasinski, J., Baliga, R., 
Wang, J., Siwik, D.A., Singh, K., Pagano, P., Colucci, W.S., Sawyer, D.B., 2001. 
Reactive Oxygen Species Mediate Amplitude-Dependent Hypertrophic and Apoptotic 
Responses to Mechanical Stretch in Cardiac Myocytes. Circ. Res. 89, 453–460. 
doi:10.1161/hh1701.096615 
Plant, T.D., Strotmann, R., 2007. TRPV4: A Multifunctional Nonselective Cation Channel 
with Complex Regulation, in: Liedtke, W., Heller, S. (Eds.), TRP Ion Channel Function 
in Sensory Transduction and Cellular Signaling Cascades. CRC Press, FL. 
Poole, D.P., Amadesi, S., Veldhuis, N.A., Abogadie, F.C., Lieu, T., Darby, W., Liedtke, W., 
Lew, M.J., McIntyre, P., Bunnett, N.W., 2013. Protease-activated receptor 2 (PAR2) 
protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required 
for sustained inflammatory signaling. J. Biol. Chem. 288, 5790–802. 
doi:10.1074/jbc.M112.438184 
Popp, R., Brandes, R.P., Ott, G., Busse, R., Fleming, I., 2002. Dynamic modulation of 
interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ. 
Res. 90, 800–6. 
Rahaman, S.O., Grove, L.M., Paruchuri, S., Southern, B.D., Abraham, S., Niese, K.A., 
Scheraga, R.G., Ghosh, S., Thodeti, C.K., Zhang, D.X., Moran, M.M., Schilling, W.P., 
Tschumperlin, D.J., Olman, M.A., 2014. TRPV4 mediates myofibroblast differentiation 
and pulmonary fibrosis in mice. J. Clin. Invest. 124, 5225–38. doi:10.1172/JCI75331 
Rajaganapathy, B.R., Chancellor, M.B., Nirmal, J., Dang, L., Tyagi, P., 2015. Bladder uptake 
of liposomes after intravesical administration occurs by endocytosis. PLoS One 10, 
e0122766. doi:10.1371/journal.pone.0122766 
Ralevic, V., Burnstock, G., 1998. Receptors for Purines and Pyrimidines. Pharmacol. Rev. 
50, 413–492. 
Ramsey, I.S., Delling, M., Clapham, D.E., 2006. An introduction to TRP channels. Annu. 
Rev. Physiol. 68, 619–47. doi:10.1146/annurev.physiol.68.040204.100431 
Rievaj, J., Pan, W., Cordat, E., Alexander, R.T., 2013. The Na+/H+ exchanger isoform 3 is 
required for active paracellular and transcellular Ca2+ transport across murine cecum. 
Am. J. Physiol. Gastrointest. Liver Physiol. 305, G303–13. 
doi:10.1152/ajpgi.00490.2012 
Robertson, S.J., Rae, M.G., Rowan, E.G., Kennedy, C., 1996. Characterization of a P2X-
purinoceptor in cultured neurones of the rat dorsal root ganglia. Br. J. Pharmacol. 118, 
951–6. 
Rong, W., Spyer, K.M., Burnstock, G., 2002. Activation and sensitisation of low and high 
threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. J. 
Physiol. 541, 591–600. doi:10.1113/jphysiol.2001.013469 
 
242 
Rossier, B.C., Stutts, M.J., 2009. Activation of the epithelial sodium channel (ENaC) by 
serine proteases. Annu. Rev. Physiol. 71, 361–79. 
doi:10.1146/annurev.physiol.010908.163108 
Ruan, H.Z., Birder, L.A., Xiang, Z., Chopra, B., Buffington, T., Tai, C., Roppolo, J.R., de 
Groat, W.C., Burnstock, G., 2006. Expression of P2X and P2Y receptors in the 
intramural parasympathetic ganglia of the cat urinary bladder. Am. J. Physiol. Renal 
Physiol. 290, F1143–52. doi:10.1152/ajprenal.00333.2005 
Ruan, H.Z., Burnstock, G., 2003. Localisation of P2Y1 and P2Y4 receptors in dorsal root, 
nodose and trigeminal ganglia of the rat. Histochem. Cell Biol. 120, 415–26. 
doi:10.1007/s00418-003-0579-3 
Sadananda, P., Shang, F., Liu, L., Mansfield, K.J., Burcher, E., 2009. Release of ATP from 
rat urinary bladder mucosa: role of acid, vanilloids and stretch. Br. J. Pharmacol. 158, 
1655–62. doi:10.1111/j.1476-5381.2009.00431.x 
Salas, N.A., Somogyi, G.T., Gangitano, D.A., Boone, T.B., Smith, C.P., 2007. Receptor 
activated bladder and spinal ATP release in neurally intact and chronic spinal cord 
injured rats. Neurochem. Int. 50, 345–50. doi:10.1016/j.neuint.2006.09.002 
Sánchez-Freire, V., Blanchard, M.G., Burkhard, F.C., Kessler, T.M., Kellenberger, S., 
Monastyrskaya, K., 2011. Acid-Sensing Channels in Human Bladder: Expression, 
Function and Alterations During Bladder Pain Syndrome. J. Urol. 186, 1509–1516. 
doi:10.1016/j.juro.2011.05.047 
Säve, S., Persson, K., 2010. Extracellular ATP and P2Y receptor activation induce a 
proinflammatory host response in the human urinary tract. Infect. Immun. 78, 3609–15. 
doi:10.1128/IAI.00074-10 
Schutz-geschwender, A., Zhang, Y., Holt, T., Mcdermitt, D., Olive, D.M., Biosciences, L., 
2004. Quantitative , Two-Color Western Blot Detection With Infrared Fluorescence. LI-
COR Biosci. 800, 1–8. 
Schwartzberg, P.L., 1998. The many faces of Src: multiple functions of a prototypical 
tyrosine kinase. Oncogene 17, 1463–8. doi:10.1038/sj.onc.1202176 
Seminario-Vidal, L., Okada, S.F., Sesma, J.I., Kreda, S.M., van Heusden, C.A., Zhu, Y., 
Jones, L.C., O’Neal, W.K., Penuela, S., Laird, D.W., Boucher, R.C., Lazarowski, E.R., 
2011. Rho signaling regulates pannexin 1-mediated ATP release from airway epithelia. 
J. Biol. Chem. 286, 26277–86. doi:10.1074/jbc.M111.260562 
Servier Medical, S., 2015. Slide kit Servier Medical Art [WWW Document]. URL 
http://www.servier.com/slidekit 
Shabir, S., Cross, W., Kirkwood, L.A., Pearson, J.F., Appleby, P.A., Walker, D., Eardley, I., 
Southgate, J., 2013. Functional expression of purinergic P2 receptors and transient 
receptor potential channels by the human urothelium. Am. J. Physiol. Renal Physiol. 
 
243 
305, F396–406. doi:10.1152/ajprenal.00127.2013 
Shahidullah, M., Mandal, A., Delamere, N.A., 2012. TRPV4 in porcine lens epithelium 
regulates hemichannel-mediated ATP release and Na-K-ATPase activity. Am. J. 
Physiol. Cell Physiol. 302, C1751–61. doi:10.1152/ajpcell.00010.2012 
Sharif-Naeini, R., Dedman, A., Folgering, J.H.A., Duprat, F., Patel, A., Nilius, B., Honoré, E., 
2008. TRP channels and mechanosensory transduction: insights into the arterial 
myogenic response. Pflugers Arch. 456, 529–40. doi:10.1007/s00424-007-0432-y 
Sibley, G.N., 1984. A comparison of spontaneous and nerve-mediated activity in bladder 
muscle from man, pig and rabbit. J. Physiol. 354, 431–43. 
Silva, G.B., Garvin, J.L., 2008. TRPV4 mediates hypotonicity-induced ATP release by the 
thick ascending limb. Am. J. Physiol. Renal Physiol. 295, F1090–5. 
doi:10.1152/ajprenal.90365.2008 
Singh, R., Lillard, J.W., 2009. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 
86, 215–23. doi:10.1016/j.yexmp.2008.12.004 
Somogyi, G.T., de Groat, W.C., 1999. Function, signal transduction mechanisms and 
plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. 64, 411–
418. doi:10.1016/S0024-3205(98)00580-3 
Somogyi, G.T., Zernova, G. V, Yoshiyama, M., Yamamoto, T., de Groat, W.C., 1998. 
Frequency dependence of muscarinic facilitation of transmitter release in urinary 
bladder strips from neurally intact or chronic spinal cord transected rats. Br. J. 
Pharmacol. 125, 241–6. doi:10.1038/sj.bjp.0702041 
Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W., Abrams, P., Herzog, A.R., Corey, R., Hunt, 
T.L., Wein, A.J., 2003. Prevalence and burden of overactive bladder in the United 
States. World J. Urol. 20, 327–36. doi:10.1007/s00345-002-0301-4 
Stout, C.E., Costantin, J.L., Naus, C.C.G., Charles, A.C., 2002. Intercellular calcium 
signaling in astrocytes via ATP release through connexin hemichannels. J. Biol. Chem. 
277, 10482–8. doi:10.1074/jbc.M109902200 
Streng, T., Axelsson, H.E., Hedlund, P., Andersson, D.A., Jordt, S.-E., Bevan, S., 
Andersson, K.-E., Högestätt, E.D., Zygmunt, P.M., 2008. Distribution and function of 
the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur. Urol. 53, 
391–9. doi:10.1016/j.eururo.2007.10.024 
Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., Plant, T.D., 2000. OTRPC4, 
a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat. 
Cell Biol. 2, 695–702. doi:10.1038/35036318 
Strotmann, R., Schultz, G., Plant, T.D., 2003. Ca2+-dependent potentiation of the 
nonselective cation channel TRPV4 is mediated by a C-terminal calmodulin binding 
 
244 
site. J. Biol. Chem. 278, 26541–9. doi:10.1074/jbc.M302590200 
Sui, G., Fry, C.H., Malone-Lee, J., Wu, C., 2009. Aberrant Ca2+ oscillations in smooth 
muscle cells from overactive human bladders. Cell Calcium 45, 456–464. 
doi:10.1016/j.ceca.2009.03.001 
Sui, G., Fry, C.H., Montgomery, B., Roberts, M., Wu, R., Wu, C., 2014. Purinergic and 
muscarinic modulation of ATP release from the urothelium and its paracrine actions. 
Am. J. Physiol. Renal Physiol. 306, 286–98. doi:10.1152/ajprenal.00291.2013 
Sui, G., Wu, C., Roosen, A., Ikeda, Y., Kanai, A.J., Fry, C.H., 2008. Modulation of bladder 
myofibroblast activity: implications for bladder function. Am. J. Physiol. Renal Physiol. 
295, F688–97. doi:10.1152/ajprenal.00133.2008 
Sui, G.P., Rothery, S., Dupont, E., Fry, C.H., Severs, N.J., 2002. Gap junctions and 
connexin expression in human suburothelial interstitial cells. BJU Int. 90, 118–29. 
Sui, G.P., Wu, C., Fry, C.H., 2004. Electrical characteristics of suburothelial cells isolated 
from the human bladder. J. Urol. 171, 938–43. doi:10.1097/01.ju.0000108120.28291.eb 
Sui, G.P., Wu, C., Fry, C.H., 2003. A description of Ca2+ channels in human detrusor 
smooth muscle. BJU Int. 92, 476–82. 
Sui, G.-P., Wu, C., Fry, C.H., 2006. Characterization of the purinergic receptor subtype on 
guinea-pig suburothelial myofibroblasts. BJU Int. 97, 1327–31. doi:10.1111/j.1464-
410X.2006.06200.x 
Sullivan, M.N., Francis, M., Pitts, N.L., Taylor, M.S., Earley, S., 2012. Optical recording 
reveals novel properties of GSK1016790A-induced vanilloid transient receptor potential 
channel TRPV4 activity in primary human endothelial cells. Mol. Pharmacol. 82, 464–
72. doi:10.1124/mol.112.078584 
Sun, Y., Chai, T.C., 2006. Augmented extracellular ATP signaling in bladder urothelial cells 
from patients with interstitial cystitis. Am. J. Physiol. Cell Physiol. 290, C27–34. 
doi:10.1152/ajpcell.00552.2004 
Sun, Y., Keay, S., De Deyne, P.G., Chai, T.C., 2001. Augmented stretch activated 
adenosine triphosphate release from bladder uroepithelial cells in patients with 
interstitial cystitis. J. Urol. 166, 1951–6. 
Sun, Y., Keay, S., De Deyne, P.G., Chai, T.C., 2001. Augmented stretch activated 
adenosine triphosphate release from bladder uroepithelial cells in patients with 
interstitial cystitis. J. Urol. 166, 1951–1956. doi:10.1016/S0022-5347(05)65726-6 
Svichar, N., Shmigol, A., Verkhratsky, A., Kostyuk, P., 1997. ATP induces Ca2+ release 
from IP3-sensitive Ca2+ stores exclusively in large DRG neurones. Neuroreport 8, 
1555–9. 
Takumida, M., Kubo, N., Ohtani, M., Suzuka, Y., Anniko, M., 2005. Transient receptor 
 
245 
potential channels in the inner ear: presence of transient receptor potential channel 
subfamily 1 and 4 in the guinea pig inner ear. Acta Otolaryngol. 125, 929–34. 
Taylor, A.H., Al-Azzawi, F., 2000. Immunolocalisation of oestrogen receptor beta in human 
tissues. J. Mol. Endocrinol. 24, 145–55. 
Teilmann, S.C., Byskov, A.G., Pedersen, P.A., Wheatley, D.N., Pazour, G.J., Christensen, 
S.T., 2005. Localization of transient receptor potential ion channels in primary and 
motile cilia of the female murine reproductive organs. Mol. Reprod. Dev. 71, 444–452. 
doi:10.1002/mrd.20312 
Tempest, H. V, Dixon, A.K., Turner, W.H., Elneil, S., Sellers, L.A., Ferguson, D.R., 2004. 
P2X and P2X receptor expression in human bladder urothelium and changes in 
interstitial cystitis. BJU Int. 93, 1344–8. doi:10.1111/j.1464-410X.2004.04858.x 
Thorneloe, K.S., Sulpizio, A.C., Lin, Z., Figueroa, D.J., Clouse, A.K., McCafferty, G.P., 
Chendrimada, T.P., Lashinger, E.S.R., Gordon, E., Evans, L., Misajet, B.A., Demarini, 
D.J., Nation, J.H., Casillas, L.N., Marquis, R.W., Votta, B.J., Sheardown, S.A., Xu, X., 
Brooks, D.P., Laping, N.J., Westfall, T.D., 2008. N-((1S)-1-{[4-((2S)-2-{[(2,4-
dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-
methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent 
transient receptor potential vanilloid 4 channel agonist induces urinar. J. Pharmacol. 
Exp. Ther. 326, 432–42. doi:10.1124/jpet.108.139295 
Timóteo, M.A., Carneiro, I., Silva, I., Noronha-Matos, J.B., Ferreirinha, F., Silva-Ramos, M., 
Correia-de-Sá, P., 2014. ATP released via pannexin-1 hemichannels mediates bladder 
overactivity triggered by urothelial P2Y6 receptors. Biochem. Pharmacol. 87, 371–9. 
doi:10.1016/j.bcp.2013.11.007 
Tobias, I.S., Lee, H., Engelmayr, G.C., Macaya, D., Bettinger, C.J., Cima, M.J., 2010. Zero-
order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and 
elastomeric device. J. Control. Release 146, 356–62. doi:10.1016/j.jconrel.2010.05.036 
Tominaga, M., Tominaga, T., 2005. Structure and function of TRPV1. Pflugers Arch. 451, 
143–50. doi:10.1007/s00424-005-1457-8 
Tong, Y.C., Hung, Y.C., Cheng, J.T., 1997. Evidence of P2Y-purinoceptor mediated bladder 
neck smooth muscle post-contractile relaxation in the male mini-pig. Neurosci. Lett. 
225, 181–4. 
Traub, O., 1989. Comparative characterization of the 21-kD and 26-kD gap junction proteins 
in murine liver and cultured hepatocytes. J. Cell Biol. 108, 1039–1051. 
doi:10.1083/jcb.108.3.1039 
Troidl, C., Troidl, K., Schierling, W., Cai, W.-J., Nef, H., Möllmann, H., Kostin, S., 
Schimanski, S., Hammer, L., Elsässer, A., Schmitz-Rixen, T., Schaper, W., 2009. Trpv4 
induces collateral vessel growth during regeneration of the arterial circulation. J. Cell. 
Mol. Med. 13, 2613–21. doi:10.1111/j.1582-4934.2008.00579.x 
 
246 
Tyagi, P., Li, Z., Chancellor, M., De Groat, W.C., Yoshimura, N., Huang, L., 2004. Sustained 
intravesical drug delivery using thermosensitive hydrogel. Pharm. Res. 21, 832–7. 
Van Ginkel, G., Raison, J.K., 1980. LIGHT-INDUCED FORMATION OF O - 2˙ OXYGEN 
RADICALS IN SYSTEMS CONTAINING CHLOROPHYLL. Photochem. Photobiol. 32, 
793–798. doi:10.1111/j.1751-1097.1980.tb04057.x 
Vassalli, J.D., Belin, D., 1987. Amiloride selectively inhibits the urokinase-type plasminogen 
activator. FEBS Lett. 214, 187–91. 
Velasco, C., Guarneri, L., Leonardi, A., Testa, R., 2003. Effects of intravenous and 
infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in 
conscious rats with bladder outlet obstruction. BJU Int. 92, 131–6. 
Vial, C., Evans, R.J., 2000. P2X receptor expression in mouse urinary bladder and the 
requirement of P2X(1) receptors for functional P2X receptor responses in the mouse 
urinary bladder smooth muscle. Br. J. Pharmacol. 131, 1489–95. 
doi:10.1038/sj.bjp.0703720 
Vlaskovska, M., Kasakov, L., Rong, W., Bodin, P., Bardini, M., Cockayne, D.A., Ford, A.P., 
Burnstock, G., 2001. P2X3 knock-out mice reveal a major sensory role for urothelially 
released ATP. J. Neurosci. 21, 5670–7. 
von Kügelgen, I., Wetter, A., 2000. Molecular pharmacology of P2Y-receptors. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 362, 310–323. doi:10.1007/s002100000310 
Von Walter, M., Michaelis, I., Jakse, G., Grosse, J.O., 2009. Trospium chloride released 
from intravesically applied plga-based carriers decreases bladder contractility in an 
isolated whole pig bladder model. Eur. Urol. Suppl. 8, 178. doi:10.1016/S1569-
9056(09)60235-9 
Vriens, J., Owsianik, G., Fisslthaler, B., Suzuki, M., Janssens, A., Voets, T., Morisseau, C., 
Hammock, B.D., Fleming, I., Busse, R., Nilius, B., 2005. Modulation of the Ca2 
permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular 
endothelium. Circ. Res. 97, 908–15. doi:10.1161/01.RES.0000187474.47805.30 
Vriens, J., Watanabe, H., Janssens, A., Droogmans, G., Voets, T., Nilius, B., 2003. Cell 
swelling, heat, and chemical agonists use distinct pathways for the activation of the 
cation channel TRPV4. Proc. Natl. Acad. Sci. 101, 396–401. 
doi:10.1073/pnas.0303329101 
Walden, P.D., Durkin, M.M., Lepor, H., Wetzel, J.M., Gluchowski, C., Gustafson, E.L., 1997. 
Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype 
in the rat, monkey and human urinary bladder and prostate. J. Urol. 157, 1032–8. 
Wang, E.C.Y., Lee, J.-M., Ruiz, W.G., Balestreire, E.M., von Bodungen, M., Barrick, S., 
Cockayne, D.A., Birder, L.A., Apodaca, G., 2005. ATP and purinergic receptor-
dependent membrane traffic in bladder umbrella cells. J. Clin. Invest. 115, 2412–22. 
 
247 
doi:10.1172/JCI24086 
Wang, P., Luthin, G.R., Ruggieri, M.R., 1995. Muscarinic acetylcholine receptor subtypes 
mediating urinary bladder contractility and coupling to GTP binding proteins. J. 
Pharmacol. Exp. Ther. 273, 959–66. 
Wang, T., Kendig, D.M., Smolock, E.M., Moreland, R.S., 2009. Carbachol-induced rabbit 
bladder smooth muscle contraction: roles of protein kinase C and Rho kinase. Am. J. 
Physiol. Renal Physiol. 297, F1534–42. doi:10.1152/ajprenal.00095.2009 
Watanabe, H., Davis, J.B., Smart, D., Jerman, J.C., Smith, G.D., Hayes, P., Vriens, J., 
Cairns, W., Wissenbach, U., Prenen, J., Flockerzi, V., Droogmans, G., Benham, C.D., 
Nilius, B., 2002a. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol 
derivatives. J. Biol. Chem. 277, 13569–77. doi:10.1074/jbc.M200062200 
Watanabe, H., Vriens, J., Janssens, A., Wondergem, R., Droogmans, G., Nilius, B., 2003a. 
Modulation of TRPV4 gating by intra- and extracellular Ca2+. Cell Calcium 33, 489–
495. doi:10.1016/S0143-4160(03)00064-2 
Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., Nilius, B., 2003b. 
Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 
channels. Nature 424, 434–8. doi:10.1038/nature01807 
Watanabe, H., Vriens, J., Suh, S.H., Benham, C.D., Droogmans, G., Nilius, B., 2002b. Heat-
evoked activation of TRPV4 channels in a HEK293 cell expression system and in 
native mouse aorta endothelial cells. J. Biol. Chem. 277, 47044–51. 
doi:10.1074/jbc.M208277200 
Wegierski, T., Hill, K., Schaefer, M., Walz, G., 2006. The HECT ubiquitin ligase AIP4 
regulates the cell surface expression of select TRP channels. EMBO J. 25, 5659–69. 
doi:10.1038/sj.emboj.7601429 
Wegierski, T., Lewandrowski, U., Müller, B., Sickmann, A., Walz, G., 2009. Tyrosine 
phosphorylation modulates the activity of TRPV4 in response to defined stimuli. J. Biol. 
Chem. 284, 2923–33. doi:10.1074/jbc.M805357200 
Wein, A.J., Andersson, K.-E., Drake, M.J., Dmochowski, R.R., 2014. Bladder Dysfunction in 
the Adult: The Basis for Clinical Management, Edn. 1. ed. Humana Press, Springer, 
New York, USA. 
Wein, A.J., Rovner, E.S., 2000. Pathophysiology and Classification of Voiding Dysfunction 
3–24. doi:10.1007/978-1-59259-198-5_1 
Willette, R.N., Bao, W., Nerurkar, S., Yue, T.-L., Doe, C.P., Stankus, G., Turner, G.H., Ju, 
H., Thomas, H., Fishman, C.E., Sulpizio, A., Behm, D.J., Hoffman, S., Lin, Z., 
Lozinskaya, I., Casillas, L.N., Lin, M., Trout, R.E.L., Votta, B.J., Thorneloe, K., 
Lashinger, E.S.R., Figueroa, D.J., Marquis, R., Xu, X., 2008. Systemic activation of the 
transient receptor potential vanilloid subtype 4 channel causes endothelial failure and 
 
248 
circulatory collapse: Part 2. J. Pharmacol. Exp. Ther. 326, 443–52. 
doi:10.1124/jpet.107.134551 
Winkler, D.G., Park, I., Kim, T., Payne, N.S., Walsh, C.T., Strominger, J.L., Shin, J., 1993. 
Phosphorylation of Ser-42 and Ser-59 in the N-terminal region of the tyrosine kinase 
p56lck. Proc. Natl. Acad. Sci. U. S. A. 90, 5176–80. 
Wiseman, O.J., Brady, C.M., Hussain, I.F., Dasgupta, P., Watt, H., Fowler, C.J., Landon, 
D.N., 2002. The ultrastructure of bladder lamina propria nerves in healthy subjects and 
patients with detrusor hyperreflexia. J. Urol. 168, 2040–5. 
doi:10.1097/01.ju.0000034023.85736.f0 
Wiseman, O.J., Fowler, C.J., Landon, D.N., 2003. The role of the human bladder lamina 
propria myofibroblast. BJU Int. 91, 89–93. doi:10.1046/j.1464-410X.2003.03802.x 
Wu, C., Gui, G.P., Fry, C.H., 2011. Intracellular Ca2+ regulation and electrophysiolgical 
properties of bladder urothelium subjected to stretch and exogenous agonists. Cell 
Calcium 49, 395–399. doi:10.1016/j.ceca.2011.03.008 
Wu, C., Kentish, J.C., Fry, C.H., 1995. Effect of pH on Myofilament Ca sup 2 Plus -
Sensitivity in Alphatoxin Permeabilized Guinea Pig Detrusor Muscle. Urology 154, 
1921–1924. 
Wu, C., Sui, G.P., Fry, C.H., 2004. Purinergic regulation of guinea pig suburothelial 
myofibroblasts. J. Physiol. 559, 231–43. doi:10.1113/jphysiol.2004.067934 
Wu, L., Gao, X., Brown, R.C., Heller, S., O’Neil, R.G., 2007. Dual role of the TRPV4 channel 
as a sensor of flow and osmolality in renal epithelial cells. AJP Ren. Physiol. 293, 
F1699–F1713. doi:10.1152/ajprenal.00462.2006 
Wüst, M., Averbeck, B., Reif, S., Bräter, M., Ravens, U., 2002. Different responses to drugs 
against overactive bladder in detrusor muscle of pig, guinea pig and mouse. Eur. J. 
Pharmacol. 454, 59–69. 
Xu, H., Zhao, H., Tian, W., Yoshida, K., Roullet, J.-B., Cohen, D.M., 2003. Regulation of a 
transient receptor potential (TRP) channel by tyrosine phosphorylation. SRC family 
kinase-dependent tyrosine phosphorylation of TRPV4 on TYR-253 mediates its 
response to hypotonic stress. J. Biol. Chem. 278, 11520–7. 
doi:10.1074/jbc.M211061200 
Xu, X., Gordon, E., Lin, Z., Lozinskaya, I.M., Chen, Y., Thorneloe, K.S., 2009. Functional 
TRPV4 channels and an absence of capsaicin-evoked currents in freshly-isolated, 
guinea-pig urothelial cells. Channels (Austin). 3, 156–60. 
Yamada, T., Ugawa, S., Ueda, T., Ishida, Y., Kajita, K., Shimada, S., 2009. Differential 
localizations of the transient receptor potential channels TRPV4 and TRPV1 in the 
mouse urinary bladder. J. Histochem. Cytochem. 57, 277–87. 
doi:10.1369/jhc.2008.951962 
 
249 
Yamaguchi, O., 2004. Response of bladder smooth muscle cells to obstruction: signal 
transduction and the role of mechanosensors. Urology 63, 11–6. 
doi:10.1016/j.urology.2003.12.002 
Yamaguchi, O., 2002. Beta3-adrenoceptors in human detrusor muscle. Urology 59, 25–9. 
Yamanishi, T., Chapple, C.R., Yasuda, K., Chess-Williams, R., 2000. The role of M(2)-
muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br. J. 
Pharmacol. 131, 1482–8. doi:10.1038/sj.bjp.0703719 
Yan, G.M., Lin, S.Z., Irwin, R.P., Paul, S.M., 1995. Activation of muscarinic cholinergic 
receptors blocks apoptosis of cultured cerebellar granule neurons. Mol. Pharmacol. 47, 
248–57. 
Yang, X.-R., 2006. Functional expression of transient receptor potential melastatin- and 
vanilloid-related channels in pulmonary arterial and aortic smooth muscle. AJP Lung 
Cell. Mol. Physiol. 290, L1267–L1276. doi:10.1152/ajplung.00515.2005 
Yao, C.Z., Uchida, T., Town-, C.M., Thompson, J.C., 1988. Age-related changes in 
gallbladder contractility and gallbladder cholecystokinin receptor population in the 
guinea pig. Mech. Ageing Dev. 46, 225–236. 
Yazaki, J., Aikawa, K., Shishido, K., Yanagida, T., Nomiya, M., Ishibashi, K., Haga, N., 
Yamaguchi, O., 2011. Alpha1-adrenoceptor antagonists improve bladder storage 
function through reduction of afferent activity in rats with bladder outlet obstruction. 
Neurourol. Urodyn. 30, 461–7. doi:10.1002/nau.20984 
Yu, W., Robson, S.C., Hill, W.G., 2011. Expression and distribution of ectonucleotidases in 
mouse urinary bladder. PLoS One 6, e18704. doi:10.1371/journal.pone.0018704 
Yu, W., Sun, X., Robson, S.C., Hill, W.G., 2013. Extracellular UDP enhances P2X-mediated 
bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/inositol 
trisphosphate pathway. FASEB J. doi:10.1096/fj.12-219006 
Yu, W., Zacharia, L.C., Jackson, E.K., Apodaca, G., 2006. Adenosine receptor expression 
and function in bladder uroepithelium. Am. J. Physiol. Cell Physiol. 291, C254–65. 
doi:10.1152/ajpcell.00025.2006 
Zacche, M.M., Srikrishna, S., Cardozo, L., 2015. Novel targeted bladder drug-delivery 
systems: a review. Res. Reports Urol. 7, 169. doi:10.2147/RRU.S56168 
Zhang, Y., Hoon, M.A., Chandrashekar, J., Mueller, K.L., Cook, B., Wu, D., Zuker, C.S., 
Ryba, N.J.P., 2003. Coding of sweet, bitter, and umami tastes: different receptor cells 
sharing similar signaling pathways. Cell 112, 293–301. 
Zheng, W., Christensen, L.P., Tomanek, R.J., 2004. Stretch induces upregulation of key 
tyrosine kinase receptors in microvascular endothelial cells. Am. J. Physiol. Heart Circ. 
Physiol. 287, H2739–45. doi:10.1152/ajpheart.00410.2004 
 
250 
Zimmermann, H., 1999. Two novel families of ectonucleotidases: molecular structures, 
catalytic properties and a search for function. Trends Pharmacol. Sci. 20, 231–6. 
 
